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STATEMENT OF ORIGINALITY. 
Section 1.
The acute and chronic use of testosterone replacement therapy in males with low 
testosterone status and chronic HF has been described in studies by members of our 
investigatory team (Malkin et al, 2006 and Pugh et al, 2003). More recently, researchers 
in Italy have conducted similar research (Caminiti et al, 2009). Although there are 
positive results regarding the use of testosterone in males with chronic HF, there is 
limited information on the physiological and biochemical consequences associated with 
decreased testosterone in this patient group. There are only two small correlation studies 
which have demonstrated moderate relationships between testosterone concentration, 
exercise capacity and right ventricular function in males with HF (Bocchi et al, 2008, 
Jankowska et al, 2009). This study will be the first direct comparison of key 
physiological and psychological outcomes in males with moderate to severe HF and 
Tow’ or ‘normal’ levels of testosterone. For this research, the study design, regional 
ethical approval, research and development approval were undertaken by myself. Also 
80% of the total data collection was undertaken by myself with assistance from Mr 
Keith Pearce and the HF specialist nurses at University Hospital South Manchester. 
Reproducibility of the echocardiography data was undertaken by Mr Keith Pearce and 
myself. Statistical analysis was performed by myself with guidance and support from 
Miss Sigrid Whiteside (Medical Statistician at University Hospital South Manchester).
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Section 2.
The acute and chronic use of testosterone replacement therapy in males with low 
testosterone status and chronic HF has been described in studies by members of our 
investigatory team (Malkin et al, 2006 and Pugh et al, 2003). More recently, researchers 
in Italy have conducted similar research (Caminiti et al, 2009). However, there is no 
research on the combined effects of exercise training and testosterone therapy in the 
chronic HF population. This randomised controlled clinical trial aimed to study the 
effects of combined exercise training and testosterone treatment on exercise capacity, 
physiological function and quality of life in males with low level testosterone. During 
this study, 90% of all data collection and supervision of the 12 week intervention was 
undertaken by myself. I received assistance from Miss Helen Lloyd, Mr Alan Ruddock, 
Professors Kevin Channer and John Saxton during the initial baseline data collection 
visit. Dr Emma Scott and Miss Anouska Me Connell provided all blinded trial 
medication injections. Mrs Sue Kesterton, Dr Garry Tew, Dr Liam Bourke and Dr 
Helen Crank all provided cover for exercise training sessions in my absence. All 
statistical analysis was performed by myself (blinded to group allocation) and Dr Helen 
Doll (Medical Statistician at the University of East Anglia) under the guidance of 
Professor John Saxton.
With the exception o f any statements to the contrary, all the data presented in this report 
are the result o f my own efforts. In addition, no parts o f this report have been copied from  
other sources. I understand that any evidence o f plagiarism  and/or the use o f  
u n a c k n o w l e d g + U''~A — * * **• A^ ta will be dealt with as a serious matter.
Signed
Date
11
Abbreviations.
17pHSD 17 beta hydroxysteroid dehydrogenase
2D two dimensional
3D three dimensional
ACE angiotensin converting enzyme
ADAM Androgen deficiency in the ageing male questionnaire
ADP adenosine diphosphate
AMP adenosine monophosphate
ANCOVA analysis of covariance
ANOVA analysis of variance
AR androgen receptor
At anaerobic threshold
ATP adenosine triphosphate
AVR aortic valve replacement
BDI Beck Depression Inventory
BMI body mass index
BNP brain natriuretic pepetide
BP blood pressure
Ca2+ calcium ions
CABG coronary artery bypass graft
CAD coronary artery disease
CHAMPS Community Health Activities Model Programme for Seniors
Questionnaire
CHF chronic heart failure
Cm/s centimetres per second
12
co2 carbon dioxide
CoA co-enzyme A
COX-1 cyclo-oxygenase-1
CRT cardiac resynchronisation therapy
c-Src proto-oncogene tyrosine protein kinase
CV cardiovascular
CVA cerebrovascular accident
DNA deoxyribonucleic acid
DSE dobutamine stress echocardiography
ED endothelial dysfunction
EDTA ethylenediaminetetraacetic acid
eNOS endothelial nitric oxide synthase
ERK-2 mitogen activated protein kinase-2
ET exercise training
f a d h 2 flavin adenine dinucleotide dehydrate
Fe C 02 fraction of expired carbon dioxide
Fe 0 2 fraction of expired oxygen
F i0 2 fraction of inspired oxygen
FMD flow mediated dilatation
FT free testosterone
GLUT glucose transporter
GM-CSF granulocyte macrophage colony stimulating factor
GP general practitioner
GTP guanosine triphosphate
hCG human choriogonadotropin
HF heart failure
HPRSD Hamilton Psychiatric Rating Scale for depression
HR heart rate
ICD implantable cardioverter defibrillator
IGF-1 insulin like growth factor -1
IHD ischaemic heart disease
IL interleukin
ISWT incremental shuttle walk test
LAEF% left atrial active emptying fraction
LA-EI left atrial expansion index
LA-PEF% left atrial passive emptying fraction
LDL low density lipoprotein
LNCaP androgen sensitive human prostate adenocarcinoma cell line
LT low testosterone
LV left ventricular
LVAD left ventricular assist device
LVEF% left ventricular ejection fraction
m metres
MCP-1 monocyte chemotactic protein-1
MET metabolic equivalent
MHz mega Hertz
MI myocardial infarction
min minutes
MLHFQ Minnesota living with heart failure questionnaire
MRI magnetic resonance imaging
MRNA messenger ribonucleic acid
NADH nicotinamide adenine dinucleotide hydroxide
14
NICE National Institute for Clinical Excellence
NIRS near infrared spectroscopy
nmol/L nano mo Is per Litre
NT normal testosterone
NT pro-BNP N terminal brain natriuretic peptide
NYHA New York Heart Association
PCG-la PPARa co-activator 1
PCWP pulmonary capillary wedge pressure
PDH pyruvate dehydrogenase
PDK-4 pyruvate dehydrogenase kinase isoenzyme-4
PET positive emission tomography
PPAR peroxisome proliferator activated receptor
PSA prostate specific antigen
RAAS rennin-angiotensin-aldosterone system
Raf-1 murine leukaemia viral oncogene ho mo log-1
RHH Royal Hallamshire Hospital
RV right ventricular
SAE serious adverse event
SF-36 V2 short form 36 version 2 questionnaire
SHBG sex hormone binding globulin
SHU Sheffield Hallam University
sICAM soluble intra-cellular adhesion molecule
SPECT single photon emission computed tomography
STH SheffieldTeaching Hospitals
St o2 percentage oxygen saturation
StAR steroidogenesis activator protein
15
STPD standard temperature and pressure, dry
sVCAM soluble vascular adhesion molecule
TAPSE tricuspid annular plane systolic excursion
TDI tissue Doppler imaging
TEM technical error of measurement
TNFa tumour necrosis factor alpha
TS testosterone supplementation
TT total testosterone
UHSM University Hospital South Manchester
UK United Kingdom
VE ventilation
Vmax maximum left atrial volume
Vmin minimum left atrial volume
V0 2 max maximal oxygen uptake
VpreA left atrial pre-contraction volume
VSD ventricular septal defect
a alpha
B beta
16
List of Tables.
Table 1. Causes of heart failure. 31
Table 2. Epidemiological studies of the aetiology of heart failure as percentage. 33 
Table 3. Symptoms and signs in heart failure. 49
Table 4. Sensitivity, specificity and predictive value of signs and symptoms in heart 
failure. 51
Table 5. New York Heart Association classification. 53
Table 6. Life extension and morbidity extension values in heart failure. 69
Table 7. Expanded appreciation of the aetiologies of low testosterone. 96
Table 8. Clinical formulations of testosterone. 100
Table 9. Baseline demographics of study sample based on total testosterone. 154
Table 10. Measurement error for key variables. 157
Table 11. 6 minute walk data based on total testosterone. 160
Table 12. LA structural and functional characteristics based on total testosterone. 162 
Table 13. LV structural and functional characteristics based on total testosterone. 164 
Table 14. Right heart structural and functional characteristics based on total 
testosterone. 167
Table 15. MLHFQ, ADAM and BDI scores based on total testosterone. 173
Table 16. NT pro BNP based on total testosterone. 174
Table 17. Adjusted baseline demographics based on free testosterone. 176
Table 18. 6 minute walk data based on free testosterone. 180
Table 19. LA structural and functional characteristics based on free testosterone. 182 
Table 20. LV structural and functional characteristics based on free testosterone. 184 
Table 21. Right heart structural and functional characteristics based on free 
testosterone. 187
Table 22. MLHFQ, ADAM and BDI scores based on free testosterone. 190
17
Table 23. NT pro BNP based on free testosterone. 191
Table 24. Adjusted baseline demographics based on bio-available testosterone. 193
Table 25. 6 minute walk data based on bio-available testosterone. 197
Table 26. LA structural and functional characteristics based on bio-available 
testosterone. 199
Table 27. LV structural and functional characteristics based on bio-available 
testosterone. 202
Table 28. Right heart structural and functional characteristics based on bio-available 
testosterone. 205
Table 29. MLHFQ, ADAM and BDI scores based on bio-available testosterone. 206
Table 30. NT pro BNP based on bio-available testosterone. 209
Table 31. Univariate Pearsons correlation of main outcome measures based on total 
testosterone. 211
Table 32. Univariate Pearsons correlation of main outcome measures based on free 
testosterone. 213
Table 33. Univariate Pearsons correlation of main outcome measures based on bio- 
available testosterone. 215
Table 34. Univariate Pearsons correlation of main outcome measures based on salivary 
testosterone. 222
Table 35. ANCOVA statistic comparing 6 minute shuttle walk between low and normal 
total and free testosterone using age as a covariate. 226
Table 36. Pathophysiological effects of inflammatory cytokines in heart failure. 280 
Table 37. Effects of testosterone supplementation on exercise capacity in 
heart failure. 292
Table 38. Topic schedule for the focus groups. 345
Table 39. Baseline characteristics of the study sample for study 2. 351
18
Table 40. Technical error of measurement for important outcomes in study 2. 353
Table 41. Endurance and strength characteristics pre and post intervention. 355
Table 42. Echo parameters for both groups pre and post intervention period. 356
Table 43. MLHFQ, ADAM, BDI and CHAMPS questionnaire data pre and post 
intervention in both groups. 367
Table 44. Blood chemistry for both groups pre and post intervention. 369
Table 45.Pearsons correlation for strength and endurance parameters based on total, 
free and bio-available testosterone. 372
Table 46. Pearsons correlation for quality of life parameters based on total, free and 
bio-available testosterone. 373
Table 47. Pearsons correlation for echocardiographic parameters based on total, free 
and bio-available testosterone. 375
Table 48. Pearsons correlation for blood chemistry based on total, free and bio- 
available testosterone. 377
19
List of figures.
Figure 1. Flow chart for suggested diagnosis of diastolic heart failure. 54
Figure 2. Patient journey for study 1. 122
Figure 3. Recruitment summary for study 1. 153
Figure 4. Bland Altman plot: agreement between two separate total testosterone 
measures. 159
Figure 5. SF36 domains based on total testosterone. 170
Figure 6. Bland Altman plot: agreement between two separate free testosterone 
measures. 179
Figure 7. SF36 domains based on free testosterone. 188
Figure 8. Blan Altman plot: agreement between two separate bio-available testosterone 
measures. 196
Figure 9. Scatter plot showing relationship between total testosterone and 6 minute 
walk. 217
Figure 10. Bland Altman plot: agreement between two separate salivary testosterone 
measures. 218
Figure 11. Scatter plot showing the relationship between salivary and 
total testosterone. 219
Figure 12. Bland Altman plot: agreement between salivary and free testosterone. 220 
Figure 13. Flow chart of patient journey and important time points for study 2. 313
Figure 14. Example of lebelling of the IMP. 319
Figure 15. Recruitment summary for study 2. 349
Figure 16. FMD of femoral artery pre and post intervention for both groups. 362 
Figure 17. Quality of life parameters pre and post intervention for both groups. 365 
Figure 18. Bland Altman plot: agreement between two separate total testosterone 
measures. 379
20
Figure 19. Bland Altman plot: agreement between two separate free testosterone 
measures.
Figure 20. Bland Altman plot: agreement between two separate bio-available 
testosterone measures.
380
381
21
List of Appendix.
Appendix 1. Ethics letter for study 1. 493
Appendix 2. Patient information leaflet for study 1. 499
Appendix 3. Case report forms for study 1. 503
Appendix 4. MLHFQ. 506
Appendix 5. Consent form example. 507
Appendix 6. SF36-V2. 508
Appendix 7. BDI. 509
Appendix 8. ADAM questionnaire. 512
Appendix 9. Ethics letter for study 2. 513
Appendix 10. Case report forms for study 2. 517
Appendix 11. CHAMPS Questionnaire. 521
Appendix 12. Patient information leaflet for study 2. 533
Appendix 13. Focus group transcription example. 540
22
Publications, presentations and conference proceedings arising from this research.
Innaugral Sports Medicine Meeting -  Sheffield Teaching Hospitals NHS Foundation 
Trust, October 2009 -  invited speaker. Testosterone supplementation in heart failure.
British Association o f Sport and Exercise Science: Cardiac Rehabilitation Subgroup 
Meeting, Metropole Hotel, Birmingham, December 2009 -  invited speaker. 
Testosterone and exercise training in heart failure.
European Society o f Cardiology Congress, Stockholm, Sweden, May 2010 -  invited 
speaker. The use of flow mediated dilatation: a clinical or research tool.
American College o f Sports Medicine, Washington, U.S.A, October 2010 -  abstract 
presentation. Combined exercise training and testosterone supplementation in males 
with low testosterone status and chronic heart failure.
European Society o f Cardiology -  Heart Failure Congress, Gothenburg, Sweden, May 
2011 - Abstract presentation: the cardiovascular effects of testosterone and exercise 
training in heart failure. European Journal of Heart Failure Supplement (2011) (10) 
(suppll): S60-S104.
Stout, M., Tew, G.A., Doll, H., Zwierska, I., Woodroofe, N., Channer, K.S. and Saxton, 
J.M. Testosterone therapy during exercise rehabilitation in male patients with heart 
failure who have low testosterone status: A double-blind randomised controlled 
feasibility study. American Heart Journal (2012), 164: 893-901.
23
Abstract.
Background: This cross-sectional study aimed to assess the effect of low testosterone 
(LT) status on functional capacity, quality of life, cardiac structure and function in 
males with moderate or severe stable heart failure (HF). Methods: 40 male patients with 
HF (ejection fraction (EF)% <45%) with low serum total testosterone (TT) <12 nmol / 
L (n =20, 71.9 ± 10.11 yrs) and normal range TT (n = 20, 66.9 ± 11.98 yrs) were 
recruited from a specialist HF clinic. The primary outcome, functional capacity, was 
assessed by the 6 min shuttle walk test. Health related quality of life (HRQoL) data was 
assessed using a licensed version of the SF36 Version 2. Additionally, Beck Depression 
Inventory (BDI), Minnesota Living with Heart Failure questionnaire (MLHFQ) and 
Androgen Deficiency in the Ageing Male (ADAM) questionnaire data was collected. 
Cardiac characteristics were assessed using detailed echocardiography analysis. Blood 
samples were taken for assessment of NT pro BNP. Results: Normal testosterone (NT) 
patients demonstrated a significantly higher 6 min walk distance (429.00 + 126.94 m; 
257.65 + 65 m, p<0.01) when compared to LT. LT patients showed significantly worse 
indices of quality of life using the SF36 V2 questionnaire. General health component 
(31.84 + 2.85 v 59.44 + 3.24, p<0.05), overall physical component score (41.39 + 17.03 
v 69.69 + 19.71, p<0.01) and overall mental component score (54.88 + 17.52 v 72.36 + 
16.58, p<0.01) higher in the NT group. There were very few cardiac changes and no 
differences in MLHFQ or BDI score between the groups. Conclusion: This is the first 
study to compare important prognostic outcomes in matched patients with HF and low 
testosterone. Additionally, this is the first paper to report significantly adverse HRQoL 
in male patients with low testosterone and HF when compared to normal range 
testosterone counterparts. LT in HF is associated with reduced functional capacity, 
together with attenuated general, physical and mental components of quality of life. 
Further research is warranted to assess the impact of testosterone supplementation on
24
these important prognostic outcomes in male patients with HF and low testosterone 
status.
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Section 1: The impact of testosterone concentration in males with heart failure.
Chapter 1: General introduction.
Heart failure (HF) is a multi-organ disease, involving the musculoskeletal, respiratory 
and endocrine systems. It is a common, debilitating condition and a major public health 
and financial burden in the Western world. The incidence and prevalence of congestive 
HF has increased together with the resulting morbidity and mortality. Worldwide it is 
estimated that 15 million individuals suffer from this condition, with 400,000 new cases 
each year in the United States of America and a total of 4.5 million Americans effected 
(Erikson, 1995). In the United Kingdom (UK), it is estimated that 900,000 people have 
HF (Al-Mohammed et al, 2010). Surveys in North West London show prevalence rates 
of 0.6 per 1000 patients aged less than 65 years and 28 per 1000 patients aged 65 years 
and over (Parameshwar et al, 1992).
As males age, there is a gradual decline in circulating bio-available testosterone 
(Betocchi, 2005). There is a general consensus that testosterone levels decline about 1% 
per year from as early as age 30 years. Noticeable declines are common after the age of 
50 years but there is great individual variability (Morales and Lunenfield, 2002).
HF also appears to be associated with decreased levels of plasma testosterone, 
supported by the fact that about 25% of men of all ages with HF have biochemical 
evidence of testosterone deficiency (Malkin et al, 2009). Low levels of testosterone 
have been correlated with disease progression in HF and may also be responsible for 
some of the features of HF, such as reduced skeletal muscle mass and function, 
cachexia, fatigue and depressed mood (Malkin et al, 2006). Furthermore, myocardial
26
cachexia, a syndrome with poor prognosis, is characterised by low levels of testosterone 
(Aukrust et al, 2009).
In addition to this it is well known that HF as a metabolic syndrome can adversely alter 
numerous endocrine, metabolic and inflammatory parameters (Jackson et al, 2000, 
Noutsias et al, 1999). The alterations can include changes in levels and sensitivity to 
insulin, growth hormone and importantly testosterone (Von Haehling et al, 2007). 
Reduced insulin sensitivity and the development of diabetes could be a major 
complicating factor of HF. It has been described that more than 40% of patients with 
HF have manifest disorders of glucose metabolism which appear independent of fat 
distribution and obesity (Aukrust et al, 2009).
Interestingly, testosterone replacement therapy at physiological doses has been shown to 
improve indices of physical function, cardiac function and also quality of life in HF 
patients (Malkin et al, 2006, Caminiti et al, 2009). These studies have shown modest 
improvements in cardiac output, maximal oxygen uptake, muscular strength and 
improved disease and health specific quality of life markers. Additionally, testosterone 
supplementation has been shown to improve arterial function via reduction in systemic 
vascular resistance (Pugh et al, 2003). Animal models have shown positive associations 
between testosterone supplementation and reduced levels of biochemical inflammation 
(Zhang et al, 2007) and also improvements in cardiac contractile performance (Scheuer 
et al, 1997). These studies are important because they suggest that when testosterone 
level is returned to the normal range there are significant improvements in important 
sequalae related to prognosis in HF.
27
Recent correlation studies have suggested that in HF, testosterone level is independently
related to peakv ° 2 , oxygen pulse and also right ventricular function (Jankowska et al, 
2009 and Bocchi et al, 2008). However, there is no research that directly compares 
parameters of physical fitness, cardiac function, quality of life and biochemical 
inflammation in male HF patients with low or normal testosterone levels.
Contradictory results have been published regarding the successful administration of 
testosterone therapy to males with HF (Caminiti et al, 2009, Malkin et al, 2006) and no 
large scale trials have aimed to determine the efficacy of supplementation. Based on 
previous observations, the efficacy of testosterone supplementation in a male HF 
population with low testosterone status is uncertain. This study aims for the first time to 
determine the effects of testosterone concentration on exercise capacity, quality of life 
and cardiac function in males with low testosterone status in comparison with normal 
testosterone in moderate or worse HF.
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Chapter 2: Literature review - Heart failure and low testosterone.
2.1: Heart failure.
2.1.1 Incidence of HF.
There has been a dramatic decline in the incidence of mortality and morbidity from 
many cardiovascular diseases over recent decades (Sytkowski et al, 1990). Conversely, 
the incidence and prevalence of congestive HF, together with the resultant morbidity 
and mortality have shown an increase throughout this time. Worldwide it is estimated 
that 15 million individuals suffer from this condition, with 400,000 new cases each year 
in the United States of America and a total of 4.5 million Americans effected (Eriksson, 
1995). In the United Kingdom (UK), surveys in North West London show prevalence 
rates of 0.6 per 1000 patients aged less than 65 years and 28 per 1000 patients aged 65 
years and over (Parameshwar et al, 1992). This statistic is reinforced by the 
Framingham Study which described a doubling in the incidence of HF for every decade 
of life reaching 3% in those aged 85-94 years (Ho et al, 1993). Large surveys have also 
been conducted in the UK during the 1990’s aiming to study left ventricular (LV) 
dysfunction using echocardiography in large populations of Glasgow and the West 
Midlands. In Glasgow the prevalence of significantly impaired LV systolic dysfunction 
in participants 25-74 years was 2.9% and in the West Midlands 1.8% in patients aged 45 
years and over (Lip et al, 1997 and Me Donagh et al, 1997). Economists have studied 
the costs of HF to the National Health Service in the UK. It has been found that in the 
year 2000 HF cost the Health Service 905 million pounds (1.91% of total UK Health 
Service expenditure). The most predominant factor for this cost was hospital admission 
(69%) followed by prescriptions for important treatment (18%). Additionally, the cost 
for secondary hospital admission and nursing home care for patients with HF was 750 
million equating to 2% of total Health Service expenditure (Stewart et al, 2002
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2.1.2: Aetiology of HF.
The aetiology of HF differs according to the population being studied. For example, in 
Western society, the most common causes of HF are coronary artery disease (CAD) and 
hypertension. In the developing countries, valvular heart disease and nutritional heart 
disease are most common (Lip et al, 2000). There are also a host of other conditions 
which can cause HF and these are listed in the summary table 1 below.
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Table 1. Causes of HF adapted from Lip et al, 2000.
Causes of Heart Failure.
Coronary artery disease:
• Myocardial Infarction.
• Ischemia.
Hypertension.
Cardiomyopathy:
• Dilated (congestive).
• Hypertrophic / obstructive.
• Restrictive (e.g. amyloidosis, sarcoidosis, haemochromatosis).
• Obliterative.
Valvular and Congenital Heart Disease:
• Mitral valve disease.
• Aortic valve disease.
• Atrial septal defect / ventricular septal defect.
Arrhythmias:
• Tachycardia.
• Bradycardia (complete heart block, sick sinus syndrome).
• Loss of atrial transport (e.g. atrial fibrillation).
Alcohol and Drugs:
• Alcohol.
• Cardiac depressants (e.g. p blockers, calcium channel blockers). 
‘High output9 cardiac failure:
• Anaemia, thyrotoxicosis, Paget’s Disease, arteriovenous fistulae. 
Pericardial Disease:
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• Constrictive pericarditis.
• Pericardial effusion.
Primary Right Heart Failure:
• Pulmonary hypertension (e.g. pulmonary embolism, cor pulmonale).
• Tricuspid incompetence.
Table 2 summarises the percentages of common aetiologies of HF in the 
western world.
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2.1.3: Pathophysiological considerations -  Heart failure.
In systolic HF, there is impairment in left ventricular ejection fraction (LV EF%) 
resulting in a decline in cardiac output. In response to this there is activation of various 
neuro-hormonal compensatory mechanisms which attempt to improve the mechanical 
efficiency of the heart. The phenomenon of which is addressed below in more detail.
Stimulation of the renin-angiotensin-aldosterone system (RAAS) via neuro-hormonal 
activation and altered autonomic control increases levels of renin, plasma angiotensin II 
and aldosterone. Angiotensin II has been found to be a potent vasoconstrictor of the 
renal efferent arterioles and systemic circulation where it stimulates release of nor 
adrenaline from sympathetic nerve terminals, inhibits vagal tone and promotes release 
of aldosterone (Jackson et al, 2000). This activation results in retention of sodium and 
water together with increased release of potassium. Furthermore, angiotensin II has 
been shown to cause anorexia and weight loss in experimental models using animals 
(Brink et al, 1996). Additional research has also suggested an increase in the levels of 
endothelin (another potent vasoconstrictor peptide) in HF, constituting adverse 
prognosis (Tsutamoto et al, 1995). Blood plasma levels of Endothelin -  1 have been 
shown to be a reliable correlate to pulmonary artery capillary wedge pressure (PCWP), 
hospital admission and death (McMurray et al, 1992). As an early compensatory 
mechanism to provide inotropic support to the failing cardiac muscle, low and high 
pressure baroreceptors further stimulate the sympathetic nervous system to increase 
heart rate (HR) and hence cardiac output. Adverse consequences of prolonged elevation 
of adrenergic drive to the cardiac muscle involve a direct toxic effect of nor-epinephrine 
on cardiac myocytes (Mann et al, 2002), facilitation of the development of ventricular 
arrhythmias (Schwartz et al, 1994), alterations in p-adrenoceptor function (Bristow et al, 
1992) and apoptosis of endothelial cells in vitro (Horiuchi et al, 1997). The alteration in
p- adrenoceptor function increases sympathetic activity and also down-regulates 
autonomic modulation of the sinus node leading to the notion that reduced HR 
variability is an important prognostic marker in patients with HF (Jackson et al, 2000).
Atrial and Brain natriuretic peptides are released by cardiac muscle in HF primarily due 
to volume overload and the corresponding atrial and ventricular stretch. These peptides 
have an antagonistic effect to those of angiotensin II on vascular tone, aldosterone 
secretion and renal-tubule sodium reabsorption (Jackson et al, 2000). As a result, levels 
of these circulating mediators in HF have become an important diagnostic marker and 
are also the subject of research interest in developing new medications that inhibit the 
enzyme that metabolises atrial natriuretic peptide (neutral endopeptidase) (Jackson et al,
2000). In untreated congestive cardiac failure, high levels of atrial and brain natriuretic 
peptide correlate closely with adverse prognosis and ultimately mortality.
HF also results in increased levels of circulating cytokines which include tumour 
necrosis factor-alpha (TNF-a), interleukins-1( IL-1), 2 (IL-2), 6 ( IL-6), 8 (IL-8) and 
their receptors (Berry and Clarke, 2000). In more detail, research has shown that TNF-a 
and IL-6 levels are elevated in relation to deteriorating functional classification and in 
this regard should also be recognised to be associated with some of the classic 
hallmarks of HF including worsening LV dysfunction, pulmonary oedema and cardiac 
remodelling (Millar et al, 1982). In relation to this, in patients with severe HF, elevated 
levels of soluble TNF receptor are a stronger predictor of early mortality when 
compared to plasma nor adrenaline, atrial natriuretic peptide or (New York Heart 
Association) NYHA classification (Berry and Clarke, 2000). Physiologically in HF, 
there is an increased production of soluble adhesion molecules via the endothelium; 
these are recognised as important mediators of endothelial-leukocyte adhesion and
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inflammatory response (Oppenheimer et al, 1991). This physiological process relates to 
the earlier notion that endothelial injury is associated with an adverse prognosis in HF. 
Other researchers have discovered that during hypoxia (an occurrence related to the 
reduced cardiac output in HF) IL-6 and the soluble adhesion molecule - 1 (sICAM-1) 
are secreted by injured endothelial cells (Sluiter et al, 1993) and vascular xanthine 
dehydrogenase enzyme is converted to xanthine oxidase. This catalyses the production 
of uric acid and its reactive bi-product superoxide (Yan et al, 1997). It has been 
hypothesised that injured vascular endothelium in HF patients may be a source of free 
radical production, triggering leukocyte activation and increased cytokine production 
(Leyva et al, 1998).
Researchers and clinicians have observed widespread endothelial cell activation 
followed closely by endothelial dysfunction (ED) in HF (Brutsaert, 2003). This ED has 
been thought to be partly responsible for the early fatigue and exercise intolerance in 
HF. This may be attributed to inappropriate, endothelial mediated, vasoconstrictor 
responses with reduced vasodilatory capacity contributing to elevated peripheral 
vascular resistance (Drexler et al, 1992). In relation to this, reduced gene expression of 
endothelial nitric oxide synthase (eNOS) and cyclo-oxygenase-1 (COX-1) has also been 
shown to be a factor in the early onset of ED in cardiac failure (Smith et al, 1996). 
Experimental research in patients with cardiac dysfunction has provided direct evidence 
of ED in both conductive and resistance coronary arteries (Treasure et al, 1990). In 
more detail, these patients displayed impaired dilatory responses to acetylcholine and 
bradykinin within the coronary circulation. The coronary ED has been attributed to 
reduced synthesis of coronary endothelial nitric oxide. The concept has emerged that 
coronary vascular ED could trigger coronary vasoconstriction, smooth muscle 
proliferation and remodelling, increased lipid deposition in the vessel wall and also
coronary thrombosis. It is evident that these processes would accelerate the 
development CAD, resulting in decreases in myocardial perfusion and indirectly 
contributing to cardiac failure.
Skeletal muscle physiology and function is abnormal in patients with HF. Muscle bulk 
is decreased and there are documented reductions in muscular strength and endurance 
(Massie et al, 1987). Early studies have found that during leg exercise, oxygen 
extraction to the exercising muscle and lactate efflux were increased, together with 
diminished total oxygen utilisation (Donald et al, 1961). This was attributed to represent 
the metabolic consequences of reduced blood flow to exercising muscle. To support this 
notion, research has suggested that skeletal muscle is histologically abnormal with a 
tendency towards anaerobic (type II) muscle fibres (Mancini et al, 1989). This research 
has also identified abnormal mitochondrial structure with reduced cristae volume and 
reduction in the key enzymes involved in the Kreb’s cycle and the oxidative chain. This 
can be supported by other research which has shown more rapid declines of 
phosphocreatine and rises in inorganic phosphate in HF patients when compared with 
healthy controls. The slope of the relationship between phosphocreatine and inorganic 
phosphate versus muscular power output (an index of mitochondrial oxidative 
metabolism) was found to be steeper in HF patients suggesting impaired oxidative 
capacity (Wilson et al, 1985).
2.1.4: Myocardial substrate metabolism and heart failure.
In order to understand the abnormalities related to myocardial substrate metabolism in 
HF, it is important to review myocardial metabolism in a normal heart. In non- 
ischaemic conditions, the majority of adenosine triphosphate (ATP) formation in the
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heart is derived from oxidative phosphorylation in the mitochondria with minor 
contribution from glycolysis and guanosine triphosphate (GTP) formation via the citric 
acid cycle (Stanley et al, 2005). The initial step in the energetic pathway is the cellular 
uptake of and utilisation of available substrate, their breakdown by P-oxidation and 
glycolysis, resulting in formation of acetyl coenzyme A (CoA) which is then fed into 
the Krebs cycle producing nicotinamide adenine dinucleotide hydroxide (NADH) and 
carbon dioxide (CO2) (Neubauer, 2007). Under normal perfusion approximately 60- 
90% of CoA results from p-oxidation of free-fatty acids and 10-40% from pyruvate 
oxidation via glycolysis and lactate oxidation (Stanley et al, 2005).
2.1.4.1: Normal myocardial carbohydrate metabolism.
Glycolytic substrate is utilised from exogenous glucose and glycogen stores. Glucose 
transport into cardiac myocytes is facilitated by trans-membrane gradients and 
sarcolemma glucose transporters (GLUT-4 and GLUT-1) (Stanley et al, 2005). Insulin 
stimulation, increased cardiac demand or myocardial ischaemia result in a shift in 
glucose transporters from intra-cellular vesicles to the sarcolemma therefore increasing 
glucose transport and uptake into the cell (Stanley et al, 1997). In addition, GLUT-4 re­
location into the sarcolemma may be facilitated by activation of adenosine 
monophosphate (AMP) -activated protein kinase, particularly during ischaemia or in 
response to exercise (Russell et al, 1999 and Russell et al, 2004). Intra-cellular glycogen 
stores may be used as an additional source of glucose 6 phosphate for uptake into the 
glycolytic pathway. Previous studies have suggested that glycogen concentration may 
be increased by an elevated supply of exogenous substrate together with, or solely by, 
increased levels of insulin (Kruszynska et al 1991). Glycogenolysis can therefore be 
activated by adrenergic stimulation, decrease in tissue adenosine triphosphate (ATP)
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concentration and increase in inorganic phosphate -  occurring typically with stressors 
such as exercise or ischaemia (Stanley et al, 1997).
Pyruvate, formed from glycolysis, may be converted to lactate, decarboxylated to CoA 
or carboxylated to oxaloacetate or malate (Stanley et al, 2005).The decarboxylation of 
pyruvate is considered to be the first irreversible step in carbohydrate oxidation, 
catalysed by the enzyme pyruvate dehydrogenase (PDH) (Randle, 1986). Importantly, 
higher levels of circulating lipids, together with increased accumulation of long chain 
fatty acid moieties (e.g. associated with diabetes or fasting) have been shown to increase 
phosporylation inhibition of PDH and decrease oxidation of pyruvate from the 
glycolytic pathway and lactate oxidation (Huang et al, 2002). Furthermore, glucose and 
pyruvate oxidation, together with related PDH activity, are attenuated by increased rates 
of fatty acid oxidation; for instance when there are elevated levels of plasma free fatty 
acids. Conversely to this, pyruvate oxidation is increased when fatty acid oxidation is 
attenuated (Kruszynska et al, 1991).
2.1.4.2: Normal myocardial fatty acid metabolism.
The concentration of plasma non-esterified fatty acid levels mainly determines the rate 
of fatty acid uptake by the myocardium (Stanley et al, 2005). As such, metabolic 
stressors such as ischaemia, diabetes or starvation which increase plasma free fatty acid 
concentration, result in increased rate of myocardial free fatty acid uptake (Stanley et al, 
2005). Regulation of plasma free fatty acid concentration is via their net release from 
triglycerides in adipocytes, facilitated by the action of hormone-sensitive lipase and 
synthesis by glycerolphosphate acyltransferase. Hormone-sensitive lipase is activated 
by catecholamines and inhibited by insulin. Accordingly, when insulin concentration is 
low and catecholamine concentration high, plasma free fatty acid concentration and
hence myocardial free fatty acid uptake and oxidation are high (Lopaschuk et al, 1994). 
Uptake of free fatty acids into the cardiomyocyte is promoted by passive diffusion or 
protein mediated transport across the sarcolemma (Stanley et al, 2005). Once within the 
sarcolemma, non-esterified fatty acids bind to fatty acid binding protein to be activated 
by esterification to fatty acyl-CoA via fatty acyl-CoA synthase (Stanley et al, 2005). 
Acyl-CoA transportation into the mitochondria is facilitated by a carnitine-dependent 
transport system, with carnitine palmitoyltransferase-I serving as the key regulator for 
the rate of this uptake (Lopaschuk et al, 1994). Fatty acid P-oxidation occurs within the 
mitochondria. This process repeatedly cleaves two carbon acetyl-CoA units in order to 
generate NADH and flavin adenine dinucleotide dihydroxide (FADH2). Bing and co­
workers in 1954 suggested four reactions, involving different, but specific enzymes, to 
facilitate fatty acid p-oxidation dependent on long, medium or short-chain fatty 
intermediates. Initially, catalysed by acyl-CoA dehydrogenase, followed by 2-enoyl- 
CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase. Finally, 3-ketoacyl-CoA 
thiolase regenerates acyl-CoA for further P-oxidation and releases acetyl-CoA for the 
citric acid cycle.
2.1.4.3: Normal myocardial ketone body metabolism.
Normal arterial plasma concentration of ketone bodies is low. Fatty acid ketone body 
formation in the liver therefore, plays a minor role as a substrate for the myocardium 
(Stanley et al, 2005). It should be highlighted however, that during starvation or poorly 
controlled diabetes, plasma ketone bodies become elevated due to low insulin and high 
fatty acid levels and as such become a major substrate for myocardial metabolism (Hall 
et al, 1996).
2.1.4.4: Electron transport chain and oxidative phosphorylation in HF.
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Research in both human and animal models of HF have shown that there is a decreased 
concentration of tissue ATP, increased concentration of adenosine diphosphate (ADP) 
and reduction in phosphorylation potential (Montgomery et al, 1992 and Shen et al, 
1999). As a result, there is significant impairment of the kinetic mechanisms of ATP 
utilisation for myocardial cell contraction and relaxation via myosin ATPase and 
sarcoplasmic reticulum Ca2+- ATPase (Stanley et al, 2005). It has previously been noted 
that HF attenuates the ability of the creatine kinase system to transfer mitochondrial 
ATP to the myofibril. In addition to this, impairment of the electron transport chain may 
be detrimental to the mitochondrial and cytosolic redox state, adversely affecting the 
concentration of ATP, ADP and phosphate and therefore, reducing the rate of influx 
through key metabolic enzymes such as PDH or phosphofructokinase (Ye et al, 2001). 
Abnormalities at the level of the mitochondria in HF are abundant. Previous studies in 
both humans and animals have suggested there is a greater incidence of mitochondrial 
membrane disruption and matrix depletion (Sabbah et al, 1992), a lower capacity for 
respiration with a variety of substrates (Sharov et al, 2000), electron transport chain 
defects together with decreased capacity for oxidative phosphorylation (Casademont 
and Miro, 2002). Although there are different theories as to the exact processes involved 
in electron transport chain complex dysfunction in HF, it is widely evident that there is 
a major disruption in oxidative metabolism at this level. To date, there is no consensus 
regarding the exact site of the lesions of electron transport chain dysfunction, whether 
the effects of this dysfunction are isolated to a group of myocytes or all cardiac 
myocytes as a whole or finally, whether dysfunction is localised to subsarcolemmal or 
intrafibrillar components of the mitochondria (Stanley et al, 2005).
2.1.5.5: Myocardial substrate metabolism in HF.
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Results are conflicting regarding myocardial substrate metabolism in heart failure, 
particularly in human models. There is however, a consensus that HF reduces the 
capacity to transduce foodstuffs into ATP (Stanley et al, 2005). Initially, in the early 
stages of HF, fatty oxidation rate is maintained. However, Paolisso et al (1994) 
observed that in established HF with NYHA Class II and III, there was increased 
extraction and uptake of plasma free fatty acid and decreased glucose uptake. 
Furthermore, it has also been established that HF increases myocardial lipid oxidation 
by as much as 50% when compared to healthy aged matched controls (Paolisso et al, 
1994). The same study also showed that in HF patients there is a significant decrease in 
myocardial carbohydrate oxidation when compared to controls. Increased plasma nor 
adrenaline concentrations corresponding to increased levels of free fatty acid where also 
noted in the HF population. This has been attributed to enhanced p-adrenergic 
stimulation and also higher levels of plasma insulin, both factors which may facilitate 
glucose uptake and oxidation by the myocardium (Stanley et al, 2005). Using other 
methods, researchers have been able to develop radiolabelled fatty acid / deoxyglucose 
analogues and with positive emission tomography (PET) have discovered increased 
uptake of fatty acid analogue and decreased uptake of deoxyglucose analogue in 
patients with NYHA class III HF (Taylor et al, 2001). In contradiction to this, Yazaki et 
al (1999) have suggested that in HF patients with idiopathic dilated cardiomyopathy, the 
process is reversed with increased myocardial glucose uptake and decreased fatty acid 
oxidation when compared to healthy controls. Davila-Roman et al (2002) have re­
affirmed the findings of Yazaki and colleagues by using l8F-deoxyglucose 6 phosphate 
infusion during PET to estimate glucose uptake. This study determined that there was 
increased myocardial glucose metabolism and decreased fatty acid utilisation in their 
population of HF patients.
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Studies of patients with end-stage HF have consistently suggested that there is down 
regulation of myocardial fatty acid oxidative enzymes -  a feature relating to the 
conversion of substrate metabolism from fatty acid oxidation towards glucose oxidation 
(Stanley et al, 2005). In more detail, explanted hearts at transplant, have demonstrated 
reduced messenger ribonucleic acid (mRNA) for the fatty acid oxidation enzymes long- 
chain acyl-CoA dehydrogenase and medium-chain acyl-CoA dehydrogenase together 
with significantly reduced protein levels of medium-chain acyl-CoA dehydrogenase 
without down-regulation of mRNA for the glycolytic enzyme glyceraldehydes-3- 
phosphate dehydrogenase (Sack et al, 1996). Pacing induced HF in a canine model, has 
also showed similar reductions in mRNA levels of key enzymes involved in the fatty 
acid oxidation pathway, but in addition, GLUT-1, GLUT-4, glyceraldehydes-3- 
phosphate dehydrogenase, PDH and pyruvate dehydrogenase kinase isoenzyme-4 
(PDK-4), providing evidence that the failing heart attenuates the expression of all 
metabolic enzymes rather than selectively suppressing fatty acid oxidation enzyme and 
potentiating the carbohydrate pathway (Razeghi et al, 2001).
In HF, impaired oxidative phosphorylation is detrimental to cardiac function due to an 
inadequate supply of ATP to cardiac myocytes. Mitochondria in HF have been found to 
have abnormal structure and contribute to a substantial reduction in oxygen 
consumption and derangement of energy production in a failing myocardium. (Ide et al,
2001). In more detail, the action of electron-transport chain complexes and ATP 
synthase capacity are attenuated together with the regulation of oxidative 
phosphorylation by phosphate ADP, AMP and creatine (Lewandowski, 2002 and 
Marin-Garcia et al, 2001).
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In advanced, end-stage HF, myocardial ATP levels decrease by up to 40% (Beer et al,
2002). However, it should be noted that average ATP levels remain sufficient for 
myosin-ATPase usage and, as such, do not contribute to pump failure (Beer et al, 2002). 
Phosphocreatine and total creatine levels have been shown to decline at an earlier stage 
and by greater values up to 70%, probably due to down-regulation of creatine-transport 
function (Ten-Hove et al, 2005). In relation to this, mitochondrial creatine kinase 
activity has been shown to reduce to 20% of normal activity and myofibrillar creatine 
kinase activity can decrease by as much as 50%. These processes clearly result in a 
drastic decline in ATP transfer, energy flux within the mitochondrial structure and a 
combined up to 70% reduction in energy delivery to myofibrils in a HF model (Liao et 
al, 1996). Increased catecholamine secretion in HF results in high workload states that 
promote artificial elevation in free ADP concentration to values twice that of normal 
human myocardium (Neubauer, 2007). Increased free ADP accumulation in the 
perimyofibrillar compartments together with compartments adjacent to the sarcoplasmic 
reticulum and sarcolemmal ion pumps serves to limit the inotropic contractile reserve of 
the myocardium, resulting clinically with dyspnoea during high workload states e.g. 
exertion (Neubauer, 2007).
31P-MR spectroscopy has been widely utilised to assess myocardial energetics in HF 
and is a robust indicator of the energetic state of the myocardium by comparing the ratio 
of phosphocreatine to ATP. As such, the creatine kinase reaction equilibrium favours 
ATP synthesis rather than phosphocreatine synthesis by a factor of 100 (Neubauer, 
2007). Resultantly, if demand for ATP outweighs ATP synthesis, then phosphocreatine 
levels decline initially with ATP only decreasing when phosphocreatine levels are 
substantially reduced. In HF however, total creatine also decreases serving to reduce the 
phosphocreatine / ATP ratio (Hardy et al, 1991). This ratio is particularly important in
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HF because it has been consistently shown to Correlate well with NYHA score (Hardy 
et al, 1991), indexes of systolic and diastolic LV impairment (Neubauer et al, 1995, 
Lamb et al, 1991) and ultimately has been suggested as the strongest predictor of 
mortality when compared to clinical and functional characteristics (Neubauer et al, 
1997).
The nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family 
(isoforms: PPARa, PPARp and PPARy) play an important role in cardiac lipid 
metabolism (Neubauer, 2007). PPARa has been suggested to be the key determinant to 
cardiac lipid metabolism by controlling the expression of enzymes directly involved in 
fatty acid oxidation. In human models, PPARa expression decreases in conjunction with 
the attenuation of fatty acid oxidation and, as such, is thought to be the principle 
mechanism in the switch from fatty acid substrate utilisation to glycolytic metabolism 
(Sack et al, 1996). PPARy coactivator-1 (PCG-la) is a nuclear receptor co-activator and 
plays a crucial role in mitochondrial metabolic function (Huss et al, 2004). PCG -la is 
able to activate genes responsible for fatty acid uptake and oxidation and also for 
oxidative phosphorylation. Primarily, these genes include PPARa and PPARp. PCG-la 
inhibition due to increased catecholamine levels in HF results in down-regulation of 
mitochondrial gene expression and therefore directly contributes to impaired oxidative 
phosphorylation (Garnier et al, 2003). Furthermore, development of HF is accelerated 
by inhibition or deficiency of PCG - la  which suggests that this nuclear receptor co­
activator may play an important cardio-protective role (Aranzy et al, 2006).
2.1.5: Diastolic heart failure.
Previously, diastolic HF was considered a more benign condition than the systolic 
counterpart and was also thought to affect only a relatively small cohort of patients.
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More recently, perspectives have altered and the prevalence of diastolic HF has 
increased to 54% of all cases of HF (Owan et al, 2006). Importantly, recent evidence 
also suggests that diastolic HF carries a similar prognosis to that of systolic HF (Cleland 
et al, 2003). Pre-disposing conditions to diastolic HF include advancing age, female 
gender, diabetes, obesity, arterial hypertension and left ventricular hypertrophy (Fischer 
et al, 2003). As a result of these pre-disposing conditions and the evolution of 
Westernised society, diastolic HF is clearly becoming more dominant.
Historically, diastolic impairment was referred to as heart failure with a normal ejection 
fraction. In this sub-group of patients, evidence for diastolic impairment was provided 
by slow LV relaxation and increased LV stiffness. In addition, more recent arguments 
have suggested that although global LV systolic function may appear normal, there are 
significant decreases in myocardial tissue Doppler velocities and abnormalities of 
ventriculo-arterial coupling. However, it is now evident that diastolic dysfunction may 
also be present in patients with known systolic failure (Skaluba et al, 2004). 
Furthermore, it has also been suggested that in patients with systolic and diastolic HF, 
the latter correlates more closely with symptoms than the former (Skaluba et al, 2004).
As a result of the challenges faced when assessing diastolic HF and the evidence of a 
close relationship to systolic HF recent opinion has categorised HF of both origins into 
a single syndrome. This ‘single syndrome’ hypothesis suggests that both forms of 
ventricular impairment result from similar pathophysiology (i.e. increased interstitial 
collagen deposition and modification to matricellular proteins) and therefore, there is a 
progression from heart failure with a normal ejection fraction to heart failure with 
reduced ejection fraction (Sanderson, 2007). Supporting research has established that in 
heart failure with a preserved ejection fraction there are increased three dimensional
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(3D) LV volumes when compared to well-matched normal patients (Maurer et al, 2005). 
Additionally, another study has showed that in prospective follow-up of patients with 
heart failure and preserved ejection fraction, 20% of participants demonstrated a 
significant decline in LV EF below 45% during a 3 month follow-up period (Cahill et 
al, 2006).
Conversely, structural, functional and molecular biological theories have been 
suggested that categorise heart failure as a ‘two-syndrome’ condition, namely, LV 
systolic impairment and normal LV systolic function with features associated with 
diastolic LV dysfunction (Paulus et al, 2007). Related to this theory, patients with 
systolic HF demonstrate eccentrically dilated, remodelled ventricles with reduced 
pumping capacity. However, in diastolic HF, patients develop concentric hypertrophy 
and a high wall mass-volume ratio (Kitzman et al, 2002). In addition to this, ultra- 
structural studies have suggested further differences between diastolic and systolic HF. 
In diastolic HF cardiomyocyte diameter and myofilamentary density is increased when 
compared to patients with systolic HF (Van Heerebeek et al, 2006). Furthermore, there 
are not only structural differences at the cellular level between systolic and diastolic HF 
but functional cellular differences have been suggested. Cardiomyocyte resting tension 
is increased in diastolic HF -  a factor which has been shown to significantly contribute 
to overall myocardial stiffness (Van Heerebeek et al, 2006). Titin, a cytoskeletal protein 
responsible for early diastolic recoil, demonstrates a less compliant isoform expression 
in diastolic HF when compared to systolic HF (Neagoe et al, 2002). At the functional 
cellular level, differences have also been observed in expression patterns of matrix 
metalloproteinases and tissue inhibitors of metalloproteinases (Paulus et al, 2007). In 
diastolic HF down-regulation of metalloproteinases combined with increased regulation 
of tissue inhibitors of metalloproteinases results in a decrease in matrix degradation. In
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systolic HF, the opposite pattern is observed, with increased matrix degradation due to 
upregulation of metalloproteinases (Ahmed et al, 2006). Pharmacological intervention 
in diastolic HF also suggests different pathophysiological mechanisms between systolic 
and diastolic HF. For example, in the PEP-CHF study (Cleland et al, 2006) it was noted 
that perindopril treatment in diastolic HF was not as effective as when used for treating 
systolic HF.
2.1.6: Diagnosis, signs and symptoms -  Heart failure.
The aforementioned pathophysiology of HF goes some way to explain the common 
clinical features and complications of this condition. Patients can present with a variety 
of symptoms which can often be non-specific. The main signs and symptoms of HF are 
listed in the table 3 below.
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Table 3. Symptoms and Signs in Heart Failure.
Symptoms:
Dyspnoea.
Orthopnoea.
Paroxysmal Nocturnal Dyspnoea.
Reduced Exercise Tolerance, lethargy, fatigue. 
Nocturnal cough.
Wheeze.
Ankle swelling.
Anorexia.
Signs:
Cachexia and muscle wasting.
Tachycardia.
Pulsus altemans.
Elevated jugular venous pressure.
Displaced apex beat.
Right ventricular heave.
Crepitations or wheeze.
Third heart sound.
Oedema.
Hepatomegaly (tender).
Ascites.
It should be noted that there are many non-cardiac conditions that can mimic the 
symptoms of HF so diagnosis by these alone is often difficult. Additionally, physical
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examination has serious limitations as many patients particularly with less severe HF 
have very few abnormalities. The following table (4) highlights the sensitivity, 
specificity and predictive value of symptoms, signs and chest x-ray findings for the 
presence of HF.
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Table 4. Sensitivity, specificity and predictive value of symptoms, signs and chest 
x-ray findings for presence of HF (EF <40%) in 1306 patients with CAD 
undergoing cardiac catheterisation (adapted from Watson et al, 2000).
Clinical Features. Sensitivity % Specificity % Positive Predictive
Value %
History:
Shortness of Breath. 66 52 23
Orthopnoea. 21 81 2
Paroxysmal 33 76 26
Nocturnal
Dyspnoea.
History of Oedema. 23 80 22
Examination:
Tachycardia. 7 99 6
Crepitations. 13 91 27
Oedema on 10 93 3
examination.
Gallop (S3). 31 95 61
Neck vein 10 97 2
distension.
Chest X-Ray
Examination:
Cardiomegaly. 62 67 32
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The European Society of Cardiology (Task Force on Heart Failure of the European 
Society of Cardiology, 1995) has developed standardised guidelines for the diagnosis of 
HF. Essentially, patients must have documented symptoms of HF e.g. breathlessness, 
fatigue and / or ankle swelling together with objective evidence of resting cardiac 
dysfunction. Alternatively, if a patient responds well to treatment targeted towards HF 
when the diagnosis is in doubt, then this is also a non-essential diagnostic indicator.
Symptoms and exercise capacity together are used to classify the severity of HF and to 
also gauge the effectiveness of treatment. The most common worldwide classification 
system currently used to achieve these aims in clinical practise is the NYHA. This can 
be summarised as follows (table 5):
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Table 5. NYHA Classification for Heart Failure. From the American Heart 
Association.
NYHA Class.
Class I: Asymptomatic.
No limitation to physical activity despite presence of heart disease confirmed by 
investigations, (e.g. echocardiography).
Class II: Mild.
Slight limitation in physical activity. More strenuous exercise causes shortness of 
breath. Most patients continue to have a normal lifestyle and employment.
Class III: Moderate.
More marked limitation of activity interfering with work and daily life. Shortness of 
breath when walking on the flat.
Class IV: Severe.
Unable to carry out activity without symptoms. Breathless at rest and usually 
housebound.
2.1.7: Diagnostic considerations for diastolic HF.
The following flowchart has been suggested for the accurate diagnosis of diastolic HF.
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Figure 1. Flow chart for the suggested diagnosis of diastolic HF. (Adapted from 
Paulus et al, 2007).
| Hew to diagnose HFNEF |
Sym ptom s or signs o f heart failure
i
Normal or mildly reduced left ventricular systolic function
LVEF > 50%
and
LVEDVI < 97 mL/m2
I
Evidence of abnorm al LV relaxation, filling, diastolic 
distensibiiity, and diastolic stiffness
Invasive H aem odynam ic m easurem ents 
m PCW  > 12 mmHg £ /E > 1 5
BNP > 2 0 0  pg/mL
r > 4 8 m s
b > 0 .2 7 Biomarkers 
NT-proBNP > 220 pg/mL
Echo -b loodflow  Doppler 
£/A>c,  < 0 .5  and DT>V,. > 280  m s E/E ' >
Ard-Ad > 30 m s
LVMI > 122 g/m2 (9); >149 g/m2 ftf)
Atrial fibrillation
1
HFNEF
There are three important criteria which all must be fulfilled in order to establish a 
diagnosis of heart failure with a normal ejection fraction. These are the presence of 
signs and symptoms of congestive heart failure, the presence of normal or mildly 
abnormal LV systolic function and finally, evidence of diastolic LV dysfunction.
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In more detail, task force guidelines for the diagnosis and management of heart failure 
(Swedberg et al, 2005) have suggested that the primary symptoms associated with 
diastolic HF include lung crepitations, pulmonary oedema, ankle swelling, 
hepatomegaly, exertional dyspnoea and fatigue. Patients with diastolic HF often present 
with dyspnoea as the earliest symptom due to pulmonary congestion (Swedberg et al, 
2005). In systolic HF, exercise intolerance is perhaps more applicable at the early stages 
due to reduced cardiac output, peripheral vasoconstriction and abnormalities at the level 
of skeletal muscle.
Consensus documentation suggests that an LV EF greater than 50% is considered to be 
a normal or mildly abnormal value for systolic function when measured using standard 
recommended techniques (Paulus et al, 2007). In conjunction with this however, for 
accurate assessment combined volumetric data of the LV should be obtained and 
indexed for body size (Paulus et al, 2007).
Objective evidence of diastolic dysfunction can be achieved using a number of 
parameters, some invasive (e.g. cardiac catheterisation) and others non-invasive 
(echocardiography and cardiac magnetic resonance imaging). Basic measurements of 
LV wall mass index may provide sufficient data to diagnose diastolic HF when tissue 
Doppler imaging (TDI) assessment is inconclusive or when plasma natriuretic levels are 
raised (Lang et al, 2006). Furthermore, blood flow Doppler parameters may be utilised 
during relaxation or diastole to provide further evidence of toward HF with a normal 
ejection fraction. Although blood flow parameters of diastolic dysfunction have 
received criticism, there is some evidence of the strength of these measurements. 
Combined use of mitral valve blood flow Doppler and pulmonary vein Doppler has 
resulted in 93% of patients with suspected HF with a normal ejection fraction showing
evidence of diastolic abnormalities (Badano et al, 2004). The more modem use of TDI 
has added further power to the assessment of diastolic parameters. Studies have 
suggested that E/e’ greater than 15 correlates well with raised filling pressures and that 
values less than 8 suggest low filling pressure (Ommen et al, 2000). The close 
correlation of E/e’ and filling pressure has also been proved in systolic HF with reduced 
EF below 50% (Nagueh et al, 1997). The gray zone E/e’ of 8-15 values are suggested as 
inconclusive and must be supported by the use of other measurements to confirm or 
refute diastolic abnormalities. Left atrial volume measures, indexed to body surface 
area, are also pivotal to the assessment of diastole. Recent evidence shows that a raised 
left atrial volume index greater than 26 mL/m2 can be utilised as a load independent 
predictor of LV filling pressures in patients with suspected HF with normal ejection 
fraction (Lim et al, 2006).
Assessment of natriuretic peptides, produced by atrial and ventricular myocardium has 
been shown to be valuable in the assessment of HF with normal ejection fraction. 
However, the sensitivity for this assessment is below 80% due to significant overlap 
between normal values and values obtained for patients with HF with normal ejection 
fraction. As such, current recommendations suggest the use of natriuretic peptides to 
exclude and not diagnose HF with normal ejection fraction, particularly when the 
patient presents with exertional dyspnoea. Natriuretic peptide measures must be 
combined with other investigations in order to gain ‘stand-alone’ evidence of diastolic 
abnormalities (Paulus et al, 2007).
2.1.8: Current treatment strategies for HF. 
2.1.8.1: Ischaemic heart disease and viability.
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This review has already established that in Westernised society, the most common cause 
of HF is ischaemic heart disease (IHD). An important facet of HF with coronary artery 
disease is the ability to predict the benefit of revascularisation in patients with ischaemic 
HF, a concept that is currently a challenge to Cardiology physicians and cardiac 
surgeons.
Current research evidence strongly supports the notion that LV function post 
myocardial infarction (MI) is an important predictor of prognosis (Buckley and Di 
Carli, 2011). It is important clinically to be able to differentiate between infarcted, 
necrosed, scarred myocardium and ischaemic myocardium that is dysfunctional but 
would improve following sufficient restoration of blood supply. Indeed, patients with 
dysfunctional but viable myocardium show substantial prognostic improvements with 
demonstrable attenuation of LV dysfunction following revascularisation techniques (Di 
Carli and Hachamovich, 2007).
There is a widely held notion that acute myocardial ischaemia rapidly results in LV 
contractile dysfunction that can persist for several hours after transient non-lethal 
ischaemia and eventually followed by restoration of myocardial contractility 
(Heyndrickx et al, 1975). Patients with coronary artery disease often demonstrate 
repeated episodes of demand ischaemia accompanied with episodes of myocardial 
dysfunction, cumulatively resulting in myocardial stunning and post-ischaemic LV 
dysfunction (Barnes et al, 2002). Historically, myocardial hibernation had been 
observed clinically in many patients. A cohort of patients with significantly impaired 
LV function who received coronary artery bypass surgery (CABG) surgery were noted 
to demonstrate improvements in contractility following revascularisation strategies. The 
underlying pathophysiology has been suggested to relate to severely reduced coronary
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flow reserve and recovery of myocardial function in hibernating regions post 
revascularisation relates to restoration of adequate coronary flow reserve (Pagano et al,
2001). As a result of underlying pathophysiological mechanisms, clinically patients 
with similar reductions in LV systolic function may have significant differences in the 
extent of viable myocardium with even extreme wall thinned regions sometimes 
benefiting from revascularisation (Camici et al, 2008). The identification of viable 
myocardium becomes critically important prognostically when LV EF is reduced below 
40% whereby 6 month mortality levels increase dramatically and decline steeply as EF 
decreases further (Multicentre post infarction research group, 1983).
Research has suggested that functional improvement post revascularisation relates to the 
amount of dysfunctional myocardium that proves to be viable (Carluccio et al, 2006). 
The study by Carluccio and colleagues demonstrated that patients with 6 or more 
dysfunctional LV regions which demonstrate viability show the greatest improvement 
in overall ejection fraction. Naturally, no improvement in ejection fraction is noted 
when there are no viable LV segments. Furthermore, significant prognostic benefit 
following revascularisation strategies have been shown in patients with severe 
ischaemic cardiomyopathy who demonstrate >20% of LV region viability when 
compared to patients with no viable myocardium (Afridi et al, 1998). Another study 
provides consistent results with the detection of myocardial viability being associated 
with a 79% decrease in cardiac mortality post revascularisation techniques compared to 
patients conservatively treated with medical therapy (Sicari et al, 2003). A 
comprehensive meta-analyses performed by Allman et al, 2002 evaluated the prognostic 
value of viability testing in 24 non-randomised studies between 1992 and 1999. This 
study reinforced the significant association between revascularisation and improved
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survival rate in patients with LV dysfunction and evidence of myocardial viability 
independent of the imaging technique used for assessment.
The increased cardiovascular risk of diabetes mellitus further increases the challenge to 
Cardiology physicians when assessing for viability with regard to prognosis in this 
cohort. This is apparent in the research by Carson et al, 2002 which demonstrated 
significantly increased mortality rates for diabetic patients post revascularisation. 
Taking this into account however, there is research evidence to suggest that diabetic 
patients with viable myocardium have similar outcome to non-diabetic patients 
following revascularisation. Improvement in LV ejection fraction and attenuation of 
unfavourable LV remodelling was found to be similar in both diabetic and non-diabetic 
patients following revascularisation, together with overall prognostic outcome (Rizello 
et al, 2006). Furthermore, a study by Cortigiani and colleagues in 2007 showed that 
diabetic and non-diabetic patients with severe ischaemic cardiomyopathy had similar 
prognostic outcome following viability assessment and revascularisation with a 22% 
and 24% 4 year survival rate. Interestingly, in this study diabetes was found to be an 
independent predictor of mortality in patients treated conservatively with medical 
therapy.
Owing to the research evidence presented, both the European Society of 
Echocardiography and the European Association of Cardiothoracic Surgery endorsed 
the use of viability evaluation prior to revascularisation to assist in the management of 
patients with ischaemic heart failure.
The STICH trial viability sub-study, published in 2011 (Velazquez et al, 2011 and 
Bonow et al, 2011), demonstrated the opposite, confirming no impact of viability on
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outcome of patients undergoing revascularisation when compared to medical therapy 
alone. Recent commentaries have however, suggested caution when interpreting the 
results of STICH (Cortigiani et al, 2012 and Perrone-Filardi and Pinto, 2012).
The main STICH investigation showed no significant all-cause mortality differences 
between patients with severe ischaemic LV impairment (EF% < 35%) undergoing 
CABG when compared to optimal medical therapy. Additionally, in the CABG group 
the secondary end-point of cardiovascular death was reduced by 19% with borderline 
significance. Composite endpoints of cardiac death and cardiovascular related hospital 
admission were significantly reduced by 26%. The authors concluded that the results do 
not definitively deny the advantage of CABG in LV dysfunction but rather provide 
provisional evidence favouring revascularisation in ischaemic heart failure.
The viability sub-study results were reported by Bonow and colleagues in the same 
journal (2011). This sub-study assessed the influence of viability on clinical outcome in 
patients assigned to medical therapy or revascularisation with CABG. The results, 
available only on half the initial STICH population, showed that survival of patients 
with viability was significantly longer than those patients without viability but 
following CABG these patients did not show any survival benefit when compared to 
medical therapy alone.
Invited perspectives and study commentaries (Cortigiani et al, 2012 and Perrone-Filardi 
and Pinto, 2012) have dissected the results of STICH and the viability sub-study. The 
research analysis of STICH by Bonow et al, 2011 clearly questions the guidelines and 
use of viability for assessment of suitability for revascularisation. Leading authority 
suggests such research findings are a setback, but when put in perspective the results
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should not be seen as the final answer. Perrone-Filardi and Pinto, 2012 highlighted 
important limitations to the data collected in STICH. The limitations included a reduced 
final population use for data analysis (half of the main trial) with comparisons of 4 
numerically unbalanced, sub-groups of patients with or without viability undergoing 
treatment with CABG or medical therapy -  raising concerns over the statistical 
adequacy of the method to identify differences between subgroups. The definition of 
viability using single photon emission computed tomography (SPECT) was not 
validated in clinical trials and the power of SPECT to distinguish regional myocardial 
recovery was considered low. Dobutamine stress echocardiography (DSE) was used 
interchangeably with SPECT for viability assessment but there are well documented 
differences in accuracy for predicting myocardial recovery post revascularisation 
between the two techniques (Camici et al, 2008). In addition, Perrone-Filardi and Pinto 
suggest that both revascularisation and medical therapy can influence LV remodelling 
thus making the impact of viability on prognosis comparing CABG with medical 
therapy unclear; a factor which may be an explanation for the association between 
viability and increased survival during the study. A significant association between 
viability and the composite endpoints was apparent following adjustment for baseline 
differences, suggesting that revascularisation and optimal medical therapy may provide 
similar benefits to patients with viable myocardium. Commentaries conclude that 
although the STICH results represent a wake-up call for Cardiology, it should not close 
the door on myocardial viability assessment pre revascularisation but highlights the 
importance of new clinical trials and new diagnostic investigations (e.g. cardiac 
magnetic resonance imaging (MRI) or positive emission tomography (PET)) to develop 
improved and more refined criteria.
2.1.8.2: Pharmacological.
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Until the late 1980’s, the mainstay of treatment for HF relied on symptom relief of fluid 
congestion by the use of diuretics with or without digoxin. Since this time, newer 
medical therapies have been developed which impact on haemodynamics, neuro- 
endocrinology and inflammation. Several classes of these newer medications, unlike the 
earlier treatments regimes, have favourable impact on morbidity and mortality (National 
Clinic Guideline Centre, 2010). The morbidity and mortality rates in HF with evidence 
of impaired LV systolic function have declined through the cumulative effects of agents 
such as angiotensin converting enzyme (ACE) inhibitors, p blockers, aldosterone 
antagonists, arterial and venous dilators and angiotensin receptor blockers. This section 
of the review will briefly summarise the main breakthrough clinical trials that highlight 
the effective use of these classes of medications.
2.1.8.2.1: Angiotensin Converting Enzyme Inhibitors (ACE Inhibitor).
Completed systematic reviews of the use of ACE inhibitor therapy have demonstrated 
significant increase in life expectancy when compared to placebo in patients with HF. In 
addition, the observed increase appears more significant in patients with increasing 
severity of LV impairment and more severe symptoms. It should be noted however, that 
all NYHA classes show improvement in life expectancy following ACE inhibition 
(Flather et al, 2000). As a result of these improvements, ACE inhibition has also been 
demonstrated to reduce hospitalisation. The Acute Infarction Ramipril Efficacy Study 
(AIRE Study) with mean follow-up of 15 months after randomisation, demonstrated all­
cause mortality reductions from 22.6% (placebo group) to 16.9% (treatment group). 
This represented an absolute mortality reduction of 5.7% and a relative risk reduction of 
27% (p=0.002) (The AIRE Study Investigators, 1993). Further research, The Acute 
Infarction Ramipril Efficacy Extension Study, followed the same study population for 
an extra 3 years. During this study, death from all causes had occurred in 117 (38.9%)
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of 301 patients randomly assigned placebo and 83 (27.5%) of 302 patients randomly 
assigned to ramipril. This demonstrated a relative risk reduction of 36% (p=0.002) and 
an absolute reduction in mortality of 11.4%. These figures correspond to 114 additional 
patients surviving for 5 years per 1000 patients treated for an average of 12.4 months 
(Hall et al, 1997). Further randomised controlled trials have shown that ACE inhibition 
can significantly improve quality of life in patients with HF (Beller et al, 1995). The 
effect of ACE inhibition on exercise performance has provided contrasting results. 
However, systematic reviews have demonstrated greater improvements in exercise 
performance in patients with more severe HF (Beller et al, 1995). As a result of these 
breakthrough clinical trials, National Institute for Clinical Excellence (NICE) Guidance 
for chronic heart failure (CHF) (2003) has concluded that treatment of HF with ACE 
inhibitors is cost effective. This is largely due to the costs saved from reduced re­
hospitalisation.
2.1.8.2.2: Diuretics.
Although newer pharmacological therapies have evolved in the treatment of HF, 
diuretics remain an important contributor to patient treatment. As a consequence of their 
prolonged historical use in HF, there are currently no large scale randomised trials 
investigating their usage. However, there is a comprehensive systematic review of 
diuretic use in HF (Faris et al, 2002). This review showed that mortality rate was lower 
for patients treated with diuretics than for control (odds ratio for death, 0.25; 95% 
confidence intervals 0.07-0.84, p = 0.03). Furthermore, admission to hospital for 
worsening HF in four small trials (total patient number of 448) showed an odds ratio of 
0.31 (95% Cl 0.15 - 0.62, p = 0.001). In six small studies comparing diuretics to active 
control, diuretics significantly improved exercise capacity in patients with HF (odds 
ratio 0.37, Cl 0.10-0.64, p = 0.007). The improvement in symptoms and exercise
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capacity with diuretic use is as a result of improved fluid control and this can be 
achieved by using loop or potassium sparing diuretics or even a combination of both 
(NICE Guidance for HF, 2003). No formal economic evaluation of diuretics has been 
undertaken for their use in HF.
2.1.8.2.3: p-blockers.
Clinical trial data are prevalent investigating the effects of p-blockers in HF. A 
systematic review of 22 randomised controlled trials showed a favourable impact on 
mortality and hospital re-admission in HF patients receiving p-blocker therapy (Shibata 
et al, 2001). This review showed that death rates in patients randomised to receive P- 
blockers compared to controls were lower (458/5657 - 8.0% and 635/4951 - 12.8% 
respectively with odds ratio 0.63, 95% confidence interval of 0.55-0.72, p<0.00001). 
Similar reductions were observed for hospital admissions for worsening HF in the p- 
blocker group (11.3 and 17.1%, respectively, odds ratio 0.63) and for the composite 
outcome of death or HF hospital admission (19.4 and 26.9%, respectively, odds ratio 
0.66). The results of this systematic review show that p-blockers reduce the risk of 
mortality or the need for HF hospital re-admission by approximately 33%. More 
recently, clinical trials have been published which investigate the effects of selective 
and non-selective P-blockers in the treatment of HF and also the use of these agents in 
elderly patients. In older patients with HF, p-blockers have shown beneficial effects on 
all cause mortality (Deedwania et al, 2004), sudden cardiac death (Flather et al, 2005), 
re-hospitalisation (Deedwania et al, 2004 and Flather et al, 2005) and also quality of life 
as assessed by the Minnesota Living with Heart Failure questionnaire (MLHFQ) (Edes 
et al, 2005). Research comparing selective versus non-selective p-blockade has also 
been undertaken. This research has suggested that selective p-blockers are associated 
with significant increases in all cause mortality (39.5% versus 33.9% for non-selective,
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relative risk of 1.17, confidence interval 1.06 -  1.28) and also sudden cardiac death 
(17.3% versus 14.4%, relative risk 1.2, confidence interval 1.01 -  1.41) (Poole-Wilson, 
2003). Studies investigating quality of life with the Minnesota Heart Failure 
questionnaire (Sanderson et al, 1999) and adverse events (Poole Wilson, 2003) have 
shown no significant differences between selective and non-selective P-blockade.
2.1.8.3: Invasive procedures.
Pharmacological therapy is considered the mainstay of therapy for patients with HF. 
However, modem technological advances have led to the development of diagnostic and 
interventional invasive procedures which may provide benefit for sub-groups of patients 
with HF. A detailed review of these procedures and devices is beyond the scope of this 
review. However, there follows a short description of the major advances in this area.
2.1.8.3.1: Cardiac resynchronisation therapy.
Cardiac resynchronisation therapy (CRT) is a relatively new advance in the treatment of 
symptomatic HF following optimal medical therapy. Research has shown that CRT 
results in reduced morbidity and mortality in HF patients who demonstrate significant 
intra or inter-ventricular dysynchrony (NICE Technology appraisal guidance 120,
2007).
2.1.8.3.2: Implantable Cardioverter Defibrillators.
Implantable cardioverter defibrillators (ICDs) can be utilised in HF patients who are 
prone to significant ventricular cardiac arrhythmias, either proven through ambulatory 
electrocardiograph monitoring or due to severely impaired LV performance. ICDs are
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commonly combined with a CRT device. However, may also be used in isolation in 
selected cases (NICE Technology appraisal guidance 95, 2006).
2.1.8.8.3: Left Ventricular Assist Devices (LVADs).
Left ventricular assist devices (LVADs) are mechanical support systems for patients 
with end-stage HF. LVADs have been shown to improve patient survival, quality of life 
and functional capacity (Rose et al, 2001 and Slaughter et al, 2009). Currently in the 
UK, LVADs are approved as a bridge to transplantation (Clegg et al, 2005, Farrar et al, 
1994). These devices have also been investigated as a bridge to decision (regarding 
suitability for transplantation) and destination therapy (Rose et al, 2001).
2.1.8.3.4: Cardiac Transplantation.
Ultimately, cardiac transplantation is the only long-term survival option for patients 
who demonstrate severe refractory symptoms of HF despite optimal medical and 
invasive mechanical therapy. Additionally, patients who develop refractory cardiogenic 
shock are also candidates for cardiac transplantation dependent on lifestyle and other 
co-morbidities. Details of transplant guidelines and techniques are however, beyond the 
scope of this review.
2.1.8.4: Rehabilitation.
Exercise rehabilitation has become commonplace in HF. A comprehensive and detailed 
review of exercise rehabilitation in HF is provided in section 2 of this thesis.
2.1.8.5: Importance of research into new modalities in heart failure.
There is a widely held notion within the medical community that despite technological 
advances in treatment of patients with HF, there is still high risk for hospitalisation and
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death (O’Connor et al, 2012). The increased risk has been attributed to numerous factors 
which include ageing, disease progression, increase frequency of hospitalisation and 
high event rates following episodes of decompensated HF with up to 30% of patients 
experiencing adverse cardiovascular (CV) events or death following HF related hospital 
admission (O’Connor et al, 2005). There is no doubt that modem therapies have slowed 
the descent towards premature mortality with some increasing the survival trend. 
However, decline is inevitable and individual patients display marked variability in their 
prognosis and responses to treatment (Aaronson and Cowger, 2012). Untreated HF has 
been found to have approximately 50% survival at 12 months (Ho et al, 1993). In 
addition, the overall prognosis for patients with HF receiving treatment is 
approximately 50% at 5 years, a value that has varied little in the past 20 years (Levy et 
al, 2002).
Clinical trial data in HF can be misleading. Although trials do show initial improvement 
in symptoms, therapies do not stop but rather prolong cardiovascular related mortality. 
Evidence of this is available from data from numerous clinical trials. Longitudinal data 
from the V-Heft 2 study of 403 patients with HF being treated with ACE inhibition 
(Enalapril) showed that 132 of the study population had died following 2.5 years of 
drug administration. Of these deaths, 107 (81%) where found to be due to complications 
relating to congestive HF and there was physiological evidence of clinically relevant 
decline due to the reduced V0 2 max values achieved in the treatment group at follow-up 
visits (Cohn et al, 1991). Another trial involving the use of ACE inhibition compared 
treatment with placebo in a population of patients with asymptomatic LV systolic 
impairment (Cohn et al, 1991). During this trial (SOLVD prevention study), 30% of the 
initially asymptomatic patients had developed symptoms of HF at 3 year follow-up. In 
addition, at this time-point, there were 313 deaths of which approximately 60% were
related to HF. The CONSENSUS trial (CONSENSUS trial study group, 1987) clearly 
showed that HF is associated with poor prognosis. Ten year follow-up data of this study 
was produced by Swedberg et al 1998. The initial study as reported earlier in this 
review, showed relative mortality reduction of 40% at 6 months and also 20% at 12 
months. Ten year data show average survival of 781 days for the treatment group when 
compared to 521 days for the placebo group. 5 survivors only remained in the treatment 
group after 10 years and there was convergence of treatment and placebo curves on 
Kaplan-Meier plots.
Malkin and Channer (2005) reviewed many of the major trials investigating medical 
therapy in HF and using Kaplan-Meier plots calculated extension to survival, morbidity 
extension and whether the Kaplan-Meier curve was divergent, divergent-convergent or 
divergent parallel. Survival extension was calculated using previous work by Torp- 
Pederson et al (1999) by passing a line through the y axis and curves at the point of the 
50th centile patient. The time difference between treatment and placebo curves on the x 
axis demonstrates this difference in median lifetimes (Malkin and Channer, 2005). 
Table 6 demonstrates the life and morbidity extension values together with Kaplan- 
Meier curve shape for the major clinical trials for HF medical therapy.
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Table 6. Life extension and morbidity extension values together with Kaplan-Meier curve shape in the major clinical trials for HF
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Table 6 re-affirms the notion that despite recent medical pharmacological therapy, 
prognosis in HF remains poor. According to Malkin and Channer, 2007, current 
treatments provide an average extension to life expectancy of around 20 months. In 
more detail, the authors state that ACE inhibition prolongs life for around 9 months, 
addition of B-blocker adds approximately a further 7 months and finally adding 
spironolactone may confer 12 months more survival.
Of course, medical pharmacological therapy is not the only technological advance 
available to HF patients in order to attempt to increase life expectancy. More invasive 
procedures involving CRT devices + or -  ICD, ventricular reconstructive surgery, 
LVAD implantation and cardiac transplantation are also other options for advanced 
severe HF patients already established on optimal medical therapy.
The CARE-HF trial (Cleland et al, 2005) randomised patients with class III and IV HF, 
LV dysfunction and evidence of ventricular dysynchrony to either CRT with medical 
therapy or medical therapy alone. 404 patients were assigned to receive medical therapy 
with 409 patients randomised to CRT with medical therapy. These patients were 
followed up for a mean of 29 months (range 18-44 months). The composite primary 
end-point was death or unplanned hospital admission with a severe cardiovascular 
event. 159 patients reached this end-point in the CRT with medical therapy group and 
224 patients reaching this in the medical therapy group. In addition, there were 222 
unplanned cardiovascular related hospital admissions in the CRT plus medical therapy 
group when compared to 384 in the medical therapy alone group. CARE-HF clearly 
indicates that CRT plus medical therapy is able to reduce hospitalisation and death over 
the course of the follow-up period. However, there is still a substantial number of
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participants in the CRT plus medical therapy group reaching composite study end­
points.
It is a widely accepted notion that only around 60-70% of patients receiving CRT 
devices together with medical therapy respond with clinical improvement probably 
resulting from lack of physiological and clinical indicators for device suitability 
(Hawkins et al, 2006). Current guidance suggests that CRT device implantation is 
warranted with electrocardiographic evidence of cardiac dysynchrony. However, some 
patients do not have co-existent mechanical dysynchrony and as such, may not benefit 
from device implantation (Vardas et al, 2007). As studies involving CRT therapy 
recruited patients with broad > 120ms QRS complex, there is no available data for 
patients with NYHA class III and IV HF with normal or slightly prolonged QRS 
duration. In addition to this data, CRT therapy is invasive and can result in potentially 
serious complication. For instance, during the CARE-HF trial procedure related 
complications included 24 patients with lead displacement, 10 patients with coronary 
sinus dissection, 8 patients with pacemaker pocket erosion, 6 patients with 
pneumothorax and 3 patients with pacemaker related infection.
Currently the only validated treatments for end-stage HF are mechanical circulatory 
support using LVAD’s or heart transplantation. The major limitation for heart 
transplantation is availability of suitable organs resulting in long waiting times. At least 
10% of patients actively waiting on the transplant list die each year before a suitable 
donor organ is discovered (Lund et al, 1010). Transplantation itself is associated with 
90% survival at 1 year and 60% survival at 10 years with evidence of absence of 
symptoms in survivors during follow-up (Taylor et al, 2007). Unfortunately, 
transplantation may not be suitable due to a multitude of risk factors, contraindications
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and co-morbidities. Factors which may dramatically increase the risk of transplantation 
include; cardio-renal syndrome namely that impaired renal function is an independent 
predictor of mortality post transplantation (Ganesh et al, 2004). Hyponatraemia carries a 
poor prognosis across all HF severities (Gheorgiade et al, 2007). Abnormal liver 
function defined by elevated bilirubin is a predictor of mortality in chronic HF and also 
post transplantation (Allen et al, 2009). Pulmonary hypertension is associated with 
dramatically increased risk of right heart failure post transplant (Taylor et al, 2009) and, 
if irreversible, is a major contraindication to transplant. Co-morbidities that increase 
risk, may contraindicate transplant or impact on survival post transplant include age 
(Taylor et al, 2009), diabetes (Mehra et al, 2006), symptomatic peripheral or 
cerebrovascular disease (Bravata et al, 2003), sepsis / active infection, recent pulmonary 
embolism, active malignancy, auto-immune disorders, substance abuse including 
tobacco, psychological factors associated with adherence to treatment (Banner et al, 
2011). Patients who are deemed suitable physiologically for transplant must be 
psychologically able to commit to a lifelong programme of monitoring and drug 
treatment.
Recent advances in mechanical circulatory support are providing alternatives for 
patients waiting for heart transplant (as a bridge to transplantation) and also for patients 
in who transplant is contraindicated (destination therapy). In addition, LVAD therapy 
may be suitable for patients in whom ventricular function is predicted to improve 
(bridge to recovery) (Lund et al, 2010). Outcome related to LVAD implantation is 
dependent upon the type of device implanted, surgical experience, device and patient 
characteristics (Lund et al, 2010). If patients are selected well against recognised 
criteria, operative mortality is approximately 5-10% (Miller et al, 2007). Other research 
has displayed improved survival to transplant from 33-70% due to improvements in
device function and increased knowledge regarding implantation and contraindications 
(Frazier et al, 2001). 1 year survival following implant is between 50 and 80% (Miller et 
al, 2007). Again, in comparison to transplantation, there are numerous contraindications 
related to LVAD implant. These include acute cardiogenic shock, non-systolic HF, co­
existing illness with reduced life expectancy, severe co-morbidity (e.g. renal disease, 
cancer, severe liver disease, severe COPD), systemic infection or infection risk, active 
bleeding, reduced platelet count, right HF not secondary to left HF, severe right 
ventricular (RV) impairment, multi-organ failure, moderate or worse aortic 
insufficiency, mechanical aortic valve replacement (AVR), LV thrombus, hypertrophic 
cardiomyopathy, ventricular septal defect (VSD), congenital heart disease, intolerant to 
anti-coagulation, obesity, psychosocial limitations to adherence to device (Lund et al, 
2010). Device failure in more modem devices is relatively rare due to a smaller number 
of moving parts. However, there are still minor risks for mechanical failure of parts, 
thrombus formation or battery failure -  all of which could be catastrophic.
This section of the review clearly identifies technologically advanced medical 
pharmacological, mechanical and surgical therapy for HF treatment. However, these are 
not without their limitation and / or significant risk and side-effects. As a result, it is of 
paramount importance that further therapeutic targets are actively researched to reduce 
symptoms and increase life expectancy in HF.
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Testosterone deficiency.
2.3: Testosterone.
2.3.1: Biochemistry and biosynthetic pathways.
In human males, testosterone is the major circulating androgen. The testes secrete 
approximately 6-7 mg of testosterone per day and this equates to 95% of total 
production of testosterone by the body (Coffey, 1988). The metabolic processes for 
conversion of cholesterol into androgens is facilitated within up to 500 million Leydig 
cells comprising a small proportion of total testicular overall volume (Rommerts, 2005). 
In addition to Leydig cell production testosterone can be produced within the adrenal 
cortex and also, in miniscule amounts, by brain cells (Baulieu, 1997).
Cholesterol may be synthesized de novo from acetate but it also may be synthesized 
from plasma lipoproteins and according to Freeman and Rommerts, 1996, for human 
Leydig cells the low density lipoprotein (LDL) fraction is the predominant extracellular 
store of cholesterol. For Leydig cells, cholesterol situated within the plasma membranes 
is the most widely available pool and is transported into the mitochondria by a vesicle- 
mediated endosomal / lysosomal network system (Rommerts, 2005). In addition, van 
Noort et al, 1988) have suggested that cholesterol transport within the mitochondria 
may be facilitated by a sterol carrier protein in conjunction with the cytoskeleton and 
vesicular system. Although the exact mechanisms for cholesterol cell transport are 
uncertain, the process results in the availability of cholesterol (C27) within the 
mitochondria to initiate the production of pregnenolone (C21). This cleavage of the side 
chain of cholesterol and the resultant development of pregnenolone within the 
mitochondria, probably under the influence of luteinising hormone, marks the initiation 
of the steroidogenic cascade (Rommerts, 2005). In normal conditions, human 
pregnenolone converting enzyme systems are insufficient for the total conversion of
pregnenolone to testosterone. Therefore, intermediates of progesterone derivatives leak 
from Leydig cells. As a result of this, the rate-limiting step for testosterone production 
is at the endoplasmic reticulum, but the rate determining step for steroidogenesis sits 
within the mitochondria governed by cholesterol side chain cleavage activity 
(Rommerts, 2005, van Haren et al, 1989).
Cholesterol side chain cleavage enzyme (P450scc) is located within the inner-membrane 
of the mitochondria and as mentioned earlier in this section, governs the initiation of the 
steroidogensis cascade (Rommerts et al, 2005). Important factors regulating the 
generation of pregnenolone from cholesterol include cholesterol availability at the inner 
mitochondrial membrane, amount and/or availability of oxygen, P450scc enzyme activity 
and the delivery of reducing equivalents to the P450scc (Rommerts et al, 2005). Simply, 
the generation of steroids from cholesterol is mainly dependent on the supply of the 
substrate to the enzyme P450scc and the amount of this enzyme situated within the 
mitochondria. It has been previously noted that P450scc concentration is regulated by 
luteinising hormone and short-term regulation of the rate of steroidogenesis is facilitated 
by the intra-cellular transfer of cholesterol from the outer to inner (cholesterol deficient) 
mitochondrial membrane. This intra-cellular cholesterol trafficking has been shown to 
be dependent on a labile steroidogensis activator protein (StAR) -not only in Leydig 
cells but also adrenal and ovarian cells (Stocco, 2001).
As stated earlier in this review, pregnenolone is the initial product of the cholesterol 
side chain process. Pregnenolone is biologically inactive and further metabolised by 
enzymes present in the endoplasmic reticulum (Rommerts, 2005). The conversion of 
C21-pregnenolone to C19 steroids via the enzymes 17-hydroxylase and Cn, 20-lyase has 
been shown to occur in a single protein, P450ci7, coded by the gene CYP17. However,
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there is different expression of enzyme activities in the testes and adrenal glands, which 
is dependent upon the micro-environment of the enzyme in the endoplasmic reticulum 
(Zuber et al, 1986). Due to a high number of steroid-converting enzymes there are a 
number of different pathways to convert pregnenolone to testosterone. However, in the 
testes, most steroids are formed via the A5-pathway with dehydroepiandosterone as the 
initial C19 intermediate (Rommerts et al, 2005). The final step of the biosynthetic 
pathway of testosterone is the reduction of the 17-keto-group by the 17p-hydroxysteroid 
dehydrogenase (17PHSD), represented by a number of different isoforms present in 
many tissues (Andersson and Moghrabi, 1997). 17pHSD type 2 enzyme also possesses 
20aHSD activity and in the testes this type 3 isoform is present mostly in Leydig cells 
(Rommerts, 2005). As such, deficiency in testicular activity of 17PHSD is accountable 
for the majority of testosterone deficiencies in human models (Geissler et al, 1994).
Normal testicular function is maintained by luteinising hormone and follicle stimulating 
hormone. In addition, Leydig cell function is primarily controlled by luteinising 
hormone (Rommerts, 2005). Chemes et al, 1996 suggest that although hormones 
regulate steroid production by controlling metabolic activities in existing cells, they are 
also integral to the control of the size of the Leydig cell population. In the foetus, there 
is a steep increase in Leydig cell population and activity. Furthermore, during the early 
neonate period, gonadotropins stimulate the development and activity of foetal Leydig 
cells resulting in similar peripheral and testicular levels of testosterone. During the rest 
of the first year of life, foetal Leydig cells degenerate, remaining dormant until puberty. 
During puberty, rising levels of plasma luteinising hormone stimulate further Leydig 
cell proliferation and differentiation resulting in adult levels of Leydig cells (Chemes, 
1996).
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Human choriogonadotropin (hCG) and luteinising hormone are both able to stimulate 
the luteinising hormone receptor (luteinising hormone being the natural ligand for 
luteinising hormone receptor). However, the binding properties of these ligands are 
significantly different. Wang et al, 2000 have shown that activated luteinising hormone 
receptors stimulate adenylyl cyclase via GTP binding proteins, resulting in the 
production of cyclic AMP (cAMP). cAMP has been shown to increase steroid 
production. However, low concentrations of luteinising hormone stimulate 
steroidogenesis without traceable increase in cAMP concentration possibly suggesting 
that cAMP is only a second messenger of the action of luteinising hormone (Rommerts, 
2005). In addition to this, phospholipids, specific phospholipases, products of 
phospholipid metabolism, calcium ions and calmodulin are vitally important for 
steroidogenic activity and signal transduction (Wang et al, 2000). Research into human 
models of signal transduction pathways is limited. However, research with rodent 
models is more abundant. In these rodent models, the activation of various signal 
transduction pathways in Leydig cells results in activation of numerous classes of 
protein kinases and kinase related pathways (Richards, 2001). Of these pathways, the 
protein kinase-A route has assumed most importance in controlling the promoter 
regions of most of the genes involved in mediating the trophic effects of luteinising 
hormone. Additionally, trophic control of steroidogenic activities within the 
mitochondrial matrix and smooth endoplasmic reticulum is thought to be achieved by 
regulation of the biosynthesis of steroidogenic enzymes via increased levels o f mRNA’s 
(Rommerts, 2005).
Leydig cells in the testis are surrounded by cells of the seminiferous tubules (e.g. Sertoli 
cells) or cells in the interstitial tissue (e.g. macrophages). Numerous authors have 
suggested that these cells have an ability to influence the function of Leydig cells in a
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paracrine manner (Saez, 1989, Saez, 1994, Gnessi et al, 1997). In more detail, follicle 
stimulating hormone may facilitate the production of Leydig cells, most possibly via 
Sertoli cell products. Additionally, conditioned media from Sertoli cells or seminiferous 
tubules is able to modify the steroidogenic activity of Leydig cells. Consensus exists 
that four criteria must be fulfilled if individual local secretion products are to be 
considered as potential paracrine factors. These are that the molecule should regulate at 
least one biological activity of the target cell, the molecule must be secreted in sufficient 
quantities to promote a physiological response, regulation of secretion of the molecule 
must be possible and changes in the local concentration of the molecule must influence 
in vivo target cell properties (Rommerts, 2005).
Androgen formation from pregnenolone occurring in the smooth endoplasmic reticulum 
of Leydig cells results from the interaction of membrane bound enzymes with steroids 
as mobile elements (Rommerts, 2005). Related to this concept, Mendel, 1989 states that 
movement of steroids within tissues depends mostly on diffusion. Importantly, binding 
proteins for androgens or other steroids play an important role in decreasing the 
concentration of unbound steroids outside of the cell and therefore, increase the 
diffusion process without effecting steroid trafficking within the cell. According to van 
Doom et al, 1974, pregnenolone, progesterone and testosterone are able to pass the 
Leydig cell membranes and together with this are also able to equilibrate rapidly 
between testicular compartments. In relation to this, Maddocks and Sharpe, 1989, 
suggest that most of the unconjugated steroids diffuse from the interstitial space to the 
blood, leaving the testis via venous flow by the principles of concentration gradients 
and flow rates of the various fluids.
81
Peripherally, steroids equilibrate quickly between organs and the blood. In support of 
this notion, Wang et al, 1981 showed that salivary free testosterone concentration is 
almost identical to blood. Testosterone concentration in tissues and fluids depends 
largely on the availability of binding proteins such as sex hormone binding globulin 
(SHBG) and albumin. Mendel, 1989 iterates that binding proteins within body fluids act 
as a storage device for steroids which have an increased rate of metabolism during 
passage of blood through the liver. It should be noted however, that SHBG and albumin 
are not essential factors for steroid homeostasis (Mendel et al, 1989). O’Malley 
elaborates on this concept by stating that changes in peripheral free testosterone 
concentration can be sensed directly by androgen receptors if there is equilibrium 
between exterior and interior of androgen target cells. Furthermore, steroid receptors 
may become partially activated by phosphorylation and it is plausible that predisposed 
receptors may become further activated by binding small amounts of steroid (O’Malley 
et al, 1995).
Put simply, the level of biologically active steroid within the body is based on supply 
and demand with rate of synthesis equal to that of degradation. Supply is dependent on 
the rate of inward transport of active steroid whereas removal depends on outward 
transport and the overall rate of degradation (Rommerts, 2005). The following 
important factors have been shown to influence the control of steroid levels in target 
cells. The flow volume and rate of blood or lymph, release from binding proteins, 
membrane transport, connective tissue and cell layers (sometimes have the ability to 
inactivate steroids) are all important factors outside the target cell. Within the target 
cell, local activation or inactivation reactions and outwards transport (Rommerts, 2005).
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Testosterone can be metabolised in many ways. Aromatisation of the A4 bond of 
testosterone results in derivation of 17p-estradiol and 5a-dihydroteststerone (Rommerts, 
2005). In oestrogen dependent target cells, the rate of synthesis of estrogens is highly 
influenced by target cell aromatase activity and the supply of androgen substrate. For 
testosterone conversion to 5a-dihydroteststerone, the two isoforms of 5a-reductase must 
be of sufficient concentration in combination with slow dihydrotestosterone metabolism 
(Rommerts, 2005). Furthermore, George et al, 1997 have shown that in prostate tissue, 
the primary oxidative enzyme 17p-hydroxysteroid dehydrogenase is able to convert 
testosterone to androstenedione, particularly when 5a-reducate activity is inhibited. 
Luke and Coffey, 1994 reported high activity of 3aHSD and low activity of 5a- 
reductase in order to efficiently optimise the amount of testosterone for testosterone- 
dependent receptor stimulation within muscle tissue. In skin and hair follicle target 
cells, conversion of testosterone to dihydrotestosterone is dependent on the balance of 
catabolism by reducing 3a or 3p-steroid dehydrogenases versus glucoronidation 
(Rittmaster, 1994).
Degradation of androgens in tissue is determined by the profile of those enzymes 
responsible for the process (Rommerts, 2005). As a result, the enzymes 5a and 5p- 
steroid reductases, 17p-hydroxysteroid dehydrogenase together with 3a and 3p- 
hydroxysteroid dehydrogenases assume importance. Steroid metabolites that are not 
bound to nuclear steroid receptors are still biologically active and as such, metabolism 
and catabolism should not be viewed as a pathway for excreting inactive steroids 
(Rommerts, 2005). Some androgen metabolites may be conjugated whilst others may be 
excreted as free steroids.
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More recently, research evidence has been collected suggesting a non-genomic action of 
androgens away from the direct activation of deoxyribonucleic acid (DNA). Heinlein 
and Chang, 2002, have showed that androgens are able to activate transcription- 
independent signalling pathways, Gue et al, 2002 have established rapid effects of 
androgens on calcium fluxes and Castoria et al, 2003, have shown that androgens affect 
intracellular phosphorylation cascades. It should be noted that the non-genomic actions 
of steroids have not been as extensively studied as genomic actions. However, there is 
strong evidence that the nucleus is not the only direct source of action for steroids. In a 
typical non-genomic model, criteria, similar to those afore-mentioned in the genomic 
model, must be adhered to. The effects should occur within a timescale of seconds to 
minutes and not prolonged to several hours following steroid exposure which is typical 
for a genomic model (Cato et al, 1988). The response must be membrane mediated and 
display an action that can be induced even when the steroid is conjugated to molecules 
which do not directly facilitate cell entry. An interesting example of this is testosterone 
and the capacity for it to bind with albumin (Foradori et al, 2008). The nature of the 
response must be lacking transcription / translation machinery activation, hence 
demonstrating that the steroid response can be initiated in systems where gene 
transcription or protein synthesis is improbable (Foradori et al, 2008).
In research, the most consistently demonstrated non-genomic effect of androgen 
exposure is a rapid change in Ca2+ (Gue et al, 2002, Lieberherr et al, 1994, Gorczynska 
and Handelsman, 1995). This calcium modulation has been shown to occur rapidly 
within seconds to minutes and because of this, it has been suggested that the androgen 
must bind to a receptor on the surface of the cell. Currently, debate is underway 
regarding the nature of this cell. Some research suggests that the classic intra-cellular 
androgen receptor coupled with signal transduction pathway may be the route
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(Gorczynska and Handelsman, 1995) whereas, other authors have suggested the role of 
a unique protein with androgen binding capability may initiate signal transduction 
cascades (Steinsapir et al, 1991).
Perhaps the most pertinent physiological example to this review of a non-genomic 
action of androgens on Ca2+ are the effects on the cardiovascular system. It has been 
shown that administration of androgens can facilitate rapid aortic and coronary arterial 
vasodilatation (Yue et al, 1995). Furthermore, administration can also facilitate 
vasoconstriction (Masuda et al, 1991). Ceballos et al, 1999 have added to this by 
suggesting a non-genomic effect of testosterone, exerted at the level of the cell 
membrane. The authors infused testosterone into rodent coronary arteries resulting in 
rapid increases in vascular resistance and complete attenuation of the effects of 
vasodilatory agents. In addition to this, other authors have showed that testosterone is 
associated with a rapid Ca2+ increase in cardiac myocytes through the activation of a 
plasma membrane androgen receptor associated with the PTX-sensitive G-protein- 
PLC/IP3 signalling pathway (Vicencio et al, 2006).
Verbist et al, 1991, using fluorescent resonance energy transfer, have demonstrated a 
direct interaction between negatively charged phospholipids and membrane ATPase 
calcium pumps. This suggests that androgen metabolites may acquire additional charges 
from sulphate residues enabling them to infiltrate the lipid / protein complex of the cell 
membrane decreasing the membrane flexibility, modulating the actions of the enzymes 
responsible for ATP hydrolysis (Zylinska et al, 1999). In further support of this concept, 
testosterone and dihydroepiandosterone, as hydrophobic steroids, have been shown to 
interact with membrane phospholipids in order to manipulate membrane fluidity (Duval 
et al, 1983).
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Androgen receptors (AR) have demonstrated an ability to activate second messenger 
pathways independent of their transcriptional activity (Foradori et al, 2008).The 
tyrosine kinase proto-oncogene tyrosine-protein kinase ( c-Src) is generally targeted to 
the inner surface of the plasma membrane and has been shown to interact with androgen 
receptors. This suggests the necessity of a membrane androgen receptor to facilitate this 
process (Foradori et al, 2008). To further support this notion, Migliaccio et al, 2000, 
have shown that the association of an androgen receptor with the SH3 domain of c-Scr 
stimulates c-Scr kinase activity in less than a minute in the androgen sensitive human 
prostate adenocarcinoma (LNCaP) prostate cancer cell line. In prostate cancer cells, the 
AR/Src/modulator of non-genomic action of oestrogen receptor association and 
subsequent mitogen activated protein kinase family activation has been found to be 
androgen dependent and also independent (Unni et al, 2004). Related to the mitogen 
activated protein kinase family signalling cascade, Kousteni et al, 2001, have suggested 
that androgen treatment may result in stimulation of two important members murine 
leukaemia viral oncogene homo log-1 (Raf-1) and mitogen activated protein kinase-2 
(ERK-2) within a window of approximately 5 minutes. This androgen induction of c- 
Src/Raf/ERK signalling is impeded by c-Scr kinase activity inhibition or treatment with 
androgen receptor antagonists (Migliaccio et al, 2000). The same authors conclude that 
androgens work through the known androgen receptor in order to activate a non- 
genomic second messenger pathway and can also function together with oestrogen 
receptors in order to induce c-Scr kinase activity as part of a complex composed of c- 
Scr, oestrogen receptors and the androgen receptor.
SHBG, a glycoprotein derived from the liver, is able to bind to testosterone, 
dehydroepiandosterone and estradiol (Mean et al, 1977). Previous research has
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suggested that serum testosterone is mainly bound to SHBG (-60%) and cell surface 
receptors for this glycoprotein have been identified in numerous tissues including the 
prostate, testis, breast and liver (Krupenko et al, 1994). The SHBG receptor is able to 
facilitate androgen activation of cAMP and phosphokinase (Foradori et al, 2008). As a 
result of this, it is feasible that androgen-SHBG stimulation of phosphokinase may alter 
the phosphorylation of androgen receptors and co-regulators, therefore modulating 
androgen receptor transcriptional activity (Foradori et al, 2008).
Research work has suggested that androgens may play a role as a membrane receptor 
because of the detection of specific androgen binding to plasma membranes of 
numerous cell types. Such cells include the endothelium (Figueroa-Valverde et al, 
2002), breast and prostate cancer cells (Hatzoglou et al, 2005, Kampa et al, 2002), 
osteoblasts (Armen et al, 2000), macrophages (Guo et al, 2002) and T-lymphocytes 
(Benton et al, 1997). To this date, the assumed membrane androgen receptor has yet to 
be identified and it cannot be accurately determined whether the modulation of Ca2+ ion 
channel activity are mediated by a specific androgen receptor or by other signalling 
pathways (e.g. SHBG or c-Scr kinase-androgen receptor complex) (Foradori et al,
2008).
Androgens have been shown to have key involvement in the human reproductory 
system (Foradori et al, 2008). In particular, androgens are fundamental to neuro­
endocrine control of the gonadotropin releasing hormone. Previous work has already 
shown that androgens are able to inhibit hypothalamic luteinising hormone secretion by 
the release of gonadotropin releasing hormone (Foradori et al, 2008). However, 
although androgens affect pituitary sensitivity to gonadotropin releasing hormone, 
research has consistently identified a neural component for the androgen regulation of
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luteinising hormone secretion without a specific neural site of action (Kalra et al, 1989). 
Research has suggested that androgens may be affecting gonadotropin releasing 
hormone secretion via trans-synaptic pathways. To elaborate on this, research by 
Belsham and colleagues (1998) have suggested a direct action of androgens on 
gonadotropin releasing hormone neurons by observing the classic androgen receptor in 
the plasma membrane of the GT-1 hypothalamic cell line. Non-genomic actions of 
androgen receptors have been suggested in GT1-7 neurons and administration of 
dehydrotestosterone and testosterone have all resulted in significant elevation in Ca2+ in
GT-1 cells within 200 seconds (Shakil et al, 2002). This finding is consistent with
2 +previous research which has stipulated that Ca changes are key in the control of 
pulsatile gonadotropin releasing hormone secretion (Shakil et al, 2002).
2.3.2: Incidence of testosterone deficiency.
As males age, there is a gradual decline in circulating bio-available testosterone 
(Bettocchi, 2005). There is a general consensus that testosterone levels decline about 
1% per year from as early as age 30 years. Noticeable declines are common following 
an age of 50 years but there is great inter-patient variability (Morales and Lunenfield, 
2002). The Hypogonadism in Males study (Mulligan et al, 2006) estimated the 
prevalence of hypogonadism in men aged 45 years or greater visiting primary care 
practises in the United States. This research identified that the prevalence of 
hypogonadism (i.e. testosterone level <300ng/dl) was estimated to be 37.8% - 836 
patients of the 2162 sampled. Furthermore, data collected from the Centres for Disease 
Control and Prevention National Health Interview Survey has indicated that 74% of 
adult men in the United States visit a general practitioner (GP) surgery annually 
(Lethbridge-Cejku et al, 2004) and in 2003, 48.4 million males were aged 45 years of 
greater in the United States. The authors extrapolated this data and estimated that 13.8
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million men aged 45 years or greater (who had visited a primary care doctor) may be 
hypogonadal. Additional research has also attempted to clarify the prevalence and 
incidence rates of androgen deficiency in a random sample of middle aged and older 
males (Araujo et al, 2004). This research also used three signs / symptoms of 
hypogonadism together with total testosterone (TT) <200 ng/dL or 200-400 ng/dL with 
free testosterone (FT) <8.9 ng/dL to stratify androgen deficiency. Studying initially 
1691 patients and a further 1087 at follow-up, it was noted that the crude prevalence of 
androgen deficiency rose from 6.0% to 12.3% in males aged 40-69 years old. 
Furthermore, it was estimated that 2.4 million US males in this age range with androgen 
deficiency. The crude incidence rate of androgen deficiency was defined as 12.3 per 
1000 person years with significant increases with advancing age. Finally, it was 
estimated that in the United States there would be 481,000 new cases of hypogonadism 
per year in males aged 40-69 years.
2.3.3: Aetiology of hypogonadism.
In normal healthy males, multiple neural inputs, endogenous opioids, testosterone, 
estradiol and other factors influence the hypothalamic secretion of gonadotropin 
releasing hormone. Additionally, these factors influence the ability of gonadotropin 
releasing hormone to facilitate secretion of luteinizing hormone (Reyes-Fuentes and 
Veldhuis, 1993). Release of gonadotropin releasing hormone is pulsatile and reaches the 
pituitary gland via the hypothalamic pituitary portal venous system which in turn is 
modulated by neural input (dopaminergic pathways) and neurotransmitters (e.g. galanin, 
neuropeptide Y and opioids). This stimulates episodic secretion of luteinizing hormone 
(Reyes-Fuentes and Veldhuis, 1993). The secretion of luteinizing hormone reaches the 
testes via the systemic circulation thus promoting tonic and episodic Leydig cell 
secretion of testosterone. Any unbound plasma testosterone acts upon target tissues
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completing the feedback loop to inhibit gonadotropin releasing hormone and luteinizing 
hormone secretion (Reyes-Fuentes and Veldhuis, 1993).
Various research studies have attempted to identify the important factors affecting 
testosterone concentrations in healthy elderly males. There have been some reports of 
circannual variations in testosterone level with increases of up to 30% noted from 
October to December in the Western hemisphere (Smals et al, 1976). However, this 
research was unable to differentiate between other confounding variables such as 
climate and latitude. In addition to this, other research has noted peak serum 
testosterone levels during spring and summer and also no significant seasonal variation 
(Svartberg et al, 2003).
Research studies of twins have identified that genes can determine as much as 25-76% 
of the total variation in plasma levels of gonadotropin, testosterone, free testosterone, 
estradiol and estrone (Meikle et al, 1988). These studies suggested a strong genetic 
influence in the tissue formation and production rate of dihydrotestosterone. Some 
authors have identified an ethnic variation in TT and SHBG levels in African males 
when compared to Caucasian males (Gapstur et al, 2002). This research identified a 
slightly higher percentage of these levels in African males. However, following 
adjustment for body composition and adiposity these small differences were nullified. 
Other research investigating the effects of ethnicity on free testosterone in Caucasian 
and Asian males has found no significant differences (Lookingbill et al, 1991).
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More recently, scientists have identified possible important genetic correlations 
affecting testosterone concentration. In more detail, this research has focussed upon AR 
gene polymorphism. The AR gene contains a polymorphic trinucleotide CAG repeat in 
exon 1. This CAG repeat encodes a physiologically relevant polyglutamine tract of 
variable length. The research work suggested that any CAG length greater than normal 
(15-31) would result in diminished AR transactivation capacity and androgen resistance 
(Chamberlain et al, 1994). Conversely, shorter AR CAG repeat lengths have been 
associated with higher prevalence of androgen sensitive diseases e.g. prostate cancer 
(Giovannucci et al, 1997) and with greater decline of serum and bio-available 
testosterone (Krithivas et al, 1999). In contrast, other research studies investigating 
Australian and Chinese males (Jin et al, 2000) Belgian males (Van Pottlebergh et al, 
2001), German males (Zitzmann et al, 2001) and Finnish males (Harkonen et al, 2003) 
have failed to demonstrate a significant relationship between AR CAG repeat length and 
levels of androgen hormones. This suggests a lack of truly consistent findings 
attributing a substantive role of the AR CAG repeat in elderly male androgen 
deficiency.
Body mass index (BMI) has been discovered to be an important influence on 
testosterone concentration, probably via its effects on SHBG. Negative associations 
have been found between SHBG and TT (Demoor and Goosens, 1970). In addition to 
this, lower serum testosterone levels tend to be more pronounced when associated with 
higher levels of abdominal obesity (Haffner et al, 1993). Physiologically, alterations in 
the neuro-endocrine regulation of testosterone secretion (via reduced mean amplitude of 
luteinising hormone pulses) have been noted to be the foundation to this decline 
(Giagulli et al, 1994).
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Increased levels of stress can stimulate the neuroendocrine stress-responsive 
corticotropic, sympatho-adrenal and somatotropic axes together with suppression of 
hypothalamic gonadotropin releasing hormone secretion (Bergendahl et al, 1998). In 
particular, inhibition of gonadotropin releasing hormone may be related to corticotropin 
stimulated secretion of endogenous opiods (Gambacciani et al, 1986). Various types of 
physical stressors (e.g. pain, injury, temperature, exercise) and also psychological stress 
have been implicated in inhibition of gonadal function and thus reduction in circulating 
testosterone concentration (Christiansen et al, 1985 and Nilsson et al, 1995).
2.3.4: Pathophysiological considerations of testosterone deficiency.
Pathophysiologically during ageing, it has been noted that although the gonadotropin 
releasing hormone mRNA cellular content does not change, there is a decrease in 
neuropeptide Y release, an excitatory peptidergic signal to gonadotropin secreting 
neurons (Pednekar and Mulgaonker et al, 1995). Additionally, p receptors and 
hypothalamic norepinephrene content has been noted to become less functional in 
ageing males, both of which are agonistic to gonadotropin releasing hormone secretion 
(Kaufman et al, 1991). Therefore, it could be stated that the reduced gonadotropin 
releasing hormone impulse strength may contribute to hypogonadism in ageing males. 
Research has also suggested that with ageing, gonadotropin releasing hormone receptor 
activated Ca2+ channels reduce their ability to mobilise Ca2+ for release thus negatively 
impacting on pituitary luteinizing hormone secretion (Miyamoto et al, 1992). 
Extrinsically testosterone can inhibit gonadotropin releasing hormone stimulated 
pituitary secretion of luteinising hormone (Miyamoto et al, 1992). This research found 
that dihydrotestosterone had no effect on luteinising hormone secretion in men when its
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levels are decreased via a 5 alphase reductase inhibitor (finasteride). However, patients 
with 5 alphase reductase deficiencies exhibited significantly increased luteinising 
hormone pulse amplitude suggesting testosterone and its 5 alphase reductase metabolite 
modulate luteinising hormone secretion.
The stress of illness is also an important modulator of pituitary function. In more detail, 
cytokines which activate the corticotropic-adrenal axis (such as IL-1 alpha) have been 
suggested to impair gonadotropin secretion (Feng et al, 1991). Animal studies have 
shown that stress activated corticotropin releasing hormone and opiates suppress the 
gonadotropin releasing hormone pulse generator. For example, in ovariectomised 
monkeys, IL-1 alpha reduces the frequency and amplitude of luteinising hormone 
secretion via arginine vasopressin (Shalts et al, 1992). In humans, older men display a 
wider dispersion of luteinising hormone and serum testosterone levels, probably 
reflecting variations in health status. In relation to this, older men also exhibit 
suppression of serum luteinising hormone concentrations during acute illness. Cross- 
sectional research has reported lower testosterone levels in patients with CAD when 
compared with age-matched controls (Alexanderson et al, 1996). In addition to this, 
other research has identified that the age-related decline in testosterone level is 
exaggerated in males with concomitant CAD (Zmuda et al, 1997). There are however, 
no conclusive research studies reporting an independent association between low 
testosterone concentration and development of fatal or non fatal MI (Contoreggi et al, 
1990). Numerous other chronic illnesses have been reported to result in lower 
testosterone concentration. For example, the hypercapnoea and hypoxia associated with 
chronic obstructive airways disease is thought to result in hypo-pituitary dysfunction 
and thus decreased serum testosterone levels (Semple et al, 1981). Chronic liver disease 
patients have been noted to present with decreased free testosterone concentrations and
increased serum concentrations of SHBG, androstenedione, and estrogens. Additionally, 
excess alcohol consumption in hepatic cirrhosis can have an additional effect on 
decreased testosterone concentration (Bannister et al, 1987). The increased plasma half 
life found in chronic renal impairment has been found to contribute to increased plasma 
gonadotropin levels. Furthermore, luteinising hormone secretion is altered due to 
abnormal gonadotropin hormone release and there is also evidence of impaired Leydig 
cell function (Handelsman and Dong, 1993).
2.3.5: Diagnosis, signs and symptoms -  Hypogonadism.
Clinically, the importance of recognising and treating hypogonadism has recently 
become more prominent. A research study conducted in 2006 on veteran males over 40 
years of age identified that hypogonadism is associated with a reduced cumulative 
survival level to 55% when compared to normal males (found to have a 75% survival 
over the 8  year study observation). Additionally, following adjustment of important 
confounding variables, hypogonadism was still found to be associated with increased 
mortality (hazard ratio of 1.88) (Laughlin et al, 2008). Importantly, further research has 
identified that hypogonadism (defined as a testosterone level <450 ng/dL) was 
significantly (45% of the study population) associated with the development of the 
metabolic syndrome and diabetes over an 11 year follow up period (Laaksonen et al, 
2004). Moreover, a study of San Bernado males identified that those with the lowest 
percentile of testosterone had increased all cardiovascular mortality even when adjusted 
for age, smoking status, exercise levels, BMI, hip ratio and alcohol consumption 
(Shores et al, 2006).
Although hypogonadism has now become widely established, it is still unclear as to 
whether this physiological process is associated with a definitive symptom complex.
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Recently published reviews and consensus panel updates have suggested that for the 
diagnosis of hypogonadism there must be both biochemical and functional evidence 
(Matsumoto, 2002). Additionally, symptom onset, age of decline of testosterone, 
velocity of testosterone decline and the threshold for significant testosterone decline are 
all uncertain factors (Martinez-Jabaloyas et al, 2007). As a consequence, together with 
biochemistry, a number of questionnaires have been designed and validated for use in 
this patient population. Perhaps the most commonly used of these questionnaires and 
the only one that has independent validation is the Androgen Deficiency in the Ageing 
Male Questionnaire (ADAM) as developed at the University of St Louis in the late 
1990’s (Heinmann et al, 1998). This questionnaire aims to highlight the most important 
functional characteristics of the age associated decline in testosterone concentration in 
order to aid diagnosis.
The clinical presentation of hypogonadism may be subtle but most commonly include 
some of the following: loss of libido, erectile dysfunction, lethargy, loss of muscle mass 
and / or strength, oligospermia, reduced bone density, testicular atrophy, gynecomastia 
and depression (Dobs, 2008). In addition to ageing, there is an expanded appreciation of 
the aetiologies of low testosterone in table 7 below:
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Table 7. Expanded Appreciation of the Aetiologies of Low Testosterone -  adapted 
from (Dobs, 2008).
Representative Disease Associated with Primary Testicular Failure.
Klinefelters Syndrome
Alkylating Chemotherapeutic Agents
Radiation Therapy
Auto-immune Destruction
Trauma
Viral Invasion
Ketoconazole
Representative Disease Associated with Centrally Mediated Hypogonadism.
Non-secretory Pituitary Tumours
Hyperprolactinemia
Prolactinomas
Granulomatous Invasion
Kallmans Syndrome
Opiate Use
Glucocorticoids
Representative Chronic Diseases with Both a Central and Testicular Effect.
Diabetes Mellitus
Obesity
Hyperinsulinism 
Starvation 
Acute Illness
Cytokine Mediated Impaired Testosterone Synthesis.
Renal Failure
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Ageing
HIV
Stress
Cancer
The classic diagnosis of hypogonadism has been based on clinical presentation with 
laboratory confirmation. Laboratory confirmation historically was based on statistical 
norms (mean + 2 s.d.). However, with the increased appreciation of the effect of 
advancing age on testosterone concentration (see aforementioned Massachusetts Male 
Aging Study Araujo et al, 2004). it is unclear whether the normal range should become 
age adjusted or averaged over the lifespan (Dobs, 2008).
Importantly, testosterone levels vary significantly diumally and also have been 
suggested to vary circ-annually (Smals et al, 1976). Additionally, as suggested earlier, 
testosterone concentration is also affected by illness and perhaps, more importantly 
SHBG concentration (Bhasin et al, 2006). The majority of circulating testosterone is 
bound to SHBG and albumin with up to approximately 3% unbound and known as ‘free 
testosterone’. Bio available testosterone refers to the sum of testosterone bound to 
albumin and unbound testosterone within the circulation. Current European Endocrine 
Society guidelines (Bhasin et al, 2006) have proposed common values for testosterone 
deficiency in ageing males but have advised caution due to large patterns of variability. 
A cut off value of 12 nmol/L for TT has been suggested as commonplace for ageing 
males, whereas values as low as 10.4 nmol/L have been utilised for younger males. In 
addition, 0.17 nmol/L has been widely used as a cut off value for free testosterone. Bio- 
available testosterone refers to unbound testosterone plus the fraction loosely bound to 
albumin. Albumin bound testosterone is thought to be readily dissociable and is
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therefore termed bio-available (Bhasin et al, 2010). Endocrinology guidelines have 
suggested that measurement of both free and bio-available testosterone are essential if 
total testosterone concentrations are borderline hypo / eugonadal or when there may be 
a possible alteration of SHBG. Older males, males with obesity, diabetes mellitus of 
chronic disease have been shown to present with increases in SHBG and thus total 
testosterone may not be a precise marker of androgen status in this population (Bhasin 
et al, 2008). Bio-available testosterone concentration < 2.5 nmol/L have been associated 
with overt hypogonadism in younger males and levels below 4.0 nmol/L have been 
considered hypogonadal and suitable for testosterone supplementation (Kapoor et al, 
2007 and Leifke et al, 2000).
2.3.6: Treatment of testosterone deficiency.
Testosterone therapy in young hypogonadal males has been associated with 
improvements in overall sexual activity scores, frequency of sexual thoughts, increased 
attentiveness to erotic stimuli and increase in frequency and duration of night-time 
erections (Alexander et al, 1997). Testosterone therapy in healthy hypogonadal males 
has also been found to increase fat free mass, muscular strength and also decrease 
overall fat mass (Wang et al, 2000, Bhasin et al, 1997 and Wang et al, 2004). In 
addition, testosterone therapy provides a dose-dependent increase in haemoglobin 
levels, which appears to be further augmented in older males (Bhasin et al, 2005). 
Testosterone therapy has also been noted to have a positive effect on mood, by 
increasing positive and decreasing negative aspects (Wang et al, 2000). Furthermore, 
other research has highlighted benefits of testosterone therapy on self reported energy 
and well-being (Rabkin et al, 1995).
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There are a number of available testosterone formulations with differing clinical 
pharmacology. Table 8  summarises the main testosterone formulations currently in use 
(adapted from Bhasin et al, 2006).
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Bhasin et al, 2006 remark that any of the aforementioned treatment options can be 
considered dependent on patient preference, pharmokinetics of testosterone action, 
treatment burden and also cost. The recommended achievable testosterone level should 
aim towards that of a normal healthy young male (dependent on local laboratory 
values). This holds true for older males with long-term chronic illness. However, this 
data was based upon males with chronic human immuno-deficiency virus (HIV) and not 
HF. It should be accepted that as this treatment has not been fully implemented in the 
HF population, these values are unavailable.
2.3.7: Testosterone as a metabolic hormone.
The metabolic syndrome has been considerably investigated in recent years, particularly 
due to its perceived association with common disease states for instance HF (Inglesson 
et al, 2006), cardiovascular disease and type II diabetes mellitus (Imam et al, 2007). The 
most common risk factors for the development of metabolic syndrome are obesity and 
physical inactivity (Ford and Li, 2006) additionally, obese individuals are more likely to 
develop insulin resistance when compared to non-obese. Insulin resistance may 
facilitate the development of additional metabolic risk factors such as elevated 
triglycerides, reduced high density lipoprotein (HDL) cholesterol levels, elevated 
fasting blood glucose concentration and hypertension (Hu et al, 2004). Geography, 
ethnicity, lifestyle, age and gender may all contribute to the development of the 
metabolic syndrome. However, research has shown that low levels of serum total 
testosterone and SHBG may also be considered as risk factors for its development in 
males (Muller et al, 2005). A recent meta-analysis supports the presence of a sex- 
dependent association between endogenous testosterone and the metabolic syndrome 
(Brand et al, 2011). This analysis identified a total of 52 studies comprising 22043
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males and 7839 females, presenting relative risk estimates or hormone levels for 
participants with or without development of the metabolic syndrome. Males with higher 
serum TT displayed a lower metabolic syndrome risk (relative risk estimate = 0.38, 95% 
confidence interval 0.28-0.50). In addition, males with higher SHBG levels displayed a 
reduced risk of development of the metabolic syndrome (relative risk estimate 0.29, 95 
% confidence interval 0.21 -  0.41). Research conducted by Laaksonen and colleagues in 
2005 has displayed the reverse to hold true. This study has indicated that male patients 
who have the metabolic syndrome at baseline will have an increased risk of developing 
testosterone deficiency (defined as total testosterone <11 nmol/L) over an extended 
follow-up period of 11  years.
The precise mechanisms linking testosterone deficiency with insulin resistance and type 
II diabetes mellitus are not fully understood. However, limited research evidence is 
suggestive of a role at the level of the major insulin-responsive target tissues; skeletal 
muscle, liver and adipose tissue. In addition, impaired insulin sensitivity in the above 
tissues is relates to deficiencies in insulin-stimulated glucose transport activity into 
skeletal muscle, impaired insulin mediated inhibition of hepatic glucose production, 
stimulation of glycogen synthesis in the liver and an attenuation of insulin inhibited 
lipolysis in adipose tissue (Kelly and Jones, 2013). In response to this, dissociated fatty 
acid release from adipose tissue becomes surplus to the energy requirements of other 
tissues including skeletal muscle and the liver. Yu and Ginsberg, 2005, suggest that this 
lipid accumulation contributes to impaired insulin responsiveness and abnormal glucose 
control.
Following castration in a rodent model, it is widely accepted that there will eventually 
be reduced muscle levels of glycogen (Leonard, 1952). Insulin stimulated glucose 
uptake into skeletal muscle is mediated by the Glut4 glucose transporter isoform
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(GLUT4) which is situated in membrane vesicles inside the cell during resting state 
(Kelly and Jones, 2013). Translocation of GLUT4 to the cell membrane, in response to 
insulin receptor signalling, binding of insulin substrate 1 and activation of intra-cellular 
signalling pathways serves to facilitate increased glucose transport into skeletal muscle 
(Bryant et al, 2002). This theory is supported by other research which has shown that in 
type II diabetics, GLUT4 expression is reduced correlating with decreased insulin 
responsiveness and defects at the level of the insulin receptor (Pessin and Saltiel, 2000). 
Cultured adipocytes and skeletal muscle cells incubated with low dose testosterone 
therapy have demonstrated an augmented regulation of GLUT4 and insulin receptor 1 
(Chen et al, 2006). In relation to this, Sato et al, 2008 have showed that testosterone 
therapy in a rodent model can facilitate phosphorylation of protein kinase B and C 
which are key steps in the insulin receptor signalling pathways for regulation of GLUT4 
translocation. The same authors have also suggested that testosterone treatment can 
influence the enzymes related to the glycolytic process. Increased activity of 
phosphofructokinase and hexokinase has been shown in cultured rat skeletal muscle 
cells following administration of testosterone. Furthermore, an increase in glucose 
oxidation has been noted in isolated sebaceous glands of castrated male mice when 
compared to controls in response to testosterone treatment. The observed increase in 
oxygenation was in parallel to an increase in glucose use in the pentose phosphate 
pathway and ultimate use in fatty acid synthesis (Sansone et al, 1971).
Pitteloud et al, 2005 have asserted that testosterone may beneficially influence the 
metabolic rate in skeletal muscle by promoting the acquisition of energy from adipose 
tissue in order to decrease fat mass. As such, the authors noted a correlation between 
expression of genes involved in skeletal muscle mitochondrial oxidative 
phosphorylation, impaired glucose tolerance and the presence of type II diabetes.
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Furthermore, ubiquionol cytochrome c reductase binding protein, which plays a critical 
role in oxidative phosphorylation, was noted to have the most significant difference 
between healthy and diabetic muscle and also a strong correlation with testosterone and 
insulin resistance.
Testosterone deficiency has been found to result in significant declines in lipid 
oxidation rate resulting in declines in resting energy expenditure and increased adiposity 
in healthy males with gonadal steroid suppression (Mauras et al, 1998). In relation to 
this, other research has shown that two weeks of testosterone treatment resulted in 
stimulation of whole body fat oxidation and reduced fat mass in testosterone deficient 
males (Birzniece et al, 2009). Although the exact mechanism behind this phenomenon 
is not well known, it has been postulated that this process may be as a result of a 
decrease in protein oxidation (Gibney et al, 2005) or indirectly on fat oxidation by 
reducing glucose oxidation (Moverare-Skrtic et al, 2006). Testosterone may be able to 
enhance lipid oxidation in muscle, improve circulating lipid profiles, sensitise myocyte 
insulin signalling and glucose metabolism, therefore protecting against the detrimental 
myocellular consequence of deregulated lipid metabolism in type II diabetes mellitus, 
obesity and the metabolic syndrome (Kelly and Jones, 2013).
The liver is an important organ for the maintenance of glucose and lipid homeostasis. 
Decreases in testosterone have been associated with attenuated expression of GLUT4 in 
liver tissue, accompanied by increased blood glucose, reduced insulin and decreased 
glucose uptake in adipose and skeletal muscle tissues (Muthusamy et al, 2009). In 
rodent models, treatment with testosterone has been shown to restore liver GLUT4 
expression and resultantly glucose uptake, leading the authors to hypothesize that the
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aforementioned GLUT4 impairment may have resulted from castration induced 
deficiency in insulin (Muthusamy et al, 2009).
Obesity and the metabolic syndrome can directly impact on liver function. Free fatty 
acids and adipocytokines in high concentration may disturb liver metabolism and result 
in development of metabolic disorders. In more detail, free fatty acids decrease hepatic 
insulin binding and extraction, increase hepatic gluconeogenesis and increase hepatic 
insulin resistance (Kelly and Jones, 2013). It can be theorised that testosterone 
supplementation could reduce free fatty acid production and correct disorders of insulin.
In males, the distribution of adipose tissue appears to influence androgen concentration 
and cardiovascular risk profiles. As such, numerous research studies have suggested that 
reduced lean body mass and increases in central adiposity are inversely correlated with 
levels of testosterone (Nielsen et al, 2007, Frederiksen et al, 2012, Kapoor et al, 2007). 
Mechanistically, lipid breakdown for energy usage in adipose tissue, influenced by 
androgens, may play an important role in fat storage and obesity (Kelly and Jones, 
2013). Further to this, research conducted by Hansen et al, 1980 has linked testosterone 
supplementation with enhanced nor-adrenaline stimulated lipolysis in isolated male rat 
fat cells. This is an important link because catecholamines are the main lipolysis 
regulating hormone in males and regulate adipocyte lipolysis through the activation of 
adenylate cyclase to produce cAMP. Protein kinase A activation by cAMP results in 
stimulation of hormone sensitive lipase and therefore facilitates accelerated lipolysis 
and increased breakdown of triglycerides (Arner, 2005).
Plasma concentration of bio-available testosterone has been show to inversely correlate 
with abdominal adipose tissue lipoprotein lipase (Ramirez et al, 1997). This enzyme has
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been suggested to play a role in the pathogenesis of obesity as it resides on the extra­
cellular surface of adipocytes and hydrolyses circulating triglyceride rich lipoproteins to 
fatty acids which then become esterifide and stored as triglyceride (Eckel, 1989). In 
relation to this, Marin et al, 1995 showed that following prolonged testosterone 
supplementation, there was a marked decrease in lipoprotein lipase activity and hence 
reductions in triglyceride storage in abdominal subcutaneous adipose tissue.
Adipocytokine production is abundant from visceral fat. IL-1, IL- 6  and TNFa 
production is increased in obesity and also stimulates production of CRP in the liver 
(Schuster, 2010). This production of pro-inflammatory cytokines by adipose tissue 
facilitates insulin resistance via direct and in-direct mechanisms together with a 
contribution to systemic and peripheral vascular inflammation associated with 
cardiovascular disease (Kelly and Jones, 2013). It has already been suggested in this 
review that testosterone is able to decrease lipid deposition and therefore has the 
potential to modulate the release of harmful pro-inflammatory cytokines into the 
circulation. This phenomenon has been proved in numerous research studies which have 
shown that testosterone supplementation can beneficially effect concentrations of IL-1, 
IL-6 , TNFa and CRP (Yang et al, 2005, Malkin et al, 2004, Kapoor et al, 2007). In 
more detail, retinol binding protein 4 has been found to precipitate insulin resistance by 
the reduction of phosphatidylinositol-3-OH-kinase signalling at the level of the muscle, 
which in turn increases the expression of phosphoenolypyruvate carboxykinase in the 
liver to inhibit tyrosine phosphorylation of ISR1 in adipose and ultimately, attenuate 
adipoocentin and PPARa activity which is characteristic of obesity (Yang et al, 2005).
2.3.8: HF and testosterone deficiency.
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HF appears to be associated with decreased levels of plasma testosterone, supported by 
the fact that about 25%-30% of men with HF and a mean age of around 60 years have 
biochemical evidence of testosterone deficiency (Malkin et al, 2009). Some studies 
have actually reported that in males with HF up to 79% of patients may suffer from low 
testosterone levels (Guder et al, 2009). All studies do, however, report a consistently 
high morbidity and mortality associated with testosterone deficiency and HF.
To support this hypothesis, research has shown that in male patients with HF, anabolic 
hormone depletion is common and an independent marker of poor prognosis 
(Jankowska et al, 2006). In this study, serum levels of three important anabolic 
hormones were measured (TT, dehydroepiandosterone sulphate and insulin-like growth 
factor 1) in 208 males with HF (median age of 63 years and median LV EF of 33%). 
Deficiencies in these anabolic hormones (below 10th percentile of healthy peers) were 
noted in all age categories of males with HF. In addition, these deficiencies were 
inversely correlated with NYHA Score (p<0.01). More importantly, circulating TT, 
dehydroepiandosterone sulphate and insulin-like growth factor l(IGF-l) were 
prognostic markers in multivariate models when adjusted for important prognostic 
factors (p<0.05). Males with HF and normal levels of all anabolic hormones had 
superior 3 year survival rates (83%, 95% confidence interval 67% to 98%) when 
compared to deficiencies in one (74% survival rate, 95% confidence interval 65% to 
84%), deficiencies in two (55% survival rate, 95% confidence interval 45% to 6 6 %) and 
deficiencies in three (27% survival rate, 95% confidence interval 5% to 49%).
Low levels of testosterone have been correlated with disease progression in HF and may 
also be responsible for some of the common features of HF, for instance, reduced
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skeletal muscle mass and function, cachexia, fatigue and depressed mood (Malkin et al, 
2006). Myocardial cachexia, a syndrome with poor prognosis (defined as a non- 
intentional loss of 6 kg lean mass in 6  months or less), has been characterised by low 
levels of testosterone (Aukrust et al, 2009). It is well known that HF as a metabolic 
syndrome can adversely alter numerous endocrine, metabolic and inflammatory 
parameters (Jackson et al, 2000, Noutsias et al, 1999). The alterations can include 
changes in levels and sensitivity to insulin, growth hormone and also testosterone (Von 
Haehling et al, 2007). Most patients with HF are affected by a gradual decline in muscle 
mass, muscular strength and also endurance performance, reflecting the 
pathophysiological imbalance and deficiency of anabolic hormones (Malkin et al, 
2010).
The importance of the relationship between testosterone deficiency, metabolic 
syndrome and heart failure is clearly clinical valid. Initial reports from the Framingham 
Study drew attention to the potential relationship between diabetes mellitus and HF 
independent of age, coronary artery disease, hypertension or BMI (Kannel et al, 1979). 
In HF, there is derangement of the glucose-insulin axis with some studies reporting up 
to 43% of patients manifesting disorders of glucose metabolism (Kontoleon et al, 2003). 
Those patients with HF and insulin resistance display an impaired ability to promote 
glucose transport into the muscle and adipose tissue. Additionally, more recent research 
has showed that impaired insulin activity inversely correlates with severity of HF, 
relates to disorder of skeletal muscle physiology, facilitates reduced muscle mass and 
can also influence prognosis (Swan et al, 1997 and Doehner et al, 2002). Further to this, 
it has been shown that stress induced increased plasma glucose levels are associated 
with increased risk for the development of HF (Capes et al, 2000), type II diabetes 
mellitus can predisposes severe presentation of HF with over 33% of patients with de-
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compensated HF manifesting type II diabetes mellitus (Kostis et al, 2005). Research has 
shown that one standard deviation increase in insulin sensitivity increased the risk of 
developing HF by approximately one third (Ingleson et al, 2005). Thus, there is a 
consensus of evidence that suggests a direct link between insulin resistance and HF, 
with a notion that insulin resistance may facilitate development of cardiomyopathy and 
also HF as a precursor to development of insulin resistance.
There are a number of theories to explain the association between altered metabolism, 
insulin resistance and HF. The most investigated concept relates to the aforementioned 
activation of the sympathetic nervous system and renin-angiotensin-aldosterone system. 
It has already been stated in this review that in response to sympathetic nervous system 
activation, there is an increase in catecholamine secretion. In addition to this however, 
there is also evidence of reduced cardiac catecholamine re-uptake (Eisenhofer et al, 
1996). The observed increase in catecholamines can facilitate myocardial oxygen 
wastage by inducing marked enzyme loss due to myocardial damage (Opie et al, 1979) 
together with norepinephrene mediated coronary vasoconstriction and increased plasma 
free fatty acid levels; other factors which contribute to oxygen wastage (Kostis et al, 
2005 and Paolisso et al, 1991). Increased levels of free fatty acids may also be 
responsible for defects in insulin signalling, potentially mediated by activation of 
protein kinase C~p, which phosphorylates insulin receptors and hence reduced capillary 
opening and myocyte glucose uptake (Wagenmakers et al, 2006). Peterson and co­
workers (2004) have also shown that insulin resistance has the ability to increase 
cardiac free fatty acid metabolism and therefore decrease cardiac muscle contractile 
efficiency in their study of obese young females without other significant cardiac risk 
factors. At cardiac level, HF mediated increases in sympathetic nervous system activity 
have been shown to reduce presynaptic norepinephrene and myocardial glucose uptake
in areas of LV impairment when compared to normal myocardial ventricular segments 
(Ashrafian et al, 2007). This suggests that altered metabolism and insulin resistance 
directly relate to local cardiac sympathetic nervous system activity and are a potentially 
important correlation in HF. In skeletal muscle, plasma free fatty acid induced insulin 
resistance has been linked with increased triglyceride, increased cellular free fatty acids, 
increased cytoplasmic fatty acid metabolites such as diacylglycerol, and activation of 
protein kinase-C and nuclear factor-kappa B (Savage et al, 2005). There is a strong 
association between muscular triglyceride content and insulin resistance but there is 
controversy regarding the specific lipid species responsible for its instigation; 
triglyceride or intracellular free fatty acid and its metabolites (Ashrafian et al, 2007). 
Savage and co-workers (2005) have investigated this concept in transgenic mice. During 
their research, it was noted that in adiposome triglyceride lipase -  null mice, despite the 
deletion of triglyceride, the reduced availability of lipase derived free fatty acids 
increased glucose utilisation and therefore facilitated a decline in cardiac insulin 
resistance. This research stipulates that in a transgenic rodent model, free fatty acids and 
their derivatives appear to be the main mediator of cardiac insulin resistance. The 
mechanism of this process appears to be either due to an alteration of glucose signalling 
or by competition with glucose signalling (Poomima et al, 2006). The accumulation of 
intra-muscular free fatty acid coenzyme A then limits attenuates glucose uptake by 
inhibiting intracellular muscle insulin signal pathways (Savage et al, 2005).
Resultantly, there is clear evidence of that testosterone deficiency and HF are inter­
changeable with a large body of evidence suggesting detailed relationships between the 
two difference clinical manifestations. It is due to this phenomenon that research studies
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are warranted to address the effects of testosterone concentration on important health 
related outcomes in HF.
Unfortunately, currently there are only two research studies that have attempted to 
identify the effect of testosterone concentration on physiological function in males with 
HF. An initial study conducted by a Brazilian research group investigated the effects of 
serum testosterone concentration on cardiovascular haemodynamics and exercise 
capacity in males with HF (Bocchi et al, 2008). This small study recruited 15 patients 
with HF (EF% of 23 + 7%) and erectile dysfunction. It was noted that serum TT 
correlated directly with distance walked during the 6  min walk test and inversely with 
diastolic blood pressure (BP), right and LV EF (p<0.004). The latter inverse correlation 
may suggest that serum testosterone could play a role in the pathophysiology of HF 
thereby worsening cardiac function. This could be related to the work carried out by 
Sullivan et al 1998, who suggested that anabolic steroids are cardiotoxic, by adversely 
affecting cellular and organ physiology in a similar way to cardiomyopathy. However, a 
contrasting hypothesis by numerous research groups has suggested that testosterone 
may be beneficial in HF (Malkin et al, 2006, 2009, Caminiti et al, 2009, Jankowska et al 
2006 and 2009). For instance, androgen therapy has previously been shown to improve 
coronary blood flow and also increase fractional shortening of cardiac fibres in a rodent 
model (Kontoleon et al 2003). In addition, previous randomised controlled trials have 
identified improved walking capacity, muscular strength and endothelial function in 
testosterone supplemented males with chronic stable HF (Malkin et al 2006, Caminiti et 
al 2009).
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In relation to this, another study conducted by a Polish research group (Jankowska et al 
2009) has shown that circulating serum TT independently relates to exercise intolerance 
with further decline of testosterone indicating further reductions in exercise capacity. 
This study identified 205 males with HF (mean EF% of 31 + 8 %) of NYHA Class I-IV. 
Using multivariate models, reduced peak V0 2 max, reduced peak oxygen pulse was 
associated with diminished total and free serum testosterone levels (p<0.01). In 
addition, following a further 2.4 year follow-up, additional reductions in circulating TT 
was associated with further reductions in peak V0 2 max and peak oxygen pulse (p<0 .0 1 ). 
In explanation of the importance of these results, the authors accept that the role of 
anabolic hormones in HF patients is poorly understood. They do suggest however, that 
testosterone may potentially affect some of the many complex pathways associated with 
exercise intolerance in HF. For example, testosterone can favourably affect skeletal 
muscle mass and the local synthesis of important growth factors (IGF 1) and also 
contractile protein synthesis (Balagopal et al, 1997). It has also been suggested that 
testosterone may potentially positively interact with peripheral mechanisms involved in 
HF pathology. For example, attenuation of ED (Miller et al, 2007), improvement in lung 
function (Svartberg et al, 2007), normalisation of baroreflex sensitivity and autonomic 
imbalance (El Mas et al, 2001) and increased muscle perfusion at rest and during 
exercise (Jones et al, 2004).
It has also been postulated that testosterone concentration may be responsible for 
impaired somatic health and worsened psyche in both a general and HF population 
(Shores et al, 2005, Jankowska et al, 2010). Jankowska et al 2006, studied how levels of 
circulating anabolic hormones affected depression and outcome in males with HF. 
Serum TT and dehydroepiandosterone sulphate were sampled in 163 males with stable 
HF (mean age 6 0 + 1 0  years, NYHA Class I/II/III/IV) together with 316 healthy males
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aged 35 - 60 years. Level of depression was assessed using the Beck Depression 
Inventory (BDI) and defined as a questionnaire score of > 16 points. The results of this 
research showed that the severity of depressive symptoms was increased in men with 
HF when compared to healthy controls in age groups 35-49 years (Beck Score of 9.9 ± 
7.3 versus 5.2 + 4.4 points, PcO.OOl) and 50-59 years (Beck Score of 14.3 + 11.9 versus 
9.1 + 4.3 points, PcO.OOl), but not among males aged 60-80 years. Furthermore, 
depression was found to be present in 20% of HF males without androgen deficiency, 
37% of males with either testosterone or dehydroepiandosterone sulphate deficiency and 
77% of males with deficiency of both anabolic hormones (p<0.0001). During regular 
follow-up in the outpatient clinics for a median of 28 months, there were 53% 
cardiovascular deaths or unplanned hospital admissions. Anabolic hormone deficiencies 
(< 1 0 th percentile of serum androgen in healthy controls) and high depression score 
index >16 points independently predicted unfavourable outcome (p<0.05).
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2.4: Aims and objectives.
Research directly comparing physiological, cardiovascular and psychological function 
in male HF patients with low and normal range testosterone is sparse. Separate, small 
correlation studies have attempted to identify the relationship between testosterone 
concentration and exercise capacity, ventricular function and depressive status in male 
HF patients. This study, however will aim to directly compare detailed physiological, 
cardiovascular functional and quality of life parameters in male patients with low range 
and normal testosterone concentrations. Importantly, this study has been designed to 
assess in more detail than previously undertaken the functional mechanics of the heart 
with respect to testosterone level in HF. In addition, this study is the first to recognise 
the importance of free testosterone and bio-available testosterone concentration in a 
population whom the traditional assessment of total testosterone may be an inaccuracy 
due to the deleterious effects of SHBG. Recognition of salivary testosterone 
measurement as a direct correlate of free testosterone and also its relationship to 
important outcomes assessed during the study is another important facet that may, in the 
future, reduce the need for semi-invasive blood sampling and also allow patients to 
provide their own testosterone samples for analysis.
This study aims to investigate if serum total testosterone, free testosterone, bio-available 
and salivary testosterone concentrations influence exercise capacity, levels of NT pro- 
BNP and quality of life in male HF patients. Testosterone deficiency is commonplace in 
the male HF population with approximately 25% of this population with a mean age of 
around 60 years effected. Testosterone deficiency may exacerbate symptoms of HF by 
further attenuating the pathophysiological processes involved.
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The objectives of this study are:
• To investigate whether patients with low testosterone status and HF have 
reduced exercise capacity, quality of life, together with an increased level of serum 
markers of LV impairment and attenuated indices of cardiac structure and function 
when compared to age-matched male HF patients with normal range testosterone.
• To gain an insight into the relationship between traditional serum measures of 
testosterone and salivary testosterone as a novel measure of testosterone status in the 
male HF population.
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Chapter 3. Materials and Methods.
3.1: Study design.
This was a cross-sectional study that recruited 40 male patients from the local HF clinic 
at University Hospital of South Manchester (UHSM). These patients were stratified into 
two groups of 20 based on analysis of their serum TT level. Patients with a TT 
concentration <12.0 nmol/L were defined as ‘testosterone deficient’ and those above 
this value defined as ‘normal range’. This cut off value is based on the range currently 
used by the department of clinical chemistry at University Hospital South Manchester 
NHS Foundation Trust and forms part of the local guideline for low testosterone at this 
institution. In addition, for completion, outcome measures were also assessed based on 
free and bio-available testosterone as recommended by European Endocrine Society 
practise guidelines (Bhasin et al, 2006). Consequently, a cut off of <0.17 nmol/L for 
free testosterone and < 4.0 nmol/L for bio-available testosterone were used (Bhasin et 
al, 2006 and Kapoor et al, 2007). This re-allocation of the groups resulted in 17 
participants with low FT and 23 participants with normal range FT and 17 with low, 23 
with normal range bio-available testosterone for separate analysis. All outcome 
measures were assessed immediately following group allocation and independent 
samples t-tests were used to determine if there were significant differences based on 
testosterone level. Correlation studies were also performed in order to assess the 
relationship between testosterone status and the outcome data collected. Salivary 
testosterone was collected as a novel marker in the HF population and was assessed 
against FT (previous research in healthy participants has shown FT and salivary 
testosterone to correlate highly) in order to ascertain its value in assessing hypogonadal
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status in a heart failure population without the need for semi-invasive blood sampling 
and also by way of avoiding testosterone parameters which are known to be affected by 
age, obesity, diabetes and chronic disease.
3.2: Patient selection and recruitment.
Following ethical approval from the local research ethics committee (appendix 1), 40 
male patients with stable HF were recruited from the Specialist Heart Failure Clinic at 
University Hospital of South Manchester NHS Foundation Trust. Patient’s were 
included or excluded from the study on the basis of the following grounds:
3.3: Inclusion criteria.
• Clinically stable HF prior to recruitment established on optimal medical therapy 
and without significant symptom change (using NYHA Score) for a period of 6 months.
• Evidence of at least moderate impairment of LV systolic function (defined by 
echocardiography within the last 6 months, as EF < 45%).
• Reduced exercise tolerance (limited by fatigue or breathlessness of cardiac 
origin -  i.e. NYHA Class II or worse).
• Over 18 years of age
3.4: Exclusion criteria.
• Unstable angina (defined by classical angina symptoms at rest).
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• Severe stable angina pectoris limiting the ability of the participant to perform the 
6 minute walk shuttle test.
• Recent (within the last 6 weeks) acute MI.
• Episodes of decompensated HF / clinical change in course of condition within 
the last 6 months (i.e. increasing symptoms or requirement of new treatment).
• Moderate or worse (defined by echocardiography) valvular heart disease.
• Uncontrolled hypertension (resting systolic BP >180mmHg, diastolic >90 
mmHg) -  as per defined cut off values for performing the 6 minute walk test (Crapo et 
al, 2002).
• Any orthopaedic or neurological illness limiting the ability to exercise.
• Bi-ventricular pacing device / Left ventricular assist device in situ**
**bi-ventricular pacing devices and LVAD patients were excluded because of the 
documented ability of these devices to provide improvements in exercise capacity and 
quality of life, as such, potentially confounding the data collected during this study. In 
addition, both devices artificially alter or prevent accurate measurement of a number of 
the echocardiographic parameters to be collected as part of this study.
3.5: Consent procedures.
Patients who were due to attend the specialist HF clinic were identified in advance by 
secretarial staff. These patients were sent an official study invite which consisted of a 
patient information leaflet (appendix 2), invitation letter and reply slip. All interested 
replies were collected by the lead researcher who informed clinic staff prior to the clinic 
appointment. Upon arrival at clinic, interested patients were free to ask any study 
related questions before they were consented for study participation. Consent was 
obtained by trained, experienced members of the research team and copies retained in 
the research file, patient case notes and also by the patient themselves (appendix 3).
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3.6: Withdrawal of patients.
Any patient, who at any stage of the study did not wish to continue, was able to 
withdraw, without their future medical care being affected. This information was made 
clear to each patient in the patient information sheet and throughout the study duration.
As this was a small-scale cross-sectional study without any intervention period, it was 
envisaged that there would be minimal risk to the patient. However, if during the course 
of data collection any patient became unwell or distressed, medical opinion was sought 
over their continuation in the study. Participants were monitored closely following data 
collection and, if needed, could be re-assessed by the consultant / registrar in charge 
prior to leaving the department. Any withdrawn patients were replaced in order to meet 
the required number of participants as determined by the formal power calculation.
121
Figure 2. Flow chart of patient journey and important time-points during the 
study.
Screening:
Eligible patients ascertained by Specialist 
Heart Failure Research Nurses at Heart 
Failure Clinic using case-notes to screen 
against eligibility criteria (University 
Hospital of South Manchester). 
Week: 0
 ___________________
Confirmation and Recruitment:
Eligible patients posted information leaflet 
and recruitment letter. Reply slip or phone 
call to heart failure clinic to confirm 
participation. At next clinic visit, opportunity 
to ask questions then consent taken. 
Weeks 1-26 inclusive (Visit 1)
__________________i z ___________________
Venous Blood Sampling for Testosterone 
Status:
Additional venous blood sample provided for 
analysis of total testosterone, albumin and 
sex hormone binding globulin (performed by 
Specialist Heart Failure Nurse following 
informed consent).
Weeks 1-26 inclusive (Visit 1)
__________________i z ___________________
Assessment and Analysis:
Data collection of all variables including 
shuttle walk, echocardiogram, NT-Pro BNP, 
and quality of life questionnaires (performed 
by Heart Failure Nurse / Chief Investigator).
Weeks 1-26 inclusive (Visit 1)
______________ i z ________________
Compilation of Final Report:
Data analysis and final report written. 
Weeks 26-52 inclusive.
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3.7: Sample size.
Caminiti et al (2009) have investigated the effects of testosterone supplementation on 
walking ability in 31 males with low testosterone and HF. Using the 6 min walk data 
from this research, the authors observed a baseline walking distance of 386.6 m + 121.0 
m. Following testosterone therapy, to a physiological normal range testosterone 
concentration at 3 month follow-up, walking distance significantly improved to 472.8 + 
138.4 m (p<0.05). The placebo group demonstrated a 6 min walk distance pre of 
390.9m + 107.4m and post 428.2m + 112.0m. This equates to a difference of 86.2m ± 
14.5m in the testosterone group (significant at p<0.05) and 37.3m + 8.7m (non­
significant) in the placebo group. Taking into account these data, this study will have 
80% power to detect a mean difference of at least 70 m with a minimum of 7 patients in 
each group at the conventional 5% significance level. As this is a small number of 
patients, a more conventional sample size of 20 patients per group will have 80% power 
to detect a mean difference of at least 16 m using 12 m as an estimate of the common 
standard deviation and at the 5% significance level. The common SD of change (12m) 
was estimated from both the SD pre and post testosterone therapy from the study by 
Caminiti et al, 2009 as an average value (i.e. average of + 14.5m and + 8.7m). This was 
considered the best option following expert medical statistical advice, as only summary 
data and no individual patient data from Caminiti et al (2009) were available in their 
published results.
3.8: Medical examination.
Before entering the study, each patient received a thorough medical examination 
performed by a clinician (Consultant Cardiologist or Cardiology Research Registrar),
during which details of surgical history, co-morbid conditions, risk factors and current 
medication details were confirmed. Patients were also screened in detail with regards to 
the study inclusion and exclusion criteria. Hormone profiles and concurrent medical 
drug use were also recorded at the beginning of the trial. Blood pressure (BP) was taken 
(manual sphygmomanometer) and a resting 12-lead ECG (ECG) was performed with 
the patient in the supine position. This formed part of the medical assessment. During 
this visit, initial assessments were also performed, and this was therefore classed as the 
patient’s first assessment visit. Most patients were able to complete all data collection 
during the initial visit. However, on certain occasions, patients were unable to devote 
sufficient time for this to be achieved. As a result, a separate visit was scheduled to 
complete all data collection, following further patient assessment. A second blood 
sample for testosterone analysis was taken at the next scheduled clinic visit as a way of 
confirming and standardising the classification of low or normal range testosterone. 
Time between first and second testosterone serum collections varied depending on 
clinical need for patient re-assessment. Longest duration between samples was 4 months 
and the shortest duration 4 weeks.
3.9: Summary of known and potential risks and benefits to the patient.
The potential for risks to occur were minimised, since all patients prior to study 
acceptance underwent a full clinical assessment performed by a Consultant Cardiologist 
or Research Registrar, during which details of surgical history, co-morbid conditions, 
risk factors and current medication details were confirmed. However, all exercise and 
strength assessments were monitored by qualified medical professionals who were all at
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least Intermediate Life Support Trained. In the event of a medical emergency, as this 
study was performed in a clinical environment, local protocol was to be followed.
There was minor potential for discomfort and distress during the exercise assessments. 
However, patients recovered relatively quickly and were monitored until resting values 
were obtained and also patients were free from symptoms before leaving the Heart 
Failure Clinic.
3.10: Safety assessments.
The University Hospital’s formal health and safety procedure was followed. A detailed 
safety assessment of the study was performed as per the risk assessment documentation 
by the Research and Development department.
3.11: Adverse events and SAE.
All members of the research team were at least Intermediate life support (ILS) trained. 
The Chief Investigator and the Heart Failure Research Nurses have extensive 
experience in working with patients with HF (i.e. > 10 years).
All adverse events were recorded and reported, as per case report forms. The Chief 
Investigator was responsible for completing the appropriate paperwork at University 
Hospital of South Manchester. After an adverse event, each patient was to be closely 
monitored for at least 30 days, or longer if deemed necessary.
The following were considered Serious Adverse Events for this study:-
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• Hospital admission for a cardiovascular event.
• Death during the course of the study.
All Serious Adverse Events were reported, and these followed Hospital established 
protocols. All Serious Adverse Events were reported to the Sponsor Research Office 
(University Hospital of South Manchester) within 24 hours of discovery by the research 
team. Dedicated report forms and reference documents justifying a Serious Adverse 
Event decision were also completed.
3.12: Data collection handling and record keeping.
Data were collected and retained in accordance with the Data protection Act 1998. All 
data were collected as per case report forms (appendix 2), validated and approved by 
University Hospital of South Manchester and the local research ethics committee, at the 
time points indicated on the flow chart.
At UHSM the Chief Investigator was responsible for the storage and quality of data 
collected. In relation to this, paper files of personal data were kept in a locked filling 
cabinet. All computer data was coded and stored on a ‘trust issue -  locked’ memory 
stick. Stored patient details and data were anonymous, since patients were assigned an 
identification number, to ensure confidentiality.
3.13: Outcome measures.
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Outcome measures were collected at the routine clinic visit only. However, if for any 
unforeseen reason participants needed another appointment to complete data collection, 
this was provided. No more than two appointments were required during data collection 
for the outcome measures.
3.13.1: Primary outcome measure -  6 minute walk.
The primary outcome measure was exercise capacity, assessed using the 6 minute (min) 
walk. The test was performed at the routine clinic consultation in accordance with 
normal clinical procedures and by guidelines developed by Crapo et al, 2002.
The 6 min walk is a symptom-limited exercise test designed to allow participants to 
achieve maximum effort tolerance. This test has been successfully utilised in a range of 
clinical populations but particularly pulmonary and cardiac patients. The 6 min walk has 
been used as a measurement of the response to a given intervention but also is utilised 
as a one-time measure of functional status of patients. In addition, the 6 min walk can 
be used as a predictor of morbidity and mortality (Crapo et al, 2002). There are 
numerous studies which have investigated the reproducibility and validity of the 6 min 
walk when compared to regular cardiopulmonary exercise testing in a HF population. 
Cahalin et al, 1996 showed intra-class correlation coefficients of 0.96 and moderately 
strong correlations with treadmill derived peak V02max. (r = 0.64, p=0.001). In addition, 
Morales et al, 1999 found excellent reproducibility with no significant difference 
between 3 separate tests (r = 0.98, p = 0.33) and also a moderate correlation with 
cardiopulmonary exercise testing derived V02max (r = 0.69, p = 0.001). The authors also 
stated that 6 min walk duration is an accurate predictor of V0 2 mzx values below 
Hml/kg/min'1. In more recent work, Guazzi et al, 2009, suggest strong correlations
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between 6 minute walk distance and V02max (r = 0.79, p <0.001) and VO2 at anaerobic 
threshold (r = 0.80, p <0.001). VE/VCO2 slope showed a weaker but still statistically 
significant correlation with 6 min walk distance (r = -0.463, p <0.001). The same 
authors tested day by day reproducibility of the 6 min walk in a cohort of 80 patients 
with good intra-class correlation coefficients of 0.78.
Prior to testing, patients were asked to rest for 10 min in a chair. During this time, BP 
and resting HR were recorded. Once baseline measures were taken, patients were 
advised as to how to accurately report their rating of perceived exertion. Following this, 
the timer was set and final instructions given. Participants walked back and forth along 
a horizontal 30 m course, marked out by two cones and completed as many shuttles as 
possible before the end of the 6 min period. Walking pace was determined by the 
patient and rest periods were also allowed during the 6 min period. Intermittently during 
the walking period, even tone encouragement was given as suggested by Crapo et al, 
2002. The end-point (distance walked in m) was reached when the participant failed to 
complete the shuttle before the signalled end time. Patients were monitored by trained 
medical staff during and post this assessment. Heart rate, perceived exertion and BP 
were also collected during this period.
3.13.2: Secondary outcome measures. 
3.13.2.1: Blood analysis.
Venous blood sampling was undertaken during the initial routine clinic visit and also at 
the next available clinical appointment in order to assess serum TT, free testosterone, 
bio-available testosterone, albumin and SHBG. This was in addition to routine
collection of NT-Pro Brain Natriuretic Peptide as a blood chemistry marker of HF 
severity for every patient in the HF clinic.
3.13.2.2: Serum testosterone, SHBG and albumin.
Serum testosterone measurements were collected before midday during each patient’s 
routine Heart Failure clinic appointment by the Heart Failure Specialist Nurses. In order 
to accurately determine testosterone concentration, a separate serum sample was taken 
at the following routine clinic appointment to ensure consistency of results (longest 
duration 4 months, shortest duration 4 weeks in-between first and second samples). 
Unless there was noted change from hypogonadal to eugonadal status, or vice versa, on 
analysis, patients were allocated to groups based on their initial testosterone 
measurement. If a significant change of testosterone status was noted, the patient was 
excluded from the analysis as all samples were measured retrospective to data 
collection. Previously, research has showed that testosterone concentrations are at their 
peak during the morning period and there may also be significant variation in values 
obtained on different days (Bhasin et al, 2010). Therefore, practise guidelines advocate 
measurement of serum testosterone on two separate occasions and during the morning 
period (Bhasin et al, 2010). Around 30% of males with low testosterone during the 
afternoon period have been shown to have normal testosterone concentration during the 
morning hours (Brambilla et al, 2007). In addition, the same authors also suggested that 
in an elderly population (i.e.65-80 years of age), the circadian variation in testosterone 
concentration becomes significantly blunted.
Serum total testosterone concentration represents the sum of unbound and protein bound 
testosterone within the circulation. The majority of circulating testosterone is bound to 
SHBG and albumin (Bhasin et al, 2010). A small amount of testosterone can be
described as ‘free’ -  normally in the range of 0.5-3% of total circulating concentration 
(Bhasin et al, 2008). Bio-available testosterone refers to unbound testosterone plus the 
fraction loosely bound to albumin. Albumin bound testosterone is thought to be readily 
dissociable and is therefore termed bio-available (Bhasin et al, 2010). Endocrinology 
guidelines have suggested that measurement of both free and bio-available testosterone 
are essential if total testosterone concentrations are borderline hypo / eugonadal or when 
there may be a possible alteration of SHBG. Older males, males with obesity, diabetes 
mellitus or chronic disease have been shown to present with increases in SHBG and 
thus total testosterone may not be a precise marker of androgen status in this population 
(Bhasin et al, 2008). Therefore, both free and bio-available testosterone concentration 
were calculated during this study to increase the accuracy of overall androgen status.
Although as stated previously in the thesis, there is not a widely accepted laboratory 
cut-off value for testosterone deficiency. However, general agreement states that values 
above 12nmol/L for TT do not usually require supplementation (Wang et al, 2009). 
Similarly, a widely held lower limit for free testosterone has been suggested to be < 
0.17 nmol/L (Bhasin et al, 2006). In addition, bio-available testosterone concentration 
< 2.5 nmol/L have been associated with overt hypogonadism in younger males and 
levels below 4.0 nmol/L are considered hypogonadal and are suitable for testosterone 
supplementation (Kapoor et al, 2007 and Leifke et al, 2000). In accordance with these 
pre-determined valves, classification into low or normal testosterone groups was based 
on TT < 12nmol/L, FT concentration < 0.17nmol/L and bio-available testosterone < 4.0 
nmol/L.
All serum blood samples were drawn from the antecubital vein in the supine position 
between 0800 hrs and 1200 hrs midday. Serum aliquots were prepared for storage at -
80°C in the Clinical Chemistry Department of UHSM. Total testosterone was measured 
from frozen samples using liquid chromatography mass spectroscopy using a previously 
validated method and by accredited clinical scientists (Thienpont et al, 2008). Serum 
samples (200pl), standards and quality controls were extracted with methyl-tert-butyl- 
ether (1ml). The supernatant was then transferred and the solvent evaporated. The 
residue was then reconstituted with lOOpl of 50:50 mobile phase (water or methanol) 
each containing 2mmol/L ammonium acetate and 0.1% formic acid. Extract (50pl) was 
directly injected onto a Synergi 4 pm Hydro-RP column (50x3mm -Phenomenex, 
Macclesfield, UK). Following elution from the column, each sample was directly 
pumped into the electrospray probe of a Quattro Micro tandem mass spectrometer 
(Waters, Manchester, UK). The mass spectrometer was programmed to operate in 
electrospray positive ionization mode. Analysis was performed isocratically with 70% 
mobile phase B, flow rate 0.6 ml/min for a total run time of 4.3 minutes. Primary 
transitions for the analytes TT 289 greater than 97 and d 2 TT 291 greater than 99 were 
monitored in multiple reaction monitoring quantification mode. No interfering peaks 
were found to be present in the extracted samples and infusion experiments indicated 
almost complete lack of ion suppression. The mean recovery was 93% for TT. The 
standard curve was linear to 50.0 nmol/L, the lower limit of quantification was
0.25nmol/L and inter / intra-assay coefficients were less than 10% for TT (range of 0.3-
0.35 nmol/L).
SHBG concentrations were measured from frozen serum aliquots using competitive 
chemiluninescent enzyme immunoassays on an Advia Centaur device (Siemens, 
Eschbom, Germany). Inter assay coefficient of variation of 6.6% at the 27.1 nmol/L 
level, 7.6% at the 48.2 nmol/L level and 7.7% at the 52.3 nmol/L level were determined. 
Albumin concentration was determined using the previously validated bromcresol green
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dye binding colorimetric method (Doumas et al, 1971) on a Hitachi 911 (Roche 
Diagnostics, Japan) analyser. Standard and specimen samples (2.5 ml, lOpl) were 
incubated for 5 minutes at 20-25°C and the increased absorbance of the binding dye 
complex was measured at 623nm. Within run coefficient of variation was 2.6%, run to 
run reproducibility was 3.1%.
Total testosterone, SHBG and albumin were used to calculate free and bio-available 
testosterone using an already validated formula as outlined below (Vermeulen et al,
1999).
Bio Test {(kai x [itllmrnm] x \FTj/{  1 +  Ar0| x [FT])] +  [FT]
(mol/L)
{~b  +  x/(b2 +  4 a [ r r ] } / 2 a ? in which
Free test 
(mol/L)
a = kat +  ki +  (kai x ki)([SHBG]  +  [df6wmm] ~~ [Tj) 
6 =  1 +  ki[SHBG] + &fr| -  (kai ■+ ki)\T]
The algorithm for which can be found at http://www.issam.ch and is routinely used for 
the calculation of free and bio-available testosterone concentration in research practise. 
In a critical review of this technique, Vermeulen et al, 1999 have showed that this 
calculation represents a simple and rapid method that yields free testosterone 
concentrations very close, if not identical, to those obtained by equilibrium dialysis.
3.13.2.3: Salivary testosterone.
In conjunction with the National Survey of Sexual Attitudes and Lifestyles working
group, the Department of Clinical Chemistry at UHSM have developed a liquid
chromatography tandem mass spectroscopy assay for the evaluation of salivary
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testosterone concentration. Salivary testosterone is a filtrate of plasma containing only 
the free fraction of testosterone and, as stated earlier in this review, free testosterone is 
often considered the most physiologically active form of testosterone available for 
metabolising in target tissue. Laboratory measurement of serum free testosterone is 
expensive and not a cost effective diagnostic test for most routine clinical laboratories 
and estimation of free testosterone from available formulae has little in the way of 
consensus (MacDonald et al, 2011). As a result, measurement of salivary testosterone 
could provide a more accurate and feasible alternative to traditional serum sampling.
Participants were asked to perform an un-stimulated passive drool technique. For this, 
each participant rinsed out their mouths with plain water, refrained from eating / 
drinking and did not brush their teeth for at least 30 minutes prior to the collection. To 
collect each sample, the patient was instructed to drool through a plastic straw into a 
collection vial. Samples were frozen at -80°C and stored in the Clinical Chemistry 
Department at University Hospital South Manchester. For analysis, samples were 
thawed, mixed and centrifuged. The clear supernatant was then utilised for the analysis. 
Sample preparation involved a liquid-liquid extraction requiring a 200pi sample with D. 
5 testosterone as internal standard and methyl-tert-butyl ether then placed at -80°C. 
Following 1 hour at 80°C, the organic layer was transferred and evaporated by heating 
and gentle N2 gas flow with the resultant residue reconstituted with a 500ml/L methanol 
mobile phase before transferring to a 96-well micro-titre plate. Liquid chromatography 
was performed using a Waters ACQUITY Ultra Performance Liquid Chromatography 
system (Manchester, UK) and a C l8  ACQUITY 1.8pm HSS T3 column (21x50mm) 
maintained at constant 45°C. The mass spectrometer was a Waters Quattro Premier XE 
(Manchester, UK) set to positive ionisation mode. Binary pump mixing of the mobile 
phases produced a linear gradient that increased from 50% to 90% methanol for 1.5
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minutes. Overall run time was 3.5 minutes. Testosterone and D5 testosterone co-eluted 
with clean, discrete and identifiable peaks at a retention time of 1.28 minutes. Intra-inter 
assay coefficient of variation were <15%. The mean recoveries from saliva samples at 3 
concentrations were 95.6%, 100.3% and 95.8% respectively.
3.13.2.4: Serum N Terminal Pro Brain Natriuretic Peptide (NT Pro-BNP).
The notion that the heart may have an endocrine function has previously been suggested 
almost 55 years ago when research identified that atrial dilatation resulted in natriuresis 
(Henry et al, 1956). Since then, detailed research has identified that cardiac myocytes 
constitute the major source of BNP-related peptides in the circulation with cardiac 
fibroblasts recently demonstrated to produce BNP (Tsuruda et al, 2002). In more detail, 
cardiac myocytes produce BNP pro-hormone, pro BNP, which is encoded from the 
BNP gene located on chromosome 1 (Hall, 2004). Following this, the protease furin 
splits Pro BNP into NT-Pro BNP and BNP. NT-Pro BNP is secreted following cardiac 
wall stress and as HF develops there is a shift in cardiac BNP production from the atria 
to the ventricles. Following its secretion, BNP binds to natriuretic peptide receptors A 
and C, biologically resulting in diuresis, vasodilatation, inhibition of rennin and 
aldosterone production together with attenuation of cardiac and vascular myocyte 
growth (Hall, 2004).
Many studies have now suggested the routine use of NT-Pro BNP in the diagnosis of 
HF -  as a result of LV systolic impairment (McDonagh et al, 2004). The same authors 
report that, in relation to other studies, the efficacy of using NT-Pro BNP as a diagnostic 
tool lies in its high negative predictive value. This high value makes NT-Pro BNP a 
useful marker to ‘exclude’ HF in a given population. It should be noted however, that 
elevated levels of NT-Pro BNP merely confirm an element of cardio-renal stress and not
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always LV systolic dysfunction. For instance, Me Donagh et al (2004) confirm that in 
their population of patients with elevated NT-Pro BNP, 10% of breathless patients had 
concentric LV hypertrophy without signs of systolic impairment, almost one fifth of the 
population had had a previous MI but no echocardiographic evidence of systolic 
impairment and 1 .8 % of the population had normal cardiac structure and function but 
significantly impaired renal function.
Blood samples were drawn from the antecubital vein with the patients in a supine 
position between 800 hrs and 1 2 0 0  hrs to coincide with serum samples for testosterone 
analysis. Samples were collected in pre-chilled tubes containing 
ethylenediaminetraacetic acid (EDTA), immediately placed on ice, and promptly 
centrifuged at 4°C by the research nurses in the heart failure unit. After separation, 
plasma was transferred to the Clinical Chemistry Department at University Hospital 
South Manchester and stored at -80°C. NT-pro BNP analysis was undertaken using an 
ELISA—a two step sandwich assay with streptavidin coated microtitre plates -  a 
technique already validated by Karl et al, 1991. The streptavidin assay does not require 
sample extraction and there is no detectable cross reactivity with ANP, NT-pro ANP, 
BNP, or urodilatin. The inter-assay and intra-assay coefficient variances were 10% and 
3% respectively. Sample recovery was between 104% and 112%.
3.13.2.5: Echocardiography.
Morphological and functional changes in cardiac structure and function were assessed 
using a commercially available ultrasound device (GE, Vingmed, Vivid 7, Norway) and 
dedicated 3.5 MHz phased array ultrasonic transducer. Each patient was assessed using 
guidelines produced by the American Society of Echocardiography (Gottinger, 2004).
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All echocardiographic measurements were averaged over 3 cardiac cycles for patients in 
sinus rhythm. If patients were found to be in atrial fibrillation at the time of 
echocardiography, 5 cardiac cycles were recorded and subsequently analysed. No 
analysis was performed on or immediately prior to ectopic beats. For analysis based on 
two dimensional (2D) speckle tracking echocardiography, stable R-R intervals were 
selected in order to further increase accuracy of the analysis.
Echocardiography is one of the most commonly performed non-invasive techniques in 
the assessment of patients with known or suspected cardiovascular disease, providing a 
comprehensive evaluation of cardiovascular structure, function and hemodynamics. 2D 
(B mode) echocardiography displays cardiac images in real-time, allowing the operator 
to obtain multiple anatomic ‘slices’ of the heart by precise angulation of the 
echocardiographic transducer.
M-mode echocardiography is a continuous 1-dimensional display of structures along a 
single anatomic line versus time and, because of its high temporal resolution, can be 
used to accurately assess valve / chamber motion and measure diameter changes over 
time. Doppler echocardiography uses ultrasonic reflections from moving red blood cells 
in order to characterise flow in the central and peripheral circulation. Therefore, this 
technique can be used during echocardiography in order to assess systolic and diastolic 
flow through valves, within the cardiac chambers and also in the major cardiac vessels. 
The four main types of Doppler used include pulsed wave, continuous wave, tissue and 
Colour. Pulsed wave Doppler can detect flow in a localised area and that is moving 
within the physiological range of velocities. Continuous wave Doppler is useful for 
measuring gradients across pathological flow jets. Colour flow mapping displays 
information as colour coded pixels (toward and away from the echo transducer) in order
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to display blood flow over a relatively large area. This technique is useful for evaluating 
flow through valves, assessing diastolic and systolic flow, assessing intra-cardiac shunts 
and measuring coronary flow.
Tissue Doppler is a relatively new technique used to detect movement of the 
myocardium over time. This technique has proved important in evaluating diastolic 
function and systolic function. In addition, during this initial study, myocardial strain 
was assessed using a comprehensive commercially available analysis system (EchoPac, 
GE, Vingmed, Norway). Longitudinal systolic strain involves assessment of the 
longitudinal myocardial fibres responsible for longitudinal shortening in systole. As the 
LV shortens in systole, thickening of the walls must also occur in order to maintain wall 
volume in an in-compressible structure (myocardium). Wall thickening reflects the 
contraction of individual muscle fibres in all directions and therefore as the outer 
contour shows little change during systole, the ventricle must also thicken inwards as 
the long axis length reduces in systole (Stoylen, 2011). As a result of this, longitudinal 
shortening also determines systolic wall thickening. Circumferential strain or mid-wall 
circumferential shortening is dependent on LV diameter only (Stoylen, 2011). 
Therefore, circumferential shortening is an inward movement of the circumferential line 
due to systolic wall thickening and as such is derived by cavity diameter, wall thickness 
and wall thickening.
For the echocardiographic assessment, participants lay in the left lateral position and 
images were obtained in concordance with the standardised minimum dataset for 
echocardiography in the UK (Chambers et al, 2009) by an experienced and accredited
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cardiac sonographer. During the echocardiographic assessment, the following 
parameters were measured:
1. Detailed volumetric assessment of the left atrium was performed in both the
apical 4 and apical 2 chamber imaging planes. Volumetric assessment was carried out in 
a similar fashion to the Biplane Method of Discs used for LV volumetric assessment. 
Accurate tracing of the left atrial border from the mitral valve annulus was performed at 
various points within the cardiac cycle and averaged according to 4 and 2 chamber 
values. Using this data, the following LA volumetric data could be calculated according 
to methods detailed by Todaro et al, 2012.
a. Left atrial pre-contraction volume ( V preA) corresponding to the onset of 
the P wave on the surface ECG.
b. Minimal left atrial volume ( V min), measured on mitral valve closure at 
end-diastole.
c. Maximal left atrial volume (Vmax), measured immediately prior to mitral 
valve opening at end-systole.
Accordingly, these values were used to calculate further parameters relating to left atrial 
active volumetric assessment as detailed by Nikitin et al, 2003.
a. Left atrial active emptying fraction (LA-AEF%) ( V prCA -  V min) /  V prCA x 100
b. Left atrial expansion index (LA-EI) ( V max -  V mjn /  V mm) x 100
c. Left atrial passive emptying fraction (LA-PEF%) (Vmax -  VprCA) / Vmax x 100
For patients who presented in atrial fibrillation at time of echocardiogram, pre
contraction volumes were not calculated due to the absence o f ‘p ’ wave on the surface
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ECG. As such, for these patients, LA active and passive emptying fractions were not 
able to be calculated.
2. Left ventricular end-diastolic diameter was measured from both parasternal long 
axis images and also apical 4 chamber images at end diastole. In addition, LV long axis 
end-diastolic length was assessed from apical 4 chamber images -  measured from the 
level of the mitral valve annulus to the LV apical endocardial border definition. The 
ratio of LV short to long axis ratio was calculated (from the 4 chamber measurements) 
in order to obtain the Sphericity Index -  an indicator of LV remodelling (Obeidat et al, 
2004).
3. Left Ventricular EF was calculated using Simpsons Biplane Method of Discs in 
patients with clear-enough echocardiographic windows. This required accurate tracing 
of the endocardial border at end diastole and systole in both apical 4 and apical 2 
chamber image planes using the mitral valve annulus as the base for the measurement. 
The percentage change in LV volume between these cycles was expressed as percentage 
EF and average values of 4 and 2 chamber measurements taken.
4. Sophisticated echocardiography analysis software (Q-analysis, GE Medical, 
Norway) was used in order to calculate longitudinal and circumferential left ventricular 
strain. Longitudinal strain was measured from the apical 4 and 2 chamber image planes 
together with the apical long axis view and averaged over at least 3 cardiac cycles with 
stable R-R intervals. Images were optimised for depth and sector width in order to 
promote accurate tracing of the myocardium with a minimum of 1 2  markers, allowing 
for detailed assessment of myocardial speckle tracking throughout the cardiac cycle. 
Images were acquired with frame rates between 60 and 80 per second according to pre­
determined best practise criteria (Mor-Avi et al, 2011) and with the intention of
avoiding loss of speckles or detriment to spatial resolution. Correlation of myocardial
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movement with the marked area was checked and adjusted if necessary to ensure 
detailed tracking of the myocardium throughout the cardiac cycle. Longitudinal strain 
was measured as the observed shortening between myocardial speckles at end-systole as 
the aortic valve closes and also the peak systolic strain value, regardless of aortic valve 
closure. Timing calibration was achieved by using Doppler echocardiography of the 
aortic valve and the R wave on the ECG in order to accurately determine aortic valve 
opening and closure thereby defining systole accurately. Timing of R wave to aortic 
valve opening, aortic valve opening to aortic valve closure and R wave to aortic valve 
closure were all measured.
5. Circumferential strain was assessed in the parasternal short axis view. Accurate 
myocardial tracing was performed at the level of the mitral valve annulus, papillary 
muscle and also cardiac apex -  defined as more distal to the papillary muscle structure 
and with none or the smallest view of the right ventricle that was achievable. The 
average circumferential shortening of myocardial fibres was calculated at end systole 
upon aortic valve closure -  defined as per the timing cycles outlined earlier. In addition, 
circumferential strain at the mitral valve level and at the apex was used in order to 
calculate ‘twist’ in degrees’ using the formula of mitral valve level (basal) rotation -  
apical rotation. In addition to this, left ventricular twist / untwist rates together with 
basal and apical rotation rates and time to left ventricular untwist / peak basal and apical 
rotation rate were measured from the circumferential strain curves. It should be noted 
that the terms twist, rotation and torsion are often used interchangeably and may 
represent different facets of cardiac mechanics depending upon the research group. 
During this study, rotation was defined as rotation of sections of the myocardium in the 
parasternal short axis imaging plane as viewed from the apical end and also defined as 
the angle between radial lines connecting the centre of mass of each specific cross
sectional plane to a specific point within the myocardial wall (Henson et al, 2000).
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Twist, as mentioned previously was defined as the absolute base to apex difference in 
rotation and is most commonly expressed as the net LV twist angle (Henson et al,
2000). In this study, torsion was simply derived from net LV twist angle normalised for 
base to apex distance (Russell et al, 2009).
It is a widely held notion that the left ventricular base and apex rotate in opposite 
directions. During isovolumetric contraction the LV apex initially rotates slightly 
clockwise before, during LV ejection, rapidly rotating oppositely in the counter­
clockwise direction (Narula et al, 2007). At the apical level, this counter clockwise twist 
seen during ejection is immediately followed by untwisting (clockwise rotation) during 
isovolumetric relaxation and the early diastolic period. Basal left ventricular rotation is 
observed at lower magnitude to the apex (Sengupta et al, 2008). Additionally, rotation 
at this level is opposite to that observed at the apex with brief counter clockwise rotation 
during isovolumetric contraction and clockwise rotation during the ejection phase. 
Naturally, there is counter clockwise rotation during isovolumetric relaxation and the 
early diastolic filling period (Sengupta et al, 2008). Of course, this mechanical 
movement of the myocardium during the cardiac cycle is closely related to myofibrillar 
geometry. As such, within the myocardium, myofibre geometry alters from a right 
handed helical structure at the sub-endocardium to a left hand structure at the level of 
the sub-epicardium (Taber et al, 1996). Therefore, it results that contraction of the 
epicardial fibres will result in apical counter clockwise rotation and basal clockwise 
rotation and the opposite phenomenon when the subendocardial fibres are activated. 
Due to the greater wrap around distance for the epicardial fibres, they become the 
dominant force when both types of fibres are activated simultaneously (Sengupta et al, 
2008). At the onset of ventricular electromechanical activation, the natural cardiac 
conduction system results in initial activation of the mid-apical septal subendocardial
layer and as such the activation transmits from apex to base. As the subendocardial
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fibres contract, subepicardial fibres become stretched to result in the initial clockwise 
rotation of the LV apex (Taber et al, 1996). Electrophysiological activation from the 
endocardium to epicardium results in subsequent fibre shortening with the subepicardial 
fibres producing the highest torque due to their greater radius and therefore dominating 
the rotational direction to counter clockwise at the apex and clockwise towards the base. 
The subsequent twisting and shearing of the subendocardial fibres during the ejection 
period, results in the storage of potential energy which is of paramount importance for 
diastolic recoil (Bell et al, 2000). This torsional recoil is facilitated by lengthening- 
shortening gradients in the LV wall with epicardial lengthening at the base / shortening 
at the apex as opposed to endocardial shortening at the base / lengthening at the apex 
resulting in an untwisting motion opposite to that of the ejection phase (Sengupta et al, 
2008). This simultaneous shortening and lengthening at the base and apex allows 
diastolic restoration without change to LV volume.
6 . Myocardial speckle tracking techniques were used in a similar manner to that 
employed when assessing LV longitudinal strain for the left atrium in apical 4 chamber 
images. Images were optimised for depth and sector width in order to achieve frame 
rates in the region of 60-80 frames per second. Following this, the left atrial border was 
carefully marked with at least 12 points to allow accurate tracing of the atrial walls. The 
mitral valve annulus was used as the base for these measurements. Care was taken to 
avoid tracking the pulmonary veins and also to ensure atrial septal movement was 
accurately mimicked. All atrial strain parameters were averaged over 3 cardiac cycles in 
sinus rhythm and at least 5 cycles in atrial fibrillation. NB. As with the aforementioned 
LA mechanical volumetric measurements, patients in atrial fibrillation at the time of 
echocardiography did not have atrial contractile properties measured. From the ensuing 
left atrial strain curves, the following parameters were assessed:
a. Peak longitudinal strain of the contractile period.
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b. Peak longitudinal strain of the reservoir period.
c. Peak longitudinal strain of the conduit period.
In more detail, myocardial shortening during the LA contractile period normally results 
in negative strain values. Strain values obtained for the reservoir phase (during 
ventricular systole) are normally positive due to the dilatation and stretch of the atria as 
the ventricle contracts. Left atrial conduit function is largely dependent upon LV 
relaxation and preload with the transfer of blood to the LV being accompanied by LA 
shortening giving rise to negative strain values (Todaro et al, 2012).
7. Tissue Doppler imaging was used to assess indices of both LV longitudinal 
systolic function and LV diastolic function together with their detailed relationship 
(Vinereanu et al, 2005).
a. Longitudinal LV Systolic Function by Tissue Doppler Imaging.
The apical 4 chamber view was obtained and optimised in order to improve image
quality, ensure accurate Doppler beam alignment and promote higher frame rates. 
Tissue Doppler Imaging was selected and the pulsed wave Doppler cursor placed over 
the septal (medial) and lateral positions of the mitral valve annulus. On the resultant 
tissue Doppler display, longitudinal systolic velocity was measured by placing a cursor 
upon the maximum systolic velocity (s’) noted for each myocardial wall and averaged 
to give S’ in cm/s (Ho and Solomon, 2006).
b. LV Diastolic Function by Tissue Doppler Imaging.
In order to assess LV diastolic function using TDI, all measurements were taken in the 
apical 4 chamber view -  optimised as previously mentioned to promote high frame rates 
and optimum Doppler alignment. Conventional LV inflow velocities (E and A wave)
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were assessed at the tips of the mitral leaflets using pulsed wave Doppler with 
optimised scale settings. Average E velocity over 3 or 5 consecutive beats was recorded. 
In addition to this, tissue Doppler imaging was obtained as above at the septal (medial) 
and lateral walls. E ’ velocity was measured and averaged over 3 or 5 consecutive beats 
and also averaged over the medial and lateral walls. E/E’ ratio was calculated to give an 
indicator of LV diastolic compliance (Nagueh et al, 1997).
In addition to left heart mechanical and functional assessment, the right heart was 
studied in detail for mechanical and functional properties. All measurements were 
undertaken on 3 separate cardiac cycles in sinus rhythm and 5 cycles when patients 
were in atrial fibrillation. Mechanical 2D speckle tracking and TDI parameters were 
measured with as constant as possible R-R interval in order to maintain consistency 
between measures. Using standard 2 dimensional imaging, the following parameters 
were assessed:
1. In the apical 4 chamber image plane, sector width and depth settings were 
adjusted in order to focus directly on the right atrium. When this was achieved, the 
image was frozen in systole when the tricuspid valve leaflets were closed. Careful 
border tracing of the right atrial area was undertaken using the tricuspid valve annulus 
as a base for the measurement.
2. In the same apical 4 chamber window, images were then optimised in order to 
accurately assess the right ventricle. In this view, right ventricular diastolic and systolic 
area was traced with reference to ECG timing of the cardiac cycle. Using the derived 
diastolic and systolic areas, right ventricular fractional area change % was calculated 
with the following formula:
(RV end diastolic area -  RV end systolic area / RV end-diastolic area)
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3. M-mode echocardiography was used to measure Tricuspid Annular Plane 
Systolic Excursion (TAPSE) from apical 4 chamber images. The m-mode cursor was 
placed through the anterior aspect of the tricuspid valve annulus ensuring that each 
image was ‘on axis’ and in-line with the m-mode cursor. Movement of the annulus 
towards the apex was recorded against time and this distance measured during systole. 
TAPSE is a measure of right ventricular longitudinal systolic function and hence a 
correlate of overall right ventricular systolic function (Zeinah et al, 2009).
4. Longitudinal strain of the right ventricle was measured from the apical 4 
chamber image plane and averaged over at least 3 cardiac cycles with stable R-R 
intervals. Images were optimised for depth and sector width in order to promote 
accurate tracing of the myocardium with a minimum of 1 2  markers, allowing for 
detailed assessment of myocardial speckle tracking throughout the cardiac cycle. 
Images were acquired with frame rates between 60 and 80 per second according to pre­
determined best practise criteria (Mor-Avi et al, 2011) and with the intention of 
avoiding loss of speckles or detriment to spatial resolution. Correlation of myocardial 
movement with the marked area was checked and adjusted if necessary to ensure 
detailed tracking of the myocardium throughout the cardiac cycle. Longitudinal strain 
was measured as the observed shortening between myocardial speckles at end-systole as 
the pulmonary valve closes and also the peak systolic strain value, regardless of 
pulmonary valve closure. Timing calibration was achieved by using Doppler 
echocardiography of the pulmonary valve and the R wave on the ECG in order to 
accurately determine pulmonary valve opening and closure thereby defining right 
ventricular systole accurately. Timing of R wave to pulmonary valve opening, 
pulmonary valve opening to pulmonary valve closure and R wave to pulmonary valve 
closure were all measured.
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3.13.2.6: Health related, disease specific and psychological quality of life.
Both HF and androgen deficiency are characterised by low mood and depression, which 
is improved by testosterone replacement therapy in testosterone deficient subjects. 
Thus, patients were instructed to complete the Minnesota Living with Heart Failure 
questionnaire (MLHFQ), the short form 36 version 2 (SF-36 v2) Health Survey, the 
Beck Depression Inventory (BDI) and the Androgen Deficiency in the Adult Male 
Screening Questionnaire (ADAM).
3.13.2.7: Minnesota Living with Heart Failure Questionnaire (MLHFQ).
The MLHFQ (appendix 4) has been designed as a disease-specific measure of quality of 
life in patients with HF (Rector et al, 1987). This questionnaire is designed to assess 
each participant perception of the effects of HF on the physical, socio-economic and 
psychological aspects of their life. There are a total of 21 questions with responses using 
a six-point Likert Scale (0-5). This questionnaire is simple to administer and relatively 
easily understood. This questionnaire has previously been shown to be valid in 
comparison to other health outcome scales where it has also demonstrated to 
differentiate between those patients with HF and more symptomatic LV impairment 
(Berry et al, 1999 and Gorkin et al, 1993). Test-retest techniques have suggested that 
initial low-scores had a tendency to increase and initial high scores tended to decrease 
following the second administration of the questionnaire (Bowling, 2001). Slight 
concerns have been raised suggesting that using the sub-scales may be less accurate in 
the quality of life assessment when compared to using the overall score (Sneed et al,
2 0 0 1 ), hence in this study, total overall questionnaire score will be utilised.
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3.13.2.8: SF-36 Version 2 Questionnaire.
The SF-36 Version 2 (appendix 5) is a 36 item questionnaire that measures eight multi­
item dimensions of general health. These include physical functioning (10 items), social 
functioning (2 items), role limitations due to physical problems (4 items), role 
limitations due to emotional problems (3 items), mental health (5 items), energy / 
vitality (4 items), pain (2 items) and general health perception (5 items). For each of 
these dimensions, item scores are coded, summed and transformed onto a scale ranging 
from 0  to 1 0 0  with zero being the worst possible health state and a hundred the best 
possible state. In addition, two further standardised summary scores can be calculated 
namely, the physical component and mental health component summary. Improvements 
have been made in the development of the SF-36 Version 2 when compared to the older 
version 1. Most notably improvements to both instruction and question wording have 
made the questionnaire less ambiguous and have removed the contentious double 
negative noted in the older version (Jenkinson, 1995). More recent research by 
Jenskinson and co-workers (1999) has shown that the SF-36 Version 2 has good internal 
validity when utilising Cronbach’s alpha statistic. Furthermore, the authors suggested 
that internal reliability statistics for the two role-functioning dimensions are higher than 
previously reported for the SF-36 Version 1. As claimed by the developers of the 
Version 2 questionnaire, fewer floor and ceiling effects were noted in the Oxford 
registry (1.32% of respondents scoring zero and 56.29% scoring 100 using version 2 
versus 7.16% versus 75.5% respectively for version 1 when observing role-physical 
dimensions).
3.13.2.9: Beck Depression Inventory (BDI).
The BDI (appendix 6 ) is the most commonly used tool for the self-assessment of 
depression in clinical research (Gottleib et al, 2004). The BDI is a short questionnaire
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containing 21 items with 4 response outcomes. The questionnaire is easy to administer 
and has a reading level equivalent to that of the fifth grade in the USA. As such, the 
scale is designed to rate the severity of depression in individuals aged over 13 years. 
Previous assessment of the scale by Beck and colleagues (1988), has shown high levels 
of internal consistency both in psychiatric (0 .8 6 ) and non-psychiatric participants (0.81). 
Furthermore, the concurrent validity of the BDI with respect to clinical ratings of 
depression and the Hamilton Psychiatric Rating Scale for Depression (HPRSD) have 
been reported to be high (Beck et al, 1988). This research identified mean correlations 
of the BDI samples (in psychiatric patients) with clinical ratings and HPRSD of 0.72 
and 0.73 respectively and 0.60 and 0.74 respectively in a non-psychiatric population. 
Depressive status is defined as a questionnaire score of >10.
3.13.2.10: Androgen Deficiency in the Ageing Male Questionnaire (ADAM).
The ADAM questionnaire (appendix 7) consists of 10 items with simple yes or no 
answers. Low testosterone status is defined as a total of 3 ‘yes’ answers or answering 
‘yes’ to questions 1 or 7 alone. The initial validation study of the ADAM questionnaire 
sampled 316 Canadian physicians aged between 40-62 years in the hope that the authors 
could identify a symptom complex to correlate with low testosterone levels (Morley et 
al, 2000). Low bio-available testosterone was noted in 25% of this population and the 
ADAM questionnaire was found to have 8 8 % sensitivity and 60% specificity to low 
serum testosterone level. Test-retest reproducibility demonstrated a coefficient of 
variation of 11.5%. Furthermore, following treatment of testosterone deficiency in a 
subset of the same population, the ADAM questionnaire was found to demonstrate an 
improvement in score in 18 out of 21 patients (p = 0.002). Although sensitivity is high, 
specificity is commonly regarded as low for this questionnaire due to the recognition 
that depression, as well as a number of symptoms commonly seen in the older person,
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will confound the attempts to successfully screen this population using a questionnaire 
based technique (Morley et al, 2006).
3.14: Measurement error.
A cohort of 10 patients was selected in order to assess the reproducibility of the main 
outcome measures. This included 6 min walk distance and important echocardiographic 
parameters. Reproducibility was assessed using the relative technical error of 
measurement (TEM) and expressed as percentage error by the formula below:
%TEM = (TEM / [M1+M2] / (2) x 100 
Where Ml is the mean of the first series of measurements, M2 is the mean of the second
series of measurements.
It should be noted that the % value obtained pertains to % change from the previous 
measurements and not an actual % unit difference from the last measurement (when 
measurements are expressed in terms of %). For example, a TEM% of 3 relates to a 3% 
error in the measurement in subsequent analyses and not a change from perhaps 28% to 
31%.
Bland Altman plots were also used in order to assess the test-retest agreement between 
initial and second TT, bio-available and FT measurements and also the agreement 
between serum FT and salivary testosterone concentration.
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3.15: Analysis of results.
Data were analysed using specialised statistical software (SPSS Version 18, Chicago, 
Illinois), by the Chief Investigator. Data were initially tested for normal distribution 
using the Shapiro Wilk statistical test due to the sample size being less than 50. Any 
data not normally distributed were transformed logarithmically and re-assessed for 
normality prior to analysis. Previously transformed data were back transformed and 
presented in the tables as geometric means. Independent samples T-tests were used to 
examine if there was a significant difference in the outcome measures between ‘low’ 
and ‘normal’ range testosterone. Furthermore, analysis of co-variance (ANCOVA) 
statistic was used to formally assess the effect of age on the primary outcome measure 
(6 min walk capacity) due to its role as a significant confounding variable and the noted 
small baseline difference in age between the groups. In addition, Pearson’s product 
moment correlation coefficient (r) was used to formally assess for bivariate 
relationships between traditional serum and salivary testosterone and pertinent outcome 
measures collected during this study. Significant correlations were set at the level 
p<0.05. All data are expressed as mean + standard deviation unless otherwise stated. 
Bland Altman plots were also used in order to assess the accuracy of traditionally 
mathematically calculated testosterone values to newer clinical measurement techniques 
and to graphically represent the differences in testosterone concentration samples from 
different clinic visits.
3.16: Quality control assurance and direct access to source documents.
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Quality control of the study was maintained by the Chief Investigator in collaboration 
with the local research ethics committee and the Sponsor research and development 
department. All appropriate risk assessments were in place prior to commencement of 
the research and also reviewed throughout the study period. The research team were 
able to provide access to source documents for inspection by authorised outside 
agencies upon written request.
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Chapter 4. Results.
4.1: Demographic Data.
A total of 76 patients were identified from the screening of patient case notes in the 
UHSM specialist heart failure clinic. Of these, 20 patients (26%) did not reply to their 
initial invitation letter and 8 (11%) patients replied as ‘not interested’ without any 
documented reason. Of the remaining 8 patients (11%) who replied as ‘not interested’, 
the most common reasons were lack of time or work commitments -  particularly due to 
the risk of over-running parking time or not wishing to pay more money for the car­
park. Other, more rare, reasons included co-morbidities preventing exercise -  such as 
previous cerebrovascular accident (CVA) (1 patient) or osteoarthritis (1 patient). As this 
initial study was not interventional, all outcomes were collected at this initial visit 
resulting in 100% compliance and no drop-out. Figure 3 below details recruitment to the 
study. The two groups were well-matched at baseline for key variables when grouped 
for TT, FT and bio-available testosterone with no significant differences observed 
between the groups with the exception of testosterone status (P<0.01). Table 9 details 
the baseline demographics for the study sample based on serum total testosterone.
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Figure 3. Recruitment summary.
76 patients identified as eligible from screening of case notes in the 
heart failure clinic at UHSM.
16 patients not 
interested.
8 no reason No further contact
documented. made.
r r
20 patients did not 
reply to invitation.
8 patients with documented 
reasons:
Lack of time due to work 
commitments (4).
Unwilling to pay for 
further car park fees or 
time running out in car 
park (2).
Unable to exercise due to 
prior CVA (1).
Unable to exercise due to 
osteoarthritis (1).
40 patients interested and 
recruited following informed 
consent and checks against 
entry criteria.
40 patients completed data collection.
Defined as TT deficient 
(n = 20), FT deficient (n = 17), Bio- 
available testosterone deficient (n = 
16).
Defined as normal range TT
(n = 20), normal FT (n = 23), normal
bio-available testosterone (n = 24).
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Table 10 presents the relative technical error of measurement of the outcome measures 
assessed in a cohort of 10 patients who underwent identical assessments on a second 
occasion.
Table 10. Measurement error for key outcomes.
Error expressed as percentage change between first and second measurement.
Test TEM% (n=10)
6 min shuttle walk 4.18
EF% 8.47
Max LA volume 6.24
LA expansion index 6.60
TDI LA ventricular systole 4.65
Peak LA strain (reservoir) 4.98
LV peak systolic torsion 7.20
LV peak untwist rate 8.74
Twist 9.21
Circumferential strain 7.24
Longitudinal strain 7.65
Sphericity index 6.40
LV diastology (E/E’) 4.21
LV longitudinal function (S wave) 4.87
TAPSE 3.10
RV fractional area change 5.74
RV peak systolic strain 3.98
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(min) minute, (EF%) ejection fraction, (max) maximum, (LA)left atrial, (TDI) tissue 
D oppler imaging, (LV) left ventricular, (TAPSE) tricuspid annular plane systolic  
excursion, (RV) right ventricular).
All outcome measures above demonstrate satisfactory technical error of measurement -  
all comfortably within 10% difference between repeated measurements. Left ventricular 
twist and untwist demonstrate the most erroneous measurement errors. However, this 
may be due to their reliance on other echocardiographic measures (apical and base 
rotation) in order to be calculated. The main outcome measure (6 min walk) 
demonstrates excellent reproducibility with a measurement error of 4%.
The Bland Altman plot (figure 4) shows the agreement between initial and subsequent 
measurement of total testosterone performed on a separate clinic visit.
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Figure 4 Bland Altman plot showing the agreement between total testosterone 
measurements on two separate occasions.
Minimum 4 weeks between initial measurement, maximum 4 months to coincide with 
routine clinic visit.
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The Bland Altman plot shows a mean difference between TT measurements of 0.15 
nmol/L (s.d. + 2.05 nmol/L). Therefore, the mean difference + 2 s.d. is + 3.95 nmol/L 
and -  4.26 nmol/L. The coefficient of repeatability is 5.10 nmol/L. Greater than 95% of 
measurements fall acceptably within the limits of agreement of + 2 s.d. The outlying 
measurements did not represent a change of testosterone status (i.e. there was no change 
from hypo to eugonadal status between measurement 1 and measurement 2).
4.2.1: Primary outcome measure -  6 min walk test.
Table 11 highlights the data from the 6 min walk test for patients grouped by total 
testosterone.
159
160
4.3: Secondary outcome measures.
4.3.1: Echocardiography.
Tables 12-14 show the echocardiographic measures used to assess, in detail, cardiac 
structure and function. Independent samples T-test data are presented as mean + s.d.
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Based on TT and using echocardiography, there were no significant differences 
observed between the groups in the detailed assessment of right heart structure and 
function.
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4.3.2: Quality of Life.
Figure 5 illustrates the SF36 Version 2 quality of life data for the low and normal range 
total testosterone groups
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Figure 5. SF36 Domains based on total testosterone status.
Based on independent samples T-test data, ^indicates P<0.05 and * indicates PcO.Ol. 
Error bars are representative of s.d.
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Figure 5 above illustrate numerous significant differences in SF36 domain score in the 
normal range testosterone group when compared to low range testosterone. There is a 
significantly higher score in the general health domain in the normal range testosterone 
group (p<0.05, 36.84 + 2.85 low versus 59.44 + 3.24 normal). In addition, all physical 
components of the SF36 demonstrate significantly higher scores in the normal 
testosterone HF patients (bodily pain 48.86 ± 12.21 low, 64.14 + 3.72 normal; role 
physical 36.25 + 22.63 low versus 71.25 + 21.4 normal; physical function 38.5 + 19.94 
low versus 67.5 ± 22.27 normal -  all p<0.001). As a result, the overall physical 
component summary score is significantly higher in the normal range testosterone 
patients (41.39 ± 17.03 in the low versus 69.69 ±19.71 in normal, p<0.01).
Similar differences are also noted in the mental domains of the SF36. Social functioning 
and role emotional domains are significantly higher in the normal testosterone group
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with p<0.01 (social functioning 55.20 + 2.43 in low compared to 76.73 + 2.16 in normal 
and role emotional 42.90 + 6.55 in low versus 73.96 + 2.46 in the normal). Additionally, 
vitality scored significantly higher in the normal testosterone group when compared to 
low testosterone (44.38 + 22.95 low compared to 59.25 + 17.96 in normal, p<0.05). The 
mental health domain of the SF36 did not demonstrate a statistically significant 
difference between the two groups (p = 0.26). Overall mental component summary was 
significantly higher in the normal testosterone HF patients (54.88 + 17.52 low when 
compared to 72.36 ± 16.58 in normal).
Table 15 illustrates the effect of testosterone status on disease specific quality of life 
using the MLHFQ, ADAM and depression status using the BDI.
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Table 15. MLHFQ, ADAM and BDI score based on total testosterone status.
Independent samples T-test. Significance at P <0.05 is highlighted with *. ** indicates 
P<0.01.
Low-range 
testosterone (n=20)
Normal-range 
testosterone (n=20)
P value
MLHFQ Score 42.31 ±20.16 32.25 ± 27.40 0.20
BDI Score 9.74 ± 6.2 6.7 ± 6.38 0.14
ADAM Score 5.41 ± 1.08 2.67 ± 0.88 0.03*
(MLHFQ) M innesota Living with H eart Failure Questionnaire, (BDI) Beck D epression
Inventory, (ADAM) Androgen deficiency in the ageing male.
There were no significant differences seen between MLHFQ score or BDI between the 
low and normal range testosterone HF patients. Low testosterone patients demonstrated 
a significantly higher ADAM score (p<0.05).
4.3.3: NT Pro BNP.
Table 16 summarises the levels of NT pro-BNP in participants with low and normal 
range TT.
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Table 16. NT pro-BNP based on total testosterone status.
Independent samples T-test. Significance at P <0.05 is highlighted with *. ** indicates 
P<0.01.
P value
Low-range total Normal-range total
testosterone (n=20) testosterone (n=20)
NT pro-BNP (pg/L) 129.36 ± 100.92 119.54 ±92.21 0.45
(NT Pro-BNP) N-term inal p ro  brain natriuretic peptide, (pg /L ) picogram s p e r  Litre
There were no observed significant differences in NT pro-BNP based on total 
testosterone status between the low and normal testosterone groups.
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4.4: Analyses based on free testosterone.
In addition to measurements of TT, recommendations by the European Endocrine 
Society suggest a thorough analysis of testosterone deficiency requires calculation of 
FT, particularly in conditions were there may be alterations in SHBG. As a result, the 
following section of results summarises the difference in key outcome measures using a 
FT concentration of < 0.17 nmol/L as a cut off value for low FT status in accordance 
with practise guidelines (Bhasin et al, 2006).
4.4.1: Adjustment of baseline demographics.
As a result of the change in groups, the baseline demographics for the analysis are 
presented in table 17. It should be highlighted that following adjustment of the low and 
normal groups based on FT, the group numbers change to n = 17 low free testosterone 
and n = 23 normal range free testosterone.
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The following Bland Altman plot (figure 6) shows the agreement between initial and 
subsequent measurement of free testosterone performed on a separate clinic visit.
Figure 6. Bland Altman plot for the agreement between free testosterone 
measurements on two separate occasions.
Minimum 4 weeks between initial measurement, maximum 4 months to coincide with 
routine clinic visit.
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This Bland Altman plot shows a mean difference between FT measurements of 0.004
nmol/L (s.d. + 0.0025 nmol/L). Therefore, the mean difference + 2 s.d. is + 0.055
nmol/L and -  0.046 nmol/L. The coefficient of repeatability is 0.0050 nmol/L. Greater
than 95% of measurements fall acceptably within the limits of agreement of ± 2 s.d. The
outlying measurements did not represent a change of testosterone status (i.e. there was
no change from hypo to eugonadal status between measurement 1 and measurement 2).
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4.4.2: Primary outcome measure -  6 min walk.
Table 18 shows 6 min walk data based on FT status. Note, again as a result of FT 
calculation, the group distributions change resulting in n = 17 low FT and n = 23 normal 
FT.
Table 18. 6 min walk data based on free testosterone status.
Independent samples T-test. Significance at P <0.05 is highlighted with *. ** indicates 
P<0.01.
Low-range free 
testosterone (n=17)
Normal-range free 
testosterone (n=23)
P value
6 min walk distance 249.00 ±111.35 413.04 ±127.09** <0.01
(m)
(m) metres,
Patients with low FT demonstrated a significantly impaired exercise capacity when 
compared to those patients with normal range FT (249.00 ± 111.35 versus 413.04 + 
127.09 m, P <  0.001).
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4.5: Secondary outcome measures.
4.5.1: Echocardiography.
Table 19 below illustrates differences in key echocardiographic variables of cardiac 
structure and function between HF patients with low FT and normal FT.
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There was a significant difference only in apical back rotation rate (P = 0.02) between 
low versus normal FT. No other significant differences were noted in echocardiographic 
parameters of LV structure and mechanics between the groups based on FT.
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4.5.2: Quality of Life data based on FT.
Figure 7 illustrates the differences in quality of life between HF patients based on low 
and normal FT.
Figure 7. SF 36 V2 Domains based on free testosterone.
Graphical data based on independent samples T-test. Significance at P <0.05 is 
highlighted with *. ** indicates P <0.01. Error bars representative of standard deviation.
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Figure 7 above illustrate that using calculated free testosterone values as a marker of 
low versus normal testosterone status, resulted in similar differences in quality of life 
between the groups as was observed when adjusted for total testosterone. In exception 
to the aforementioned results, no significant difference was noted in the vitality domain 
of the SF36 when groups were stratified by FT.
Table 22 illustrates how the differences between low and normal free testosterone status 
impacts upon disease specific quality of life using the MLHFQ, ADAM and depression 
status using the BDI.
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Table 22. MLHFQ, ADAM and BDI Score based on Free Testosterone status.
Independent samples T-test. Significance at P <0.05 is highlighted with *. ** indicates 
P <0.01.
Low-range 
FT (n=17)
Normal-range 
FT (n=23) P value
MLHFQ Score 41.19 ±20.60 34.35 ± 27.78 0.40
BDI Score 9.31 ±6.26 7.39 ± 6.50 0.36
ADAM Score 6.50 + 2.34 5.43 + 2.97 0.24
(MLHFQ) M innesota Living with H eart Failure Questionnaire, (BDI) Beck D epression  
Inventory, (ADAM) Androgen deficiency in the ageing male.
There were no significant differences seen between MLHFQ score or BDI between the 
low and normal range free testosterone HF patients. In contradiction to previous results, 
there was no significant difference in ADAM score between the low and normal FT 
groups.
4.5.3: NT pro BNP based on FT.
Table 23 summarises the levels of NT pro-BNP in participants with low and normal 
range FT.
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Table 23. NT pro-BNP based on free testosterone status.
Independent samples T-test. Significance at P <0.05 is highlighted with *. ** indicates 
P<0.01.
Low-range Normal-range P value
FT (n=17) FT (n=23)
NT pro-BNP (pg/L) 129.69 ±101.17 117.42 ±92.01 0.51
(N T pro  BNP) N  term inal brain natriuretic peptide, (pg/L) p icogram s p e r  Litre.
There were no observed significant differences in NT pro-BNP based on free 
testosterone status between the low and normal testosterone groups.
191
4.6: Analyses based on bio-available testosterone.
This section displays the results based on determination of bio-available testosterone 
and a cut off value of < 4.0nmol/L for testosterone deficiency as per the guidance stated 
previously.
4.6.1: Adjusted baseline demographics.
Adjustment of data based on bio-available testosterone results in 17 patients with low 
bio-available testosterone and 23 patients with normal range bio-available testosterone.
Table 24 shows the adjusted baseline demographics for this sample.
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Table 24 above suggests that both groups are well matched at baseline. No significant 
differences were observed between low and normal testosterone group baseline 
characteristics using independent samples t-tests with the exception of total testosterone, 
bio-available and free testosterone (all p < 0.001).
Figure 8, Bland Altman plot shows the agreement between initial and subsequent 
measurement of bio-available testosterone performed on a separate clinic visit.
Figure 8. Bland Altman plot for the agreement between bio-available testosterone 
measurements on two separate occasions.
Minimum 4 weeks between initial measurement, maximum 4 months to coincide with 
routine clinic visit.
l  -l ❖  D i f f e r e n c e
M e a n  D i f f e r e n c e  
M e a n  D if f .  ±  2 S D
Average Bio-available testosterone concentration (nmol/L)
The Bland Altman plot shows a mean difference between bio-available testosterone 
measurements of 0.014 nmol/L (s.d. + 0.38 nmol/L). Therefore, the mean difference + 2 
s.d. is + 0.76 nmol/L and -  0.73 nmol/L. The coefficient of repeatability is 0.76 nmol/L. 
Greater than 95% of measurements fall acceptably within the limits of agreement of + 2 
s.d. The outlying measurements did not represent a change of testosterone status (i.e. 
there was no change from hypo to eugonadal status between measurement 1 and 
measurement 2).
4.6.2: Primary outcome measure -  6 minute walk.
Table 25 shows 6 min walk data based on bio-available testosterone status.
Table 25. 6 min walk data based on bio-available testosterone status.
Independent samples T-test. Significance at P <0.05 is highlighted with *. ** indicates 
P<0.01.
Low-range bio- 
available testosterone 
(n=17)
Normal-range bio- 
available testosterone 
(n=23)
P value
6 min walk 291.62 ± 110.44 420.88 ± 158.30** <0.01
distance (m)
(min) minute, (m) metres
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Patients with low bio-available testosterone demonstrated a significantly impaired 
exercise capacity when compared to those patients with normal range bio-available 
testosterone (291.62 ± 110.44 versus 420.88 ± 158.30m, p < 0.01).
4.7: Secondary outcome measures.
4.7.1: Echocardiography based on bio-available testosterone.
Tables 26-28 below illustrate differences in key echocardiographic variables of cardiac 
structure and function between HF patients with low and normal bio-available 
testosterone.
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testosterone. This mirrors the findings of both total and free testosterone group allocations.
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Table 29 shows significant differences in several of the physical and mental domains of 
the SF-36 questionnaire. Role physical, physical functioning and bodily pain are all 
significantly higher in the normal bio-available testosterone group (44.01 ± 25.90 versus 
68.35 ± 25.26, 44.17 + 23.00 versus 66.25 + 23.91 and 57.81 ±30.13 versus 74.22 + 
30.00 respectively. All P<0.01). This results in a significant difference in overall 
physical component score in favour of the normal bio-available testosterone group 
(48.49 ± 21.32 versus 66.11 + 22.31, P = 0.02). For the mental components of the SF- 
36, there is a significant difference in social functioning (61.46 + 23.58 versus 73.43 + 
17.84, P = 0.04)) and a significant difference in overall mental component summary 
(58.61 + 18.43 versus 71.14 + 17.89, P = 0.04) in favour of the normal bio-available 
testosterone group. There were no significant differences in MLHFQ, BDI or ADAM 
scores between low and normal bio-available testosterone.
4.7.3: NT pro BNP based on bio-available testosterone.
Table 30 documents NT pro-BNP values based on bio-available testosterone 
concentration.
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Table 30. NT pro-BNP based on bio-available testosterone status.
Independent samples T-test. Significance at P <0.05 is highlighted with *. ** indicates 
P<0.01.
Low-range Normal-range P value
Bio-available Bio-available
testosterone (n=17) testosterone (n=23)
NT pro-BNP (pg/L) 112.37 ±84.42 143.63 ±76.56 0.23
(N T pro  BNP) N  terminal brain natriuretic peptide, (pg/L ) p icogram s p e r  Litre.
There were no observed significant differences in NT pro-BNP based on bio-available 
testosterone status between the LT and NT groups.
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4.8: Correlation studies.
Tables 31-33 highlight the relationship observed between total, free and bio-available 
serum testosterone concentration and the main important outcome measures assessed 
during the course of the study.
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Table 31. Summary of main outcome measure univariate Pearson’s correlation (r)
with total testosterone. * indicates P <0.05, ** P <0.01
Variable TT
r value
TT
P value
6  min walk distance (m) .504** <0.001
SF36 General Health .154 0.33
SF36 Bodily Pain .196 0.23
SF36 Role Physical .467** <0.01
SF36 Physical Function .354* 0.02
SF36 Physical Summary .343* 0.03
SF36 Vitality -.003 0.96
SF36 Role emotion .274 0.09
SF36 Social functioning .052 0.75
SF36 Mental health -.050 0.76
SF36 Mental Summary .117 0.47
EF% -.024 0.89
LA max volume .049 0.88
LA strain conduit .024 0.91
LA strain reservoir .019 0.78
LA strain contractile .079 0.49
LV twist .087 0.74
LV untwist .054 0.65
LV torsion .079 0.55
RV area change % .120 0.29
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TAPSE (mm) .016 0.93
Peak S wave velocity (cm/s) .029 0.86
Age (yrs) -.155 0.34
NYHA Score -.011 0.95
(min) minute, (m) metres, (SF -36j short fo rm  36  version 2 questionnaire, (EF%) 
ejection fraction, (%) percentage, (LA) left atrium, (LV) left ventricle, (RV) right 
ventricle), (TAPSE) tricuspid annular plane systolic excursion, (mm) millimetres, (cm/s) 
centimetres p e r  second, (yrs) years, (NYHA) N ew York H eart Association.
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Table 32. Summary of main outcome measure univariate Pearson’s correlation (r)
with free testosterone. * indicates P <0.05, ** P <0.01
Variable FT
r value
FT
P value
6 min walk distance (m) .589** <0.001
SF36 General Health .240 0.14
SF36 Bodily Pain .090 0.88
SF36 Role Physical .540** <0.001
SF36 Physical Function 0.451** 0.003
SF36 Physical Summary 0.441** 0.004
SF36 Vitality .068 0.68
SF36 Role emotion .361* 0.02
SF36 Social functioning .143 0.38
SF36 Mental health .026 0.14
SF36 Mental Summary .220 0.17
EF% .011 0.95
LA max volume .044 0.87
LA strain conduit .029 0.90
LA strain reservoir .019 0.79
LA strain contractile .088 0.55
LV twist .090 0.81
LV untwist .050 0.75
LV torsion .088 0.60
RV area change % .201 0.19
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TAPSE (mm) .020 0.92
Peak S wave velocity (cm/s) -.002 0.99
Age (yrs) .017 0.92
NYHA Score .006 0.97
(min) minute, (m) metres, (SF-36) short form  36  version 2 questionnaire, (EF%) 
ejection fraction, (%) percentage, (LA) left atrium, (LV) left ventricle, (RV) right 
ventricle), (TAPSE) tricuspid annular plane systolic excursion, (mm) millimetres, (cm/s) 
centimetres p e r  second, (yrs) years, (NYHA) N ew York H eart Association.
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Table 33 Summary of main outcome measure univariate Pearson’s correlation (r)
with bio-available testosterone. * indicates P <0.05, ** P <0.01
Variable BioT 
r value
BioT 
P value
6 min walk distance (m) .579** <0.001
SF36 General Health .244 0.19
SF36 Bodily Pain .78 0.74
SF36 Role Physical .598** <0.01
SF36 Physical Function 499** 0.003
SF36 Physical Summary .487** 0.002
SF36 Vitality .070 0.28
SF36 Role emotion .387* 0.03
SF36 Social functioning .097 0.44
SF36 Mental health .036 0.54
SF36 Mental Summary .297 0.30
EF% .021 0.90
LA max volume .052 0.81
LA strain conduit .087 0.90
LA strain reservoir .081 0.70
LA strain contractile .080 0.50
LV twist .074 0.60
LV untwist .041 0.71
LV torsion .088 0.71
RV area change % .201 0.22
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TAPSE (mm) .100 0.82
Peak S wave velocity (cm/s) .004 0.79
Age (yrs) .011 0.45
NYHA Score .001 0.92
(min) minute, (m) metres, (SF-36) short form  3 6  version 2 questionnaire, (EF%) 
ejection fraction, (%) percentage, (LA) left atrium, (LV) left ventricle, (RV) right 
ventricle), (TAPSE) tricuspid annular plane systolic excursion, (mm) millimetres, (cm/s) 
centimetres p e r  second, (yrs) years, (NYHA) N ew  York H eart Association.
These tables (31-33) indicate that there is a strong positive relationship between total, 
free and bio-available testosterone concentration and 6 minute walking distance 
(p<0.01). In addition, a strong positive relationship exists between total, free and bio- 
available testosterone concentration and the role physical, physical function and 
physical component summary domains of the SF36 (p<0.05 for TT and p<0.001 for FT 
and Bio-available testosterone).
Figure 9 shows the linear relationship between total testosterone and the main study 
outcome (6 minute walk).
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Figure 9. Scatter-plot of serum total testosterone and 6 min walk distance. Linear 
regression lines included to demonstrate the relationship between the indices. * 
indicates P<0.05 and ** indicates P<0.01.
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4.9: Salivary testosterone.
As a novel marker of testosterone concentration in a male HF population, salivary 
testosterone was measured. The following Bland Altman plot shows the agreement 
between initial and subsequent measurement of salivary testosterone performed on a 
separate clinic visit.
Figure 10. Bland Altman plot showing agreement between salivary testosterone 
measurements on 2  separate visits.
Minimum 4 weeks between initial measurement, maximum 4 months to coincide with 
routine clinic visit.
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The Bland Altman plot shows a mean difference between salivary testosterone 
measurements of -0.31 nmol/L (s.d. + 3.70 nmol/L). Therefore, the mean difference + 2 
s.d. is + 7.09 nmol/L and -7.70 nmol/L. The coefficient of repeatability is 7.14 nmol/L.
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Greater than 95% of measurements fall acceptably within the limits of agreement of ± 2 
s.d.
The scatterplot in figure 11 shows the relationship between salivary and total 
testosterone concentrations. Linear regression lines included to demonstrate the 
relationship between the indices. * indicates P<0.05 and **indicates PcO.Ol.
Figurell. Scatter plot of total testosterone and salivary testosterone concentration.
(
Linear regression lines included to demonstrate the relationship between the indices. * 
indicates P<0.05 and ** indicates PcO.Ol.
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The scatter-plot illustrates a strong positive correlation between salivary testosterone, 
total testosterone (r = .848, p<0.001) and free testosterone (r = .865, pcO.001).
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Salivary testosterone is a filtrate of plasma containing only the free fraction of 
testosterone and, as stated earlier in this review, free testosterone is often considered the 
most physiologically active form of testosterone available for metabolising in target 
tissue. As such, a Bland Altman plot is appropriate to assess the agreement between 
traditional serum sampling for measurement of FT and the use of simple salivary 
collection as a novel technique in a heart failure population.
Figure 12 Bland Altman plot for the agreement between salivary and serum free 
testosterone measurements.
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This plot shows good agreement between two different methods for the analysis of free 
testosterone concentration. >95% of values fall within + 2 s.d with one clear outlying 
value. The data show a mean difference of -16.05 pmol/L with s.d. of 74.57 pmol/L.
220
This results in + 2 s.d of 133.09 pmol/L and -  2 s.d. of 165.19 pmol/L. The calculated 
coefficient of variation is 149.14 pmol/L.
In addition, table 34 below details the observed relationship between salivary 
testosterone concentration and the main outcome measures summarised previously in 
this result section.
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SF36 Mental health .031 0.22
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(min) minute, (m) metres, (SF-36) short form 36 version 2 questionnaire, (EF%) ejection fraction, (%) percentage, (LA) left atrium, (LV) 
left ventricle, (RV) right ventricle), (TAPSE) tricuspid annular plane systolic excursion, (mm) millimetres, (cm/s) centimetres per second,
uot!Q££sa?\5
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Given the close relationship observed between serum free testosterone and salivary 
testosterone concentration, there are similar correlations observed based on salivary 
testosterone.
There is a strong positive relationship between salivary testosterone concentration and 
walking distance (p<0.01). In addition, a strong positive relationship exists between 
salivary testosterone concentration and the role physical, physical function and physical 
component summary domains of the SF36 (p<0.001).
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4.10: Additional statistics performed based on observations of initial data.
Although not statistically significant using independent samples t-tests, it is evident 
from the baseline characteristics that low testosterone participants are, on average, 
slightly older than the normal testosterone counterparts. It is possible that age could 
influence the results of the primary outcome measure hence resulting in a significant 
between group differences in walking ability. In order to adjust the comparison taking 
into account age as a covariate, ANCOVA was undertaken to assess further the effect of 
age in the comparison. The results for TT and FT are presented in the table 35 below.
Table 35. ANCOYA statistic comparing 6 minute walk capacity between low and 
normal testosterone with age added as a covariate. * P <0.05, ** P<0.01
6 minute walk distance 
(m).
6 min walk p 
value. P value for age as 
a covariate.
Low-range TT 257.65 ± 106.87 <0.001 0.07
Normal-range TT 429.00 ± 126.94
Low-range FT 249.00 ± 111.35 <0.001 0.06
Normal range FT 413.04 ± 144.71
TT (total testosterone), FT (free testosterone)
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The table for ANCOVA indicates that age does not significantly affect walking distance 
when added as a covariate to the between group analysis. However, it does demonstrate 
a trend towards effecting walking distance of both low and normal range TT and FT.
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Chapter 5. Discussion.
This is the only study to date to compare two well-matched groups of male patients with 
HF and biochemical and functional evidence of low or normal total, free and bio- 
available testosterone concentration. Participants recruited to the low TT group were 
found to have an average TT concentration of 9.21 + 1.84 nmol/L compared to a mean 
TT concentration of 17.82 + 5.31 nmol/L in those with normal range TT. A value of 
9.21 nmol/L for TT is parallel with previously published European Endocrinology 
guidance that suggests a total testosterone concentration of <10.4 nmol/L as a marker of 
testosterone deficiency (Bhasin et al, 2006) and also further evidence suggesting that 
values of >12.4 nmol/L generally do not require supplementation (Wang et al, 2009). 
Nevertheless, these recommendations also state that functional evidence of testosterone 
deficiency should be present, and as such, all patients in the low TT group demonstrated 
a positive androgen deprivation score of >3 using the ADAM questionnaire. Although, 
as stated later in this discussion, our data suggests that there should be caution when 
applying the ADAM questionnaire in this patient population.
More rigorous analysis of testosterone concentration is now widely recommended in 
patients who have borderline hypogonadal TT concentration or in patients who may 
have possible alterations of SHBG. More elderly males, males with obesity, diabetes 
mellitus or chronic diseases (such as cancer, lung disease, heart failure and HIV) have 
been shown to present with increases in SHBG and thus total testosterone may not be a 
precise marker of androgen status in this population (Bhasin et al, 2008). In response to 
this, a novel feature of this research was the comparison of groups based upon 
calculation of bio-available and free testosterone concentration. Calculated FT values 
for the low testosterone group were 0.132 + 0.33 nmol/L and 0.271 ± 0.67 nmol/L for 
the normal testosterone group and bio-available concentrations were 3.04 + 0.91 nmol/L
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and 6.62 + 1.15 nmol/L for low and normal testosterone groups respectively. There is 
much less published evidence available regarding specific cut off values for low FT and 
bio-available testosterone. However, suggestions from the European Endocrine Society 
are that FT values <0.17 nmol/L represent hypogonadism and usually require 
supplementation (Bhasin et al, 2006). In addition, Leifke and colleagues (2000) have 
shown that bio-available testosterone concentration in an older population <_4 nmol/L is 
consistent with hypogonadism and these patients would benefit from testosterone 
supplementation.
There are wide variations in laboratory ‘cut-off values for low total testosterone 
varying from 8.0 nmol/L to 12.0 nmol/L in healthy populations (Bhasin et al, 2006). 
Endocrinology guidelines are clear that variations in laboratory serological techniques 
and the use of questionnaires can further impact on the diagnostic accuracy of 
measuremenr of testosterone concentration. Total testosterone is widely reported to be 
at its lowest in the early hours of the day before 10:00 am (Diver et al, 2003). Many of 
the studies assessing diurnal testosterone variation were performed in a younger 
population with diminished numbers of older participants. In elderly patients, although 
the diurnal variation in testosterone concentration persists, it may be substantially 
blunted (Crawford et al, 2007). Additionally it has been suggested that testosterone 
levels vary markedly throughout a 24 hour period and measuring testosterone levels in 
the same individual in a 12 hour period cannot be relied upon to make accurate 
conclusions over androgen status (Spratt et al, 1988). Furthermore, around 30% of 
males with low testosterone sampled during the afternoon period have been shown to 
have normal testosterone concentration when sampled during the morning hours 
(Brambilla et al, 2007). In this study, all patients recruited were sampled for 
testosterone status on two separate occasions prior to midday. All second samples were
taken between a period of 4 weeks to 4 months following the initial visit to coincide 
with routine clinical appointments. Bland Altman analysis of the repeated measures of 
testosterone did not, on the whole, show any marked deviation from initial 
measurements (mean difference between TT measurements of 0.15 nmol/L, s.d. + 2.05 
nmol/L, mean difference + 2 s.d + 3.95 nmol/L and -  4.26 nmol/L., coefficient of 
repeatability 5.10 nmol/L, mean difference for FT of 0.004 nmol/L, s.d. + 0.0025 
nmol/L, mean difference + 2 s.d + 0.055 nmol/L and -  0.046 nmol/L. coefficient of 
repeatability 0.0050 nmol/L and bio-available testosterone mean difference 0.014 
nmol/L, s.d. + 0.38 nmol/L, mean difference + 2 s.d. + 0.76 nmol/L and -  0.73 nmol/L. 
with a coefficient of repeatability is 0.76 nmol/L). More than 95% of repeated 
measurements were within + 2 s.d. of the mean difference for all of the constituents of 
testosterone concentration. There were a minor amount of outlying values of which 
none resulted in a shift from eugonadal to hypogonadal status or vice-versa. All samples 
were batch analysed using the same serological technique and additional parameters 
calculated using well-recognised formulae by an accredited biochemistry laboratory and 
clinical scientist. Initial samples only were used for the group stratification and 
subsequent analysis. Secondary samples were used merely to provide clarity to the 
initial measurement and to provide a gauge to the reproducibility of measurements in a 
variable known to display significant variation.
Recruitment to the study was uncomplicated with target numbers according to the 
power calculation achieved within the set timescales. Furthermore, all participants who 
entered the study completed all data collection on the same day as their regular 
outpatient clinic appointment. As such, there was a full data-set for each of the 
participants. Some echocardiographic parameters were not measured in all patients due 
to the limitation of ultrasound in patients with increased BMI and a minority of patients
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with atrial fibrillation at the time of analysis. The two groups were well matched at 
baseline using total serum testosterone, free testosterone and bio-available testosterone 
as the grouping variable. Potential confounding variables to total testosterone 
concentration were those factors which are known to alter SHBG. For this study these 
variables were age, weight, co-morbidities and BMI. Although the low testosterone 
group is slightly more elderly (71.9 ± 10 yrs compared to 66.9 + 11.98 yrs) there was no 
significant difference at baseline using independent samples t-tests (p = 0.162). Further 
assessment of the groups using ANCOVA and age as a covariate in the between groups 
analysis resulted in no significant effect of age on walking distance when stratified by 
either TT or FT (p = 0.06 and 0.07 respectively). Clearly this indicates a strong trend 
towards age influencing the results and hence future studies with larger sample sizes 
should be undertaken to fully assess the effect of age on walking distance in this 
population.
Other potential confounding variables to 6 min walk performance in HF (i.e. NYHA 
class, EF, NT pro-BNP, age and BMI) were not statistically different, using independent 
samples t-tests, between the two groups at baseline. The only significant differences 
observed in baseline parameters were total, bio-available and free testosterone 
concentration (p<0.001). The baseline characteristics of the study population were in­
keeping with other trials investigating the impact of low testosterone in the male HF 
population and typically a more elderly population (Malkin et al, 2006, Malkin et al, 
2004,Caminiti et al, 2009, Jankowska et al, 2009).
This initial study shows that HF patients with low testosterone have significantly 
diminished exercise capacity (as assessed by a 6 min shuttle walk) when compared to a 
well-matched group of HF patients with normal range testosterone. This study reported
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a mean increase of 171.35 + 37.10 m in HF patients with normal total testosterone 
concentration when compared to those patients with low total testosterone (p<0.001). 
These differences were observed despite objective evidence of the participants 
exercising to a similar intensity (i.e. no significant difference in maximal HR or RPE 
between the groups) and were also apparent when data was stratified according to free 
and bio-available testosterone. Other studies using a different research design have also 
indicated that total testosterone and other anabolic hormone deficiency can 
detrimentally impact on exercise performance in HF. These studies associated reduced
levels of TT to significant reductions in peak v ° 2  (Jankowska et al, 2009, Caminiti et 
al, 2009) and 6 min walk distance (Bocchi et al, 2008). Furthermore, the work of 
Jankowska et al, 2009 showed similar positive correlations between exercise capacity 
and testosterone concentration as observed in our study. Such findings have also proved 
consistent with associations observed in elderly males without clinical evidence of HF 
(Haydar et al, 2000). No other research has sought to investigate parameters related to 
endurance performance in a similar population based on free and bio-available 
testosterone.
Previous work has suggested that improved exercise capacity in HF associated with 
higher levels of TT may be due to improved indices of cardiac function (Bocchi et al, 
2008 and Jankowska et al, 2009). This hypothesis has been formulated on the basis that 
TT has been shown to inversely correlate with both LV and RV EF% (Bocchi et al
2008) and testosterone therapy has been shown to improve indices of cardiac structure 
and function in animal and human models (Yan-Zhou et al, 2007 and Malkin et al, 
2006). However, this study generally provides contradictory results. Largely, there were 
no significant differences in any of the detailed indices of cardiac structure, function and 
mechanics based upon testosterone concentration as assessed by echocardiography
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during the course of this study. Only significant differences in left atrial passive 
emptying fraction and left ventricular basal back rotation rate were observed for total 
and free testosterone with the addition of left atrial expansion index when groups were 
based on bio-available testosterone.
No other study has extended to measuring cardiac functional characteristics in such 
detail in this population and it is plausible that these significant differences may reflect 
a subtle improvement in diastolic cardiac parameters based on testosterone 
concentration. Left atrial passive emptying fraction is a representative marker of left 
atrial conduit function and as such, early left ventricular diastolic filling (Nikitin et al, 
2003). Left atrial expansion index is a marker of atrial reservoir function. The left 
atrium acts as a reservoir by collecting blood from the pulmonary veins during 
ventricular systole and as such, this has been shown to be an important determinate of 
cardiac output (Suga, 1974). The rate at which the left ventricle untwists has previously 
been proposed to represent left ventricular relaxation (Dong et al, 2001). Diastolic 
untwist represents elastic recoil due to the release of restoring forces generated during 
the preceding systole (Nagueh et al, 2009). Untwisting rate or recoil rate plays an 
important role in diastolic filling due to suction generation and attenuation of this 
phenomenon has been assumed to contribute to diastolic impairment in diseased hearts 
(Fuchs et al, 2004). More recently however, it has been shown that untwisting rates are 
retained with diastolic abnormalities and normal ejection fraction but impaired in 
patients with significant systolic dysfunction (Wang et al, 2007). Furthermore, time to 
left ventricular untwist and untwist velocities have both been shown to be reduced in 
patients with systolic dysfunction and increased filling pressures (Sengupta et al, 2008). 
In this study, patients with low and normal testosterone concentration all demonstrated 
significant LV systolic impairment (e.g. for total testosterone an EF% of 28.31 + 7.07
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for low versus 30.72 + 6.25 for normal range testosterone). Thus, the observed 
difference in twist mechanics together with subtle changes in left atrial function may be 
an indicator of higher filling pressure in patients with lower levels of testosterone. In 
contradiction to this theory, many other important echocardiographic parameters 
assessed during the course of this study that relate to diastolic filling show no 
significant difference between groups based on testosterone concentration.
There are however, limitations to the echocardiographic parameters used during this 
study for the assessment of both LV systolic and diastolic function. For LV systolic 
function, clinical trial echocardiographic guidance suggests that measurement of LV 
ejection fraction based on LV volumes obtained by the method of discs should be 
performed (Gottdiener et al, 2004). This technique minimises but not eliminates the 
mathematical assumptions evident in other methods and also allows for corrections 
based on LV geometry. However, limitations arise when the apex is fore-shortened, the 
endocardium is inadequately viewed and there is limitation by reliance on only two LV 
planes. The literature quotes Biplane Simpsons EF reproducibility of +7% (Himmelman 
et al, 1988) and test-re-test reliability of +5% (Gottdiener et al, 1995). In this current 
study, we quoted a 8.5% measurement error in EF by the same operator on two different 
occasions. This error and the documented limitations in the literature may be a factor in 
the lack of statistical change noted in our results. Longitudinal velocity assessment 
using PW Doppler can also be limited by a number of factors. PW Doppler assessment 
of tissue movement is only able to provide information regarding a specific point of the 
myocardium determined by sample volume positioning, components perpendicular to 
the ultrasound beam remain unknown and there is significant angle dependency. TDI 
velocities may also be influenced by global heart motion, movement of adjacent 
structures and also blood flow (Mor-Avi et al, 2011). During this study we
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demonstrated good reproducibility of the TDI peak s’ velocities when measured on 
separate occasions (measurement error around 5%) and many of the limitations of TDI 
can be overcome using 2D speckle tracking echocardiography. Furthermore, our TDI 
velocities were measured at end-expiration in order to reduce global heart motion. 2D 
speckle tracking echocardiography also demonstrates some technical limitations. In 
more obese populations with limitated echocardiographic images, it is possible that 
endocardial border tracking may be inaccurate. 2D speckle tracking echocardiography is 
also limited in patients with acoustic shadowing or reverberations (Mor-Avi et al, 
2011). Tracking software algorithms use a priori knowledge of ‘normal’ LV function 
and as such, there may be errors when assessing regional abnormalities or when 
assessing neighbouring segments (Mor-Avi et al, 2011). It is important to recognise the 
afore-mentioned limitations of the techniques when evaluating these results. The use of 
contrast agents to effectively assess LV endocardial borders can be undertaken to 
enhance the quality of data and utilising other techniques previously shown to provide 
more accurate assessment of LV volume and EF such as 3D echocardiography or 
cardiac MR could be performed in newer studies.
In the present study, LV diastology was assessed in detail. However, in order to provide 
an improved assessment of LV diastolic function, more parameters could be assessed. 
Although guidelines for the assessment of diastolic function in clinical trials suggest 
using E/e’ as this parameter seems the least subject to inter/intra-observer variability 
(Gottdiener et al, 2004), more recent recommendations have suggested the use of 
additional parameters to increase the accuracy of results (Nagueh et al, 2009). For 
instance, more detailed assessment of MV inflow properties (e.g. isovolumetric 
relaxation time, E/A ratio, deceleration time as a minimum), assessment of pulmonary 
venous flow and analysis of flow propagation velocities. When assessing clinical trial
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participants with significantly impaired LV systolic function (EF% <40%), MV E:A 
ratio, isovolumetric relaxation time and MV deceleration time have been shown to 
provide an excellent indication of filling pressures (Gottdiener et al 2004). Assessment 
of diastolic parameters in this study is further compromised by a small proportion of 
patients in atrial fibrillation at time of echocardiographic examination (15% normal TT 
and 25% low TT). Atrial fibrillation may cause artificial increases in LA volumes 
together with artificial remodelling of the LA independent of filling pressures, loss of 
atrial contractile properties and significant beat to beat variability in measurements 
obtained. In order to counteract this last point, all measurements in patients with atrial 
fibrillation were repeated over at least 5 cardiac cycles but overall diastolic assessment 
in atrial fibrillation is limited and this should be remembered when interpreting the 
results of this study.
Correlation analyses incorporating total, free and bio-available testosterone did not 
reveal any significant relationships between testosterone concentration and cardiac 
structure, function and mechanics. It is feasible that this study was under-powered to 
detect many changes in cardiac structure and function however, the lack of trends to 
differences in the majority of measures and the weak correlations observed raises doubt 
over this hypothesis. Echocardiography cannot exclude changes at the bio-chemical and 
cellular myocardial level, and as such, future research should aim to measure these 
outcomes for a more in-depth cardiac assessment. Perhaps future research should aim to 
involve more detailed cardiac investigation, for instance cardiac MRI. In relation to 
cardiac function, there was no significant difference in NT pro-BNP concentration 
between the groups. As NT pro-BNP is a marker of severity of HF this finding lends 
further support to the lack of observed differences in aspects of cardiac function.
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Testosterone may act more directly at the muscular or vascular level in order to promote 
increases in walking performance. Testosterone can favourably affect skeletal muscle 
mass and the local synthesis of growth factors (IGF 1) and acontractile protein synthesis 
(Balagopal et al, 1997). Testosterone may also positively interact with peripheral 
mechanisms involved in HF pathology. For example, attenuate ED (Miller et al, 2007), 
improve lung function (Svartberg et al, 2007), normalise baroreflex sensitivity and 
autonomic imbalance (El Mas et al, 2001), reduce the levels of circulating inflammatory 
cytokines found to impede LV contractility and muscular performance (Yan Zhou et al,
2009) and increase muscle perfusion at rest and during exercise (Jones et al, 2004). 
Future research should aim to investigate these concepts in more detail. These studies 
should aim to directly measure endothelial function and perform detailed muscle 
strength and endurance assessment in order to elucidate the role of testosterone 
concentration on both vascular reactivity and muscular function. In addition, future 
research should collect information as to the levels of important inflammatory cytokines 
which may promote cardiac and skeletal muscle dysfunction.
Importantly, in HF, there are other factors which may influence endurance capacity, 
overall muscular strength and cardiac function. For instance in HF there is derangement 
of the glucose-insulin axis with some studies reporting up to 43% of patients 
manifesting disorders of glucose metabolism (Kontoleon et al, 2003). It has been shown 
that low levels of serum total testosterone and SHBG are risk factors for development of 
the metabolic syndrome in males (Muller et al, 2005). Patients with HF and insulin 
resistance have an impaired ability to promote glucose transport into skeletal muscle 
cells and adipose tissue. Moreover, research has showed that impaired insulin activity 
inversely correlates with severity of HF, relates to disorder of skeletal muscle 
physiology, facilitates reduced muscle mass and can also influence prognosis (Swan et
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al, 1997 and Doehner et al, 2002). Further reports have also suggested that insulin 
resistance may deteriorate cardiac performance in HF, due to cellular disruption of 
cardiac metabolism (Chang et al, 2005). Testosterone supplementation towards the 
physiological range has been shown to significantly improve fasting blood glucose and 
insulin levels, together with significant improvements in cholesterol level and waist to 
hip ratio (Kapoor et al, 2007). Mechanistically, cultured adipocytes and skeletal muscle 
cells incubated with low dose testosterone therapy have demonstrated improved 
regulation of GLUT4 and insulin receptor 1 (Chen et al, 2006). Furthermore, Sato et al, 
2008 have showed that testosterone therapy in a rodent model can facilitate 
phosphorylation of protein kinase B and C, key pathways in insulin receptor signalling 
pathways for the regulation of GLUT4 translocation. The same authors have also 
suggested that testosterone treatment can influence enzymes related to the glycolytic 
process. Increased activity of phosphofructokinase and hexokinase has been discovered 
in cultured rat skeletal muscle cells following administration of testosterone. Hence 
normal levels of free and bio-available testosterone may therefore indirectly correct the 
aforementioned abnormalities at skeletal muscle level in testosterone deficient 
participants to promote increases in walking performance. Previously, bio-available 
testosterone has been shown to inversely correlate with abdominal adipose tissue 
lipoprotein lipase (Ramirez et al, 1997), an enzyme suggested to play a role in the 
pathogenesis of obesity as it resides on the extra-cellular surface of adipocytes and 
hydrolyses circulating triglyceride rich lipoproteins to fatty acids which then become 
esterifide and stored as triglyceride (Eckel, 1989). Marin et al, 1995 showed that 
following prolonged testosterone supplementation towards a normal range, there was a 
marked decrease in lipoprotein lipase activity and hence significant reductions in 
triglyceride storage in abdominal subcutaneous adipose tissue. It is plausible that in our 
study, disorders of glucose metabolism and insulin resistance may have contributed to
the differences seen in exercise capacity and indirectly quality of life between low and 
normal testosterone groups. In particular, gross malfunction of skeletal muscle 
energetics and attenuated ability to utilise energy for muscular work would directly 
result in the observed difference in 6 minute walk distance. This study showed no 
differences in body mass, BMI or resting BP between the groups, but blood samples 
were not taken for fasting insulin or glucose assessment. As a result, the impact of 
insulin resistance on exercise tolerance in our cohort of patients with low testosterone 
status remains unknown. This clearly warrants investigation in future research which 
should aim to collect data regarding components of the metabolic syndrome together 
with detailed aspects of skeletal muscle contractile function and energetic in a male 
heart failure population.
There were significant improvements in many domains of the SF36 version 2 in both 
the physical and mental components in normal testosterone when compared to low 
testosterone. These improvements resulted in highly significant improvements in overall 
physical component summary (p<0.001) and significant improvements in mental health 
component summary (p<0.05). In addition, significant correlations were seen between 
testosterone concentration and physical function, role physical and physical component 
summary domains of the SF36. No other research has compared quality of life variables 
bases on testosterone concentration in HF, particularly with patients also grouped by 
free and bio-available facets. However, in testosterone deficient, healthy, elderly males, 
testosterone therapy has been shown to significantly improve overall quality of life as 
assessed using the SF-12 questionnaire following 48 weeks of regular supplementation 
when compared to placebo (Tong et al, 2010). Logically, the significant improvements 
noted in exercise ability in this study should translate to improved overall perception of
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physical and mental quality of life and the aforementioned physiological theories to 
improved 6 minute walk performance could be indirectly proposed as precursors to 
these improvements in quality of life. However, Malkin et al, 2006 observed no 
improvement in general health score following testosterone therapy in their elderly HF 
patients, despite significant improvements in exercise capacity. Interestingly, during this 
study no significant changes were seen in BDI or MLHFQ score between groups based 
on testosterone concentration. This is in contradiction to other research which has 
shown that low levels of circulating anabolic hormones resulted in increased depressive 
symptoms in younger males with HF (Jankowska et al, 2006). The same authors in an 
older population however, were unable to replicate this improvement in depressive 
symptoms, a finding similar to this study. During this study, no change was noted in 
NYHA score between the two groups. In contradiction to this, Malkin et al, 2006 
observed improvements in NYHA score in testosterone treated HF males when 
compared to placebo. Similarly to the current study, no changes were noted in relation 
to depression or HF related quality of life.
An interesting outcome in this study was that there were significant differences in many 
generic SF-36 health outcomes but no improvements noted in disease specific quality of 
life using the MLHFQ. Although there is some overlap of inquiry between the two 
questionnaires -  particularly with regard to physical fitness, the MLHFQ is shorter with 
less emphasis on these parameters. The MLHFQ also questions the clinical 
consequences of HF by enquiring about hospital admission, the financial impact and 
side effects related to medical treatment. It is probable that for this study, the MLHFQ 
was insufficiently focussed around the physical and mental parameters to allow for 
significant differences to be achieved when compared to the more detailed SF-36 
Version 2. Additionally, as this study was short duration and the MLHFQ enquires
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regarding only recent (last month) changes in HF status, this questionnaire may have 
been limited by the strict inclusion and exclusion criteria to our study. Patients were 
clinically stable for a period of 6 months without any change to medication or NYHA 
status and as such, these facets may decrease the power of disease specific 
questionnaires to detect significant differences between the groups in this study.
As stated above, in the current study, all participants were clinically stable and also 
actively taking a full complement of anti-failure medications for a period of at least 6 
months. This may, in some part, explain the lack of change in HF specific quality of life 
(NYHA and MLHFQ). ADAM questionnaire score was significantly higher in the low 
total testosterone participants but not when the groups were based on free or bio- 
available testosterone. This data reinforces the use of the ADAM questionnaire as a 
valuable addition to serological assessment of total testosterone deficiency but does not 
support its use in patients who have low free or bio-available testosterone concentration. 
Importantly, many facets examined within the ADAM questionnaire overlap 
significantly with the clinical symptoms of HF, (e.g. reduced libido, lack of energy, 
decreased strength and / or endurance, depressive symptoms, tiredness and lack of 
concentration). This may partially explain the lack of observed difference in ADAM 
score when groups were based on free and bio-available testosterone. Future research in 
larger clinical populations should aim to identify if using a hypogonadal screening 
questionnaire such as the ADAM is feasible in patients with established HF.
There were no significant differences noted between NT pro-BNP concentrations in low 
testosterone when compared to normal testosterone. To date, no research has compared 
this outcome in this patient group. As NT pro-BNP represents a marker of severity of
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HF, the lack of significant differences implies that HF is not responsible for the 
differences between low and normal testosterone patients in this study. To lend further 
support to this theory, no differences were seen in NYHA score and MLHFQ score 
between the groups -  however, the limitations of the MLHFQ have been previously 
mentioned. Other researchers have also demonstrated no improvement in NT pro-BNP 
concentration despite testosterone supplementation in deficient HF males (Malkin et al, 
2006). In concurrence with this study, the authors observed no change in NT pro-BNP, 
but a significant improvement in exercise capacity suggestive of a role other than 
cardiac for the mechanical improvements noted in exercise ability based on testosterone 
concentration. There is evidence however, that testosterone supplementation can 
improve serum markers of inflammation and cardiac dysfunction. Yan-Zhou et al 
(2007) demonstrated in rodent models that testosterone supplementation reduces the 
imbalance between IL-10 and TNF-a thereby reducing LV remodelling and improving 
LV systolic function. This study did not measure serum markers of inflammation and as 
such, further research is implied to asses for this more closely in this patient population.
A novel feature of this study is the additional measurement of salivary testosterone in 
the HF population. At present, there is no consensus cut off value for low levels of 
salivary testosterone due to inconsistencies in analysis techniques and lack of available 
data in different clinical populations. In normal healthy populations, salivary 
testosterone is a filtrate of plasma containing only the free fraction of testosterone and, 
as stated earlier in this review, free testosterone is often considered the most 
physiologically active form of testosterone available for metabolising in target tissue 
(MacDonald et al, 2011). In addition, following exogenous administration of 
testosterone, salivary testosterone increased in parallel with total testosterone without 
significant change in SHBG binding capacity in serum (Wang et al, 1981). This further
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clarifies the suggestion that salivary testosterone represents closely serum unbound or 
free testosterone (Nieschlag et al, 2006).
This study has demonstrated for the first time that salivary testosterone measurement is 
valuable in the HF population. Salivary testosterone concentration correlated strongly 
and significantly (p<0.001) with total testosterone in this study. In addition, Bland 
Altman plot analysis showed that repeated measurements of salivary testosterone are 
accurate (mean difference of -0.31 nmol/L, s.d. + 3.70 nmol/L, mean difference + 2 s.d. 
+ 7.09 nmol/L and -7.70 nmol/L) and also confirms the close agreement between 
traditional serum FT measurements in a HF population (mean difference -16.05 pmol/L, 
s.d. of 74.57 pmol/L,+ 2 s.d of 133.09 pmol/L and -  2 s.d. of 165.19 pmol/L). This 
perhaps may reduce the need for semi-invasive blood sampling or allowing patients to 
provide their own sample without need for medical assistance in the future.
Undoubtedly, the aforementioned close relationships between salivary testosterone and 
free testosterone during this study resulted in similar relationships seen against 
important outcome measures when using Pearson product moment correlation. Larger 
scale studies should aim to accurately address the true cut-off value for salivary 
testosterone which predicts true testosterone deficiency in a HF population. This study 
had an insufficient sample size for this to be achieved. However, it is predictable that 
such values will correlate closely to those of the free fraction of testosterone given the 
closeness of the observed relationship in this study.
The results of this study suggest a possible role for testosterone replacement therapy in 
this patient population to augment both exercise capacity and quality of life. Although 
work has already been undertaken in this area, results are contradictory and there is
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scope for adequately powered studies to investigate more detailed aspects of 
physiological function. Studies should also aim to identify if testosterone 
supplementation can be combined with other therapeutic interventions such as exercise 
training to augment any improvements that may be seen. Detailed physiological, 
biochemical and cardiovascular assessments should be undertaken in any future 
research to ascertain the mechanisms behind any observed improvements. In particular, 
future research should aim to measure aspects of skeletal muscle function -  including 
strength and endurance, fasting blood glucose, insulin and vascular endothelial function 
in order to bring further clarity to the mechanisms involved any improvements seen.
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Chapter 6. Summary and Future Research.
This study was designed to investigate the physiological and psychological impact of 
low testosterone status on functional capacity, cardiac function and quality of life in 
males with stable HF. Currently, limited data is available regarding the effects of low 
testosterone on the aforementioned outcomes in males with HF. Initial work by 
Jankowska et al, 2009 and Bocchi et al, 2008 have showed that testosterone levels are 
correlated to VC^ max and RV function in HF. However, no direct comparison between 
low and normal range testosterone has been undertaken and there is currently no 
research investigating the effects of low testosterone on general health related quality of 
life and advanced aspects of cardiac structure and function in HF. Importantly, this 
study has been designed to assess in more detail than previously undertaken the 
functional mechanics of the heart with respect to testosterone level in HF. In addition, 
this study is the first to recognise the importance of free testosterone and bio-available 
testosterone concentration in a population whom the traditional assessment of total 
testosterone may be an inaccurate due to the deleterious effects of SHBG. Recognition 
of salivary testosterone measurement as a direct correlate of free testosterone and also 
its relationship to important outcomes assessed during the study is another important 
facet that may, in the future, reduce the need for semi-invasive blood sampling and also 
allow patients to provide their own testosterone samples from home for analysis.
The principle finding of this study is that male patients with low serum and salivary 
testosterone together with moderate or worse systolic HF have significantly impaired 
exercise capacity as assessed by the 6 min walk when compared to males with normal 
range testosterone. Furthermore, several SF36 domains of quality of life in both the 
mental and physical domains are significantly worse in HF patients with low levels of 
testosterone. These differences seem independent of age, NYHA score, BMI, NT-Pro
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BNP and EF%. Detailed cardiac assessment largely revealed that there was no 
significant difference in cardiac function based on testosterone concentration. However, 
there were minor interesting differences seen in some parameters relating to left 
ventricular diastole.
Future research should aim to assess adequately the safety and efficacy of testosterone 
supplementation in male patients with stable HF. In addition, future studies should aim 
to address, in more detail, the physiological mechanisms responsible for poorer exercise 
capacity in this patient population. Important outcomes should assess detailed, structural 
skeletal muscle parameters which related to improvements in strength and endurance, 
vascular adaptation with a focus on endothelial function, inflammatory markers which 
may affect detailed indices of cardiac and skeletal muscle cellular function, glucose and 
insulin levels with other components of the Metabolic Syndrome and perhaps use more 
detailed techniques to investigate cardiac function (e.g. 3D echocardiography or cardiac 
MRI).
To date, there are only small-scale studies that have addressed the effects of testosterone 
therapy on important prognostic outcomes in HF (Malkin et al, 2004 and 2006, Caminiti 
et al, 2009). Any future studies should be designed in order to inform a larger, perhaps 
multi-centre trial investigating the effects of testosterone supplementation in HF. This 
should be achieved by not only focussing on the changes in important health variables 
but by also providing detailed feasibility data. Earlier in this study it was highlighted 
that although treatments for HF have improved prognosis, there is still substantial 
morbidity and mortality associated with this condition. It is important that future 
research explores strategies that could augment the physiological benefits of
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testosterone supplementation in order to provide improved prognostic outcome in 
patients with HF to reduce the burden of HF related costs on health services.
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Section 2. Testosterone therapy during exercise rehabilitation in males with heart 
failure who are testosterone deficient.
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Abstract.
Background: The efficacy of exercise therapy for evoking improvements in key health 
outcomes in elderly male CHF patients with low testosterone status (< 15mmol/l) is 
unknown. The primary aim of this study was to assess the feasibility of a 12-week 
exercise program, with and without testosterone supplementation, in this patient sub­
group. Secondly, to collect preliminary data on changes in key health outcomes evoked 
by the two interventions. Methods: Forty male CHF patients (67.1 + 6.3 years with low 
testosterone < 15mmol/l) were randomly allocated to exercise training plus testosterone 
supplementation or exercise training plus placebo. Intramuscular injections of 
testosterone/placebo were administered at baseline and then every other week during the 
intervention period. Compliance to the intervention, shuttle walk distance, peak oxygen 
uptake, muscular strength, muscle oxygen saturation, central and peripheral 
cardiovascular function, biochemical profile and health and disease related quality of 
life were assessed at baseline and immediately after the 12-week intervention. Results: 
28 patients completed the study. Peak oxygen uptake, time-to-minimum tissue 
oxygenation, and incremental shuttle walk test performance were improved in both 
groups (p<0.05), with no significant group-by-time interaction. Body mass index was 
decreased in the exercise plus testosterone group only (p<0.05). Leg strength and 
biochemical status did not change in either group (p>0.05). Conclusion: An exercise 
and testosterone intervention in hypogonadal males with CHF is safe and feasible. 
Experience recruiting these patients and the attrition data produced from this study 
suggest that future exercise and testosterone interventions in this clinical group should 
be conducted as multi-centre clinical trials.
249
Chapter 1. General introduction.
Testosterone deficiency is positively correlated with cardiac output (Kontolean et al, 
2003) and exercise capacity (Malkin et al, 2006) in patients with HF. Significant 
improvement in both these parameters has been observed following testosterone 
replacement therapy (Parameshwar et al, 1992, Pugh et al, 2002 and Pugh et al, 2003). 
Although the mechanisms behind this process are poorly understood, improvement in 
exercise capacity has been shown to be positively correlated with increase in serum 
testosterone level (Malkin et al, 2006). Additionally, this was accompanied by a small 
increase in internal LV length in a recent study (Malkin et al, 2006). Evidence from 
animal studies suggests that anabolic androgens can attenuate skeletal muscle fatigue in 
response to exercise (Tamaki et al, 2001). Testosterone replacement therapy has also 
been shown to reduce circulating levels of inflammatory mediators, such as TNF-a and 
IL-ip as well as total cholesterol in patients with established CAD and testosterone 
deficiency (Malkin et al, 2004, Malkin et al, 2004). Circulating levels of inflammatory 
mediators are elevated in HF and may be related to ED and clinical deterioration in 
these patients.
Interestingly, chronic administration of physiologic replacement doses of testosterone 
can delay the time to ischemic threshold during treadmill walking in elderly males with 
established CAD (Malkin et al, 2004). A rapid mode of action is indicated, as 
improvements in ischemic threshold have been observed after as little as one month of 
intramuscular testosterone replacement compared with placebo (Malkin et al, 2004). As 
testosterone is a vasodilator, this could explain its anti-ischemic effects on cardiac 
function during exercise. However, it is currently unknown whether the vasodilatory
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effects of testosterone can influence the fatigability of skeletal muscle in a similar 
fashion.
It is now widely accepted that exercise training (ET) can safely increase exercise 
capacity in stable HF patients. An improvement in skeletal muscle strength and 
endurance has been reported after resistance training regimens (Gordon et al, 1996 and 
Pu et al, 2001). More recent studies have also reported improvements in dynamic 
quadriceps and hamstrings strength and endurance following combined aerobic and 
resistance training programmes (Senden et al, 2005) and provided evidence that this 
combined training approach is superior to aerobic training alone for improvement of LV 
function in patients with HF (Delagardelle et al, 2002). There is also evidence that 
short-term programmes of ET lasting for 12 weeks can reduce the circulating levels of 
inflammatory mediators such as TNF-a, soluble intracellular adhesion molecule 
(sICAM-1) and soluble vascular adhesion molecule (sVCAM-1), which are elevated in 
HF (Adamopoulos et al, 2001). However, a need for more clinical trials aimed at 
evaluating the long-term effects of physical training on functional status, morbidity and 
mortality in these patients has been highlighted (Freimark et al, 2007).
Considering the low functional capacity of male HF patients (Malkin et al, 2006), an 
investigation of strategies that have the potential to augment the response to exercise 
rehabilitation in order to improve prognosis is clearly warranted in this patient group. 
To date, the efficacy of exercise therapy for evoking improvements in key health 
outcomes in elderly male patients with HF and low testosterone status have not been 
studied. Neither is it known whether the effects of exercise training in HF can be 
augmented by testosterone supplementation.
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Chapter 2. Literature review.
2.1: Exercise training and HF.
2.1.1: Exercise intolerance.
The inability to perform exercise without discomfort is often one of the primary 
symptoms exhibited by patients with HF and is often the sole reason for seeking 
medical attention. As discussed earlier in this review, the main pathological 
consideration in systolic HF is impairment in LV EF resulting in a decline in cardiac 
output and in up to 50% of patients may be related to HF with normal ejection fraction 
but impairment in filling parameters. It is therefore expected that there is a strong 
correlation between resting ventricular function and exercise capacity. Previous reports 
however, contrast this theory and have shown poor correlations between resting EF and 
exercise tolerance (Franciosa et al, 1981). This has prompted numerous investigators to 
attempt to elucidate the important factors involved in exercise intolerance and the use of 
therapeutic measures to improve exercise tolerance in patients with HF. This section of 
this literature review will aim to understand the main pathological factors involved in 
exercise intolerance in HF and will review the effect of ET in attempts to improve 
physiological correlates and symptom onset.
A reduced ability to perform aerobic exercise is commonplace in HF. This has been
attributed to inadequate blood flow to active skeletal muscle due to reduced cardiac
output (Sullivan and Cobb, 1992). Patients with HF typically achieve less than 50% of
the maximum cardiac output achieved by healthy individuals at peak exercise. Stroke
volume is decreased at rest and only rises to approximately 50-65ml compared to 100ml
in healthy participants. This is in addition to a significant reduction in exercising
maximal HR in HF patients (Franciosa et al, 1981). Dilated left ventricles with
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significantly reduced EF also demonstrate poor increases in stroke volume during 
exercise, primarily because of a blunted ability to increase preload and EF (Hakki et al,
1984). Simply, an already dilated left ventricle operates close to its maximal volume 
having already utilised most of its preload reserve. Failure to increase systolic emptying 
by increasing EF derives from impaired intrinsic contractility, reduced a-adrenergic 
responsiveness, elevated systemic vascular resistance (see earlier discussion 
surrounding the renin-angiotensin system) and a blunted peripheral arterial vasodilator 
response to exercise (Pina et al, 2003). Consequently, the only way patients with HF can 
increase cardiac output is by increase in HR. Previous studies have shown only slightly 
reduced maximal HR in HF patients with almost identical slope of increase when 
compared to normal participants. However, many patients with HF have elevated 
resting HR and therefore reduced HR reserve and also achieve lower HR at maximal 
exercise (Sullivan and Cobb, 1992). Although a strong correlation has been observed 
between the degree of aerobic capacity impairment and the reduction in maximal 
cardiac output (Sullivan and Cobb, 1992), other research has demonstrated weak
correlations between peak exercise V(^2and EF in patients with HF (Wilson et al,
1995). In relation to this, it has also been discovered that peak v ° 2  does not correlate 
closely with NYHA score or subjective quality of life questionnaire data (Wilson et al, 
1995). This data suggests that although reduced EF and hence cardiac output is an 
important factor in exercise intolerance in patients with HF, there are other detrimental 
physiological processes that contribute to this phenomenon.
Many of the pathophysiological characteristics of HF as mentioned previously in this 
thesis would have an adverse effect on exercise tolerance. For example, stimulation of 
the RAAS (Vinereanu et al, 2005) would preclude inadequate blood flow to exercising
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muscles via an inability to decrease vascular resistance by vasodilatation. This theory 
has been supported by research which discovered reduced fore-arm blood flow at rest 
and during exercise in patients with HF when compared to healthy controls (Zelis et al, 
1974) and also failure of exercising leg vascular resistance to decrease normally during 
exercise in HF potentially as a result of excessive sympathetic stimulation (Zelis et al,
1988).
The afore-mentioned widespread endothelial cell activation and dysfunction (Brutsaert, 
2003) would negatively impact on vasodilatory capacity during exercise in HF. This 
notion has been supported by studies demonstrating that endothelial-dependent 
dilatation of the forearm vasculature is impaired in HF via a reduction in the release of 
nitric oxide (Kubo et al, 1991). The peripheral vasculature endothelium secretes the 
lipid soluble gas nitric oxide in response to increased flow through the target vessel 
lumen via its enzyme endothelial nitric oxide synthase (eNOS) in a similar manner to 
coronary resistance vessels mentioned previously. This release of nitric oxide via shear 
increased pulse pressure and pulsality in the resistance vessels promotes vasodilatation 
in normal animal models in order to normalise shear stress (Green et al, 2004). 
Abnormalities of this response can cause reduced peripheral vasodilatation and hence 
tissue perfusion in patients with HF. Additionally, it has been shown that degree of 
impairment in endothelial-dependent dilatation is correlated with exercise tolerance and 
NYHA score (Nakamura et al, 1994).
Perhaps closely related to these concepts is the capacity of the vasculature to 
redistribute cardiac output to the working skeletal muscle during exercise. There is 
some research evidence that suggests that the reduction in muscle blood flow correlates 
closely with reductions in cardiac output (Yamabe et al, 1995). However, other research
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suggests that this reduction is somewhat out of proportion to maximal cardiac output. 
Researchers at Duke University in the U.S.A have identified that the percentage of 
cardiac output distributed to both legs during exercise was attenuated in patients with 
HF (51%) when compared to healthy controls (76%) (Sullivan and Cobb, 1992). 
Therefore, as a result of abnormal vascular resistance in exercising muscle and further 
abnormalities in redistribution of flow (e.g. maintained flow to non-exercising tissue) 
there may be considerable hypo-perfusion and fatigue in exercising muscle.
The pathophysiological characteristics of skeletal muscle in HF described earlier in this 
review can also contribute adversely to exercise tolerance in this patient group. For 
example, increased oxygen extraction and lactate efflux together with diminished total 
muscular oxygen utilisation (Donald et al, 1961), identified changes in mitochondrial 
structure and function together with increased type II muscle fibres (Mancini et al,
1989) and declines in phosphocreatine with rises in inorganic phosphate (Wilson et al,
1985) suggests that skeletal muscle alterations may contribute to abnormal oxygen 
extraction, substrate utilisation and consequently exercise tolerance in HF.
Researchers in London, U.K. have described a newer ‘muscle hypothesis’ that may
contribute to HF related exercise intolerance (Piepoli et al, 1996). The metabolic stasis
of the muscle is monitored by the activation of ergoreceptors whose fibres increase
ventilation and sympathetic outflow. Reduced LV function leads to skeletal muscle
wasting together with associated abnormalities in muscle metabolism and function. In
response to this, exaggerated ergoreflex activation occurs that leads to excessive
sympathetic vasoconstriction of non-exercising beds and an excessive ventilatory
response to exercise. Consequently this increases peripheral resistance and reduces
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muscle perfusion. The authors also state that this process combined with a catabolic 
state (see earlier) may eventually lead to worsening LV function and remodelling thus 
progressing severity of HF.
In HF, there is derangement of the glucose-insulin axis with some studies reporting up 
to 43% of patients manifesting disorders of glucose metabolism (Kontoleon et al, 2003). 
Initial reports from the Framingham Study drew attention to the potential relationship 
between diabetes mellitus and HF independent of age, coronary artery disease, 
hypertension or BMI (Kannel et al, 1979). Patients with HF and insulin resistance 
display an impaired ability to promote glucose transport into the muscle and adipose 
tissue -  factors which may clearly affect physiological function of exercising muscle. 
Additionally, more recent research has showed that impaired insulin activity inversely 
correlates with severity of HF, relates to disorder of skeletal muscle physiology, 
facilitates reduced muscle mass and can also influence prognosis (Swan et al, 1997 and 
Doehner et al, 2002).
2.2: Benefits of ET in HF.
2.2.1: Exercise capacity.
Numerous studies have identified positive benefit effects of ET relating to exercise
capacity considering both exercise duration and peak v ° 2 . Study design has included
randomised controlled trials, parallel or cross-over training with a marked variance in
participant numbers ranging from 6 to 99. Exercise intervention duration has ranged
from 3 weeks up to 24 weeks with periods of maintenance extending up to 1 year. The
ET programme has varied by numerous factors including setting (home versus gym
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supervised), type of exercise modality (cycling, treadmill, Pole Striding, outdoor 
exercise) and exercise intensity from low level to moderate -  high intensity training. 
Another study has included both aerobic conditioning elements combined with strength 
training (Smart et al, 2007). Improvements in peak oxygen uptake have ranged from 6% 
in a study of Pole Striding for 30 minutes three times per week (Collins et al, 2004) to 
31% in a study simply using outdoor walking for 10 minutes six times per day, twice a 
week (Hambrecht et al, 1995). A fairly recent meta-analysis has suggested that the
greatest mean increase in peak v ° 2  was identified in the research studies involving 
either continuous or intermittent aerobic exercise or combined aerobic and strength
training (Smart et al, 2004). The authors reported increases in v < ^ 2  of 16.5% and 15% 
compared with increases of 9% in studies involving only strength training. This 
analysis also asserted that most improvement in oxygen uptake seems to occur early in 
the intervention (by week 3) but can continue up to 6 months dependent upon patient
compliance to the ET regimen. Overall, average increase in v ° 2  in the same meta­
analysis of 81 studies with a total of 2387 patients was identified as 17% in the 57 
studies that incorporated direct measurement of oxygen consumption.
A study conducted by the European Heart Failure Training Group (1998) reviewed the 
progress of 134 stable HF patients studied in randomised controlled trials of physical 
training. All patients underwent training on a cycle ergometer for 20 minutes 4-5 days 
per week. Patients were instructed to exercise at 70-80% of a pre-determined peak HR 
with calisthenics added in 40% of the patient population. Exercise training duration 
ranged from 6 weeks to a maximum of 16 weeks with the majority (69.4%) of patients 
training at home. The study concluded that the positive effects of exercise in stable HF 
are confirmed and independent of age and gender. A significant training effect of 13%
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increase in peak v < ^ 2  and 17% increase in exercise duration was found to be associated 
with improved autonomic indices such as resting catecholamines and HR variability. 
Interestingly, in this study, improvement in oxygen consumption was higher following 
16 weeks of training when compared to 6 weeks -  contradictory to other research 
(Smart et al, 2004).
More recent research has used high intensity exercise training up to 90-95% of peak
v ° 2  for 4 minute intervals (Wisloff et al, 2007). This study recruited 27 patients with 
stable HF post MI all receiving optimal medical therapy. These patients were elderly 
with a mean age of 75.11 ± 11.1 years and had severely impaired LV systolic function 
(mean EF% of 29%). Patients were randomised to receive high intensity ET or 
moderate continuous ET for a total of three sessions per week (2 supervised and 1 
unsupervised home based). High intensity ET as above was interpolated with 3 minute 
active recovery pauses for a total exercise time including warm and cool-down of 38 
minutes. Moderate continuous ET involved walking for a total of 47 minutes at 70-75%
of peak ^ ^ 2 . Results showed that aerobic interval ET was superior to moderate
continuous ET by evoking significant improvement in v ° 2  (46% versus 14%,
p<0.001). In addition to this, improvements in peak v ° 2  were associated with
decreased LV volumes in systole and diastole, increased EF by approximately 35% and
also decreased pro-BNP by 40%. Improvements were also identified in FMD of the
brachial artery and vastus lateralis muscle mitochondrial function in the aerobic interval
ET group only. This study supports the hypothesis that high intensity aerobic interval
ET is safe in elderly patients with HF. Additionally, this type of training can produce
superior effects to traditional moderate continuous training. The authors suggest that a
combination of LV reverse remodelling, improved LV contractility, increased
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endothelial function and mitochondrial function all result in superior exercise capacity 
as assessed by peak v ° 2  in post-infarct HF patients.
Mechanistically, the integration of several factors seems to be responsible for the 
increase in peak oxygen uptake following ET in patients with HF. Central myocardial 
function appears to be improved documented by increases in peak cardiac output 
response. A study performed by researchers in the Duke University and Durham 
Veterans Medical Centre in the U.S.A identified slightly decreased or unchanged 
cardiac output during rest or sub maximal exercise but increased maximal exercise 
cardiac output from 8.9 + 2.9 L/min to 9.9 + 3.2 L/min following ET (Sullivan et al, 
1988). However, it is suggested that this increase is not solely responsible for the
increases in peak v ° 2  following training (Working Group on Cardiac Rehabilitation 
and Exercise Physiology, 2001). Reduced vasoconstriction of nutritive arterioles within 
the active skeletal muscles in combination with improved oxygen extraction and 
metabolic function at the active skeletal muscle are also important contributing factors. 
Research has identified significant systemic vasodilatation at rest, during sub maximal 
and peak exercise following ET intervention in HF patients (Coats et al, 1992 and 
Sullivan et al, 1988). This work highlighted increased blood flow to the exercising leg 
during peak exercise (from 2.5 + 0.7 L/min to 3.0 + 0.8 L/min) together with a strong 
tendency for decreased leg vascular resistance at peak exercise (from 4 8 + 1 4  mmHg 
/L/min to 42 + 12 mmHg/L/min). Consequently this research also identified that time 
course to ventilator derived anaerobic threshold and oxygen consumption at this point
are also increased due to ET (+ 1.8 minutes at V (^ 2  of 13.7 + 0.7 ml/kg/min -  compared
to a V ( ^2 of 11.9 ± 0.8 ml/kg/min prior to exercise training). This suggests delayed
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reliance on inefficient anaerobic pathways for energy production during exercise 
training.
2.2.2: Exercise training and cardiac systolic function.
There are a number of inconsistent results focussing on myocardial adaptations to ET in 
the HF population. Much work has suggested that any improvement in exercise capacity 
is due to peripheral adaptations. However, there is research evidence that suggests ET 
has a favourable effect on myocardial and coronary vessel adaptation. A recent meta­
analysis has identified a number of research studies that have investigated the effects of 
ET on LV systolic function and LV volumes (Haykowsky et al, 2007).
Studies indicate that aerobic training can reduce adverse LV remodelling in patients 
with HF. These changes are supplementary to any benefits that occur due to 
pharmacological intervention. In more detail, studies indicate that aerobic training can 
provide consistent benefits to EF. Haykowski et al (2007) examined nine trials utilising 
aerobic training and measuring its effect on EF. They observed a mean weighted 
difference in EF of +2.59% to +3.21%. Strength training in isolation was found to be 
inconclusive when assessing benefits to EF. However, this is based solely on one trial of 
strength training alone in HF. Trials have used a combination of aerobic and strength 
training interventions in patients with HF. These studies have also proved inconclusive 
for their effects on EF with a weighted mean difference of 0.37% to 2.97% (Haykowsky 
et al, 2007). Conversely, other research studies that have investigated the effects of 
aerobic training on myocardial function in HF patients have not documented any 
significant changes in resting or exercising EF (Belardinelli et al, 1995 and 1998).
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There appears to be more convincing evidence within the literature in favour of the 
beneficial effect of ET on LV volume. Aerobic training has predominantly been utilised 
in this HF population. However, there are also studies combining aerobic and strength 
training. Using weighted mean difference, ET has been found to be associated with a 
significant decline in end diastolic volume (-9.75 ml) and also end systolic volume (- 
12.31 ml) (Haykowski et al, 2007). These findings are in contrast to early observations 
by Judgutt and colleagues (Judgutt et al, 1988) who found that ET early post MI was 
associated with increased myocardial thinning, remodelling and worsening EF. This 
early observation served to fuel concerns over the effectiveness of ET in a post MI 
population. However, more recent observations have confirmed that ET not only 
reduced LV volumes (Haykowsky et al, 2007), has showed no detrimental effects to LV 
wall thickness and thinned infracted segments (Dubach et al, 1997), but has been shown 
to attenuate unfavourable LV remodelling (using long-term exercise training) in post MI 
patients with significant LV dysfunction (Gianuzzi et al, 1997).
The mechanisms behind improvements in central cardiac function are not well known. 
Theories have however, been postulated by various investigators. Studies have found 
that ET can result in decreased levels of the important patho-physiological 
vasoconstrictive hormones common to HF. An important study by Braith and co­
workers has suggested that ET favourably affects levels of aldosterone, angiotensin II, 
vasopressin, atrial natriuretic peptide and brain natriuretic peptide, epinephrine and 
norepinephrine levels (Braith et al, 1999). The importance of these hormones in HF has 
been discussed earlier in this review. Reduced levels of these hormones serve to 
promote peripheral vasodilatation. This reduction in cardiac afterload reduces pumping
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strain on an already compromised ventricle and hence attenuates the process of 
ventricular remodelling. In relation to this point, other research has shown that ET can 
also decrease sympathetic tone and increase vagal activity in patients with HF (Coats et 
al, 1992). Such improvement in sympatho-vagal activity can further contribute to 
reduced vascular load and attenuation of LV remodelling. The work carried out by 
Hambrecht and colleagues (Hambrecht et al 1995) and Bellardinelli and co-workers 
(1995, 1996, 1999) has shown that beneficial changes in LV volume and peak exercise 
stroke volume as a result of aerobic ET were correlated to the decline in both resting 
and exercising systemic vascular resistance. Furthermore, it was discovered that this 
type of training can facilitate improvements in myocardial contractility and diastolic 
filling in patients with markedly impaired LV systolic function. Therefore, the finding 
of improved EF in a recent meta-analysis of clinical trials (Haykowsky et al, 2007) may 
be explained thus; peripheral vasodilatation results in decreased cardiac afterload -  
attenuating LV remodelling. Improvements in venous return due to peripheral 
vasodilatation results in increased diastolic filling and improved stretching of cardiac 
myocytes as the ventricle swells to an increased end diastolic volume (increased cardiac 
preload). Myocyte stretching increases the sarcomere length resulting in an increase in 
force generation via additional increases in troponin-c calcium sensitivity and the 
related increased rate of cross bridge attachment and detachment (amount of tension 
developed by individual muscle fibres). This mechanism enables the cardiac muscle to 
eject the additional venous return and improve cardiac stroke volume.
2.2.3: Exercise training and cardiac diastolic function.
The effects of ET on LV diastolic function are less studied when compared to systolic 
functional parameters. However, the relevance of diastolic function in determining
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prognosis and survival in HF has emerged as clinically important. Research studies have 
identified that ventricular filling abnormalities, together with systolic dysfunction, not 
only increase severity of patient symptoms (Rihal et al, 1994), but are also a powerful 
predictor of future cardiac events and consequently mortality (Pinamonti et al, 1993). 
To reinforce this concept, previous research has identified that exercise intolerance in 
HF is more closely related to left atrial pressure than to LV systolic EF (Bellardinelli et 
al, 1996). As a result, abnormalities of relaxation and filling during exercise can 
potentially be involved in reducing aerobic exercise capacity in this patient group. 
Within the literature, there is conflicting data with regard to the effects of ET on 
parameters of diastolic function. In studies of patients with diastolic dysfunction alone, 
there are similar improvements to exercise capacity and quality of life as seen with 
those patients who have systolic HF (Freimark et al, 2005). There are however, 
contradictory results regarding the effects of ET on central cardiac aspects of 
diastology.
There are contradictory results regarding the effects of ET on diastolic function in HF 
patients. Studies have however, noted significant improvements in some diastolic 
parameters in response to ET when compared to controls Bellardinelli et al, 1996, 
Stolen et al, 2003, Cheuk-Man et al, 2004, Malfatto et al, 2009). In particular, the 
improvement in diastolic parameters has also been found to correlate well with
improvements in peak v ° 2  suggesting an important role of diastole in the increased 
endurance performance noted as a result of ET in HF patients (Bellardinelli et al, 1996). 
It has been hypothesised that an altered loading state of the LV as a response to ET 
could be an important mechanism in the reduction of LV stiffness. No specific 
mechanism has been suggested to preclude this phenomenon. Together with the
aforementioned peripheral adaptations which may contribute to an improvement in 
systolic contractility and also diastolic filling, there are also possible coronary vascular 
and myocardial adaptations that may contribute to enhanced diastolic function 
following exercise training. For example, animal studies have suggested that the uptake 
of calcium by the myocardial sarcoplasmic reticulum can be enhanced by ET in HF 
patients, inducing both functional and structural coronary vascular adaptation (Laughlin 
and Me Allistair, 1992). ET has also been found to attenuate the vasoconstrictor 
response to norepinephrine via decreased receptor signal transduction rate in a- 
adrenergic receptors of coronary vascular smooth muscle (Carrier et al, 1978). ET can 
also improve bradykinin induced coronary endothelial secretion of relaxing factors, thus 
improving coronary artery sensitivity (Muller et al, 1991). Together these factors can 
drastically improve myocardial perfusion which may play an important role in 
enhancing early diastolic filling (Bellardinelli et al, 1996). It should be noted that all of 
the echocardiographic indexes of diastolic function used in the studies above are 
directly load-dependent. Therefore, as previously discussed, it is sensible to suggest that 
any therapeutic intervention that affects chamber volume and peripheral resistance can 
have positive effects on diastolic function. Improved peripheral arterial function via the 
positive effects of ET on the detrimental pathological hormones secreted in HF (Braith 
et al, 1999) serves to improve venous return, thus enhancing diastolic filling. The 
significant reduction in LV elastance following physical training noted in one of the 
studies above (Malfatto et al, 2009) could be related to positive ventricular remodelling 
-  particularly, because in the same study, there was a significant improvement in a 
correlate of remodelling namely LV mass index (Colucci et al, 2007).
2.2.4: Exercise training and muscle function.
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As previously highlighted in this review, peripheral muscle abnormalities can be 
regarded as one of the principle reasons for poor exercise tolerance in patients with HF. 
Reduced muscle mass and structural mal-adaptation occurs frequently and is linked to 
malnutrition, de-conditioning and the toxicity of circulating inflammatory cytokines. 
Researchers have investigated the effects of ET on patients with HF and have 
determined that the biochemical and histologic changes in skeletal muscle have been 
found to correlate closely with those of classical de-conditioning (Holloszy and Coyle, 
1984). Early studies investigating the effects of ET on skeletal muscle structure and 
function showed that regular physical training delays anaerobic metabolism also 
improving aerobic exercise capacity via increased oxidative capacity of the working 
skeletal muscle (Hambrecht et al, 1995). This initial study showed significant increases 
in the oxidative capacity of skeletal muscle as suggested by changes in volume density 
of cytochrome oxidase positive mitochondria which were also found to be significantly 
correlated with changes in functional capacity and peak oxygen uptake.
Similar improvements in oxidative metabolism have been suggested by other
researchers (Minotti et al, 1990). Single arm ET for 28 days yielded a two-threefold
increase in endurance associated with a slower increase in inorganic phosphate and a
decline in phosphocreatine ratio versus work load slope -  together indicating an
improvement in oxidative metabolism. Needle biopsies of the vastus lateralis muscle
following aerobic ET in patients with HF has derived that ultra-structural abnormalities
in muscle fibre distribution of HF patients can be corrected and that any increases in
aerobic capacity are closely linked to changes in mitochondrial ultrastructure
(Hambrecht et al, 1997). In this study, surface density of mitochondrial inner border
membrane increased by 92% and surface density of mitochondria cristae by 41%. The
more pronounced increase in inner border membranes suggests a higher increase in
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cytochrome c-oxidase activity (a rate limiting enzyme) at inner border membranes of 
mitochondria when compared to mitochondrial cristae in muscle cells.
HF patients are known to have an increase in type II muscle fibres with low aerobic 
potential (Mancini et al, 1989). An increased quantity of these muscle fibres therefore 
promotes reduced muscle performance during exercise as slowly contracting, high 
endurance fibres are required to perform low intensity exercise such as walking or 
climbing stairs. Hambrecht and colleagues (Hambrecht et al, 1997) documented that 
physical exercise enhances oxidative capacity across both muscle fibre types and hence 
a correction towards improved oxidative capacity. In addition, the increase in aerobic 
enzyme content was found to be an important contributing factor to the reduced levels 
of lactate accumulation in exercising muscle at sub-maximal workloads. More recent 
research by Norwegian investigators (Larsen et al, 2002) has suggested that aerobic ET 
promotes an increased area and thickness of type IIB muscle fibres. Together with this, 
they found no significant correlation between these muscular adaptations and increased 
endurance performance. The authors suggest that any increases in maximal aerobic 
capacity is partly due to a shift toward aerobic metabolism with less lactic acidosis, 
increased respiratory muscle strength and a further shift to a normalised ergo-reflex 
response to exercise thus reducing pathological hyperventilation.
Researchers in the UK used 3IP nuclear magnetic resonance spectroscopy to measure
phosphocreatine depletion, muscle acidification and adenosine diphosphate increase
during plantar flexion exercise in the calf muscle of HF patients before and following 8
weeks of physical training (Adamopoulos et al, 1993). Initially, all variables were
significantly increased in HF patients when compared to controls, but following ET,
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phosphocreatine depletion and the increase in adenosine diphosphate during exercise 
were significantly reduced. Additionally, phosphocreatine recovery half time was also 
significantly reduced. Together, these findings indicate a marked correction of the 
impaired oxidative capacity of skeletal muscle in HF achieved by exercise training. 
Skeletal muscle mitochondrial adenosine triphosphate production rate has been 
postulated as an integrated measure of muscle oxidative capacity (Williams et al, 2007). 
During this research, resistance training was found to be significantly associated with 
several indices of muscle oxidative capacity. These included citrate synthase activity (an 
oxidative enzyme) and intact mitochondrial adenosine triphosphate production rate.
With these changes being strongly related to increases in peak v ° 2  following a period 
of circuit resistance training. Interestingly, the substrate combination with the most 
significant response (pyruvate and malate) stimulates the effect of carbohydrate 
metabolism. This is appropriate because during the intervention for this study patients 
exercised at high intensity (>85% of peak). As a result, much of the increased demand 
for adenosine triphosphate resynthesis via oxidative mechanisms would be met by 
carbohydrate metabolism. Another finding of this study was the increase in the lactate 
threshold as a result of ET when compared to controls. Intra-cellular acidosis inhibits 
adenosine triphosphate supply from oxidative phosphorylation in skeletal muscle 
(Jubrais et al, 2003) thus limiting oxidative flux to levels below mitochondrial capacity. 
The delayed onset of lactic acidosis during exercise serves to maintain oxidative flux for 
longer periods during incremental exercise.
Improvements in major aerobic enzymes such as cytochrome c-oxidase has also been 
related to improvements in local and systemic levels of some of the detrimental 
inflammatory cytokines found in HF as mentioned previously in this review.
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Collaborative work between German and Swiss researchers has studied the influence of 
regular physical exercise on skeletal muscle cytokine and inducible nitric oxide 
synthase expression (a known inhibitor of cytochrome c-oxidase production) (Gielen et 
al, 2003). Baseline analysis during this study showed that patients with HF demonstrate 
increased expression of TNF-a, IL-la and 11-6 in biopsies from skeletal muscle 
indicating a local intramyocyte production of inflammatory cytokines. Following a 6 
month programme of physical exercise there was a significant reduction in local 
expression of these inflammatory cytokines in the skeletal muscle of patients with HF 
with virtually unchanged levels of serum cytokine levels. Additionally, expression of 
inducible nitric oxide synthase was reduced by over half following the 6 months of 
exercise training. It has been postulated that in HF, the combination of a low cardiac 
output and ED, may promote repetitive skeletal muscle ischemia (Paulus, 1999). In 
ischemia-reperfusion situations, reactive oxygen species are rapidly generated and have 
been suggested to play a pro-inflammatory role at muscular level in HF (Gielen et al, 
2003).
It has already been established that regular physical exercise beneficially effects anti- 
oxidative enzyme expression (Powers et al, 1994) and this could serve to decrease local 
pro-inflammatory cytokine production. Similarly, oxidative stress has been shown to 
play an important role in inducible nitric oxide synthase production (Punzalan et al, 
1999). The inducible nitric oxide synthase promoter region has been found to contain an 
anti-oxidant responsive element whereby reactive oxygen species increase inducible 
nitric oxide synthase expression. Therefore, it is plausible that the previously mentioned 
anti-oxidant effects of ET may play a direct role in the attenuation of inducible nitric 
oxide synthase expression. Niebauer and colleagues (Niebauer et al, 1998) have noted
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an association between low serum levels of insulin like growth factor-I and reduction in 
lean muscle mass of patients with HF.
Other research has identified that local insulin like growth factor-I expression is 
significantly attenuated in HF patients when assessed using skeletal muscle biopsy 
(Schulze et al, 2000). These studies promote the hypothesis that decreased levels of 
systemic and local insulin like growth factor-I occur with advancing stages of HF. In the 
latter of these two studies, it was noted that the local reduction in insulin like growth 
factor-I levels was independent of serum concentrations which remained virtually 
normal thus suggesting an independent local mechanism for insulin like growth factor-I 
production. ET is a natural form of muscular stretch exposure and has been found to 
significantly increase skeletal muscle insulin like growth factor-I protein levels without 
significant change in serum concentrations in animal studies (Eliakim et al, 1997). 
Consequently, a research study investigating the effects of ET on insulin like growth 
factor-I expression in patients with HF has resulted in a twofold increase in insulin like 
growth factor-I levels post intervention (Hambrecht et al, 2000). This seminal research 
suggests that with adequate aerobic training the catabolic state of skeletal muscle in HF 
can be attenuated or even reversed as a result of exercise training.
2.2.5: Endothelial function.
As previously stated in this review, vasodilatory capacity during exercise is severely 
blunted in patients with HF. The reduction in arterial response during exercise due to 
alterations in endothelial and flow-dependent vasodilatation of resistance arteries seems
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to be a key factor in the pathophysiology of reduced exercise tolerance. Research work 
has however, proposed that HF patients who have undergone ET show marked 
improvements in endothelium dependent relaxation.
Endothelial cell dysfunction is commonplace in HF and other cardiovascular disease 
states (Kubo et al, 1991, Green et al, 2004, Nakamura et al, 1994) and can detrimentally 
reduce peripheral vasodilatation during exercise thus resulting in poor exercise 
performance. The importance of ET in these conditions has become more relevant 
because decreased endothelial function (as characterised by decreased nitric oxide 
vasodilator activity) has been show to be an important early marker of vascular disease 
(Green et al, 2004). Exercise training itself promotes repeated exposure to significant 
alterations in cardiovascular haemodynamics. The onset of physical activity and the 
related mechanical contraction of exercising muscles results in an immediate increase in 
blood flow to the working muscles which can rise to levels up to 100-fold (Anderson et 
al, 1985). In order to facilitate this increased flow, vaso-active metabolites are released 
from the muscle into the interstitial fluid to act directly on terminal arterioles.
It has been suggested that flow changes associated with metabolic vasodilatation are not
enough to account for the significant augmentation of flow to the periphery during ET
(Maiorana et al, 2003). The same authors have considered an additional hypothesis to
explain the co-ordinated dilatation of smaller and larger vessels to improve peripheral
blood flow. The ‘ascending vasodilatation’ hypothesis theorises that vasodilatation
begins in the micro-vessels and serially progresses more proximally along the arterial
tree to larger size vessels. Physiologically, it has been proposed that during exercise
training, target vessels are bathed in interstitial fluid containing by-products of
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metabolism which encourages peripheral dilatation. In normal subjects, this dilatation 
encourages increased flow velocity in more proximal vessels and hence increases shear 
stress, promoting endothelial release of nitric oxide and more proximal vasodilatation. 
Further research has indirectly supported this concept by concluding that flow mediated 
dilatation of conduit arteries in response to muscle ischemia is in the majority dependent 
upon an increase in nitric oxide bio-availability in larger arteries (Joannides et al, 1995).
The effects of ET on endothelial function have been thoroughly investigated. Peripheral 
abnormalities in HF have been previously determined in this review and their 
relationship to peak oxygen uptake and therefore prognosis warrant this level of 
investigation. Two early studies in the late 1990’s have found significant improvements 
in nitric oxide related endothelial dependent function following 4 and 8 weeks of 
handgrip ET in patients with HF. This significant change was not associated with any 
improvement in endothelial independent dilatation (Homig et al, 1996 and Katz et al,
1997). The earlier of these studies demonstrated no significant improvement in nitric 
oxide related endothelial function in the untrained contra-lateral limb which strongly 
supports the argument that training adaptations to handgrip exercise result from local 
adaptations (Hornig et al, 1996).
A further study conducted by Hambrecht and colleagues (Hambrecht et al, 2000) noted
that combined supplementation with oral L-arginine and handgrip ET resulted in
superior blood flow responses to acetyl choline when compared to either intervention
alone. Thus suggesting that increased substrate availability compliments shear stress
induced up-regulation of endothelial nitric oxide synthase. It should be noted that other
research has provided contradictory results to those mentioned above. Bank and
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colleagues observed no significant improvement in acetyl choline response to handgrip 
ET in their HF cohort when compared to healthy controls who had significant 
improvements in both endothelial dependent vasodilatation and peak hyperaemic blood 
flow (Bank et al, 1998).
More research has been undertaken assessing the effects of whole body exercise on 
vascular function. 6 months of cycle training resulted in localised improvements in 
femoral artery basal and stimulated nitric oxide related dilatation (Hambrecht et al, 
1998). This occurred without change in smooth muscle response to glyceryl trinitrate. 
Perhaps more importantly, this type of ET was associated with significant 
improvements in exercise capacity, reduced LV end diastolic diameter and reduced total 
peripheral resistance. Furthermore, the reduced total peripheral resistance correlated 
well with acetyl choline enhanced flow in the lower limb. This improvement could 
explain the previously mentioned role of the peripheral circulation in reducing afterload, 
increasing preload and therefore improving cardiac systolic and diastolic parameters 
(Bellardinelli et al, 1996).
Other research has used combined aerobic and resistance ET in the form of circuit
sessions for an intervention period of 8 weeks (Maiorana et al, 2000). This type of
training was found to significantly improve forearm resistance vessel function in
patients with HF when compared to controls. Furthermore, this study specifically
avoided repetitive forearm muscle training during the circuit training intervention thus
suggesting a systemic effect of training. This type of training also suggested slight
improvement to endothelial dependent vasodilatation which is consistent with
concomitant changes to vascular structure and smooth muscle function. Further
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clarification of a systemic effect of ET on nitric oxide related endothelial function was 
provided by Linke and co-workers (Linke et al, 2001). This group studied the effects of 
cycle training over a period of 4 weeks on endothelial function in patients with HF 
when compared to controls. Training of the legs resulted in improved acetyl choline 
mediated and flow mediated dilatation responses in the radial artery with no concurrent 
change in vascular smooth muscle function.
To conclude, in patients with HF, it appears that ET of high enough intensity and that 
activates sufficient muscle mass to produce increases in pulse wave dynamics and shear 
stress can improve localised and systemic arterial nitric oxide related ED without 
significant changes in vascular smooth muscle function.
Exercise training in patients with CAD has also been shown to bring about similar 
improvements to those with individuals HF. ET large muscle groups predominate this 
research and the studied effects range from the periphery to the coronary arterial tree. 
Hambrecht and colleagues (Hambrecht et al, 2000) used coronary arterial flow wires 
during cardiac catheterisation to assess the effects of cycle training for 4 weeks on 
coronary endothelial function. The intervention resulted in significant improvements in 
endothelial dependent vasodilatation in epicardial coronary and resistance vessels 
without significant change in independent endothelial function.
Research focussing upon ET and peripheral arterial function in CAD has yielded 
positive results. Gocke and co-workers (Gocke et al, 2002) described improved flow 
mediated dilatation in the tibila artery following 10 weeks of leg ET without any change
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in response to glyceryl trinitrate. Disappointingly, although there was a 1.9% increase in 
brachial artery flow mediated dilatation this was not statistically significant. Another 
study focussing on circuit training, which again avoided forearm exercise, resulted in 
significant improvements in brachial artery flow mediated dilatation without any change 
in vascular smooth muscle function (Walsh et al, 2003). This is further satisfactory 
evidence suggesting that ET of sufficient calibre and intensity can improve systemic 
nitric oxide mediated endothelial function in patients with CAD. Mechanistically, 
endothelial nitric oxide synthase mRNA and vascular protein expression have been 
found to be higher in trained individuals with CAD when compared to controls 
(Hambrecht et al, 2003). Additionally, increased endothelial nitric oxide synthase 
phosphorylation was found to be significantly correlated with the changes in acetyl 
choline induced peak flow velocity following exercise training, supporting the theory 
that increased quantity of endothelial nitric oxide synthase protein may promote an 
improvement in endothelial function via shear stress induced phosphorylation.
It appears that ET can improve endothelial function in patients with known CAD. 
Clearly, any improvements in coronary artery function may improve myocardial 
perfusion and hence cardiac function together with reductions in the incidence and 
severity of myocardial ischemia (Schuler et al, 1992).
2.2.6: Biochemical and inflammatory markers.
The increased activation of several neuro-hormonal systems and increased production of 
peptides such as nor-epinephrene, angiotensin II, aldosterone, endothelin-1 and pro-
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inflammatory cytokines are well documented pathophysiological hallmarks of HF and 
have been previously described in this review.
Cytokines are small molecular weight protein molecules secreted by cells in response to 
a variety of stimuli. Cytokines may act in an autocrine, juxtacrine or paracrine manner 
and are suggested to be secreted by neighbouring ‘producer’ cells (Bozkurt, 2009). They 
are able to influence the biological behaviour of other neighbouring ‘target’ cells. 
Overproduction of cytokines results in over-spill into the peripheral circulation. Once 
freely available within the peripheral circulation cytokines are able to exert endocrine- 
like effects (Bozkurt, 2009). Additionally, cytokines can be produced by a number of 
different cell types of numerous tissue origins. In HF, two major classes of cytokine 
have been identified. These are vasoconstrictor cytokines (e.g. endothelin) and 
vasodepressor cytokines such as TNFa and IL-6.
Early reports from the Framingham study (2003) showed the inflammatory cytokines
IL-6 and TNFa were able to identify asymptomatic older participants at future risk of
developing HF. Initial research studies have suggested that the pro-inflammatory
cytokines TNFa, IL-1, 6 and 18 are produced by nucleated cells within the myocardium
(Anker and von Haehling 2004). The cytokine hypothesis of HF describes the process
of over-secretion of inflammatory cytokines in response to a particular trigger (e.g.
ischaemia or cardiac injury) Braumwald (2009). Furthermore, this hypothesis suggests
that TNFa, IL-1, 6 and 18 are produced by the damaged myocardium, a factor which is
augmented by stimulation of the sympathetic nervous system. This process results
skeletal and cardiac muscle hypoperfusion due to reductions in cardiac output and
allows the production of monocytes. These monocytes, in turn, produce further
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inflammatory cytokines which are able to exert their biological effect on the 
myocardium resulting in cell apoptosis and necrosis (Anker and von Haehling, 2004). 
IL-6 levels have been shown to increase in humans following acute myocardial 
infarction (Finkel et al, 1992). This glycoprotein consists of two functional chains, as a 
binding protein (IL6R) and also as a docking protein able to transmit the intracellular 
signal (Hirano, 1991).
Further research has suggested that IL-6 is able to induce a hypertrophic response in 
cardiac myocytes via activation of the common receptor gpl30 (Yoshida et al, 1996) 
and TNFa results in left ventricular dilatation via the activation of matrix 
metalloproteinases (Seta et al, 1996) and is able to induce immediate and delayed 
negative inotropic effects to impair myocardial contractility (Bozkurt, 2009). The 
immediate pathway has been shown to be mediated by activation of the neuromyelinase 
pathway (Oral et al, 1997) and the delayed pathway mediated by nitric oxide derived 
blunting of p adrenergic signalling (Balligand et al, 1993). In fact, when expressed at 
sufficiently high concentration, cytokines are able to mimic many important aspects of 
the HF phenotype such as pulmonary oedema, LV remodelling, foetal gene expression 
and cardiomyopathy (Bozkurt, 2009).
In particular, TNF is able to bind to the adult cardiac monocyte via the receptors
TNFR1 and TNFR2 (Torre-Amione et al, 1996). This research also showed that adult
human cardiac myocytes express both types of TNF receptors with TNFR1 responsible
for mediating negative inotropic effects. In addition, when both receptors are
proteolytically cleaved from cell membrances they are able to subsist in the circulation
as soluble receptors sTNFRl and sTNFR2 (Bozkurt et al, 1996). These receptors are
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able to bind to their ligand as well as inhibit the cardiotoxic effects of TNF and as such 
are capable of rapidly neutralising the aforementioned cardiotoxic effects (Bozkurt et al, 
2009).
Inflammatory cytokines such as TNFa, IL-1 and IL-6 have been shown to increase the 
expression of oxygen free radicals, inducible nitric oxide synthase and stimulate 
apoptosis in endothelial cells via oxidative stress, thus facilitating widespread ED 
(Adamopoulos et al, 2001). Increased activation of pro-inflammatory cytokines has also 
been associated with increased expression of inducible nitric oxide synthase and 
decreased expression of insulin like growth factor-1 in the skeletal muscle of patients 
with HF. As mentioned above, this creates potential for decreased skeletal muscle 
performance by attenuating mitochondrial efficiency and also promoting skeletal 
muscle apoptosis (Hambrecht et al, 2000).
Cell adhesion molecules are a diverse system of proteins and adhesive receptors which 
have the ability to orchestrate biological actions such as embryogenesis, cell growth and 
differentiation as well as inflammatory processes (Mulvihill et al, 2002). These 
adhesion molecules have been shown to be important in the mediation of the 
pathological processes involved in the progression of atherosclerosis and acute coronary 
syndromes. The most abundant family of adhesion molecules within the human body 
are the immunoglobulin superfamily (Mulvihill et al, 2002). This family, which 
accounts for up to 50% of leukocyte membrane glycoproteins, are able to serve as
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receptors for growth factors, receptors for the Fc region of immunoglobulins and also as 
cellular counter-receptors for integrins (Mulvihill et al, 2002).
Increased release of cytokines and oxygen free radicals in HF has been shown to induce 
the expression of endothelial adhesion molecules (intercellular adhesion molecule-1, 
vascular cell adhesion molecule-1). These adhesion molecules enter the circulation via 
activation of endothelial cells (measured as soluble adhesion molecules sICAM -1 and 
sVCAM-1) and may play an important role in deterioration of endothelial function in 
this patient group (Noutsias et al, 1999). The exact biological role of soluble cell 
adhesion molecules is fairly unclear. These soluble forms are released into the 
circulation from the cell surface via proteolytic cleavage of the extra-cellular protein 
(Gearing et al, 1993). This process has been suggested as a means to controlling cell 
adhesion (Mulhivill et al, 2002). Importantly, much research has suggested a strong 
link between serum levels of soluble adhesion molecules and cardiovascular events. For 
instance, research has shown that sICAM-1 levels, in patients enrolled into the 
Physicians Health Study (Ridker et al, 1998), are elevated in ‘healthy’ males who are at 
increased risk for future cardio-vascular events. A similar finding has been observed in 
the female population. In the Womens Health study, sICAM-1 levels were found to 
correlate well with future risk of cardiovascular events in apparently healthy females 
(Ridker et al, 2000).
Similarly in patients with established coronary heart disease and in acute coronary 
syndromes, disruptions to sICAM-1 and sVCAM-1 levels in serum can be observed. In 
patients with angiographically diagnosed coronary artery disease, increased levels of 
sICAM-1 and sVCAM-1 were predictive of future cardiovascular events (Blankenberg
et al, 2001). Additionally, Shyu et al, 1996 reported increased levels of sICAM-1 in 
patients with acute coronary syndrome. sICAM-1 was been established as the most 
powerful predictor of future cardiovascular events in an asymptomatic population and 
sVCAM-1 has been shown to be more powerful when predicting future events in 
patients with established atherosclerotic disease (Mulvihill et al, 2002). Therefore, there 
is a commonly held belief that serum soluble adhesion molecules represent the vascular 
inflammatory component of the atherosclerotic process.
In further detail, ICAM-1 is expressed at low levels by numerous cell types to include 
leukocytes and endothelial cells. As a result, Ridker et al, 1997) suggest that elevated 
levels of sICAM-1 in healthy individuals who later develop cardiovascular events 
probably represents a low level inflammatory process analogous to elevated levels of C- 
reactive protein. Expression of VCAM-1 has been shown to occur only on activated 
endothelial and vascular smooth muscle cells. This may suggest that sVCAM-1 can 
serve as a potential marker of overall plaque burden and has already shown its 
predictive value in patients with diabetes and established atherosclerotic disease (Jager 
et al, 2000 and Blankenberg et al, 2001), groups who are known to have an activated 
endothelium.
Table 36 summarises the known pathophysiological effects of inflammatory cytokines.
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Table 36. Adverse Pathophysiological Effects of Inflammatory Cytokines in HF
(adapted from (Adamopoulos et ah 2001).
1. Cardiac.
Promotion of LV remodelling.
Attenuated cardiac contractility. 
Cardiomyocyte hypertrophy.
Cardiomyocyte apoptosis.
Cardiac Fibrosis.
2. Vascular.
Progression of atherosclerotic process. 
Oxidative stress.
Vasoconstriction.
Endothelial cell apoptosis.
Adverse vascular remodelling.
3. Skeletal Muscle.
Reduced skeletal muscle blood flow. 
Anabolic / catabolic metabolism imbalance. 
Inhibition of protein synthesis.
Muscle cell apoptosis.
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Cachexia.
BNP is a cardiac neurohormone secreted from the ventricles in response to volume 
expansion, pressure overload and hence myocyte stress. As previously mentioned in this 
review (and comparable to the above table), the most important adverse effects of 
increased levels of BNP include reduced skeletal muscle blood flow and cachexia, 
promotion of LV remodelling, reduced cardiac contractility, progression of 
atherosclerosis, increased oxidative stress, nitric oxide impairment, vasoconstriction, 
endothelial cell apoptosis and adverse vascular remodelling (Anker et al, 2004).
Intense physical exercise has been shown to influence inflammatory reactions within the
blood as denoted by delayed increase of acute phase proteins such as C-Reactive Protein
and an attenuated acute phase reaction following regular physical exercise. Taken
together this suggests an anti-inflammatory role of regular ET (Mattusch et al, 2002). A
number of studies have investigated the effects of regular physical ET on markers of
inflammation in patients with heart disease. Aerobic ET can be utilised as an
immunomodulatory treatment in HF. Early research has shown significantly reduced
plasma TNF-a levels together with increased skeletal muscle capillary density, which
resulted in improved flow reserve of exercising skeletal muscle in HF patients (Larsen
et al, 2001). Similar ET programmes have been shown to positively intervene in the
inflammatory and apoptotic cascade in patients with HF. There can be potential
significant reductions in the major potent cytokines TNF-a and IL-6 (Larsen et al, 2002,
Adamopoulos et al, 2001, Adamopoulos et al, 2002, Le Maitre et al, 2004), but also the
soluble receptors of these cytokines which are the products of a monocyte / endothelial
cell interaction and biological determinants of circulating inflammatory cytokine
281
function (Adamopoulos et al, 2002). Additionally, representative apoptosis mediators 
such as soluble Fas and soluble apoptosis inducer Fas ligand (which are known to be 
elevated in HF), can also be mediated by aerobic ET. It has been suggested that this 
attenuation may play an important beneficial role in the peripheral immune response, 
improve patient symptoms and improve prognosis in patients with HF (Adamopoulos et 
al, 2002). Soluble apoptosis inducer Fas ligand is a TNF-a related cytokine which is 
synthesized as a membrane bound protein. This can be changed via proteolytic cleavage 
into soluble form to promote intercellular Ca++, homeostatic alterations, caspase 
activation, apoptotic gene transcription and apoptotic cell death following cross-linkage 
with receptor Fas (Adamopoulos et al, 2003). The significant correlations noted 
between improved exercise capacity and reduced levels of TNF-a and sFasL plasma 
levels in response to a programme of aerobic ET suggests that this type of intervention 
can, at least partially, suppress pro-inflammatory cytokine activation and therefore 
attenuate the clinical deterioration noted in HF (Adamopoulos et al, 2002).
Other research from the same group in Greece has demonstrated that aerobic ET can
reduce certain peripheral inflammatory markers (Adamopoulos et al, 2001)
representative of macrophage-endothelial cell adhesive interaction and basal parts of the
complex inflammatory cytokine network. This study utilised home-based aerobic
training to evaluate the levels of inflammatory cell growth factor granulocyte
macrophage colony-stimulating factor (GM-CSF), monocyte chemotactic protein
cytokine (MCP-1) and the soluble adhesion molecules sICAM-1 and sVCAM-1. The
significant improvement noted in all of these inflammatory markers was closely
correlated with improvements in endothelial function and exercise capacity. This
suggests that regular aerobic ET can, by virtue of its anti-inflammatory and anti-
apoptotic roles, beneficially affect peripheral immune responses perhaps by reversing
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the aforementioned deleterious effects of inflammation on endothelial structure and
function.
2.2.7: Exercise training and the Metabolic Syndrome.
The metabolic syndrome is a public health problem worldwide with significant 
evidence, already published, suggesting that levels of fitness and increasing physical 
activity are essential in regression of this condition. The earlier section of this thesis has 
already highlighted the possible relationship between components of the metabolic 
syndrome and heart failure, particularly with respect to insulin resistance. Therefore, the 
close relationship between the metabolic syndrome and cardiovascular disease and the 
potential beneficial effects warrants discussion as part of this thesis.
Lakka et al, 2003 showed important correlations between cardiorespiratory fitness, 
amount of leisure time physical activity with development and progression of the 
metabolic syndrome in over a thousand males with no evidence of type II diabetes, 
CVD or cancer. This study unequivocally demonstrated that males engaging in less than 
one hour physical activity per week were 60% more likely to develop or already have 
the metabolic syndrome. Additionally, La Monte et al, 2005 demonstrated similar 
correlations between cardiorespiratory fitness and incidence of the metabolic syndrome 
in over ten thousand participants (1491 of these female). Furthermore, adjustment for 
lifestyle factors including dietary choices has been shown not to alter the association 
between overall cardiorespiratory fitness and the metabolic syndrome (Finley et al,
2006). Not only overall cardiorespiratory fitness has been shown to be an important 
predictor or marker for development of the metabolic syndrome. Muscular strength and
lean body mass are also related to this condition. In the large Aerobics Centre 
Longitudinal Study, Jurca et al (2004) demonstrated that each of the five metabolic 
syndrome components were inversely related to muscular strength as determined by a 
one repetition maximum bench press and leg press. In addition, the effects of muscular 
strength on the metabolic syndrome components were independent to cardiorespiratory 
fitness and also BMI. This data provides significant evidence that both aerobic fitness 
and muscular strength provide preventative effects on metabolic syndrome risk. Overall 
mortality data demonstrates strongly the public health burden of the metabolic 
syndrome. In a large study, Katzmarzyk et al (2004) investigated the effects of 
cardiorespiratory fitness and mortality on almost twenty thousand males separated into 
healthy and those with metabolic syndrome components. Accruing 196,466 man years 
of follow-up, the authors showed relative risks of all cause and CVD mortality of 1.29 
and 1.89 for men with the metabolic syndrome when compared to healthy counterparts. 
Additionally, overall mortality risk was 5.18% in the healthy unfit group compared to 
1.95% in the healthy fit group. In the metabolic syndrome, overall mortality risk was 
5.15% in the unfit group and 2.69% in the fit group indicating that unfit healthy males 
show higher all-cause and CVD mortality rates per 10,000 man years of follow up than 
fit males with the metabolic syndrome. There was also a significant dose-response 
relationship between cardiorespiratory fitness and mortality in males with the metabolic 
syndrome reinforcing the aforementioned concept that cardiorespiratory fitness may be 
as powerful predictor of mortality as the entire metabolic syndrome components 
combined and should be included as a feature of the syndrome.
There are relatively few studies of sufficient detail that have investigated fully the
effects of exercise training on the metabolic syndrome in entirety, rather than individual
components of the syndrome. Perhaps the two most detailed and landmark trials are the
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Studies of a Targeted Risk Reduction Intervention through Defined Exercise Trial 
(STRRIDE) (Johnson et al, 2007) and the study of Katzmarzyk et al 2003, which 
assessed the effects of ET in the metabolic syndrome on the population of the 
HERITAGE Family Study. The STRRIDE study showed that a low amount of moderate 
intensity exercise (e.g. around 19km of walking per week) and a high amount of 
vigorous activity (e.g. around 32km of jogging per week) improved the metabolic 
syndrome when compared to controls. The high amount, vigorous intensity group only 
reported decreases in BMI. In the HERITAGE study, the presence of metabolic 
syndrome and component risk factors were determined prior to and following 20 weeks 
of supervised ET (3 days per week at 55% V02max for a duration of around 30 minutes, 
progressing up to 75% V02max for 50 minutes duration). This study reported that 
following ET, 31% of participants diagnosed with the metabolic syndrome using the 
ATP III criteria were no longer classified following ET.
Insulin resistance has been suggested as the leading connection between physical 
inactivity and the metabolic syndrome (Roberts et al, 2013). As discussed previously in 
this review, aerobic training has been shown to increase insulin action in the skeletal 
muscle of healthy individuals and research evidence has shown that ET can increase 
insulin sensitivity from 25-50% in numerous age and population groups to include 
normal healthy males (Dela et al, 1992), healthy females (Evans et al, 2001), obese 
populations (De Fronzo et al, 1987), young participants (Yfanti et al, 2011), older 
participants (Di Pietro et al, 2001), first degree relatives of known diabetics (Barwell et 
al, 2008), type II diabetics (Dela et al, 1995) and sedentary adolescents (van der 
Heidjden et al, 2009).
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Studies investigating aerobic training versus control with respect to insulin sensitivity 
have identified differences in glycogen storage in response to insulin (Ebeling et al, 
1993), increases in insulin signalling proteins (glycogen synthase, GLUT4, GLUT4 
vesicle associated protein) (Ebeling et al, 1993) and decreased insulin receptor substrate 
1 /2, insulin receptor with no difference in protein kinase B (Yu et al, 2001). Research 
conducted by Dela and colleagues 1993 and 1995 has identified increases in non- 
oxidative glucose disposal which was associated with increased glycogen synthase 
mRNA and also increases in GLUT4 protein concentration (26%) which matched their 
observed increases in maximum insulin stimulated leg glucose uptake (25%), a strong 
positive correlation noted between the two variables. Other research has also shown 
significant improvements in GLUT4 uptake in response to exercise training with values 
ranging from 22% up to 60% (Christ-Roberts et al, 2004, Houmard et al, 1996 and Dela 
et al, 1994). In addition, Christ-Roberts et al, 2004 have shown that ET resulted in 
increased insulin sensitivity, increased glycogen synthase fractional activity together 
with increased phosphoionisitide-3 kinase activity. No changes were seen in insulin 
receptor substrate-1 associated phosphoionisitide-3 kinase activity, in agreement with 
other research investigating short-term exercise training in the metabolic syndrome 
(Tanner et al, 2002).
In addition to traditional continuous aerobic training, research has attempted to identify
the benefits of more modern high intensity interval training in the metabolic syndrome.
It has already been established earlier in this review that intermittent high intensity
interval training can result in greater improvement in V0 2 max when compared to
traditional training methods (Wisloff et al, 2007). Furthermore, research by Tremblay et
al, 1994 has shown that 20 weeks of interval training resulted in greater reduction is
percent body fat when compared to continuous aerobic training despite over 50% less
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total energy consumption during the interval training regimen. This, for the first time, 
demonstrated that improvements in fat mass are not related to actual energy expended 
during exercise but related to exercise intensity. Little et al (2010 and 2011) has shown 
that interval training can increase insulin receptor phosphorylation to a greater extent 
than continuous training and also noted significant improvements (119% increase) in 
GLUT4. It has been hypothesized that glycogen depletion as a result of high intensity 
intervals may induce the improvements in insulin sensitivity.
2.2.8: Exercise training and quality of life.
Many reports have assessed the effects of different types and intensities of ET on 
quality of life and health status in patients with HF, either as a primary or secondary 
outcome measure. Studies have used numerous, validated questionnaires to assess 
varying aspects of health status including general health, mental health, physical fitness 
anxiety and depression and disease specific quality of life indices.
Earlier studies performed in the late 1990’s have used a variety of questionnaire models 
to assess quality of life in HF patients. Exercise training resulted in significant 
improvements in the Feelings of Being Disabled subscale of the Heart Patients 
Psychological Questionnaire and also highly significant improvements in the Self 
Assessment on General Wellbeing Questionnaire (Wielenga et al, 1998). The same 
authors did not discover any significant improvements in the Sickness Impact Profile 
which was attributed to the fact that this is a generic questionnaire and not specifically 
tailored to HF patients. Conversely, other research conducted around the same time has 
shown significant improvements in the Sickness Impact Profile (Tyni-Lenne et al,
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1998). It was noted that the documented significant improvements in functional 
capacity during this study could explain the perceived reduction of disability. Another 
study (Bellardinelli et al, 1999) utilised the popular Minnesota Living with Heart 
Failure Questionnaire. This study again, documented significant improvements in 
Quality of Life which closely followed the course of improved peak oxygen uptake. The 
same improvements have also been noted by other research groups (Miche et al, 2009). 
However, other research using the Minnesota Questionnaire has not found significant 
improvements in health related quality of life (Gottleib et al, 1999). The same authors 
also did not find any significant improvement in other measures of quality of life, 
namely the Functional Assessment Questionnaire and the Centre for Epidemiological 
Studies Depression Questionnaire. It was suggested that either there was a poor 
correlation between peak exercise performance and the ability to perform routine daily 
activities or the tests utilised were not sensitive enough to detect significant 
improvements.
More recent research conducted since the turn of the century has again produced 
contradictory results. Of those studies that utilised the Minnesota Living with Heart 
Failure Questionnaire (Tyni-Lenne et al, 1998, Smart et al, 2007, Janowska et al, 2008) 
significant improvements in health related quality of life were noted in all patients with 
systolic dysfunction and even in a group of patients with diastolic dysfunction following 
supervised exercise training. Simply, these authors have suggested that by physical 
training all the significant major muscle groups involved in daily activities it is possible 
to reduce the burden of HF on everyday tasks and hence improve health related quality 
of life. The documented physiological improvement in physical function in many of 
these studies serves to support this theory.
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Two more recent studies have used the generic SF36 questionnaire to look at quality of 
life in more detail (Smart et al, 2007, Miche et al, 2009). Both of these studies 
demonstrated statistically significant improvements in quality of life score. One study 
showed significant improvements in all domains of the SF36 following supervised ET 
in a group of patient with LV systolic dysfunction (Smart et al, 2007) whilst the other 
research study documented changes in the physical sum scale only Miche et al, 2009). 
Additionally, in patients with diastolic dysfunction, some improvements in SF36 
domains were also noted following ET (Smart et al, 2007).
Two studies utilised specific questionnaires assessing anxiety and depression before and 
following ET in HF patients (Smart et al, 2007, Miche et al, 2009). The results were 
contradictory. The initial study conducted by an Australian research group (Smart et al,
2007) suggested significant improvements in the Harc-Davis Cardiac Depression Scale. 
However, more recent research has shown no significant improvements in the Hospital 
Anxiety and Depression Scale in their sample of HF patients (Miche et al, 2009). This 
discrepancy could be explained thus; patients who exhibit improved functional capacity 
and improvement in their ability to perform daily activities can display an improved 
outlook due to their improved sense of wellbeing. However, as the majority of patients 
studied with HF are of the older generation, these patients tend to feel more content 
with their surroundings which makes it more difficult to observe significant 
improvements following an exercise intervention. This is reinforced by Fahrenberg and 
co-workers (Fahrenberg et al, 2000) who suggest that as cardiovascular patients age 
their reported levels of contentment improve to levels of ‘extremely high’. Another 
suggested reason for the lack of significant change in the older generation has been the
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‘disability paradox’. This implies that patients who have a poor physical condition 
report a good sense of physical and emotional health (Paul et al, 2007).
The timescale of the improvements in quality of life noted in HF patients as a response 
to ET has been highlighted by the work in the HF Action Trial (Flynn et al, 2009). This 
large, randomised controlled trial showed that health status improved more during the 
initial 3 months of the intervention for the exercise group when compared to the 
controls. Additionally, this improvement persisted throughout the follow-up period and 
included important subscales of the Kansas City Cardiomyopathy Questionnaire 
namely; physical limitations, quality of life and social limitations. This highlights that 
short interventions of ET in the HF population (<3 months) is sufficient to exert 
changes in domains of quality of life and also that these changes can be maintained over 
a long period of follow-up (up to 3 years).
2.3: Testosterone supplementation in HF.
2.3.1: Testosterone replacement therapy and functional capacity.
Currently there are only a small number of randomised trials that have assessed the use 
of testosterone replacement therapy in patients with HF and low testosterone. Larger, 
multicentre trials are needed in order to ascertain the complete importance of this 
therapeutic aid in this population. However, some important factors must be considered 
prior to initiation of these trials.
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High doses of testosterone can be cardiotoxic and may also adversely affect the 
progression of CAD (Malkin et al, 2009). It should be noted however, that all studies to 
date have utilised low physiological replacement doses of testosterone in patients with 
known hypogonadal levels. It has to date not been established if testosterone therapy 
can be safely employed in patients with HF and normal testosterone levels.
It has been recently discovered that in males with hypogonadism and HF, the level of 
circulating testosterone is independently related to peak oxygen consumption and peak 
oxygen pulse (Jankowska et al, 2009). A small number of randomised studies have 
assessed the effect of physiological testosterone replacement therapy on exercise 
capacity and endurance performance in the HF population. The following table (37) 
illustrates the main studies that have addressed this.
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Although there are currently few studies available investigating the effects of 
testosterone supplementation on exercise tolerance in HF, there is conclusive evidence 
that testosterone therapy can improve exercise tolerance. This occurs in short and long 
term follow-up and with testosterone administration of different sources (i.e. injection 
fortnightly, long acting injection or adhesive skin patch). Not only is there a 
documented increased walking distance on shuttle tests but also physiologically
documented increases in key determinants of endurance performance such as peak . 
Explanation of the improvement in exercise tolerance remains unclear. However, an 
Italian research group have identified that changes in muscle performance may provide 
some insight (Caminiti et al, 2009). It has been stated previously in this review that 
there are documented changes in morphology and function of skeletal muscles in 
patients with HF -  independent to reduced peripheral flow (Hare et al, 1999, Sendenet 
al, 2005, Janowska et al, 2008, Kida et al, 2008, Williams et al, 2007). Maladaptive 
muscle fibre atrophy, increased abundance of type II glycolytic fibres and the resultant 
reduced oxidative metabolic capacity have been shown to correlate with poor exercise 
tolerance and increased VE/VCO2 slope in HF (abnormal enhanced muscle ergoreflex) 
(Hambrecht et al, 1995). The work undertaken in Italy documented significantly 
increased muscle strength and work output following testosterone supplementation. The 
authors hypothesised that this representative improvement in overall muscle function 
may decrease the abnormal muscle metaboreflex contribution to the ventilatory 
response to exercise, reducing the VE/VCO2 slope and therefore improving exercise 
tolerance.
To further reinforce this hypothesis, other work (in non-HF animal models) has shown 
that anabolic supplementation at physiological doses is capable of accelerating fast to
slow twitch muscle fibre type conversion and also increase the number of type I 
oxidative fibres, co-existent in improving the relative oxidative capacity of skeletal 
muscle (Ustunel et al, 2003). Although explained in less detail, the work undertaken by 
Pugh and colleagues (Pugh et al, 2004) has also suggested that microscopic changes in 
muscle metabolism and structure not detected by their muscle analysis techniques may 
explain the increase in exercise tolerance noted in their study. However, it should be 
noted that there was not a significant increase in muscle strength in this small-scale pilot 
study.
2.3.2: Testosterone replacement therapy and cardiac function.
Data regarding the effect of testosterone supplementation on cardiac structure and 
function in HF patients is sparse. It has previously been determined that in HF patients 
with erectile dysfunction there is a significant inverse correlation between resting right 
and LV EF and testosterone level (Bocchi et al, 2008). This suggests testosterone levels 
may exert an influence on cardiac structure and function. However, research studies so 
far in human subjects have showed little or no effect of testosterone supplementation in 
physiological doses. Two of the studies in the table above measured indices of cardiac 
structure and function (Malkin et al, 2006, Caminiti et al, 2009). The earlier study 
conducted by Malkin et al demonstrated a minor but significant increase in LV length -  
but no serial change in other aspects of cardiac function. The later study by Caminiti et 
al does not show any significant effect of testosterone supplementation on cardiac 
structure or function as measured by echocardiography. This is disappointing as animal 
models appear to demonstrate a more pronounced cardiac response to testosterone 
supplementation. For example, an early study has shown that following gonadectomy, 
both male and female rats demonstrated loss of weight and reduced cardiac contractile
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function. Furthermore, supplementation with testosterone was shown to improve cardiac 
contractile function in male rats and also (but to a lesser extent) in female rats with 
concomitant testosterone and estrogen supplementation (Scheuer et al, 1997). 
Physiologically, gonadectomy was found to be associated by decreases in cardiac 
myosin ATPase activity and a shift in heavy chain myosin isoenzymes from pattern Vi 
to V 3 . The administration of testosterone in males and estrogen and testosterone in 
females seemed to reverse this pathological process. Additionally, ganodectomised male 
rats were found to have an increased duration of cardiac relaxation in perfused hearts 
(with moderate afterload) when compared to their intact counterparts. Administration of 
testosterone was successful in resolving this process to normal, probably via alterations 
in biochemical control of diastole such as by the sarcoplasmic reticulum (Scheuer et al, 
1997). This early study does suggest that sex hormones can have an important 
modulating role on cardiac systolic and diastolic function. More recently, research in 
rats has suggested that administration of testosterone can attenuate unfavourable cardiac 
remodelling and improve contractile performance probably mediated by decreasing 
levels of TNF-a (Zhang et al, 2007). As discussed previously, TNF-a is one of the 
primary cytokines involved in the catabolic processes in HF. It is known to result in LV 
dysfunction, remodelling, pulmonary oedema, muscle wasting and cardiomyopathy in 
human subjects when overexpressed (Adamopoulos et al, 2001). It was identified that 
one important factor in the cardiac remodelling process in HF is extra-cellular matrix 
fibrosis or over-degredation (Zhang et al, 2007). Matrix metalloproteinases have been 
shown to be the most prominent system in this process with TNF-a being the main 
stimulatory mechanism (Miyamoto et al, 2005). Testosterone therapy has been shown to 
significantly decrease the myocardial expression of matrix metalloproteinases and also 
reduce levels of myocardial hydroxyproline (elevated in HF and reflect the information 
of deposited collagen proteins) hence, attenuating excessive proliferation of collagen
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proteins to prevent ventricular remodelling. These beneficial effects of testosterone 
were attributed to TNF-a suppression or down regulation of matrix metalloproteinase 
directly (Zhang et al, 2007). It should be noted however, anabolic androgen abuse such 
as that traditionally noted in high level competitive athletes has been shown to 
drastically alter myocardial function. Increases in cardiac mass due to severe LV 
hypertrophy can result in severe diastolic dysfunction -  independently of the effects of 
strength training (Urhausen et al, 2004). As a result of this, testosterone dose level 
compared to body weight may be an important factor in any resultant central cardiac 
response. It is important however, to maintain safe levels of supplementation to avoid 
adverse physiological effects and there is little or no published research on the safety of 
intermediate levels of testosterone supplementation on cardiac function in any patient 
group.
2.3.3: Testosterone replacement therapy and arterial function.
To date, there is only one study available that has assessed the effects of testosterone 
replacement therapy on arterial function in males with HF. This small-scale study 
utilised a balloon flotation catheter inserted into the pulmonary circulation in order to 
measure systemic vascular resistance, PCWP and pulmonary artery pressure in 12 males 
who received 60mg of testosterone via the buccal route (Pugh et al, 2003). 
Haemodynamic parameters were assessed at baseline and at increments up to 360 
minutes post treatment. Acute administration of testosterone was noted to significantly 
increase cardiac output when compared to placebo (10.3 + 4.6% increase from baseline) 
accompanied by a reduction in systemic vascular resistance (-17.4 + 9% from baseline, 
p<0.0001) in the treatment group only. Importantly, the relative decrease in systemic 
vascular resistance suggests that the increased cardiac output is due to arteriolar
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vasodilatation and therefore reduction of cardiac afterload. Moreover, it is previously 
well documented that testosterone acts as an acute vasodilator in coronary, mesenteric, 
subcutaneous and pulmonary vascular beds (Jones et al, 2004). Detailed laboratory 
investigation has suggested that testosterone acts as an L-type calcium channel blocker 
at the smooth muscle level via a non-genomic pathway (English et al, 2002). Indeed, 
early studies investigating calcium channel blockers has shown that they too can acutely 
decrease systemic vascular resistance and increase cardiac output in a similar fashion to 
acute testosterone supplementation (Vetrovec et al, 1993).
Testosterone supplementation has also been shown to be particularly beneficial to 
arterial function in patients with CAD and hypogonadism. This becomes relevant to this 
review because ischaemic heart disease is well established as the most common cause of 
HF (Malkin et al, 2010). Furthermore, as coronary arterial disease may co-exist with HF 
the increased myocardial oxygen demand resulting from poor cardiac output and 
significant coronary artery stenosis may impact more prominently on quality of life.
A study conducted by researchers in the UK assessed the effects of high dose and
physiological dose intravenous testosterone on brachial artery reactivity in 22 males
with angiographically significant (>70%) coronary artery stenosis (Ong et al, 2000).
Patients were randomly assigned to receive testosterone or placebo and crossed over the
following week to receive the physiological dose versus placebo. Brachial artery studies
were then performed 1 hour following drug infusion. This was the first randomised
study that demonstrated a significantly increased flow mediated response to testosterone
supplementation in males with CAD. High dose intravenous testosterone more than
doubled the flow mediated dilatation (FMD) response in males with CAD (placebo
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FMD% 3.16 ± 1 .9  versus high dose testosterone FMD% of 6.86 ±  3.72). Physiological 
dose of testosterone also demonstrated a trend to increased flow mediated response but 
this was non-significant (p 0.59). It was suggested that testosterone administration 
enhances flow mediated endothelium-dependent mechanisms rather than receptor 
mediated responses. The authors conclude that testosterone may act in a similar role to 
anti-oxidants by prolonging the vascular effect of nitric oxide.
In support of this, other researchers have assessed brachial artery response to long-term
oral supplementation of testosterone in patients with significant CAD (Kang et al,
2002). This study recruited 35 males who were randomised to placebo and treatment
groups. The treatment group received oral testosterone undecanoate 160mg daily for 4
weeks followed by 80mg testosterone undecanoate for 8 weeks in addition to all
concurrent medication. Brachial artery reactivity was assessed in response to flow
mediated dilatation and also nitro-glycerin mediated dilatation. There was a significant
increase in brachial artery flow and nitroglycerin mediated dilatation in the testosterone
group only when compared to baseline (FMD% 3.2 ± 3.0 increase to 5.6 ± 4.0 and GTN
4.7 ±4.1 increase to 9.7 ± 5.0 both p<0.05). The authors concluded in a similar fashion
to previous reports that testosterone supplementation improves endothelial dependent
and in this report endothelial independent dilatation probably via testosterone
prolonging the vascular effects of nitric oxide. The only study to date assessing the
effects of testosterone replacement therapy in hypogonadal males with CAD was
performed by researchers in Sheffield, UK (Malkin et al, 2004). This randomised, single
blind, crossover study recruited 12 males with angiographically significant coronary
artery stenosis (>70%) and biochemical evidence of hypogonadism. Participants were
randomly assigned to receive testosterone (fortnightly intra-muscular injection of 1 ml -
lOOmg) or placebo for 1 month. Exercise treadmill tests were performed at baseline and
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immediately following cessation of intervention. Following 1 month participants were 
crossed over to the other arm of the trial. The results of this study indicated that TS 
significantly increased time taken to reach ischemic threshold during exercise tolerance 
testing when compared to placebo (81 second (48) average increase in time taken to 
reach -1mm ST depression in the treatment group -  7.2 seconds (32) in controls). It was 
suggested that TS in this form has a rapid mode of action as these changes were seen 
following only 1 month of treatment. In addition, the vasodilatory properties of 
testosterone were attributed to the improved anti-ischemic action.
2.3.4: Testosterone replacement therapy and muscle function.
Currently there are few studies that have investigated the effects of testosterone 
supplementation on muscular strength, muscular endurance and detailed physiological 
aspects of muscle function in patients with HF. Of course, it is widely acknowledged 
that androgen supplementation can increase lean mass, voluntary muscular strength and 
reduce fat mass in healthy populations (Isidori et al, 2005). Additionally, research has 
investigated the effects of testosterone supplementation in patients with morbid 
conditions such as HIV, metabolic syndrome, advanced malignancy, lung disease and 
chronic kidney failure. These trials have again, showed consistent improvements in 
body composition and physical strength (Johns et al, 2005 and Johansen et al, 1999).
Perhaps the most detailed assessment of testosterone administration and muscular 
strength in HF patients has been recently undertaken by Caminiti and colleagues in Italy 
(Caminiti et al, 2009). This double-blind randomised controlled trial, as previously 
mentioned, investigated the effects of testosterone supplementation in 70 males with HF
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on various indices of physical, biochemical and social function. Assessment of leg 
muscle strength was performed using isokinetic and isometric dynamometry of the 
quadriceps muscle group of the dominant leg. The results of the study indicated that 
supplementation can significantly increase maximum voluntary contraction (from 116.7 
+ 26.3 to 135.6 + 21.2 Newton m) when compared to placebo who did not demonstrate 
any significant change. Furthermore, it was also noted that the treatment group could 
produce a significantly higher peak torque from baseline (74.0 + 17.4 to 83.4 + 16.3 
Newton m) when compared to placebo. This study also calculated quadriceps muscle 
fatigue index using an in-built computer package within the dynamometer. There was a 
significantly improved fatigue index from baseline in the treatment group only (-42.4 + 
13%, p = 0.03) when compared to the placebo group. This research group postulated 
that the improvements in leg muscle strength and work output may be due to similar 
mechanisms as to the afore-mentioned improvements in endurance capacity.
The predominant shift toward type II glycolytic muscle fibres in HF; the ‘muscle- 
hypothesis’ results in an abnormal metabo-reflex during exercise which results in 
detrimental neuro-hormonal activation, abnormal haemodynamic, autonomic and 
ventilatory response to exercise (Janowska et al, 2008 and Hambrecht et al, 1995). As 
stated previously, possible reductions in the abnormal muscle ergoreflex contribution to 
ventilatory response to exercise would improve VE/VCO2 slope therefore improving 
ventilatory efficiency. Importantly, other research groups can support this notion. 
Anabolic administration at physiological dosage has been shown to accelerate fast to 
slow twitch muscle fibre conversion and also significantly increase the abundance of 
type I oxidative fibres -  both of which are pertinent in the pathophysiology of HF 
(Hambrecht et al, 1997 and Ustunel et al, 2003).
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The earlier research work of Malkin and colleagues highlighted in the table above 
(2006) also assessed a crude marker of muscular strength. Dominant handgrip strength 
was assessed both pre and post treatment with testosterone or placebo. It was noted that 
the testosterone group only showed significant improvements in handgrip strength 
(treatment effect o f +1.6+ 1.1, p = 0.04 testosterone versus placebo at 12 months). No 
physiological mechanism other than improved anabolic function was discussed as the 
precursor of this change. However, it is plausible that the physiological mechanism as 
proposed by Caminiti et al (2009) could contribute to this improvement.
2.3.5: Testosterone replacement therapy and inflammatory markers.
As previously highlighted in detail during this review, HF is characterised by significant 
sub-clinical inflammation. Inflammatory cytokines such as tumour necorisis factor 
alpha, IL-1 and 6 and soluble adhesion molecules are elevated and known to contribute 
to insulin resistance, cachexia and poor prognosis in HF. Anticytokine biological drugs 
such as etanercept and infliximab have been developed and also shown to reduce the 
levels of circulating cytokines but have also been documented to increase all-cause 
mortality (Anker et al, 2002).
In animal models testosterone supplementation has been shown to favourably impact on 
cytokine levels and also improve LV remodelling in HF (Yan-Zhou Zhang et al, 2007). 
This research, conducted in China, investigated the effects of testosterone 
supplementation in 85 Sprague-Dawley rats with induced MI and HF. Following this 
surgery, rats were randomly assigned to receive 12 weeks supplementation with
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testosterone or placebo. Echocardiography, blood sampling and tissue analysis was 
performed in order to determine cardiac function, biochemical levels of inflammatory 
cytokines and cardiac tissue levels of inflammation. The results of the study showed 
that rats supplemented with testosterone (5mg/kg every 2 weeks for 12 weeks) 
documented higher LV EF (41.9 + 10.5% versus 33.2 + 7.5%) when compared to 
placebo. Additionally, the treatment group also demonstrated higher levels of serum IL- 
10 (an anti-inflammatory cytokine which induces the production of specific cytokine 
inhibitors such as IL-1 receptor antagonist, thus serving as a counter mechanism to 
TNF-a production) and lower levels of TNF-a (both p<0.05) when compared to the 
placebo. Cardiac tissue levels of TNF-a, mRNA and matrix metalloproteinase mRNA 
was also significantly lower in the testosterone group when compared to placebo. 
Physiologically, the imbalance of inflammation and anti-inflammation may result in 
decreased myocardial contractility, ventricular dilatation, myocardial remodelling, 
increased cardiac myocyte apoptosis and cardiac cachexia (Ceconi et al, 2001). The 
authors hypothesise that this imbalance in a HF model is likely due to the presence of 
LV dysfunction. Testosterone supplementation serves to partially preserve LV function 
and this is associated with a concomitant modestly prevented inflammation / anti­
inflammation imbalance. Therefore, the testosterone associated increase in IL-10 and 
decrease in TNF-a has been proposed to be due to suppression of macrophage 
production of TNF-a with an increase in CD4+T lymphocyte production of IL-10 
(D’Agostino et al, 1999 and Liva and Voskhul, 2001).
Human studies investigating the effects of testosterone supplementation in HF on
inflammation have however, produced disappointing results. The only available data
investigating this was conducted by Pugh et al (2004). This research investigated the
effects of testosterone administered via three different routes (i.e. 2, 30mg buccal tablets
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over a period of 6 hours, fortnightly lOOmg intra-muscular injection for 3 months or 
5mg transdermal daily for 3 months) on serum levels of TNF-a in 94 patients with 
hypogonadism and HF. The results of this investigation showed that although whole 
blood incubation with testosterone reduced significantly lipo-polysaccharide induction 
of TNF production, there was no significant change in serum levels of TNF-a pre and 
post TS in any of the three routes of administration. In conclusion, the authors suggest 
that the clinical improvements noted in trials of testosterone therapy and HF are likely 
due to other factors rather than reduced serum levels of inflammation.
Research in other clinical populations has however, suggested a beneficial role for the 
effect of testosterone supplementation on inflammatory cytokines in males with low 
testosterone. A study conducted by Malkin and colleagues (2004) investigated the 
effects of testosterone supplementation on inflammatory cytokines in hypogonadal 
males. Many of the participants included in the study were diagnosed with primary 
testicular failure. Participants received standard fortnightly intra-muscular injections of 
testosterone. Serum samples were collected for the assessment of TNF-a, IL-1, 6 and 10 
pre and post the intervention period of 1 month. The results showed significant declines 
in TNFa and IL-1 when compared to baseline (TNFa -3.1 + 8.3 pg/ml and IL-1 -1.32 + 
5.2 pg/ml, P = 0.012). Although no exact mechanism for this process was discussed, the 
authors declared that this trial is one of very few investigating the in-vivo effects of 
testosterone supplementation on cytokine levels and stated a benefit to patients 
presenting with testosterone deficiency and established vascular disease.
Perhaps leading on from, but contradicting, this initial research, Kapoor et al, 2007
investigated the effects of testosterone supplementation on adipocytokines in
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hypogonadal males with type II diabetes mellitus. This double-blind placebo controlled 
randomised controlled trial recruited patients to testosterone supplementation versus 
placebo using a similar supplementation methodology to above. The authors did not 
observe significant decreases in TNF-a or IL-1 levels as a result of testosterone 
replacement therapy during this trial. However, at baseline there were significant 
correlations between low levels of testosterone and an elevated inflammatory profile.
2.3.6: Testosterone replacement therapy and quality of life.
Data regarding the effects of testosterone supplementation on quality of life is sparse. 
This research has already discussed the impact of low testosterone status on quality of 
life in both healthy and chronically diseased population (see section 1). One of the 
seminal studies investigating the effects of testosterone replacement therapy on 
ischaemic threshold and quality of life in HF males with low testosterone (Malkin et al, 
2004) reported significant improvements from baseline in Beck Depression Inventory 
(BDI), general health screen questionnaire and Androgen deficiency in ageing male 
(ADAM) scores (all Wilcoxon matched pairs - p<0.05) in the treatment arm of the trial 
only. This study supplemented a small number of males (n = 10) intra-muscularly with 
Sustanon 100 fortnightly for a total of 12 weeks. When analysed for significant 
differences between the treatment and placebo groups, both BDI and ADAM 
demonstrated significant between group improvements. No discussion of the 
mechanisms behind this improvement was postulated by the authors. However, their 
findings of improved time to ischaemic threshold and reduced levels of circulating 
inflammatory markers such as TNF-a can potentially facilitate improvement to quality 
of life by reducing patient symptoms and increasing their exercise ability. Naturally, 
due to the increased serum concentration of testosterone towards normal range in the
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treatment group, it is plausible that improved ADAM scores are related to increased 
serum TT concentration.
A further study conducted by Malkin and co-workers (2006) investigated the effects of 
a skin patch preparation of testosterone supplementation in males with HF and low 
testosterone when compared with placebo. This 12 month trial demonstrated no 
significant improvement in BDI or Minnesota living with heart failure questionnaire 
(MLHFQ) score following the intervention period. This was despite significant 
improvement in functional capacity as assessed by the incremental shuttle walk test 
(ISWT) and heart failure symptoms as assessed by NYHA score. The authors suggest 
that route of testosterone administration may play a role in the non-significant quality of 
life scores obtained in the study. The skin patch preparation was poorly tolerated and 
also resulted in lower mean total testosterone levels in the treatment group when 
compared to previous studies. However, this contradicts the observed improvement in 
functional capacity. Simply, this small-scale study may have been under-powered to 
detect significant changes in questionnaire data.
2.4: Aims.
To date the efficacy of exercise therapy for evoking improvements in key health 
outcomes in males with HF and low testosterone status has not been studied. Neither is 
it known whether the effects of exercise training can be augmented by testosterone 
supplementation in this patient group. The literature provides compelling evidence of 
benefit for both exercise training and testosterone replacement therapy on numerous 
physiological and psychological outcomes in HF patients.
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Therefore the aims of this study are:
• To assess the feasibility of a combined 12 week exercise rehabilitation and 
adjunctive testosterone therapy intervention in males with HF and low testosterone 
status in terms of recruitment, compliance to the intervention, reproducibility of 
outcome measures and attrition.
• To obtain preliminary data on the impact of the exercise and testosterone 
intervention on key health outcomes assessing both physiological and psychological 
function in this patient group.
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Chapter 3. Materials and Methods.
3.1: Trial Design.
This feasibility study was designed as a two-arm, double-blind, placebo-controlled trial 
in order to provide sufficient detail to inform a larger scale phase III clinical trial. After 
completion of the baseline assessments, treatment groups were allocated according to a 
pre-determined randomisation schedule. The clinical trials pharmacist prepared a 
blocked randomisation schedule using a table of random numbers. Medication numbers 
were allocated in ascending sequential order to ET plus testosterone supplementation 
(TS) or ET plus placebo. Outcome measures were assessed at baseline and 12 weeks.
Patients randomised to testosterone therapy were administered Sustanon injection 
(Sustanon 100, Organon Laboratories, Cambridge, UK), and by form of comparator, 
those patients randomised to placebo therapy received saline (18mg in 2ml, 0.9% w/v 
NaCl, PL01502/0006R, Hameln Pharmaceuticals Ltd, Gloucester, UK). Testosterone 
and placebo therapy were administered by intramuscular injection every two weeks for 
12 weeks.
3.2: Randomisation.
Patients were randomly allocated to one of the two study groups. Treatment groups 
were allocated according to a pre-determined randomisation schedule. The pharmacy 
department at Sheffield Teaching Hospitals NHS Foundation Trust prepared a blocked 
randomisation schedule using a table of random numbers. Medication numbers were 
allocated in ascending sequential order. The blocked randomisation protocol was 
designed to ensure equal treatment numbers at fixed points throughout the course of the
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study. During this study, permuted blocks were used and randomisation into these 
blocks was achieved using a table of random numbers. A limitation of using blocked 
randomisation, particularly small blocks, is the possibility of researchers predicting the 
next treatment. However, this is certainly less possible in a double-blind trial design. In 
order to reduce selection bias, the investigators were unaware of block size. All 
randomisation and allocation was performed by a clinical trials pharmacist who was not 
involved in the research study and had significant experience in administration 
medication for clinical trials. All randomisation procedures and treatment allocations 
were double-checked by other members of the clinical trials pharmacy team also not 
involved in the study.
3.3: Blinding.
Members of the research team responsible for the assessment of the primary and 
secondary outcomes and those who supervised the exercise training sessions were 
blinded to group allocation. These team members were also unaware as to treatment 
allocation for each participant until study closure. This ensured that both groups were 
identically encouraged and motivated to undertake exercise training, in order to 
minimise bias.
The duration and sequence of all study visits and procedures to be undertaken, was as 
per the flow chart below (figure 13).
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The end of the trial was classed as the date when the last patient attended and performed 
their last post-intervention assessment. Following this visit, and once the data was 
analysed and inputted, the database was locked.
3.4: Patient selection and recruitment.
Following ethical approval from the local research ethics committee (appendix 8), 41 
ambulant male patients, over 18 years, with stable HF (longer than 6 months) and 
initially with a blood testosterone level of less than 12 nmol/L and symptoms of 
hypogonadism were recruited from Cardiology Clinics at the Royal Hallamshire 
Hospital, Sheffield between September 2007 and October 2009. Due to recruitment 
problems and time constraints for study completion, the total testosterone cut off value 
was increased to 15 nmol/L based on guidance from the Clinical Chemistry Department 
at Sheffield Teaching Hospitals NHS Foundation Trust and discussion with the lead 
investigator who had significant experience in working with patients with low 
testosterone and heart failure. It should be noted however, that during this recruitment 
phase (cut of <15 nmol/L) only one participant (total testosterone 12.9 nmol/L) was 
over the previous cut-off value and all other participants recruited (n=5 displayed 
testosterone concentration below the initial cut-off value of < 12nmol/L. Patients were 
included and excluded from study participation on the following grounds.
3.5: Inclusion Criteria.
• Symptoms of hypogonadism -  defined by positive androgen deprivation score.
• Serum TT concentration up to 12 nmol/L initially, extended to 15 nmol/L 
latterly.
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• Clinically stable HF prior to recruitment established on optimal medical therapy 
and without significant symptom change (using NYHA Score) for a period of 6 months.
• Evidence of severe or worse impairment of LV systolic function (defined by 
echocardiography as EF less than 35%).
• Reduced exercise tolerance (limited by fatigue or breathlessness of cardiac 
origin, i.e. NYHA Class II or worse).
• Over 18 years of age.
3.6: Exclusion Criteria.
• Unstable angina (defined by classical angina symptoms at rest).
• Recent (within the last 6 weeks) acute MI.
• Episodes of decompensated HF / clinical change in course of condition within 
the last 6 months (i.e. increasing symptoms or requirement of new treatment).
• Moderate or worse (defined by echocardiography) valvular heart disease.
• Uncontrolled hypertension (resting systolic BP >180mmHg, diastolic >100 
mmHg) -  as per defined cut off values for performing exercise tolerance testing (British 
Cardiac Society / Society for Cardiological Science and Technology Joint Guidelines 
for Physiologist Led exercise testing, 2008).
• Renal insufficiency (serum creatinine > 200umol/l).
• Urologic disorders.
• Any orthopaedic or neurologic illness limiting the ability to exercise.
• Patients with prostate specific antigen (PSA) level above the age adjusted 
normal range.
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• Patients already prescribed androgen replacement therapy.
• Patients with a peanut/soya allergy -  due to the nature of the testosterone
replacement therapy formulation.
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Figure 13. Flow chart demonstrating participant journey and im portant time- 
points during the study.
Assessments/Analysis at SHU
Exercise capacity (ISWT)
Blood sampling and certain blood 
analysis
- soluble adhesion molecules 
(sICAM-1, sVCAM-1)
- systemic inflammatory mediators 
(TNF-a and CRP)
Skeletal muscle contractile function tests.
Peak oxygen uptake (v ° 2 ) and 
lower-limb skeletal muscle oxygenation. 
Psychological health status and 
quality of life assessment 
(questionnaire data collection and 
analysis).
Cardiovascular function.
Agree to participate.
Confirmation of medical eligibility.
Familiarisation visit at SHU and informed consent taken.
Medical assessment at SHU, conducted by lead medic from the RHH 
Baseline assessment of all outcomes (week 0)
Screening: Cases ascertained by clinicians and outpatient nurses at the RHH outpatient 
clinics and during attendance for outpatient visits at NHG.
Randomisation into groups: performed by the clinical trials pharmacist at RHH. 
Allocated according to a pre-determined randomisation schedule.
Assessments/Analysis at STH
Blood analysis -
- testosterone analysis
- full blood count
- glucose concentration
- brain natiuretic peptide
- lipid profiles
- sex hormone binding globulin
Weeks 1-12 of Intervention. For each patient this will either be:-
Post Intervention Assessment of all Outcomes (week 12/13).
- placebo therapy administered 
every 2 weeks at STH.
- Twice weekly exercise at SHU
Exercise + placebo
- testosterone therapy administered every 
every 2 weeks at STH.
- Twice weekly exercise undertaken at SHU.
therapy.
Exercise + testosterone therapy.
Assessments/Analysis at SHU
• Exercise capacity (ISWT).
Blood sampling and certain blood
analysis
- soluble adhesion molecules
(sICAM-1, sVCAM-1)
- systemic inflammatory mediators
(TNF-a and CRP)
• Skeletal muscle contractile function tests.
• Peak oxygen uptake ( v ° 2 ) and
lower-limb skeletal muscle oxygenation.
• Psychological health status and
quality of life assessment
(questionnaire data collection and
analysis).
• Cardiovascular function.
Assessments/Analysis at STH
• Blood analysis -
- testosterone analysis.
- full blood count.
- glucose concentration.
- brain natiuretic peptide.
- lipid profiles.
- sex hormone binding globulin
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Eligible patients were identified based on strict adherence to the aforementioned 
inclusion and exclusion criteria both by trained research nurses and the investigator. 
Eligibility was confirmed through screening patient notes of all males who attended the 
Cardiology outpatient clinics at the Royal Hallamshire Hospital. In addition, weekly 
visits by the research nurse to the Northern General Hospital (part of Sheffield Teaching 
Hospital NHS Foundation Trust) were undertaken in order to follow the same process 
for the Cardiology clinics over at that site.
3.7: Consent procedures.
In addition to the initial letter sent out to patients with the patient information sheet 
(appendix 9), a tear- off slip was also attached, which patients returned to the primary 
investigators, to register interest in study participation. Patients had approximately 10- 
14 days to decide whether or not to take part in the research. If any patients did not 
initially return the tear-off slip attached to the patient information sheet, they were sent 
a follow-up letter reminding them of the study. Patients who did not respond to this 
letter were not contacted further, since it was assumed that these patients did not wish to 
participate in the study.
Informed consent was obtained from those patients who were interested in study 
participation. This was obtained at the initial consultation session, following prior 
familiarisation with all equipment and the study protocol, and once all patient's 
questions and concerns have been answered and addressed. Informed consent was 
obtained in the presence of a witness, by one of the primary investigators who had 
considerable work experience with cardiac patients (> 5 years).
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3.8: Withdrawal of patients.
Any patient, who at any stage of the study did not wish to continue, could withdraw, 
without their future medical care being affected. This information was made clear to 
each patient in the patient information sheet and throughout the duration of the study.
Throughout the study each patient was carefully monitored, in terms of health and 
fitness status, and also in terms of blood testosterone levels. Patients were withdrawn 
from the study immediately, if they developed undue discomfort or distress, resulting 
from the exercise sessions, if it was deemed to be negative to their health. Equally, 
patients were withdrawn if they developed chest pain, indicated by an abnormal ECG to 
be cardiac related, or if testosterone or prostate specific antigen (PSA) status was 
altered. Data obtained up to the time of withdrawal from each patient, was utilised in the 
overall analysis of the study data, on the basis of intention to treat analysis. However, 
once withdrawn, then no further data was collected from these patients. For safety 
reasons these patients were followed up for at least 30 days after the last administration 
of testosterone / placebo, as applicable.
3.9: Sample size.
A formal power calculation was not undertaken, as the primary aim of this study was to 
assess the feasibility of a 12-week program of exercise rehabilitation (with and without 
TS) in male HF patients with low testosterone status, in terms of recruitment, 
willingness to be randomized, compliance and attrition (Arain et al, 2010). A second 
aim of the study was to obtain preliminary data and report on outcome standard 
deviations to inform sample size estimates for a larger scale randomized controlled trial.
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3.10: Medical examination.
Before entering the trial, each patient received a thorough medical examination 
performed by a clinician (Consultant Cardiologist or Research Registrar), during which 
details of surgical history, co-morbid conditions, risk factors and current medication 
details were confirmed. Hormone profiles and drug use were also recorded at the 
beginning of the trial. Blood pressure was taken (manual sphygmomanometer) and a 
resting 12-lead ECG performed with the patient in the supine position.
3.11: Testosterone replacement therapy.
It was imperative that prior to patients undertaking the study they had not previously 
received testosterone replacement therapy. During this study patients were administered 
testosterone therapy or placebo in an identical fashion and also blinded to which 
treatment they were receiving. For ease of administration (since the preparation was 
readily available, cheaper than adhesive skin patches and provided a direct comparison 
with placebo), a commercially available testosterone replacement therapy (Sustanon  
100, Organon Laboratories, Cambridge, UK)  or placebo therapy (0.9%  saline, Hameln 
Pharm aceuticals Ltd Gloucester, UK)  was given by a trained researcher, not in any way 
involved in the study, via intramuscular injection of 1ml every two weeks for 12 weeks, 
as previously found successful in a similar patient population (Malkin et al, 2006).
Study medication was stored and dispensed by the trial sites' pharmacy department -
clinical trial section in accordance with good clinical and manufacturing practice. Drug
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accountability was monitored as per the attached case report forms. Professor Kevin 
Channer (Consultant Cardiologist, Royal Hallamshire Hospital (RHH)) was responsible 
for overseeing the administration of the respective drug, and completion of the 
appropriate paperwork. For patients recruited onto the trial, study medications were 
stored at the Sheffield Hallam University Centre for Sport and Exercise Science site in a 
locked cupboard within a temperature controlled room with restricted access.
3.12: Description of the packaging and labelling on the investigational medicinal 
product (IMP).
For the placebo arm of the study, sodium chloride (0.9% 2ml glass ampoules) was 
purchased. Due to the fact that saline ampoules cannot be provided to match Sustanon 
directly, the pharmacy department at the RHH, under the supervision of Helen Bowler 
(Pharmacy Clinical Trials Manager) packed the ampoules in identical boxes labelled so 
as to blind the contents. As per the protocol and to maintain blinding, only 1ml of saline 
was drawn, and injected into the patient. The remaining amount in each ampoule was 
discarded.
The identity of the ampoules was only revealed once the box was opened, thus the 
doctor / research assistant administering the injections was un-blinded to the 
randomisation schedule. Therefore, this individual was not responsible for the 
recruitment, selection, assessment or training of patients during the study period. In 
order to maintain patient blinding, all injections were drawn and prepared (with 
packages discarded) prior to patients entering the clinical room for administration.
318
Figure 14. An example of the labelling on the IMP.
Keep out of reach of children 
Store in a dry place, below 26 degrees C, protect from light 
1 Ampoule for injection containing either:
SODIUM CHLORIDE B.P 0.9% w/v
or SUSTANON 100 INJECTION
Inject 1ml by intramuscular injection 
in accordance with study protocol STH14394 
Discard any remainder immediately 
For single use only. Use only if clear and particle free 
FOR CLINICAL TRIAL USE ONLY 
RHH Dept, of Cardiology 
Investigator Prof. K. Channer, Sponsor STH NHS Foundation Trust 
Patient name._______ Date:________ _.
Medication No  Visit No______
Pharmacy Clinical Trials, RHH, Sheffield. S10 2JF.
3.13: Potential interactions with testosterone.
For study safety, all known potential, negative interactions with testosterone 
replacement therapy (Sustanon 100) were studied and patients were checked for these 
concomitant interactions prior to enrolment onto the study.
3.13.1: Anticoagulants.
Increased anticoagulant effects and bleeding have been observed in patients who were 
taking a number of oral anticoagulants when prescribed concomitantly with anabolic 
steroids or other related therapies (e.g. danazol, testosterone). Bleeding may occur if the
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anticoagulant dosage is not reduced appropriately. The principle author’s previous 
research studies using Sustanon in patients taking warfarin have not found any 
significant interaction or side effects. However, as a result, during this study patients 
who were taking warfarin had an additional INR measurement at 5-7 days after starting 
drug therapy (active and placebo) so that warfarin dose adjustments could be made if 
deemed necessary.
3.13.2: Insulin.
Testosterone can enhance the blood sugar reducing effects of insulin. The concurrent 
use was monitored, and a reduction in the dosage of the anti-diabetic agent was 
undertaken if needed.
3.13.3: Ciclosporin.
Theoretically, concomitant administration of ciclosporin and anabolic steroids may 
result in increased ciclosporin blood levels and toxicity. Patients receiving concomitant 
therapy were advised to attend for additional blood tests to ensure safe levels of 
ciclosporin.
3.13.4: Paclitaxel.
Testosterone, a known inhibitor of the isoenzyme CYP2C8, inhibits the metabolism of 
paclitaxel to its primary metabolite 6-alpha-hydroxypaclitaxel, in vitro. The 
pharmacokinetics of paclitaxel may also be altered in vivo in the presence of a CYP2C8 
inhibitor. Therefore, patients receiving paclitaxel therapy were not recruited for study 
participation.
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3.13.5: Peanut / Soya allergy.
Sustanon 100 contains Arachis oil (peanut oil) and should not be taken / applied by 
patients known to be allergic to peanut. As there is a possible relationship between 
allergy to peanut and allergy to Soya, patients with Soya allergy were not recruited to 
the study.
3.14: Monitoring of patient compliance.
A record was maintained to monitor patient attendance and compliance to the study. 
Patients unable to attend a pre-arranged appointment time were offered an alternative 
appointment. Those patients absent without prior notification were contacted on the day, 
and a further suitable appointment will be offered.
3.15: Adverse Events and Serious Adverse Events (SAE's).
All members of the research team were at least Intermediate Life Support trained. The 
Chief Investigator (Prof Kevin S. Channer) also had extensive experience in running 
and administering testosterone therapy trials (Pugh et al, 2004, Malkin et al, 2006, Pugh 
et al, 2004, Malkin et al, 2004).
All adverse events were recorded and reported, as per the case report forms. At each
visit, each patient was questioned regarding AE’s, either to the exercise regimen or to
the drug therapy. The author and chief investigator were responsible for completing the
appropriate paperwork at Sheffield Hallam University and at the Royal Hallamshire
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Hospital, respectively. After an AE each patient was closely monitored for at least 30 
days, or longer if deemed necessary.
During the research study, the following adverse events were documented:
1. Patient unable to exercise due to gout -  related to cardiac medication.
2. Patient unable to continue exercise due to increase in severity of peripheral 
vascular disease.
3. Recurrence of paroxysmal atrial fibrillation previously documented in patient 
notes. Patient was unwilling to continue.
4. Complications with regard to ICD and anti-arrhythmic medication. This patient 
also contracted swine flu during the intervention and therefore was excluded due to a 
long interruption in exercise sessions.
5. One patient was severely injured in a road traffic accident following the initial 
study consultation but prior to baseline assessments.
None of these adverse events were deemed study related by the lead physician and 
hence no further action was taken to alter study protocol. All adverse events were 
classified using a combination of Good Clinical Practise guidance and the clinical 
knowledge of the research team.
The following were considered SAE’s for this study:-
1. Hospital admission for a cardiovascular event.
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2. Diagnosis of prostate cancer after 30 days of entry on to the trial.
3. Death during the course of the study.
All SAE's were to be reported to the research office at Sheffield Teaching Hospitals 
NHS Foundation Trust within 24 hours of discovery by the research team. Dedicated 
report forms and reference documents justifying a SAE decision were completed. 
However, no SAE were noted for this research study.
3.16: Safety assessments.
The University’s formal health and safety procedures were strictly followed. A detailed 
safety assessment of the study was performed as per risk assessment documentation. 
This was designed to identify the likelihood and consequences of an untoward event 
occurring.
3.17: Data collection handling and record keeping.
Data was collected and retained in accordance with the Data protection Act 1998. All 
data was collected as per the case report forms (appendix 9), validated and approved by 
STH, at the time points indicated on the flow chart which clearly outlines which data 
was collected at SHU (the Centre for Sport and Exercise Science) and which at STH 
(Sheffield Teaching Hospitals - Royal Hallamshire Hospital).
At the Centre for Sport and Exercise Science, the author was responsible for the data 
collection, recording and quality of data at this site. The chief investigator had the
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overall responsibility for data collected and recorded at the Royal Hallamshire Hospital
At both sites, any paper files of personal data were kept in a locked filling cabinet. 
Stored patient details and data were anonymous, following randomisation, since patients 
were assigned an identification number, to ensure confidentiality. Any computer 
generated data was coded and stored on ‘locked’ memory sticks. All data is to be stored 
for a maximum of 2 years, in order to ensure that all data analysis has been performed.
3.18: Exercise training.
Cycle ergometry constituted the main component of the aerobic ET regimen. Exercise 
intensity was set at 50% of the maximum short-term exercise performance, determined 
by a steep ramp test every 4 weeks (3 minutes of unloaded pedalling, then work rate 
increments of 12.5 W every 10 seconds at a crank rate of 60 rpm) (Senden et al, 2005). 
An interval training regimen was used, incorporating 30 seconds of exercise with one 
minute interpolated rest periods for a total exercise time of 15 minutes (i.e. 10 repeats). 
Each aerobic exercise session was followed by two to three sets of low to moderate 
intensity resistance exercises for five main muscle groups: quadriceps, hamstrings, 
pectorals, latissimus-dorsi and deltoids. Each supervised exercise session lasted for 
approximately 45-50 minutes in total and patients attended 2 sessions per week. The 
venue for supervised exercise was the Exercise Science Laboratory at Sheffield Hallam 
University.
3.19: Outcome measures.
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3.19.1: Incremental shuttle walk test.
Unless otherwise stated, outcome measures were assessed at baseline and 12 weeks in 
all patients. The primary outcome measure was exercise capacity, assessed using the 
incremental shuttle walk test (ISWT), as described in previously published work 
(Malkin et al, 2006). Two tests were performed prior to starting treatment, one at the 
screening visit following informed consent and the second before randomisation during 
collection of all baseline outcomes in order to allow for a learning effect (as per ISWT 
instruction documents -  available from Singh,S. Dept Respiratory Medicince, Glenfield 
Hospital -  initial reference study - Singh et al, 1992). The best ISWT result was 
recorded and this was consistently the second ISWT in all patients.
The ISWT is a symptom-limited exercise test with a progressive increase in workload 
designed to allow subjects to achieve maximum effort tolerance. The test was originally 
developed to assess patients with chronic obstructive pulmonary disease (COPD) and it 
is in this cohort, that the original correlations with peak V0 2 max were observed (Singh et 
al, 1992). More recently, Lewis et al (2001) described successful reproducibility of this 
test in patients with severe HF awaiting cardiac transplantation. The authors suggested a
close correlation between ISWT distance and peak v ° 2  which is represented by the
regression equation v ° 2  = 0.022 x distance + 6.4 (where v ° 2  = peak V (^ 2  and 
distance = distance walked during ISWT) with r = 0.73, p = 0.0001. In addition, the 
ISWT was found to be highly reproducible with mean walking distances of 400 + 146m 
(walk 1) versus 401.3 + 129m (walk 2), r = 0.90, p = 0.0001.
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Prior to commencement of the ISWT, patients rested for 10 minutes. During this period, 
resting BP and HR were recorded. In addition, a thorough and detailed explanation of 
the Borg rating scale of Perceived Exertion was undertaken. Participants were instructed 
on how to safely perform the test and to also detail any symptoms observed both during 
and following testing. As this test is maximal, trained intermediate life support staff and 
resuscitation equipment were on hand to ensure the safety of each patient. During the 
ISWT, subjects walked back and forth along a horizontal 10 m course, marked out by 
two cones aiming to complete the shuttle before a pre-recorded signal from a cassette 
player, which shortened incrementally after each shuttle. The end-point (distance 
walked in metres) was reached when the subject failed to complete the shuttle before the 
signal. Immediately on completion of the ISWT, BP, HR and RPE were recorded. Each 
participant was then allowed to recover in the sitting position for a length of time that 
allowed all symptoms, BP and HR measurements to return to pre-testing values.
3.19.2: Blood analysis.
Serum blood samples for assessment of IL-6, TNFa, sVCAM-1 and sICAM-1 were 
collected at the time of the initial data collection visit at Sheffield Hallam University 
Centre for Sport and Exercise Science. All serum blood samples were drawn from the 
antecubital vein in the supine position. Serum aliquots were prepared for storage at - 
80°C in Centre for Sport and Exercise Science at Sheffield Hallam University. Samples 
were also collected at the end of the study during the post intervention assessment. A 
batch analysis of pre and post intervention samples was performed, on study 
completion, by an accredited laboratory scientist as part of the research team in the 
Biomedical Research Centre at Sheffield Hallam University.
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Total testosterone, glucose, insulin, SHBG, albumin, full blood count, lipid profiles 
(triglyceride, high and low density lipoprotein (HDL) and (LDL)), C-reactive protein 
(CRP) and NT pro-BNP were collected during the initial screening visit to the Royal 
Hallamshire Hospital prior to official study enrolment. Two samples were collected for 
total testosterone and SHBG assessment on separate hospital visits with the initial total 
testosterone value obtained used for acceptance onto and analysis during the study. 
Patients were advised to attend the blood sampling clinic as early as possible during the 
morning hours. However, no official times of attendance were logged during the study.
Testosterone and SHBG analyses were performed on the day of patient attendance at the 
Royal Hallamshire Hospital Clinical Chemistry Department for the initial screening 
visit in order to ascertain total testosterone values against the inclusion criteria for the 
study. During post intervention assessments at Sheffield Hallam University, blood 
samples were taken for the later assessment of testosterone, SHBG and albumin at the 
Royal Hallamshire Hospital. These samples were prepared and stored at -80°C at the 
Centre for Sport and Exercise Science for batch analysis at study completion. All 
sample analysis at the Royal Hallamshire Hospital Clinical Chemistry department was 
undertaken by accredited laboratory technicians. Laboratory techniques for the analysis 
of serum testosterone, SHBG, albumin and NT pro-BNP were documented in detail in 
the previous section of this thesis, together with the equations used in order to calculate 
free and bio-available testosterone.
All Quantikine HS ELISA human immuno-assays were manufactured by R and D
Systems Inc, Minneapolis, USA. IL-6, TNFa, sICAM-1 and sVCAM-1 were analysed
employing a quantitative sandwich enzyme immuno-assay technique with mono-clonal
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specific antibodies pre-coated onto microplates by an accredited laboratory scientist as 
part of the research team in the Biomedical Research Centre at Sheffield Hallam 
University.
For the assessment of IL-6, a serum separator tube was used and samples were allowed
to clot for 30 minutes before centrifugation at 1000 x g for a total of 15 minutes.
Aliquots were prepared and stored at -80°C for batch analysis to be performed at the end
of the study. Reagent preparation involved reconstitution of the lyophilized substrate
with 6.0mL of substrate diluent, 10 minutes prior to use. Amplifier solution was
reconstituted with the lyophilized amplifier with 6.0mL of amplifier diluents, again at
least 10 minutes prior to usage. IL-6 standard was reconstituted with 5.0mL of the
calibrator diluent (RD6-11) resulting in a stock solution of 10 pg/mL. The standard was
allowed to sit for 15 minutes with gentle agitation prior to making the stock solutions.
lOOpL of assay dilutent RD1-75 was added to each well, followed by 100fiL of
standard or sample. This was covered with an adhesive strip and incubated for 2 hours
at room temperature on a horizontal orbital microplate shaker set at 500 rpm. Wells
were washed using wash buffer and 200pL of IL-6 conjugate added. This was covered
with an adhesive strip and further incubated for 2 hours at room temperature on the
shaker. Following further washing, 50pL of substrate solution was added to each well
and incubated for 60 minutes at room temperature. Then, 50jxL of amplifier solution
was added to each well and incubated for a further 30 minutes at room temperature
following being covered with an adhesive strip. 50[xL of stop solution was then added to
the wells. A microplate reader as used to determine the optical density of each well at
490nm. Wavelengths were corrected to 650nm prior to calculation of results. Average
duplicate readings were obtained for each standard, control and sample and the average
zero standard optical density subtracted from this value. Standard curves were
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produced for each set of samples analysed. Intra-assay precision was calculated on three 
samples of known concentration and tested 20 times. Co-efficient of variation were 
6.9%, 7.8% and 7.4% respectively. Inter-assay precision was determined on 3 samples 
of known concentration. Co-efficient of variation were 9.6%, 7.2% and 6.5%. Average 
recovery was 94% (range 87-99%).
For sICAM analysis, serum aliquots were prepared in the same way as above. Reagent 
preparation involved dilution of 23mL of wash buffer concentrate into de-ionized water 
to prepare 500mL of wash buffer. The substrate solution was prepared by mixing the 
colour reagents A and B and protecting from direct light. ICAM-1 standard was 
reconstituted with l.OmL of de-ionized water to produce a stock solution of 250 ng/mL, 
mixed and allowed to sit for 15 minutes with gentle agitation. 800pL of calibrator 
diluents was pipetted into 50ng/mL tubes and 500pL of calibrator diluents into the 
remaining tubes. The stock solution was used to produce a dilution series. lOOpL of 
sICAM-1 conjugate was added to each well and also lOOpL of standard, control and 
sample to each well before covering and incubation at room temperature for 90 minutes 
on a horizontal microplate shaker. Following the washing procedure, 200pL of substrate 
solution was added to each well and incubated on the bench for 30 minutes at room 
temperature. Then 50pL of stop solution was added to each well prior to determining 
the optical density of each well within a 30 minute period. Wavelengths were corrected 
to 570nm and standard curves created from average duplicate readings of standards, 
control and sample. Intra-assay co-efficient of variation for 3 samples were 3.7%, 5.2% 
and 5.0% respectively. Inter-assay co-efficient were 6.7%, 5.4% and 4.4%. Mean 
recovery was 104% (range 90-109%).
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sVCAM-1 serum aliquots were prepared in a similar manner to previous analyses. 
Substrate solution, wash buffer, calibrator dilutent and sVCAM standard were all 
prepared in a similar manner to that for sICAM-1. 500pL of calibrator diluents (RD5P) 
was pipetted into tubes and the stock solution used to make a dilution series. lOOpL of 
sVCAM-1 conjugate was added to each well followed by lOOpL of standard, control or 
sample. This was covered with an adhesive strip and allowed to incubate for 90 minutes 
at room temperature. Following washing with the pre-prepared buffer solution, 100pL 
of substrate solution was added to each well immediately, protected from light and 
incubated for a further 20 minutes. 50pL of stop solution was added to each well and 
colour change observed. The optical density of each well was determined within 30 
minutes and wavelength corrected to 570nm. As previously, average duplicate readings 
were made for each standard, sample and control. Intra-assay co-efficient of 2.3%, 3.5% 
and 3.6% were noted. Inter-assay co-efficients were 7.8%, 7.7% and 5.5%. Mean 
recovery for serum samples was 96% (range 89-99%).
TNFa serum aliquots were prepared in the same way as those above. Wash buffer was
prepared by diluting 100 mL of wash buffer concentrate into de-ionized water to
prepare 1000 mL. Lyophilized substrate was reconstituted with 6.0mL of substrate
diluent 10 minutes prior to use. The lyophilized amplifier solution was reconstituted
with 6.0mL of amplifier diluent and allowed to stand for 10 minutes before use. TNFa
standard was reconstituted with the volume of calibrator diluent (RD6-13) to produce a
stock solution of 32 pg/ml. This was allowed to sit for at least 15 minutes before gently
agitating prior to making the dilutions. Poly propylene tubes were used to make a
dilution series. 50pL of assay diluents (RD1F) was added to each well and mixed well
prior to use. 200pL of standard, sample or control were also added per well. This was
then incubated at room temperature for 3 hours. Following washing, 200pL of TNFa
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HS conjugate was added to each well (allowed to incubate for 2 hours at room 
temperature) and after further washing, 50pL of substrate solution added to each well. 
This was further incubated for 1 hour at room temperature before adding 50 pL of 
amplifier solution to each well and incubating for a further 30 minutes. Finally, 50 pL of 
stop solution was added to each well and determination of optical density of each well 
performed within 30 minutes using a ,icroplate reader set to 490nm. Wavelength 
correction was set to 690nm. Average duplicate readings were calculated for each 
standard, control or sample and standard curves developed. Intra-assay co-efficient were 
8.7%, 4.3% and 3.1% and inter-assay co-efficient were 10.4%, 7.2% and 7.4% 
respectively. Mean recovery was 93% for serum samples (range85-98%).
CRP serum aliquots were prepared in the same way as those previously mentioned.
20mL of wash buffer was diluted into de-ionized water to make 500mL of wash buffer.
20 mL of calibrator diluent (RD5P) was diluted into80mL of de-ionized water. Colour
reagents A and B were mixed together with equal volume within 15 minutes of use.
These were protected from light. The CRP standard was prepared by pipetting 200pL of
calibrator diluent into 6 polypropylene tubes. 200pL of the standard was added to the
25ng/ml tube in order to create the dilution series. lOOpL of assay diluent was added to
each well and 50pL of standard, control or sample also added per well. This was
covered with the provided adhesive strips and allowed to incubate at room temperature
for 2 hours. Following a detailed washing procedure, 200pL of CRP conjugate was
added to each well and further incubated for 2 hours at room temperature. Following a
final washing procedure, 200pL of substrate solution was added to each well, protected
from light and incubated on the bench at room temperature for 30 minutes. Finally,
50pL of stop solution was added and colour changes observed. Optical density was
assessed within 30 minutes with a microplate reader set at 450nm. Average duplicate
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readings were calculated for each standard, sample or control and subtracted from the 
average zero standard optical density. Standard curves were produced. Intra-assay co­
efficient were 4.4%, 3.8% and 8.3%. Inter-assay co-efficient were 6.0%, 7.0% and 
6.6%. The mean recovery was 100% (range 92-11%).
3.19.3: Skeletal muscle contractile function.
Dynamic strength and endurance of the dominant leg quadriceps and hamstrings was 
measured using an isokinetic dynamometer (Biodex System 3 dynamometer, Biodex 
Medical, NY, USA). The test protocol comprised a 5-minute warm-up on a cycle 
ergometer, 3 repetitions at an angular velocity of 1.0 rad.s'1, 5 repetitions at 3.0 rad.s'1 
and 20 repetitions at 5.3 rad.s'1, followed by a cool-down on a cycle ergometer. A 2- 
minute rest period was applied between each set of repetitions and the main outcome 
measures were peak torque and total amount of muscular work (endurance) performed 
at each angular velocity. This protocol was recently shown to be safe for measuring 
skeletal muscle strength and endurance in HF patients (Senden et al, 2005). This 
protocol took approximately 15 -20 minutes to complete. Isometric strength of the 
forearm muscles was also assessed using a hand-grip dynamometer.
3.19.4: Peak oxygen uptake ( V0 2) and lower-limb skeletal muscle oxygenation.
Peak V 02 was assessed using incremental cycle ergometry (Excalibur, Lode,
Groningen, The Netherlands). The test began at a power output of 25 W and increased
by increments of 25 W every 3 minutes to maximal exercise tolerance. The test was
terminated when the patient became restricted by clinical symptoms or the crank rate of
60 rpm could not be maintained. Blood pressure, HR, perceived exertion (Borg scale
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range 6-20) and 12 lead ECG recordings (Marquette CaSE 15, Wisconsin, U.S.A.) were 
made after 10 minutes of supine rest and within the last 30 seconds of each work-rate 
increment. Pulmonary gas exchange variables were also measured breath-by-breath 
(CaSE EX670 PulmoLab, Kent, U.K.) for assessment of peak V 0 2 and anaerobic 
threshold (A t). The system oxygen and carbon dioxide analysers were calibrated before 
each test using gases of known concentrations. Inspired and expired volumes were also 
calibrated using a 3-L syringe. At is used to detect the beginning of excess CO2 
production resulting from the buffering of H+ arising from lactic acid production and 
represents the shift towards anaerobic metabolism seen towards the end of intense 
exercise. Anaerobic threshold was derived using the ventilatory slope (VE/VCO2) 
method. Peak oxygen uptake was derived as the highest 20 second average. Patients 
were monitored closely during recovery until all physiological variables and any 
reported symptoms returned to baseline values. As the test was maximal, medical 
supervision was on hand together with emergency equipment and appropriately trained 
staff.
Ventilatory gas exchange data obtained during exercise testing aims to provide a more 
precise measurement of total body workload together with a significant increase in the 
information gained regarding cardio-pulmonary function when compared to exercise 
time alone (Sullivan et al, 1989). Such techniques are remarkably valuable in patients 
with HF whereby the main symptom is exercise intolerance together with exertional 
dyspnoea, partly related to ventilation-perfusion mismatch at the level of the lung 
(Creager et al, 1982). In order to accurately determine oxygen uptake, it is imperative to 
accurately measure a number of variables. In a basic model, determination needs only 3 
components, the fraction of oxygen in the expired air, the fraction of carbon dioxide in
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the expired air and the volume of inspired or expired air. In this model, oxygen uptake 
can be simply equated to the product of ventilation (VE) in a known interval together 
with the fraction of oxygen in the same ventilation which has been utilised by working 
muscle (Myers, 1997). However, more accurate and correct measures of oxygen uptake 
require the input of more detailed components. The previous statement assumes that 
expired air is dry and also that inspired / expired volumes are equal. Initially, the 
fraction of inspired oxygen (Fi0 2 ) is affected by ambient temperature, barometric 
pressure and humidity. These variables must therefore be assessed and FiC>2 adjusted as 
a consequence. Furthermore, as oxygen uptake is defined by the difference between the 
fraction of oxygen in inspired and expired ventilation, both inspired and expired 
ventilation values must be known. Inspired volume can be measured from the expired 
volume and the relative concentrations of carbon dioxide and oxygen, utilising the 
difference of between the fraction of inert gases (which do not affect physiological gas 
exchange in humans) in the expired air and the fraction of inert gases in the atmosphere 
(Myers, 1997). As a result of these detailed inter-variable relationships, oxygen uptake 
becomes:
V 02 1/min STPD = (1 -  Fe02 -  FeC02) / 0.7904 x (Fi02 x FeC02) x VE L/minSTPD
Where: STPD is standard temperature and pressure, dry, FeC>2 is the fraction of expired
oxygen, FeC02 is the fraction of expired CO2, FiC>2 is the fraction of inspired oxygen,
VE is expired volume and 0.7904 is the concentration of nitrogen in the inspired air.
Peak v °2and At have become widely utilised measurements in the assessment of
patients with HF (Kleber et al, 2004). Low levels of peak v °2are well known to 
identify patients at increased mortality risk (Francis et al, 2000). Relating to this,
VE/VCO2 slope enhancement in HF, which may be due to increased physiological / 
anatomical dead space, ventilation-perfusion mismatch, abnormal pulmonary vascular 
haemodynamics and disordered ventilatory reflex control have been suggested to yield
similar prognostic power to peak v ° 2  It is for this reason, that At has been suggested as 
a routine component of the analysis of cardiopulmonary exercise testing in the HF 
population (Francis et al, 2000).
Local muscle haemoglobin saturation was monitored at rest, during exercise and 
recovery using near infrared spectroscopy (NIRS; NIRO 300, Hamamatsu, Welwyn 
Garden, UK). This is a non-invasive technique, in which a light emitting/detecting 
probe is placed on the skin over the vastus lateralis muscle. NIRS is an optical 
technique that can be used for the non-invasive measurement of tissue oxygenation and 
haemodynamics. It is based on the relative tissue transparency for light in the near- 
infrared region and on the oxygen-dependent absorption changes of haemoglobin and 
myoglobin. Haemoglobin, myoglobin, and to a lesser extent cytochrome oxidase, are 
the most important chromophores absorbing near-infrared light in skeletal muscle 
tissue. Haemoglobin is the main component of erythrocytes and the oxygen carrier of 
the blood. Myoglobin is present within the skeletal muscle cells and facilitates 
intracellular oxygen transport. Due to identical spectral characteristics, it is not possible 
with NIRS to distinguish between haemoglobin and myoglobin. However, the 
contribution of myoglobin to the overall signal has previously been described as 
minimal (-10% Mancini et al, 1994). Therefore, the degree of light absorption is 
thought to be primarily dependent on the amount of oxygen attached to haemoglobin in 
the small arterioles, venules and capillaries (Boushel et al, 2001). Cytochrome oxidase 
is the terminal enzyme of the mitochondrial respiratory chain reaction transferring the
electrons to molecular oxygen. Because the amount of cytochrome oxidase in muscle is 
relatively low as compared with haemoglobin and myoglobin, changes in cytochrome 
oxidase are lost within the noise of the signal. Therefore, the contribution of cytochrome 
oxidase in the studies of this thesis has been omitted.
The continuous-wave NIRS employed in this study generates light at four wavelengths 
(775, 810, 850 and 910 nm), which is transported to the tissue by means of an optical 
fibre bundle called an optode. A second optode transports the light to the detector and is 
placed parallel to the light source, directly on the skin over the muscle or other tissue of 
interest. The light penetrates the skin, sub-cutaneous fat layer and muscle, and is either 
scattered or absorbed within the tissue. The light scattering originating from the source 
occurs in any direction, but the light detected by the second optode is thought to 
describe a banana shape (Boushel et al, 2001). Back-scattered light is returned as an 
optical signal and analysed using a procedure called spatially resolved spectroscopy to 
produce a ratio of oxygenated haemoglobin / myoglobin to total haemoglobin / 
myoglobin, expressed as percentage saturation (St02). Muscle StC>2 changes during 
exercise reflect the balance between oxygen delivery and tissue oxygen utilisation; a 
mismatch being reflected by a drop in StC>2 relative to baseline. Resting StC>2, StC>2 peak 
drop during exercise, and StC>2 at the end of exercise were assessed during the exercise 
protocol.
3.19.5: Echocardiography.
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Morphological and functional changes in cardiac structure and function were assessed 
using a commercially available ultrasound device (Terason T3000, Terason Ultrasound, 
Teratech, Burlington, U.S.A.) and dedicated 3.5 MHz phased array ultrasonic 
transducer. Each patient was assessed using guidelines produced by the American 
Society of Echocardiography (Gottinger, 2004). A detailed description of the use of 
echocardiography and the methods employed in this study are given in section 1, but 
due to functional restrictions of the ultrasonic device, not all the previous parameters 
could be assessed in this study population. The following echocardiographic parameters 
were assessed during this study (please see section 1 for added detail about each 
method).
1. LA volumes were measured at the following points:
c. Left atrial pre-contraction volume ( V preA) corresponding to the onset of 
the P wave on the surface ECG.
d. Minimal left atrial volume (Vmin), measured on mitral valve closure at
end-diastole.
e. Maximal left atrial volume (Vmax), measured immediately prior to mitral
valve opening at end-systole.
These values were used to calculate further parameters relating to left atrial active 
volumetric assessment
a. Left atrial active emptying fraction (LA-AEF%) ( V PrCA -  V min) /  V preA x 100
b. Left atrial expansion index (LA-EI) (Vmax -  Vmin / Vmin) x 100
c. Left atrial passive emptying fraction (LA-PEF%) ( V max -  V preA) /  V max x 100
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For patients who presented in atrial fibrillation at time of echocardiogram, pre 
contraction volumes were not calculated due to the absence of ‘p ’ wave on the surface 
ECG. As such, for these patients, LA active and passive emptying fractions were not 
able to be calculated.
8. Left ventricular end-diastolic diameter was measured from both parasternal long 
axis images and also apical 4 chamber images at end diastole. LV long axis end- 
diastolic length was assessed from apical 4 chamber images -  measured from the level 
of the mitral valve annulus to the LV apical endocardial border definition. The ratio of 
LV short to long axis ratio was calculated (from the 4 chamber measurements) in order 
to obtain the Sphericity Index.
9. Left Ventricular EF was calculated using Simpsons Biplane Method of Discs in 
patients with clear-enough echocardiographic windows.
10. Tissue Doppler imaging was used to assess indices of both LV longitudinal 
systolic function and LV diastolic function together with their detailed relationship
11. Careful border tracing of right atrial area was undertaken using the tricuspid 
valve annulus as a base for the measurement.
12. Right ventricular diastolic and systolic area was traced with reference to ECG 
timing of the cardiac cycle. Using the derived diastolic and systolic areas, right 
ventricular fractional area change % was calculated with the following formula:
(RV end diastolic area -  RV end systolic area / RV end-diastolic area)
13. M-mode echocardiography was used to measure Tricuspid Annular Systolic 
Plane Excursion (TAPSE) from apical 4 chamber images.
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3.19.6: Assessment of arterial reactivity using Flow Mediated Dilatation.
Endothelial dependent flow mediated dilatation of the femoral artery was assessed using 
a commercially available ultrasound device (Terason T3000, Terason Ultrasound, 
Teratech, Burlington, U.S.A.) and a compatible 7-12 MHz linear array vascular probe. 
The primary goal of this assessment was to create a shear stress stimulus that produces a 
nitric oxide dependent response in order that flow mediated dilatation can be used as a 
direct marker of nitric oxide availability and hence endothelial function. A common 
technique originally applied by Celermajer and co workers (Gottinger, 2004) was used 
in order to achieve this. Baseline femoral arterial diameter was measured in the 
longitudinal plane by a qualified ultra-sonographer together with pulsed wave Doppler 
measurements of arterial flow. A BP cuff was placed immediately above the knee joint 
and inflated rapidly to supra-systolic pressure for a period of 3 minutes. The occlusion 
of blood flow to the lower limb serves to produce an ischemia induced reactive 
hyperaemia. Following the 3 minute period of continued arterial imaging, the BP cuff 
was rapidly deflated resulting in increased shear stress to return blood flow to the 
ischemic region. A further 2 minutes of arterial scanning was performed in order to 
allow adequate time for sufficient arterial response. Images were recorded and edited 
for analysis of arterial diameter to be undertaken by a dedicated computer software 
package (Brachial Tools, MIA, IA, U.S.A) previously validated in a number of research 
studies (Stout, 2009). The computer software was calibrated to accurately reflect arterial 
diameter over time and changes in vessel diameter were logged graphically in frames 
per second ratio. Maximum percentage change in arterial diameter following cuff 
deflation was noted when compared to an averaged baseline trace using a graphically 
represented diagram of arterial diameter change over time.
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3.19.7: Psychological health status and quality of life.
Both HF and androgen deficiency are characterised by low mood and depression, which 
is improved by testosterone replacement therapy in testosterone deficient subjects. 
Thus, at baseline and 12 weeks, patients were asked to complete the MLHF 
questionnaire, the SF-36 v2 Health Survey, the BDI and the ADAM screening 
Questionnaire. A detailed explanation of the MLHF, SF-36 version 2, BDI and ADAM 
questionnaires can be found in section 1 of this thesis.
3.19.7.1: Community Healthy Activities Model Program for Seniors Questionnaire 
(CHAMPS) Physical Activity Questionnaire.
Physical activity behaviour in everyday life, outside of the exercise intervention, was 
measured at baseline and 12 weeks by the Community Healthy Activities Model 
Program for Seniors Questionnaire (CHAMPS) Physical Activity Questionnaire for 
older adults. The CHAMPS questionnaire has shown a 6 month stability range from 
0.58 to 0.67 using intra-class correlation coefficients and significant sensitivity to 
change (p<0.001) Stewart et al (2001). See appendix 11.
In order to adequately address the issue of measuring physical activity levels in older 
adults as outcomes of interventions, several issues need to be considered. The most 
important of these concepts have been described as; assessing appropriate types and 
amounts of the activities assessed, designing questions and methods to allow accurate 
reporting, minimising socially desirable responding and enhancing sensitivity to change 
(Stewart et al, 2001). As a consequence, Stewart and co-workers (2001) have designed a 
self report questionnaire which can provide several physical activity measures in the
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older generation. The questionnaire houses 41 items assessing a number of physical 
activities both light and more vigorous that is applicable to an older generation. The 
initial response to each item is a simple ‘yes’ or ‘no’ to participation in that activity in 
the last 4 weeks. Following this, the participant must decide how many times a week the 
activity was usually performed. A space is provided to write this answer. Finally, for 
each activity performed, the participant must circle how many total hours (in a typical 
week) the activity was undertaken.
From the questionnaire responses, Stewart and colleagues (2001) have provided coded 
algorithms so that researchers are able to derive important physical activity measures 
from the data obtained; namely frequency per week and estimated caloric expenditure 
per week in physical activity. In order to achieve this, Stewart et al (2001) made 
adjustments to the originally devised metabolic equivalent values (MET values), of 
Ainsworth et al (1993) to values that correspond with older adults performing the same 
activities. As part of the coding process, researchers must create a new duration variable 
for each activity. The new duration variable is then multiplied with the corresponding 
‘adjusted’ MET value to create a new weighted duration variable. The caloric 
expenditure per week variable can then be calculated for each activity by multiplying 
the weighted duration variable by 3.5 (ml/kg/min which is equal to 1 MET) and then 60 
to give METS / hour and by weight in kilograms (kg) divided by 200. This formula 
must be applied across all activities to give total caloric expenditure per week. During 
this study, total METS/hour over all activities were calculated as a comparator between 
treatment groups. This is summarised by the formula below:
METS/hour = New coded duration variable x adjusted ‘older’ person MET value for
activity x 3.5 x 60
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This formula was used for each activity performed and added together for the total 
MET/hour score, where 3.5 (ml/kg/min) = 1 metabolic equivalent. Therefore 3.5 x MET 
value will give actual ml/kg/min of oxygen uptake for each exercise undertaken (from 
ACSM Guidelines for Exercise Testing and Prescription, 7th Edition, 2006).
3.19.8: Qualitative assessment of testosterone therapy and exercise intervention 
(Focus Groups).
Focus groups were utilized as the method of qualitative inquiry because they facilitate 
group interaction and, in turn, may generate more abundant data than single or group 
interviews (Kitzinger, 1995). Participants are therefore, encouraged to talk to each 
other, ask questions, exchange anecdotes and comment regarding their own experiences 
and points of view. Focus groups are particularly useful for exploring the knowledge 
and experiences of study participants and can be used to examine not only patients 
thoughts, but expanding on this to generate data on how and why each patient thinks the 
way they do (Kitzenger, 1994).
In addition to this, the focus group method can facilitate exploration and clarification of 
participant opinion using means that would be less accessible in one to one interviews 
(Kitzinger, 1995). Focus group discussion appears particularly appropriate when the 
facilitator provides a series of open ended questions and aims to encourage their 
participants to explore issues of importance to them, using their own vocabulary, 
perhaps even generating their own questions and pursuing topics that are important to 
them(Basch, 1987).
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Importantly, focus groups allow researchers to utilize different forms of communication 
that people use in day to day interaction, including jokes, anecdotes, teasing, and 
arguing. Therefore, participant responses become more varied and may even be less 
formal than responses obtained during an interview situation (Kitzinger, 1995).
Four groups of 6 participants (n = 24) were randomly chosen from those patients who 
were consented for and completed the intervention study. Patients were randomly 
selected using a fishbowl technique based on each participants allocated study number. 
As part of this technique, a researcher not related to study data collection randomly 
picked out 24 patient numbers from a container. These participants were then invited to 
partake in the focus group sessions. There was no other specific inclusion criterion. 
Patients were of a mixed age and consisted of those who received testosterone therapy 
and those who received placebo. At the time of the discussions, patients and researchers 
were unaware of the group allocation. However, these participants consisted of 12 
patients from testosterone and exercise group and 12 patients from testosterone and 
placebo group. Some of the patients involved already attended local health clubs 
regularly. Each focus group meeting was undertaken in a private meeting room at the 
Centre for Sport and Exercise Science, Sheffield Hallam University, lasted for 
approximately 30-45 minutes and were all performed one week following completion of 
the final participants post intervention assessment. A topic schedule was created in 
order to achieve the aforementioned aims of the sessions (table 38). However, groups 
were encouraged to elaborate and raise their own issues. Each focus group was chaired 
by the chief investigator who has substantial experience (>15 years) of working with 
patients with cardiovascular disease but lesser experience when conducting focus group 
sessions. Resultingly, advice was sought from experienced qualitative researchers 
regarding the effective management and scheduling of each session. Each focus group
session was digitally recorded and subsequently transcribed (appendix 13 shows 
example of transcription). The facilitator together with two other (non-study related 
researchers) coded all the transcripts with the computer package (QSR NVivo Version 
8. QSR International 1999-2009). The resulting data were analysed using the principle 
of constant comparison in order to identify the most important themes and categories of 
response.
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Table 38. Topic schedule for the focus group session.
Process evaluation o f the lifestyle 
intervention.
Reasons for participation.
Frequency, intensity and duration of 
exercise sessions.
Contact with exercise specialists.
Format of the exercise training sessions. 
Reasons for continuation with programme.
Influences of structured programme on 
current methods of exercise training. 
Opinions of other medical professionals 
involved with patient outside of study. 
Barriers to exercising.
Support received.
Role of different medical professionals 
involved in the programme.
Comparison to current commercial gym 
environment and staffing.
Negative factors associated with the 
intervention.
Recommendation for future exercise 
intervention design and implementation.
Outcomes from the lifestyle intervention.
Perceived benefits of the lifestyle 
intervention.
Perceived problems with the lifestyle 
intervention.
Disease specific quality of life. 
Relationship with health professionals. 
Future continuation with similar training 
regimen.
Advice to other patients with heart failure.
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3.19.9: Focus group data analysis.
Qualitative research is becoming increasingly more popular in health service research 
and can be used to study novel interventions designed to improve patient care (Dy et al, 
2005). No singularly appropriate way to conduct qualitative data analysis has been 
proposed. However, it is well regarded that the process begins during collection of the 
data and continues throughout the course of the study (Bradley et al, 2007). For 
accuracy and consistency in qualitative data analysis, the following steps have been 
suggested to ensure a systematic approach allowing for open discovery of emergent 
concepts (Bradley et al, 2007).
Initially, reading of the data facilitates deeper understanding of its meaning, together 
with the identification of emergent themes without losing connections between concepts 
and context. Following this initial phase, the data can now become coded. These codes 
should be applied to paragraphs, sentences or even words within the data to catalogue 
key concepts without losing their context. Using a ‘grounded theory’ approach, data is 
reviewed line by line and as concepts are selected, codes are assigned. During 
progression of data analysis, specifications of the codes can be developed and refined to 
fit the data. In this approach, the researcher can identify text that represents similar data 
to that already coded to ascertain if they reflect the same concept. The constant 
comparison method, initially developed by Glaser and Strauss, 1967, involves the 
refinement of existing codes and the development of new codes to fit with the context of 
the data being analysed. In this way, the codes structure evolves inductively, reflecting 
the ‘ground’ or direct experiences of the participants (Bradley et al, 2007).
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3.20: Statistical analyses.
On the whole, data were normally distributed, with the exceptions of the NYHA 
questionnaire, ISWT perceived exertion, inflammatory markers and NT pro-BNP, 
which were normalised using logarithmic transformation before analysis. Analysis of 
Covariance (ANCOVA) was used to assess differences between the groups, with the 
baseline value used as a covariate (Vickers et al, 2001). Analysis of Variance (ANOVA) 
was used to assess differences in the baseline characteristics of the groups and paired t- 
tests were used to assess changes from baseline within the groups. Only data for patients 
who completed the study were included in the analyses, and no adjustments were made 
for multiple comparisons. Bland Altman plots were formulated in order to assess the 
accuracy or repeated measurements of testosterone and Pearson product moment 
correlation studies were performed on all baseline data (including participants who did 
not complete the programme) to assess for relationships between teststoerone and 
outcome measures assessed during the study. Statistical significance was set at P < 0.05, 
and results are expressed as means + SD.
3.21: Measurement error.
A cohort of 10 patients was selected in order to assess the reproducibility of the main
outcome measures. This included 6 min walk distance, v ° 2 , endothelial function using 
flow mediated dilatation and important echocardiographic parameters. Reproducibility 
was assessed using the relative technical error of measurement (TEM) and expressed as 
percentage error by the formula below:
%TEM = (TEM / [M1+M2] / (2) x 100 
Where Ml is the mean of the first series of measurements, M2 is the mean of the second
series of measurements.
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Chapter 4. Results.
4.1: Demographic data.
A total of 957 patients were identified from the screening of patient notes, 
echocardiographic and angiographic data (figure 14). These were sent an official letter 
inviting them to participate in the study. Of these, 638 patients (67%) did not reply and 
were sent another invitation letter. Following this, 15 replied as ‘not interested’ without 
any documented reason and 623 did not respond to the second invitation letter. Of the 
196 patients (20%) who replied as ‘not interested’ to the original invitation letter, the 
most common reasons for not wanting to participate were lack of time or work 
commitments. Other reasons included co-morbidities that the participant felt would 
prevent them from exercising, a lack of transport and/or too great a distance to travel to 
the research centre. Two patients were unable to participate because they were already 
receiving testosterone therapy. Of the remaining 123 patients who were assessed for 
entry into the study, 82 were screened out for not fulfilling the eligibility criteria and the 
remaining 41 patients (4% of those initially contacted) were successfully recruited and 
randomized. 1 of these patients did not start the study intervention due to time 
constraints re study completion. Attrition over the 12-week period of the exercise 
intervention was high. Five patients from the testosterone group (25%) and seven 
patients in the placebo group (35%) were lost to follow-up (overall 30%). Two patients 
dropped out due to time constraints but all others were due to co-morbidities. None of 
the patients dropped out due to study-related adverse events. Hence, 28 patients (3% of 
those contacted initially) completed the study protocol (n=15 testosterone and n = 13 
placebo; figure 15).
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Figure 15. Recruitment summary.
957 Patients contacted from screening of case notes, echocardiographic and
angiographic data.
No time (n = 56)
Too far to travel (n = 19)
No transport (n = 10)
Co-morbidities (n = 22)
Disabled (n = 3)
Caring for partner (n = 2)
Receiving testosterone 
already (n = 2)
Work commitments (n = 76)
Live abroad for part of year 
(n = 6)
Prostate cancer (n = 11)
Other co-morbidities (n = 8)
Unable to exercise (n = 9)Gout (n = 1)
Normal testosterone (n = 36)Peripheral Vascular Disease 
(n =2) Severe valve disease (n = 2)
RIP in car accident (n = 1) Awaiting heart 
transplantation (n = 1)Recurrent Paroxysmal 
Atrial Fibrillation, (n = 1). Awaiting other major 
surgery (n = 5)Implantable Defibrillator 
Dysfunction (n = 1) Decompensated heart 
failure (n = 3)No time (n = 2)
Deemed clinically unsafe to 
participate in exercise 
intervention (n = 7)
Legionnaires Disease (n = 1)
Failed to attend and un- 
contactable (n = 1)
Chest Infection (n = 1)
Swine Flu (n = 1)
196 ‘not 
interested’
82 screened out 
(failed inclusion 
criteria).
319 patients responded 
to initial invitation
41 recruited and 
randomised.
623 Not replied to second 
letter -  excluded from 
study.
638 second letters sent 
out to non-responders.
15 replied ‘not interested’ 
No reason specified.
123 Agreed to Participate and Assessed for 
Eligibility.
1 patient did not start 
study due to time 
constraints re study 
completion.
12 dropped out.
28 completed study 
workflow.
Placebo group (n = 
13).
Treatment group 
(n=15).
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As this was a preliminary/feasibility trial, data analysis was based on the 28 patients that 
completed the study. We successfully implemented the exercise intervention and 
injections in all these patients. Additionally, compliance to the twice-weekly exercise 
sessions was excellent, with all 24 supervised exercise sessions being attended (100%) 
and patients in both groups receiving all six fortnightly injections (either testosterone or 
placebo). The groups were particularly well matched at baseline. There was a strong 
trend to an increased walking distance at baseline in the placebo group (p = 0.05). No 
other differences were noted. Baseline demographics of the cohort are presented in table 
39.
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Table 39. Baseline characteristics of the study sample.
Testosterone (N=15) Placebo (N=13)
Characteristics
Age (y) 68.3 ±5.3 65.9 ± 8.8
Stature (m) 178.1 ±4.5 176.4 ±3.1
Body mass (kg) 90.2 ± 7.4 93.6 ± 11.1
Body mass index (kg/m2) 28.7 ± 1.8 30.1 ±3.5
Systolic BP (mm Hg) 137 ±11 139 ±18
Diastolic BP (mm Hg) 80 ±5 84 ± 9
Resting HR (beats/min) 76 ±13 71 ± 9
Total Testosterone (nmol/L) 10.4 ± 2.7 11.2 ±2.6
Free Testosterone (nmol/L) 0.230 ±0.081 0.230 ± 0.070
Bio-available testosterone (nmol/L) 3.98 ±1.07 3.75 ± 1.48
SHBG (nmol/L) 31.4 ±9.7 34.7 ±11.6
Albumin (g/L) 39.87 ± 2.98 40.24 ± 1.74
NYHA Score 2.5 ± 0.5 2.5 ± 0.5
Left ventricular end-diastolic volume (mis) 118.04 ±36.12 131.64 ±32.67
Left ventricular EF (%) 21.3 ±9.7 28.0 ± 6.0
Aetiology of HF
Ischaemic 13 (87%) 7 (54%)
Hypertensive 0 3 (23%)
Idiopathic dilated cardiomyopathy 1 (7%) 2 (15%)
Unclear 1 (7%) 1 (8%)
Co-morbidities
Ischaemic heart disease 12(80%) 6 (46%)
History of previous Atrial fibrillation 5 (33%) 5 (38%)
Atrial fibrillation at data collection 2 (13%) 2 (15%)
Hypertension 5 (33%) 4(31%)
Diabetes 5 (33%) 4(31%)
Chronic obstructive pulmonary disease 4 (27%) 5 (38%)
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Peripheral arterial disease 1 (7%) 0
Medication
Beta Blocker 12 (80%) 10 (77%)
ACE Inhibitor 15 (100%) 11 (85%)
Calcium Channel Blocker 2(13%) 1 (8%)
Diuretic 6 (40%) 7 (54%)
Aldosterone Receptor Blocker 2 (13%) 2 (15%)
Digoxin 1 (7%) 1 (8%)
Anti-Arrhythmic 4 (27%) 2 (15%)
Anti-platelet 7 (47%) 9 (69%)
Anticoagulant 5 (33%) 5 (38%)
Statin 12 (80%) 10 (77%)
2(y) years, (m) metres, (kg) kilogrammes, (m ) m etres squared, (mmHg) m illim etres o f  
mercury, (min) minute, (nmol/L) nanomols p e r  Litre, (NYHA Score) N ew  York H eart 
Association Score, (ACE) Angiotensin converting enzyme, (EF%) ejection fraction, 
(SHBG) sex hormone binding globulin, (HR) heart rate, (BP) blood pressure
4.1.1: Measurement error of data collection techniques.
Table 40 presents the relative technical error of measurement of the outcome measures 
assessed in a cohort of 10 patients who underwent identical assessments on a second 
occasion. Error is expressed as percentage change between initial and second 
measurement on a separate occasion.
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Table 40: Technical Error of Measurement.
Test TEM%
ISWT 3.58
V 02 4.10
Handgrip strength 3.70
FMD% 21.63
Muscular strength and endurance 4.10
NIRS time to minimum TOI 19.30
Sphericity index 7.21
LV diastology (E/E’) 4.66
LV longitudinal function (S wave) 5.25
LV EF% 8.94
LA max volume (mis) 5.12
LA min volume (mis) 5.10
RV area diastole (cm2) 5.10
RA area systole (cm2) 4.98
LA expansion index 6.98
LA passive emptying fraction 6.41
LA active emptying fraction 7.14
(ISWT) incremental shuttle walk test, (VO2 ) maximal oxygen uptake, (FMD) f lo w  
m ediated dilatation, (%) percentage, (NIRS) near infrared spectroscopy, (TOI) tissue 
oxygenation, (LV) left ventricular, (LA) left atrial, (RV) right ventricular, (mis) 
millilitres, (cm ) centimetres square.
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With the exception of NIRS time to minimum TOI (19.3%) and FMD (21.6%), other 
tests demonstrate good reproducibility with values under 10%. It has been recognised 
that one of the major limitations of FMD assessment is its poor reproducibility, even 
when performed by skilled operators (Stout, 2009). Time to minimum TOI data 
collection was hindered during testing by the inability to completely block out all light 
to the sensing electrodes. This was particularly difficult to achieve especially when the 
participant was performing intensive dynamic leg exercise during the recording period. 
The vigorous leg movement also resulted in oxygenation curves which were, at times, 
difficult to interpret.
4.2: Endurance performance.
All patients underwent detailed physiological assessment of endurance and strength 
performance. Table 41 illustrates the data obtained to assess aerobic and strength 
capability pre and post the 12 week intervention period.
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No significant differences were observed in markers of endurance performance between 
the groups. Numerous significant within group improvements were however noted. 
Maximum shuttle walk distance (418.7 ± 153.7 m increased to 492.7 ± 215.3 m in the 
treatment group and 556.2 ± 112.1 m versus 661.5 ± 158.8 m in placebo, p<0.05), peak
v ° 2  (15.0 ± 4.4 ml/kg/min increasing to 18.2 ± 4.8 ml/kg/min in the treatment arm 
(p<0.001) with no significant difference in placebo) and maximum power output 
obtained during cycle ergometry (88.3 ± 20.8 W to 103.3 ± 31.1 W in treatment group 
and 94.2 ± 23.2 W increasing to 105.8 ± 20.8 W, p<0.05 in the exercise only group) all 
increased in relation to baseline. In addition, the time to minimum tissue oxygenation 
during cycle ergometry significantly increased in both groups (p<0.01 exercise only and 
p<0.05 in the treatment group) suggesting delayed onset of muscular fatigue.
In addition to the endurance parameters, there were significant within group 
improvements in muscular strength confined to the testosterone treated group only. 
Between group differences were insufficient to become statistically significant. Knee 
extension and flexion at 60°/s demonstrated increased torque in the treatment arm only 
(122.2 ±51.7 Nm compared to 134.0 ± 44.7 Nm, p<0.05 and 50.3 ± 21.5 Nm increasing 
to 62.9 ± 22.0 Nm, p<0.05 respectively). There was also a significant increase in knee 
flexion at 180°/s in the treatment arm only (46.5 ± 20.8 Nm to 55.3 ± 24.6Nm, p<0.05).
Handgrip strength demonstrated a significant within group improvement in the placebo 
group (44.5 ± 7.6 kg to 47.0 ± 9.0 kg, p<0.05). No significant within group differences 
were seen.
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4.3: Echocardiography parameters of cardiac structure and function.
Echocardiographic parameters of cardiac structure and function are presented in the 
table 42.
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No significant changes in cardiac structure and function were observed between the two 
groups. There was a significant (p<0.05) increase in left atrial emptying fraction within 
both groups (2.49 ± 1.54 versus 5.67 + 1.88 for exercise and testosterone and 1.68 + 
1.04 versus 5.69 + 2.1 lfor exercise and placebo).
Figure 16 details the observed change in FMD % from baseline in the testosterone 
treated and placebo groups.
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Figure. 16. Changes in flow mediated dilatation of the femoral artery in both 
groups.
Data are presented as means with error bars representing SD. E+T: testosterone 
supplementation (ET); E+P: placebo (EP).
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No significant change in flow mediated dilatation of the femoral artery was noted in 
either group in response to treatment or placebo when compared to baseline.
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4.4: Indices of quality of life.
Questionnaire data pre and post intervention are presented in the figures 17 and table 
42.
Figure 17. SF-36v2 quality of life domains at baseline and end-point.
Data are presented as means with error bars representing SD. T: testosterone 
supplementation P: placebo. *P<0.05; **P<0.01 indicates significance of group 
difference from baseline (paired t-test). ^PcO.OS significant ANCOVA.
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There was a significant improvement in the general health (p<0.001), role physical 
(p<0.05), physical summary (p<0.05), role emotional (p<0.05) and mental health 
summary (p<0.05) domains of the SF36 questionnaire in the treatment group only 
following the intervention period. ANCOVA results were only significant for the SF- 
36v2 domains of bodily pain (P=0.037) and vitality OP=0.046), favouring the EP group. 
There was also a significant improvement in physical functioning in the EP group 
(p<0.05).
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There was no significant between group difference in New York Heart Association 
Score in the treatment and placebo groups. There was however, significant within group 
differences in NYHA Score pre and post intervention (testosterone group 2.5 + 0.5 to 
1.8 + 0.7, p<0.001 and placebo 2.5 + 0.5 to 1.8 + 0.4, p<0.001).
Non-significant increases in self-reported physical activity levels from baseline were 
observed in both groups (45.5 ± 34.1 to 56.7 ± 22.0 MET-hours/week and 58.4 ± 49.2 to 
72.6 ± 41.7 MET-hours/week for EaT versus EP, respectively; ANCOVA p=0.291).
There was a significant improvement in Beck Depression Questionnaire Score in the 
testosterone group (10.4 ± 8.7 to 6.6 ± 3.8, p<0.05) following the intervention period. 
No such differences were observed in the placebo group. ANCOVA however, was not 
significant (p = 0.39).
There is a significant reduction in ADAM Questionnaire Score (and hence improved 
androgen status) in the testosterone and exercise group (6.2 ± 1.7 to 4.6 ± 2.5), there is 
no significant change in the EP group. No significant ANCOVA statistic between 
groups is noted (p = 0.24).
Slight trends towards improved Minnessotta living with HF score were noted in both 
groups. However, these were not statistically significant.
4.5: Blood chemistry.
Blood chemistry variables pre and post intervention are presented in the table 44.
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There were no differences between the groups in circulating levels of NT pro-BNP or 
inflammatory markers. However, a decrease in TNF-a from baseline is noted in the EP 
group only (p<0.05). This decrease is not statistically significant using between group 
analysis.
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5.0 Correlation and Bland Altman analyses.
In order to assess for detailed relationships between important variables involved in the 
analyses, Pearson product moment correlation were performed on important health 
outcomes assessed during this study. These analyses were based on total testosterone, 
free testosterone and bio-available testosterone in the same format as study 1.Tables 45- 
48 detail the correlations observed. Additionally, Bland Altman plot was used to show 
the agreement between initial and second measurement of total testosterone. For 
completeness, these plots are also presented for free and bio-available testosterone. 
Figures 18-21 represent Bland Altman limits of agreement plots for total testosterone, 
free testosterone, bio-available testosterone and SHBG.
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There were no significant correlations between markers of endurance performance and muscular strength when based on total, free or bio-
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Table 47 details Pearson correlation coefficient for echocardiographic parameters based on total, free and bio-available
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7
There were no significant correlations noted between NT pro-BNP, adhesion molecules 
or inflammatory cytokines when based on total, free or bio-available testosterone.
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Figure 18. Bland Altman Plot showing the agreement between initial and
subsequent total testosterone analysis.
Average total testosterone (nmol/L)
Difference 
— ®*»Mean Difference 
—  Mean Diff. ± 2SD
There is good agreement between sequential measures of total testosterone on two 
separate visits. Mean difference of -0.21 nmol/L , s.d. l.OlnmoI/L. Therefore, mean 
difference +2 s.d. is 1.82 nmol/L and -2 s.d. is -2.24 nmol/L. Coefficient of 
reproducibility is 2.02. One value out lies the + 2 s.d.
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Figure 19. Bland Altman Plot showing the agreement between initial and
subsequent free testosterone analysis.
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This Bland Altman plot shows that generally, there is good agreement between 
subsequent calculations of free testosterone based on SHBG, total testosterone and 
albumin. Mean difference is small at -0.0016 nmol/L with s.d. of 0.002 nmol/L. 
Therefore, mean + 2 s.d. is 0.05nmol/L and mean -  2 s.d. is -0.05 nmol/L. 
Coefficient of repeatability is 0.004. 3 repeated measurements fall outside of + 2 s.d 
for the sample.
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Figure 20. Bland Altman Plot showing the agreement between initial and
subsequent bio-available testosterone analysis.
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0.5 -
■Q_ro‘ro>re■o15
❖  Difference 
— *^Mean Difference 
—  Mean Diff. ± 2SD
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-0.5 %
’W m
Average bio-available testosterone (nmol/L)
The Bland Altman plot displays reasonable agreement between subsequent 
calculations of bio-available testosterone based on total testosterone, albumin and 
SHBG. The mean difference is -0.08 nmol/L with s.d. of 0.37 nmol/L. Therefore, +2 
s.d. is 0.67 nmol/L and -2 s.d is -0.81 nmol/L. The coefficient of reproducibility is 
0.74.
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6.0 Focus group evaluation of the intervention.
There were seven important themes and categories of response that emerged from 
the focus group discussions. These are presented below. Participant quotes have been 
included from different focus groups to provide a detailed portrait of the types of 
responses for each theme.
Confidence to continue exercising in the future
Patients recognised that continuation with ET was important for maintaining the 
perceived benefits gained from study participation. However, it was also recognised 
that without the support of the study team this would be a difficult undertaking. 
Participants were concerned that without having strict appointment times to attend 
for sessions and a supervised ET session with others in the same situation they 
would discontinue ET and be reluctant to attend other gymnasiums. In contrast 
however, it was noted that the experience of ET taught the participants how to 
perform different types of exercise safely in their own homes or in local health clubs. 
Although many participants did not regularly exercise previously due to concerns 
about their condition, they felt that they now have more idea about the level they can 
push themselves to during ET and daily activities. This has given them more 
confidence to perform ET. However, patients were in agreement that once the 
exercise sessions were completed it was unlikely that many of them would continue 
with ET due to the lack of experienced instructors in health clubs in whom they felt 
confident during ET.
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“What you have to do when you finish is to keep the momentum going. 
Otherwise you start settling back into old ways”.
“You just need someone to push you into it. You know, you’ve made an 
appointment and so you come -  don't you?”
"It needs to be that we go somewhere with your mates so that you can push 
each other. I f  you are doing it at home then you just say - Oh, I  don’t feel
like doing it today”.
“It is up to us to look after our own health and this programme has 
reminded me that I  should be doing this myself. We can do a lot of the 
exercises at home and that is important”.
“There is nothing to take you any further at the end”.
“For people like us in order to take the burden off the NHS you really need 
something in place at the end”.
Role in giving advice to patient's with similar conditions
Patients indicated that they themselves could undertake an important role in giving 
advice to other patients with the same condition. It was stated that the experience of 
performing ET and the benefits gained from the sessions should be promoted to 
other patients with testosterone deficiency and HF. Participants appeared confident
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in being able to discuss the benefits of the intervention and how these benefits 
translate to everyday activities and to improvements in quality of life. In addition, it 
was generally felt that large organisations such as the National Health Service were 
failing in this respect and were wasting money and resources in other ‘less 
important’ areas.
“They must do exercise. It is important and gets you much fitter ”.
“It makes daily life easier ”.
“It is up to people like us to promote this -  we should advertise these sort o f  
programmes and more people will benefit”.
“The NHS is not doing a good enough job and wasting money on other
things that are pointless”.
Perceptions about the exercise intervention
Patients felt that they could have been pushed harder by increasing the intensity of 
the ET. Although, it was thought that initially the programme was strenuous enough, 
participants felt that later during the trial they could have tolerated a more strenuous 
programme. It was also felt that there could have been more variety during the ET, 
perhaps by the use of a wider range of gym equipment. It was suggested that more 
variety could have helped participants in extending themselves while allowing them 
to learn how to use equipment found in local health clubs. It was noted that to reduce
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the burden on the National Health Service, there should be more community based 
specialist exercise facilities especially since a minority of patients found travel to and 
from the exercise centre difficult. Some believed they would have benefited from 
more formal educational advice surrounding ET and diet to promote more effective 
weight loss. One member of the group thought that the ET sessions were a little 
rushed and they could be improved by allowing more time in the gymnasium.
“I could probably have been pushed a little harder and maybe got even more
f i t”.
“I  felt as though it could be a little more intensive. For instance I  would have 
liked to have done a warm up on the treadmill or perhaps the main training 
on a treadmill rather than a bike. That way, you can get your whole body 
working rather than just your legs”.
“I  would have preferred more time walking on the treadmill because that’s 
what I do all the time. It helps me improve that specific area. I  never cycle
anywhere”.
“Maybe dietary and educational advice should also be included because 
weight is a massive problem for lots o f  people”.
Perceived roles o f medical professionals
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There were varied responses regarding the role of medical professionals in 
promoting and understanding ET and testosterone therapy in HF. Patients felt more 
positive when the general practitioner and consultant cardiologists were interested in 
the research and the format of the ET sessions. In contrast, there were a number of 
negative comments related to medical professionals. It was felt that many nurses still 
hold the opinion that patients with HF are unable to exercise and must dramatically 
reduce the level of physical activity within their daily lives. It was felt that general 
practitioners did not do enough to promote ET, or know about appropriate health 
clubs or instructors qualified to supervise ET for HF patients. Annual check-ups or 
meetings with heart specialists were suggested as an important factor for both 
maintaining health and preventing disease progression. Some of the participants had 
not seen a medical professional for a couple of years and thought that screening and 
education for those patients with features of HF at an early stage would be an 
acceptable way to prevent significant disease progression and could ultimately save 
National Health Service resources. Of those patients who had joined health clubs, 
there was concern that instructors could not safely supervise HF patients and would 
be unable to recommend adequate lifestyle changes or beneficial exercises to 
perform. This resulted in participants not renewing gym memberships for fear of 
becoming unwell during exercise and with the perception that instructors were not 
qualified to deal with adverse health effects. Finally, it was perceived that physicians 
do not have enough time to adequately explain the condition of HF and the range of 
therapeutic options available to the patients. Contact times were too short and seen as 
quick ‘in and out’ appointments.
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“Doctors and nurses are interested in the course [trial] and also the outcome
o f it”
“My doctor is keen to see the results and I  have asked if  he will prescribe me
testosterone”.
“They have different opinions, some say don ’t exercise. That’s rubbish
because I  know I  can ”.
“I  never see the consultant anymore. I  have been discharged and they don’t 
follow me up to check anything. They don’t force you to exercise”.
“I f  they spent more they may save money by sorting out problems in the 
earlier stages where it doesn’t cost as much”.
“The [health-club] instructors seem clueless and unable to help especially if  
you tell them you’ve got heart problems”.
“I  asked my GP to send me to an exercise class but he didn’t know about any 
or where to go. That’s useless. They should be promoting these things to 
heart patients not making it more difficult to get there”.
“They know what things can help us. They just don’t push it enough because 
they are too busy and want you in and out quickly”.
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Motivation during the trial
Motivational factors identified by patients included the perception of significant 
improvement in exercise capacity and strength through participation. Patients felt 
that motivation was enhanced by the use of group sessions where competition and 
team behaviour proved beneficial. In particular, patients appreciated making new 
contacts with others who had similar health complaints. Some participants described 
significant weight loss as another important factor in wanting to attend the sessions. 
Other important motivational factors included social support, interest in the results of 
the trial and also the fact that they perceived that this provision was the only safe 
option available for HF patients. The two groups who were felt to have provided the 
most support to participants during the intervention were family and fellow 
participants. Family members encouraged patients to attend the sessions and were 
able to motivate them to attend. Many participants stated that they continued in the 
trial because of the opportunity to meet with others who had similar health issues.
The support provided by health professionals, physicians and researchers involved in 
the programme was seen as positive.
“My motivation was that I  wanted to get fitter and also find out i f  it was the 
exercise or testosterone or whatever made you feel better ”.
“I  could see myself getting fitter and losing weight”.
“People will be a lot more motivated when you get to know the results. The
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encouragement will come from the results”.
“The best thing for me was coming and seeing the other guys in my group 
every week. We could chat about things and still get on with the exercises. It 
made the sessions seem more fu n ”.
“I  prefer to come here with the people who have similar problems”.
“We all got on together so that was an important part o f  the programme”.
“I ’m grateful to all the people here who have helped me”.
“My family also motivated me to come. They wanted what was best for me so 
made it easier for me to get here”.
“Family was very important in getting me out o f  the house and attending”.
“We need more places like this with experienced staff that you have 
confidence in when you are exercising”.
Negative effects
Minor physical effects of the ET were discussed, and included buttock soreness from 
exercising on the cycle ergometer and local muscular pain from strength training
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exercises. Some patients described delayed onset muscular soreness following the 
ET sessions and reported general tiredness towards the end of the week -  especially 
those patients who were also still in full time employment.
“Tired at first but the more I  did Ife lt better”.
“Sometimes sore in the morning but that soon wore o ff \
“Night and day after were difficult as I  used to ache quite a bit. I  thought I  
might get use to it but I  never did. Maybe I  was pushing too hard at times”.
“Sore back after cycling and when doing sit ups”.
“Muscle aches when doing some o f  the strength exercises”.
Perceived health benefits
Most participants felt that the main benefit of the intervention was a sense of 
increased fitness. Participants were encouraged by the increases in endurance 
capacity, muscular strength and improvements in health related quality of life. They 
described a sense of improved confidence in performing daily tasks and, for some of 
them, more confidence in attending health clubs for the first time. The significant 
weight loss associated with the ET was also a source of increased confidence and
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wellbeing. Participants valued the professionalism of the fitness instructors and 
researchers and the excellent facilities provided within the research centre -  
particularly the exercise and fitness assessment equipment.
“For me it’s been an excellent course and I ’m grateful to all the people here 
who have helped me. I  have noticed it very much because I  do a physical job  
and my breathing has improved very much recently"
“Just fitness alone and the confidence definitely makes you improve”.
“I  could walk further and get up hills without getting as short o f  breath ”.
“Training has made me more confident and fitter”.
“Exercise and injections made me feel great during the day”.
“Yes the strength is coming back more and more”.
“The professionalism was important together with meeting friends in the 
gym. I  really enjoyed the training”.
“I  have lost weight as a result o f  doing this”.
“I  had to buy another pair o f trousers last week because my suit is too big. 
That must be very beneficial to us heart patients -  losing weight”.
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Chapter 5: Discussion.
This is the first study to evaluate the feasibility of a 12-week program of exercise 
rehabilitation, with and without testosterone replacement therapy, in a more elderly 
(mean age of 68.3 + 5.3 years for the treatment group and 65.9 ± 8.8 years for the 
placebo group respectively) male HF population with bio-chemical evidence of low 
testosterone. This study was designed as a feasibility study because the efficacy of 
ET in patients with HF and testosterone deficiency had not yet been studied and, in 
addition, neither was it known whether testosterone treatment was able to augment 
the effects of exercise in this population. Thus by collecting this preliminary data, 
the impact of this intervention on pertinent health outcomes was studied with the aim 
of planning a future larger scale trial and detail issues which may impact on the 
successful management of future research studies.
Patients recruited to this trial had average total and free testosterone levels of 10.9 
nmol/L (314 ng/dl) and 0.229 nmol/L (6.6 ng/dl), respectively. These values are 
similar to those reported by Vermeulen et al, 2001 for the lowest 1% of healthy non- 
obese males aged 20-40 y (11.0 nmol/L and 0.225 nmol/L, respectively) and are 
widely considered to represent the threshold for androgen deficiency (Vermeulen et 
al, 2001). Using these cut-off values, 61% of the men in our cohort were classified as 
androgen deficient on the basis of testosterone status, although all but two of them 
(95%) with testosterone levels of 11.9 nmol/L (343 ng/dl) and 12.9 nmol/L (371 
ng/dl) were experiencing symptoms of hypogonadism (as evidenced a score of >3 on 
the ADAM questionnaire). Previous clinical experiences have demonstrated that the 
official diagnosis of hypogonadism is challenging. Guidelines have reported wide
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variations in laboratory ‘cut-off values for low testosterone varying from 8.0nmol/L 
up to 12.0nmol/L in healthy populations (Bhasin et al, 2006). In addition, the same 
guidelines are clear that variations in laboratory serological techniques and the 
additive use of questionnaires can further impact on the diagnostic accuracy of 
testosterone deficiency. Using the upper cut off value of 12 nmol/L as suggested by 
Bhasin et al, 2006, then all but one of our participants would be classified as 
testosterone deficient based on total testosterone concentration. Due to challenges 
faced in recruitment to the trial, a desicion was made to increase the acceptable total 
testosterone concentration for inclusion into the study to <15 nmol/L. Clearly, this 
increase would have resulted in recruitment of participants with ‘threshold’ or even 
lower end of normal range testosterone onto the trisl and as such, affected the results. 
During the time of increasing the cut-off range, only one participant (with a 
testosterone concentration of 12.9 nmol/L) was recruited with a value above the 
originally defined range of < 12 nmol/L.
Previous work has reported that in order to fully assess testosterone status, sampling 
of both bio-available and free testosterone concentration is paramount. Elderly 
males, males with obesity, diabetes mellitus or chronic diseases (such as cancer, lung 
disease, heart failure and HIV) have been shown to present with abnormal increases 
in SHBG and thus due to its detailed binding relationship with testosterone, total 
testosterone may not be a precise marker of androgen status in this population 
(Bhasin et al, 2008). The mean free testosterone concentration observed during this 
study (0.229 nmol/L) is higher than the suggested cut-off range of 0.17 nmol/L for 
low free testosterone suggested by Bhasin et al, 2006. Therefore, as this population 
is more elderly, a proportion of patients were obese, with diabetes mellitus and
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taking into account the history of chronic disease (HF), then it is plausible that 
inclusion into the study based solely on total testosterone may be unsuitable and a 
combination of free and bio-available concentrations should also be used. It could 
therefore, be argued that based on free testosterone concentration, this sample was 
not truly testosterone deficient. However, in support of our research design, all other 
research investigating testosterone deficiency in a cardiac population have used cut­
off values based solely on total testosterone (Caminiti et al, 2009, Malkin et al, 2006, 
Malkin et al, 2004).
Testosterone levels are widely reported to be at their lowest in the early hours of the 
day before 10:00am (Diver et al, 2003). However, many of the studies assessing 
diurnal testosterone variation were performed in a younger population with a 
minority of older participants. In more elderly populations, the diurnal variation in 
testosterone concentration persists, but is substantially blunted (Crawford et al, 
2007). It has been reported that testosterone levels vary markedly throughout a 24 
hour period and measuring testosterone levels in the same individual in a 12 hour 
period cannot be relied upon to make accurate conclusions over androgen status 
(Spratt et al, 1988). Around 30% of males with low testosterone sampled during the 
afternoon period have been shown to have normal range testosterone concentration 
when sampled during the morning hours (Brambilla et al, 2007). Each participant in 
the current study was advised to attend testosterone screening as early as possible in 
the morning and were sampled over two visits on separate days with the initial value 
being used for study inclusion. No patients switched from hypo to eugonadal status 
following second testosterone measurement and these values were consequently used 
to advise as to the accuracy of repeated measurements in this population whilst
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confirming the initial diagnosis of testosterone deficiency. Bland Altman limits of 
agreement plots confirm that over the two visits to the clinic there was good 
agreement between respective measures of testosterone. An important limitation of 
the sampling technique was that participants were screened at a busy out-patient 
hospital clinic and this ensured that definitive times of blood collection could not be 
confirmed.
Exercise intervention duration in HF populations have ranged from 3 weeks up to 24 
weeks with periods of maintenance extending up to 1 year, incorporating sessions 2 
or 3 times per week. Our ET programme lasted for a period of 12 weeks and 
incorporated sessions twice weekly. Previous ET programmes in HF have varied by 
setting (home versus gym supervised), type of exercise modality (cycling, treadmill, 
Pole Striding, outdoor exercise) and exercise intensity from low level to moderate -  
high intensity training. In our study, the ET regime involved high intensity cycling 
interval training followed by endurance related resistance training of the major 
muscle groups used in everyday activities. The incorporation of high intensity 
exercise resulted from recent work by Wisloff et al, 2007 who demonstrated greater 
improvements in aerobic conditioning, endothelial function and levels of 
inflammation following such a regime in HF patients when compared to more 
traditional moderate continuous training when performed thrice weekly over a period 
of 3 months. Although overall duration of exercise programme is the same in our 
study, recruitment challenges related to time commitments of patients and the 
amount of travel required to and from the research centre resulted in reducing our 
planned number of exercise sessions from three to two per week. Most other research 
has used exercise sessions at least thrice weekly in their interventions in HF patients 
and as such, it is plausible that greater improvements may have been noted in our
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study with an increased number of exercise sessions per week. Combining our 
reduced number of exercise training sessions per week and the borderline 
testosterone deficient status when using free and bio-available testosterone, it is 
possible that greater within and between group interactions may have been noted if 
patients were defined as hypogonadal with all measures of testosterone and also if 
there were greater than two exercise sessions per week. As such, the design of future 
research should aim to increase the frequency of exercise sessions and also be more 
stringent on the bio-chemical definition of hypogonadism in order to provide an 
increased opportunity for health outcome improvement in response to the 
intervention. Any future design however, should be mindful of the challenges 
presented in this study regarding recruitment and attrition.
The recruitment rate for this study was very low (4%) but similar to that reported for 
a recent randomized controlled trial of similar community-living elderly people 
(Forster et al, 2010). Despite this, the characteristics of our patient cohort, including 
age, BMI, baseline aerobic fitness and quality of life, were comparable to those 
previously reported for HF patients recruited to exercise trials (Nilsson et al, 2008, 
Wisloff et al, 2007, Sabelis et al, 2004, Kemps et al, 2008). The observed difficulties 
experienced in recruitment to the trial may be due to a number of factors.
Patients were initially contacted by post by gathering details from Cardiology clinic 
patient lists and assessment of eligibility through access to patient notes. It could be 
suggested that approaching participants via post is a less reliable method of 
recruitment when compared to other more pro-active methods. Research conducted 
by Treweek et al, 2009 has assessed the effectiveness of techniques used to recruit
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participants to clinical trials. This showed that better recruitment techniques include 
providing educational material together with study invitations, including video 
material documenting the health benefits involved in trial participation, providing 
telephone contact from patients with similar health conditions to encourage 
recruitment and also providing significant financial remuneration for trial 
participation. Although this study did not have sufficient funding for the 
development of video aids, booklets or to provide significant financial remuneration 
(although travel and parking subsidies were provided), recruitment may have been 
improved with increased presence by research staff at specialist HF clinics, by using 
telephone reminders in conjunction with invite letters in a similar manner to 
Nystuen et al, 2004 who found this method significantly improved participation, or 
by improved promotion of the research by consulting physicians.
Attrition was also high in our patient cohort (30%), but within the range (0-39%) of 
that reported in a meta-analysis of physical activity interventions in cardiac patients 
(Conn et al, 2009). The main reasons for patient drop-out were age-related co- 
morbidities and infectious disease, consistent with previous studies of elderly HF 
patients (Lloyd-Williams et al, 2003). A proportion of the participants without 
significant co-morbidities preventing continued participation dropped out due to time 
constraints. This was also a major factor involved in the initial recruitment process. 
The study design involved significant travel to and from the recruiting centre, 
together with occasional visits, (on top of already scheduled standard care clinic 
visits) to the sponsoring institution. This significant time-burden was sufficient to 
deter many participants from entering onto the study, particularly when still in full­
time employment. This has also been documented by other researchers who have
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showed that tiredness on top of a working week can be a main determinant of drop­
out in exercise based interventions in HF patients (Wisloff et al, 2007). During this 
study, the researchers did provide scheduled exercise training sessions outside of 
normal working hours but the extra pressure of these on top of a working week was 
considered too great in some cases.
In order to improve attrition in future trials, it may be beneficial to reduce the 
commitment of travel to other centres by employing a part home based exercise 
regime similar to that performed by participants in the BRUM-CHF Study (Jolly et 
al, 2009). However, although this study significantly reduced drop-out when 
compared to other exercise trials in HF, there were no significant improvement in 
health related outcomes from baseline. This may, in part, be due to the reduction in 
supervision and therefore decreases in training intensity and lack of compliance with 
individual exercise prescription. Other methods which have been shown to improve 
attrition in exercise based trials in HF, and may have improved attrition in this study, 
have included cognitive behavioural strategies and especially motivational 
interviewing. These strategies encompass goal setting, problem solving, positive 
feedback, reinforcement and group interaction. Importantly, such strategies were 
found beneficial in the short-term only (6 months) and ineffective when used in the 
longer duration (Tierney et al, 2012). In addition, studies have shown that self- 
efficacy when undertaking exercise to be an important determinant of future 
adherence (Anderson et al, 2006). These strategies employ peer support, observation 
methods of other patients with similar conditions performing training and support 
from family and friends in order to overcome barriers to exercise.
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Although attrition was low, compliance to the exercise sessions and injections was 
excellent (100%) in the 28 patients who completed all assessments. It is likely that 
the latter was strongly influenced by our flexible approach to organising exercise 
sessions around patient commitments and contributing to their travel expenses. There 
were no adverse events resulting from the exercise sessions or injections. Minor 
local reaction (redness) was noted in the injection site on a small number of 
occasions. In addition, patients taking Warfarin experienced slightly increased 
bleeding from the injection site when compared to the other participants. Due to the 
effects of testosterone therapy on anti-coagulation and blood glucose concentration, 
there was a possibility that Warfarin and / or anti-diabetic agent dosage may have 
been altered as part of patients’ regular clinic regimen. All patients who were taking 
Warfarin attended for an additional INR measurement at around 5-7 days following 
their first injection, independent of their treatment allocation and, as these potential 
side effects to the therapy were explained to each participant prior to recruitment and 
were also detailed in the study information leaflet, it is feasible that changes made to 
their regular medical therapy may have un-blinded patients to their treatment 
allocation during the trial. At the initial exercise training session of each new week, 
patients were screened in detail regarding their symptoms, side-effects and for any 
alterations to their medication. It should be noted that no changes were needed to 
either Warfarin or anti-diabetic medication dosage as part of this trial for patients 
receiving either testosterone therapy or placebo. Patients in both the treatment and 
placebo groups attended for extra blood analysis at 5-7 days, therefore there was no 
discrimination based on group allocation during the study and hence no un-blinding 
at this stage.
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Testosterone is a widely used steroid and has received media coverage for its use in 
the sporting arena as a successful doping method to increase muscular strength, 
endurance and aggression. As such, many participants who took part in the trial were 
able to use their own knowledge of the suspected effects of the treatment, together 
with the information provided in the study leaflet, to speculate as to the nature of 
their allocation during the trial. This treatment effect has been previously reported by 
Schultz and Grimes, 2002 who suggest that treatment side-effects or significant 
clinical improvements are both potential factors that can un-blind both participants 
and researchers to group allocation. During our trial, many participants at some point 
commented that they were probably receiving testosterone and not placebo. 
However, the same participants at other times were not convinced re their group 
allocation. There were no significant side-effects related to testosterone therapy 
during the trial and as such, these could not be used to suggest a group allocation. In 
addition, similar improvements in most outcomes were seen in both treatment and 
placebo groups suggesting that the addition of exercise therapy to testosterone 
treatment may have masked the effects of testosterone treatment.
Although caution needs to be applied when interpreting preliminary outcome data 
from feasibility trials, improvements in peak power output in the treatment and 
placebo groups (17% v 12%, respectively) were accompanied by improvements in 
shuttle walk performance (18% v 19%). Furthermore, the treatment group showed 
improvements from baseline in peak oxygen uptake (21%), time to minimum tissue 
oxygenation and leg strength, which were not apparent in placebo. The observed 
improvement in aerobic exercise capacity was similar to that reported previously for
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HF patients following programs of aerobic exercise lasting 4-24 weeks (Bellardinelli 
et al, 1995, Dubach et al, 1997, Jette et al, 1991) but greater than that reported for 
younger HF patients after a similar 26-week program of combined aerobic interval 
exercise and resistance training (Senden et al, 2005, Sabelis et al, 2004) Considered 
together, our results show that male patients with low testosterone status achieved 
similar exercise-induced improvements in aerobic exercise tolerance as other patient 
cohorts who were not classified as androgen deficient.
The observed greater improvements in aerobic exercise tolerance, muscle 
oxygenation and leg strength in the treatment group when compared to placebo were 
non-significant using ANCOVA for between group comparisons. This might simply 
reflect the small sample size, but we cannot exclude the possibility that synergy 
between exercise and testosterone treatment is short-lived. Indeed, although 
supplementation at similar doses has been shown to acutely improve muscular 
strength, aerobic capacity and time to ischemic threshold in men with HF (Malkin et 
al, 2006, Malkin et al, 2004) and CAD (Pugh et al, 2004) supra-physiologic levels of 
testosterone shortly after administration are often followed by sub-physiologic levels 
towards the end of the dosage cycle (Nieschlag et al, 2004). Our study supports this, 
as the testosterone levels assessed two weeks after the final injection were similar to 
those measured at baseline in the treatment group. While higher dosage testosterone 
treatment might be needed to markedly augment the effects of exercise and 
testosterone therapy in this patient group, higher dosage testosterone has been 
associated with elevated risk of cardiovascular events in a recent study of frail 
elderly males with mobility limitations (Basaria et al, 2010). This finding however, 
is not consistent with previous meta-analyses (Calof et al, 2006, Haddard et al, 2007,
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Fernandez-Balsells et al, 2010) and might be a reflection of the small sample size 
and characteristics of the study population. Further trials with larger numbers of 
participants are needed to establish whether higher dosage supplementation when 
administered in the clinical setting is safe and can augment the improvements in 
aerobic exercise capacity and muscular strength observed in this study. In order to 
alleviate the pulsatile nature of testosterone injections, other preparations are 
available that may provide a ‘long-acting’ effect. Testosterone dermal patches have 
traditionally provided a response that mimicks the natural diurnal variation of 
testosterone over a 24 hour period (Bhasin et al, 2006). These patches can be applied 
daily or can even be long acting therefore reducing the need for daily application. 
Perhaps the major implication of the use of such patches is the previously observed 
high rate of skin reactions and therefore intolerance to the treatment (Malkin et al, 
2004).
Physiological mechanisms for the noted improvements in aerobic capacity, tissue 
oxygenation and muscular strength and endurance, although non-significant, have 
been suggested in the literature. In HF, there is derangement of the glucose-insulin 
axis with studies reporting up to 43% of patients manifesting disorders of glucose 
metabolism (Kontoleon et al, 2003). Research has shown that low levels of serum 
total testosterone and SHBG are risk factors for development of the metabolic 
syndrome in males (Muller et al, 2005). Patients with HF and insulin resistance have 
an impaired ability to promote glucose transport into skeletal muscle cells and 
adipose tissue. Moreover, research has showed that impaired insulin activity 
inversely correlates with severity of HF, relates to disorder of skeletal muscle 
physiology, facilitates reduced muscle mass and can also influence prognosis (Swan
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et al, 1997 and Doehner et al, 2002). Further reports have also suggested that insulin 
resistance may further deteriorate cardiac performance in HF, due to cellular 
disruption of cardiac metabolism (Chang et al, 2005). Testosterone supplementation 
towards the physiological range has been shown to significantly improve fasting 
blood glucose and insulin levels, together with significant improvements in 
cholesterol level and waist to hip ratio (Kapoor et al, 2007). Mechanistically, 
cultured adipocytes and skeletal muscle cells incubated with low dose testosterone 
therapy have demonstrated improved regulation of GLUT4 and insulin receptor 1 
(Chen et al, 2006). Furthermore, Sato et al, 2008 have showed that testosterone 
therapy in a rodent model can facilitate phosphorylation of protein kinase B and C, 
key pathways in insulin receptor signalling pathways for the regulation of GLUT4 
translocation. The same authors have also suggested that testosterone treatment can 
influence enzymes related to the glycolytic process. Increased activity of 
phosphofructokinase and hexokinase has been discovered in cultured rat skeletal 
muscle cells following administration of testosterone. Physiological replacement of 
testosterone may therefore indirectly correct the aforementioned abnormalities at 
skeletal muscle ultrastrctural and cellular level to promote increases in walking 
performance.
Other research has also identified that changes in muscle performance may explain 
improvements in exercise capacity in HF patients receiving testosterone replacement 
therapy (Caminiti et al, 2009). Maladaptive muscle fibre atrophy, increased 
abundance of type II glycolytic fibres and reduced oxidative metabolic capacity have 
been shown to correlate with poor exercise tolerance and increased VE/VCO2 slope
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in HF (abnormal enhanced muscle ergoreflex) (Hambrecht et al, 1995). It has been 
hypothesised that a representative improvement in overall muscle function may 
decrease the abnormal muscle metaboreflex contribution to the ventilatory response 
to exercise, reducing the VE/VCO2 slope and therefore improving exercise tolerance 
(Caminiti et al, 2009). To further reinforce this hypothesis, work in non-HF animal 
models has shown that anabolic supplementation at physiological doses is capable of 
accelerating fast to slow twitch muscle fibre type conversion and also increase the 
number of type I oxidative fibres, co-existent in improving the relative oxidative 
capacity of skeletal muscle (Ustunel et al, 2003). In relation to this, muscle 
oxygenation assessment in our study, using NIRS, demonstrated improved time to 
minimum oxygen saturation reinforcing the aforementioned concepts that there is an 
improved ability of the skeletal muscle to uptake and utilise oxygen to power 
muscular work. Furthermore, Pugh et al, 2004 have also suggested that microscopic 
changes in muscle metabolism may explain the increase in exercise tolerance noted 
in their earlier study.
During this study, post intervention blood samples were not taken for fasting insulin 
or glucose assessment. Hence, the impact of insulin resistance on exercise tolerance 
in our cohort of patients with low testosterone status is unknown. Additionally, 
detailed microscopic analysis of muscle fibre types or invasive muscle biopsy was 
not performed as part of our study and therefore no information regarding a switch of 
fibre types or increase in key energy related enzymes or molecules could be 
elucidated from our data. These facets clearly warrant further investigation and other 
studies should attempt to provide a more holistic approach to skeletal muscle 
structure and function. In addition, NIRS assessment of muscle oxygenation in our
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study demonstrated poor reproducibility (up to 19% error between repeated 
measurements) mainly due to the difficulties experienced in completely blocking 
artificial light sources and the mechanics of cycle ergometry with a probe placed on 
the thigh muscle. Our patients were generally overweight (mean 90.2 ± 7.4 kg for 
treatment and 93.6 ± 11.1 kg for placebo with BMI of 28.7 ± 1.8 versus 30.1 ± 3.5 
respectively) and subcutaneous fat has been shown to have a large impact on NIRS 
signal (Me Cully and Hamaoka et al 2000). These authors suggest that increase in 
adipose tissue results in poor absorption, higher returning signals and thus less signal 
change in experimental conditions. Me Cully et al, 1997 have argued that for 
clinically reliable measurements, in their cohort of elderly patients with vascular 
disease, BMI measurements would need to be certainly less than 32, a value close to 
those observed in our present study. The lack of reproducibility and difficulties 
observed in measurements suggest that perhaps other techniques should be utilised to 
provide a more accurate assessment of muscle oxygenation in future studies.
Small reductions in body mass and BMI were observed in the treatment and placebo 
groups. Previously, Malkin et al, 2006 reported no change in BMI in hypogonadal 
HF patients receiving chronic testosterone supplementation or placebo control, 
whereas other studies have reported increases in body mass and BMI in HF patients 
and other clinical groups receiving testosterone treatment (Caminiti et al, 2009, 
Johns et al, 2004, Johansen et al, 1999). Hansen et al, 1980 has linked testosterone 
supplementation with enhanced nor-adrenaline stimulated lipolysis. This is an 
important link because catecholamines are the main lipolysis regulating hormone in 
males and regulate adipocyte lipolysis through the activation of adenylate cyclase to 
produce cAMP. Protein kinase A activation by cAMP results in stimulation of
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hormone sensitive lipase and therefore facilitates accelerated lipolysis and increased 
breakdown of triglycerides to reduce subcutaneous fat (Arner , 2005). Additionally, 
plasma concentration of bio-available testosterone inversely correlates with 
abdominal adipose tissue lipoprotein lipase (Ramirez et al, 1997). This enzyme has 
been suggested to play a role in the pathogenesis of obesity as it resides on the extra­
cellular surface of adipocytes and hydrolyses circulating triglyceride rich 
lipoproteins to fatty acids which then become esterifide and stored as triglyceride 
(Eckel, 1989). Marin et al, 1995 showed that following prolonged testosterone 
supplementation, there was a marked decrease in lipoprotein lipase activity and 
hence significant reductions in triglyceride storage in abdominal subcutaneous 
adipose tissue. Additionally, it is widely appreciated that ET facilitates overall 
weight loss and it is possible that an increase in total energy expenditure during the 
study (i.e. two 60 minute, supervised exercise sessions per week) could facilitate 
enough calorific deficit to promote weight loss. Hence, the reductions in body mass 
and BMI that we observed may have resulted from significant alteration in the 
amount and function of the proteins / enzymes responsible for lipolysis or fatty acid 
breakdown or more simply by a decrease in body fat percentage associated with 
increased energy expenditure attributable to the supervised exercise sessions or free 
living physical activity (CHAMPS questionnaire data) but in the absence of body fat 
measures or biochemical analysis of subcutaneous adipose, this could not be 
verified.
No changes in circulating levels of NT pro-BNP or the inflammatory markers were 
observed in either group, except for a small decrease in TNF-a from baseline in the 
placebo group. Interestingly mean NT pro-BNP concentrations were elevated in both
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groups pre and post intervention. All patients entering onto this trial were clinically 
stable HF patients with no recent change in medication or increase in severity of 
disease classified by change in NYHA score. However, all patients in this study 
demonstrated significantly impaired LV EF% (mean 21.3 + 9.7% for the treatment 
group and 28.0 ± 6.0% for the placebo group), there was overall evidence of 
increased left ventricular end-diastolic volume (118.04 + 36.12 treatment versus 
131.64 + 32.67 placebo), and evidence of increased left atrial volume (72.18 ± 14.12 
mis treatment versus 69.59 ± 18.74mls placebo), diastolic E/e’ was borderline or 
normal and there was evidence of reduced longitudinal systolic velocities measured 
by TDI peak s’ wave. It is feasible that some of these parameters could contribute to 
an increase in NT pro-BNP. Importantly, Maeder et al, 2010 have noted that lower 
EF%, lower peak longitudinal s’ velocities and increased LV end-systolic wall stress 
are all important determinants of increased levels of NT pro-BNP. Furthermore, the 
same authors state that LV contractile dysfunction per-se is not representative of a 
mechanical load that could contribute to BNP gene expression and it is probable that 
LV end systolic wall stress is a more likely regulator of this. LV end systolic wall 
stress could not be determined accurately from the measurements obtained during 
this study as it requires more invasive cardiac assessment. However, reduced 
longitudinal velocities could play a role in the elevated values obtained. S’ is 
dependent on afterload and as such may represent structural abnormalities of the 
myocardium such as fibrosis (Borlaug et al, 2007). In particular, s’, in addition to 
NT pro-BNP, has been shown to independently predict mortality in community 
based studies (Mogelvang et al, 2009). The paracrine effects of BNP have been 
shown to inhibit myocardial fibrosis in a rodent model (Walther et al, 2003). 
Therefore a plausible theory for increased BNP expression in this study may be a
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physiological attempt to impair the fibrotic process in the presence of a reduced s’ 
velocity. As no direct markers of cardiac fibrosis were measured during this study, 
this theory can only be speculative and warrants further investigation.
Kim and Januzzi (2011) suggest applying caution to elevated NT pro-BNP levels. 
Although elevated levels are certainly important prognostic indicators of acute and 
/or deteriorating HF, other factors may contribute to increases in concentration. 
Pulmonary hypertension, valvular disease, atrial fibrillation, advancing age and renal 
dysfunction may all contribute to increasing NT pro-BNP levels. (Kim and Januzzi, 
2011). Pulmonary artery pressure and renal function were not measured during the 
course of this study so could not be commented upon. However, patients were 
excluded from analysis if there was presence of significant valve disease and only a 
minority of patients had documented persistent atrial fibrillation. It has been 
mentioned previously however, that this was a more elderly study population which 
may, in part, explain the elevation to NT pro-BNP. Other researchers have observed 
considerable (up to 30% co-efficient of variation) difference in NT pro-BNP in 
stable HF patients at yearly follow-up (Schou et al, 2007). This is further reinforced 
by Bruins et al, 2004 who noted significant within day, day to day and week to week 
coefficient of variability in NT pro-BNP measurements of 9, 20 and 35% 
respectively. As only pre and post samples were analysed, we are unable to comment 
on variation to levels as part of this study.
The lack of observed change in NT pro-BNP in the present study contradicts the 
findings of other studies investigating ET in HF. Previous work has demonstrated 
significant reductions in NT pro-BNP as a result of aerobic ET when compared to no
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training in a HF population (Giallauria et al, 2008, Passino et al, 2008). Previous 
studies have also provided evidence that aerobic ET can attenuate and/or improve 
adverse LV remodelling in HF (remodelling which can occur as a result of increased 
inflammatory markers such as TNF-a) (Giannuzzi et al, 1997, Haykowski et al, 
2007) whereas the evidence for changes following testosterone therapy is equivocal 
(Malkin et al, 2006, Caminiti et al, 2009). Aerobic ET has also been reported to 
reduce levels of TNF-a in HF patients (Larson et al, 2001, Adamopoulos et al, 2001) 
and there is evidence that testosterone therapy favourably affects serum levels of 
inflammatory markers in patients with established HF and hypogonadism (Malkin et 
al, 2004, Malkin et al, 2004). While the exercise and testosterone stimulus in the 
treatment group may have been insufficient to evoke changes in cardiac parameters 
and inflammatory markers, it is also likely that the study was underpowered for 
detecting changes in these outcomes.
In relation to no significant differences in inflammatory markers or NT pro-BNP in 
this study, there were no significant differences noted with respect to cardiac 
structure or function. In the current literature there are equivocal results regarding 
the effects of ET on central cardiac structure and function. Some studies have shown 
marked improvements in EF (Myers et al, 2002, Gianuzzi et al, 2003). Conversely, 
others have demonstrated no improvement and perhaps detriment to overall EF 
(Bellardinelli et al, 1995 and 1996, Klocek et al, 2005). ET has been shown to 
improve diastology via an increase in early filling rates and more favourable E:A 
ratio using mitral valve Doppler (Stolen et al, 2003, Cheuk-Man et al, 2004 ). In 
addition, testosterone supplementation has been shown to increase overall LV length 
(Malkin et al, 2006) but overall cardiac assessment in testosterone studies has been
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fairly limited. There is evidence in rodent models that testosterone supplementation 
can improve EF due to the marked reduction of circulating inflammatory markers 
responsible for cardiac apoptosis (Zhang et al, 2007), a finding not yet observed in 
human models or in those of the present study. The lack of significant change noted 
in this study may simply reflect an absence of synergy between testosterone therapy 
and cardiac parameters. However, the lack of change may also be reflected by a 
small sample size (under-powered) or perhaps an inadequate assessment of cardiac 
functional parameters in this study.
There are several limitations to the echocardiographic parameters used during this 
study for the assessment of LV systolic and diastolic function. For LV systolic 
function, clinical trial echocardiographic guidance suggests that measurement of LV 
ejection fraction based on LV volumes obtained by the method of discs should be 
performed (Gottdiener et al, 2004). This technique minimises but not eliminates the 
mathematical assumptions evident in other methods and also allows for corrections 
based on LV geometry. However, limitations arise when the apex is fore-shortened, 
the endocardium is inadequately viewed and there is limitation by reliance on only 
two LV planes. The literature quotes Biplane Simpsons EF reproducibility of ±7% 
(Himmelman et al, 1988) and test-re-test reliability of ±5% (Gottdiener et al, 1995). 
In this current study, we quoted a 9% measurement error in EF by the same operator 
on two different occasions. This error and the documented limitations in the 
literature may be a factor in the lack of statistical change noted in our results. 
Longitudinal velocity assessment using PW Doppler can also be limited by a number 
of factors. PW Doppler assessment of tissue movement is only able to provide 
information regarding a specific point of the myocardium determined by sample
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volume positioning, components perpendicular to the ultrasound beam remain 
unknown and there is significant angle dependency. TDI velocities may also be 
influenced by global heart motion, movement of adjacent structures and also blood 
flow (Mor-Avi et al, 2011). During this study we demonstrated good reproducibility 
of the TDI peak s’ velocities when measured on separate occasions (measurement 
error around 5%). Our TDI velocities were measured at end-expiration in order to 
reduce global heart motion. It is important to recognise the afore-mentioned 
limitations of the technique when evaluating these results. In order to improve 
accuracy and reliability in future studies more advanced 2D echocardiographic 
techniques can be utilised. For instance, more detailed information regarding cardiac 
deformation using speckle tracking echocardiography (unable to be performed in the 
present study due to limitations of equipment) and use of contrast agents to 
effectively assess LV endocardial borders can be undertaken to enhance the quality 
of data. Additionally, other techniques have been shown to provide more accurate 
assessment of LV volume and EF such as 3D echocardiography or cardiac MR. 
Future studies should attempt to use these techniques in sufficiently powered 
samples in order to more accurately address the issue of systolic function in this 
population.
In the present study, LV diastology was assessed using LA diameter, LA volume and 
TDI E/e’. In order to provide an improved assessment of LV diastolic function, more 
parameters can be assessed in any future work. Although guidelines for the 
assessment of diastolic function in clinical trials suggest using E/e’ as this parameter 
seems the least subject to inter/intra-observer variability (Gottdiener et al, 2004), 
more recent recommendations have suggested the use of additional parameters to
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increase the accuracy of results (Nagueh et al, 2009). For instance, more detailed 
assessment of LA function throughout the cardiac cycle due to its role in modulating 
ventricular filling through the reservoir, conduit and contractile properties, 
assessment of pulmonary artery systolic and diastolic pressures, more detailed 
assessment of MV inflow properties (e.g. isovolumetric relaxation time, E/A ratio, 
deceleration time as a minimum), assessment of pulmonary venous flow, analysis of 
flow propagation velocities and detailed deformation measurements of the LV - 
particularly the untwisting phase may have yielded further important information 
regarding diastolic function. Furthermore, in clinical trial participants with 
significantly impaired LV systolic function (EF% <40%), MV E:A ratio, 
isovolumetric relaxation time and MV deceleration time have been shown to provide 
an excellent indication of filling pressures (Gottdiener et al 2004). Assessment of 
diastolic parameters in this study is further compromised by a small proportion of 
patients in atrial fibrillation at time of echocardiographic examination (13% 
treatment and 15% placebo groups). Atrial fibrillation may cause artificial increases 
in LA volumes together with artificial remodelling of the LA independent of filling 
pressures, loss of atrial contractile properties and significant beat to beat variability 
in measurements obtained. In order to counteract this last point, all measurements in 
patients with atrial fibrillation were repeated over at least 5 cardiac cycles. Studies 
are needed on sufficiently modem echocardiographic devices to address these 
imaging limitations in order to provide more accurate and comprehensive assessment 
of diastole in this clinical population.
Early work conducted by Malkin et al (2006) has shown that testosterone acutely 
dilates resistance vessels in patients with HF, supported by the earlier research of
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Pugh et al, 2003. There was no change noted in FMD as an in direct marker of 
endothelial function in either group following the intervention in our study. Pugh et 
al, 2003 observed that testosterone therapy acutely reduces peripheral vascular 
resistance in males with stable HF. Additionally, ET has also been shown to 
improve the vasodilatory properties of resistance vessels by evoking changes in 
endothelial function together with LV pre and afterload (Gokce et al, 2002, Walsh et 
al, 2003, Hambrecht et al, 2003). Research investigating the effects of ET in HF has 
also shown beneficial improvements in flow mediated dilatation response (Gokce et 
al, 2002, Walsh et al, 2003) particularly in the arterial territory of frequently 
exercised muscles. FMD assessment using ultrasonography during this study 
demonstrated poor reproducibility and this together with a likely underpowered 
population may explain the lack of significant change in parameters of 
cardiovascular structure and function.
Atrial fibrillation has been shown to impair vascular responsiveness to vascular shear 
stress and the loss of cyclic stretch of atrial endocardial cells (the atria being an 
important endocrine organ in the modulation of vascular function) may result in 
attenuated expression of nitric oxide synthase by the increased atrial production of 
superoxide and resultant oxidative injury from disorganised atrial cell contraction 
(Guazzi et al, 2006). In fact, restoration of sinus rhythm has been shown to improve 
endothelail function in patients with lone AF and also partially in patients with AF 
and other co-morbidities such as hypertension and diabetes (Geneveley and Pfeffer, 
1988). A minority of patients in the present study had atrial Fibrillation at time of 
FMD assessment. However, a greater number of patients in both groups had a 
significant past history of paroxysmal AF and this coupled with evidence of
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increased left atrial volumes may contribute to the lack of differences observed both 
within and between groups.
Improvements from baseline were observed in several SF-36v2 domains for 
treatment group together with reductions in BDI and ADAM scores. However, 
significant between group effects were only observed for the SF-36v2 domains of 
bodily pain and vitality in favour of the placebo group. In placebo, there was also an 
increase from baseline in the physical functioning domain of the SF-36v2 but no 
change in BDI or ADAM scores. Importantly, many facets examined within the 
ADAM questionnaire overlap significantly with the clinical symptoms of HF, (e.g. 
reduced libido, lack of energy, decreased strength and / or endurance, depressive 
symptoms, tiredness and lack of concentration). This may partially explain the lack 
of observed difference in ADAM score between groups, and as such, suggests that 
this questionnaire may not be as effaceable in the setting of testosterone deficiency 
and HF. Aerobic exercise has previously been shown to evoke improvements in total 
SF-36 score (Smart et al, 2007, Miche et al, 2009) and Minnesota Living with Heart 
Failure Questionnaire score (Smart et al, 2007, Tyni-Lynn et al, 1998, Jankowska et 
al, 2008) in male HF patients, though superior changes have been reported after 
high-intensity interval exercise (Nilsson et al, 2008, Wisloff et al, 2007). Evidence 
for the effect of exercise training on depression scores is equivocal, with 
improvements in younger patients (Smart et al, 2007) and no change in older patients 
(Miche et al, 2009) being previously reported. Furthermore, testosterone therapy has 
been shown to improve New York Heart Association HF classification, without 
changing depression index or HF symptom score (Malkin et al, 2006). Our results
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suggest that testosterone supplementation might augment the health benefits of 
exercise in terms of depression and androgen deficiency symptoms in male HF 
patients with low testosterone status. However, the treatment group had greater 
perceived health impediments (as evidenced by the MLHFQ scores) and higher 
depression scores at baseline. As the effects of exercise on these health outcomes 
might be more pronounced in patients with lower initial perceived health status and 
there is considerable overlap of ADAM and MLHFQ symptoms, the true impact of 
testosterone therapy during exercise rehabilitation needs to be confirmed in larger- 
scale randomized controlled trials.
This is the first study to provide a qualitative evaluation of exercise training in 
elderly male HF patients with low testosterone status. Seven emergent themes 
emerged from the qualitative data analysis, namely confidence to continue exercising 
in the future, role in giving advice to patient’s with similar conditions, perceptions 
about the exercise intervention, perceived roles of medical professionals, motivation 
during the trial, negative effects and perceived health benefits.
Confidence to continue exercising following the intervention was an emergent theme 
with both positive and negative considerations. Exercise that can be undertaken 
within the patients’ own home was considered important. Participants were less keen 
to attend public exercise facilities and the knowledge gained on how to exercise 
safely and intensely in their own environment was important to them. In relation to 
this point, other participants suggested that without the motivation of a ‘strict’ 
appointment time as part of a supervised research study, they may soon return back
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to their old lifestyle despite the noticeable improvements brought about by ET. 
Previous research has identified significant improvements in physiological function 
and quality of life with home-based exercise programmes in cardiac patients (Chien 
et al, 2008, De Mello-Franco et al, 2006). However, scientific literature has shown 
that adherence to home based ET is not comparable to supervised programmes, with 
reported 60-70% adherence initially, declining consistently throughout the 
intervention period (Hambrecht et al, 2000). Reduced adherence associated with 
home-based ET may result in smaller training effects and hence, less noticeable 
improvements in quality of life when compared to supervised ET (Chien et al, 2008).
Patients indicated that they could play an important role in health promotion by 
encouraging the use of exercise training to patients with HF. They were keen to 
suggest that the health service could utilise their knowledge to help educate other 
patients on the benefits of ET in HF. Research using HF patients as a source of 
education to peers is sparse. However, one study has suggested that group education 
by peers can produce a positive effect on coping, confidence, outlook and spousal 
relationships in a HF population (Stewart et al, 2001). The main drivers to 
improvement were described as patient input, co-facilitation, similarity of group 
members and the provision of information and support.
Perceptions of the exercise intervention were mainly centred on how it could be 
improved by increasing the variety of exercise equipment, the addition of lifestyle 
advice (education sessions), increasing the intensity of the sessions and progression 
onto other ET programmes at the end of the intervention period. Patients exercised at 
pre-determined intensities as part of an aerobic interval training programme (Wisloff
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et al, 2007) and had limited choice of exercise intensity or modality. Lifestyle advice 
has become an integral feature of ET in cardiac rehabilitation (Blue et al, 2005) and 
has been shown to improve patient outcome in HF patients (Me Allister et al, 2004), 
Hence, a more challenging exercise programme, incorporating lifestyle advice, a 
broader range of exercise training modalities, and a clear plan for self-directed 
exercise at the end of the period of supervision would have been more attuned to the 
specific needs of our patient cohort.
Patients observed that other medical professionals were vital in educating patients 
about the benefits of ET and testosterone therapy. However, there were varied 
opinions regarding the ability of medical professionals to perform this role. 
Specialist HF nurses are now employed in most major cardiac centres and their role 
is to co-ordinate a multi-disciplinary team of medical professionals to care for 
patients in and outside of the hospital setting. The role of HF nurses is to evaluate the 
learning needs of patients, assess how best to provide the information and under 
what timescales. In addition, HF nurses have the skills and motivation to provide 
individualised, evidence-based education to HF patients (Blue et al, 2005). 
Additional educational resources such as books, leaflets, videos, web-pages, 
computer packages have also been used successfully in patient education, 
particularly when combined with tele-monitoring of patient progress (Louis et al 
2003). Despite this, qualitative perceptions from our cohort of elderly males with 
low testosterone status suggest that more could be done to promote the benefits of 
exercise and provide structures to facilitate engagement.
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Key motivational factors for adherence to the programme were the perceived 
increases in strength and endurance, together with a description of significant weight 
loss. Scientific literature supports the use of ET and testosterone therapy for 
increasing muscular strength and endurance in HF patients (Pugh et al, 2004, 
Caminiti et al 2009, Jankowska et al 2008, Malkin et al 2006), and our results 
suggest that reinforcing these health benefits to patients could be important for 
continued participation. Social support was also important to programme adherence. 
The main support network comprised family members, other participants and health 
professionals involved in the research study. This support network has been 
described in the scientific literature. It has been shown previously that quantity of 
contact and social support from researchers, health professionals and fellow exercise 
participants during an intervention influences the impact that the intervention has on 
functional and psychological quality of life dimensions and adherence (Burke et al, 
2006). Furthermore, intention to engage in physical activity, self-efficacy for 
physical activity and magnitude of the health effects experienced from engraining in 
a physically active lifestyle are all associated with the level of support from 
important others and family (Carron et al, 1996).
Many of the patients had not previously undertaken regular physical activity. 
Negative physical side effects were an emergent theme, however, no side effects 
were considered serious adverse events and most were related to muscle soreness 
following strength training. Tiredness was also a factor in patients that were 
combining exercise sessions with a full working week. Previous research in an 
elderly HF population supports our finding that high intensity aerobic interval 
training (Wisloff et al 2007) and supervised strength training (Radzewitz et al, 2002)
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can be safely implemented in HF patients without observing serious adverse events. 
However, HF symptoms such as tiredness can be a main determinant of drop-out 
from ET training interventions (Piepoli et al, 2011). Future research should be 
mindful of the potential for negative health effects and include strategies to address 
them.
Patients experienced health benefits from their engagement with the intervention, 
consistent with previous studies (Pugh et al, 2004, Caminiti et al 2009, Jankowska et 
al 2008, Malkin et al 2006). Perceived improvements in endurance capacity, 
muscular strength, weight loss and overall quality of life were important, as they 
enabled patients to increase their daily activities and consider health club 
membership. Many studies have shown that regular ET in HF results in significant 
gains in aerobic exercise capacity (Flynn et al, 2009, McKelvie et al, 2002, 
Hambrecht et al, 2000, Wisloff et al, 2007), local muscular performance (Smart et al, 
2007, Flynn et al 2009) and quality of life (Jankowska et al, 2008, Larsen et al, 2001, 
Wisloff et al, 2007, Radzewitz et al, 2002). Our results show that ET is a valuable 
therapeutic tool to increase confidence, physical activity levels and important health 
outcomes in HF patients with low testosterone status. Furthermore, patient 
perceptions of improved health status appear to be an important motivational factor 
for continued participation in ET
Analysis of the focus groups should be interpreted in the context of some limitations. 
The views expressed are from 24 males with HF and testosterone deficiency who 
consented to be randomised into a clinical trial. Therefore, these views may not be 
representative of all males with HF and low testosterone status and cannot be
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extrapolated to female HF patients. As low testosterone status is prevalent in up to 
25% of elderly male HF patients, more research aimed at investigating adherence, 
attrition, motivational characteristics and changes key health outcomes resulting 
from programmes of ET is warranted. Finally, 12 weeks may be considered a 
relatively short duration for a therapeutic interventions and more valuable insights 
may be gained from interventions of longer duration.
In summary, this randomized controlled double-blind feasibility trial showed that 
testosterone therapy during a program of exercise rehabilitation is feasible in elderly 
HF patients with low testosterone status. We also showed that elderly male HF 
patients with low testosterone status can tolerate high-intensity aerobic interval 
training and our data show that these patients can experience physiological benefits 
from participation. Additionally, testosterone supplementation induced some 
improvements in aerobic fitness, leg strength, depression and SF-36v2 quality of life 
domains that were not observed in the placebo group. While being mindful of the 
challenges encountered during recruitment and the observed level of attrition, some 
of our preliminary results provide a solid foundation for a larger-scale, multi-centred 
randomized controlled trial.
Qualitatively, ET is well tolerated and induces important perceived health benefits in 
elderly male HF patients with low testosterone status. Perceived health benefits were 
associated with the social experience of exercising with other participants and 
noticeable improvements in functional capacity and/or weight loss. Social support 
and the health benefits gained were important motivating factors for adherence to the 
ET programme. Knowledge gained on the safety of exercising with HF enabled
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some patients to become more physically active in their home environment. 
However, there were some concerns that adherence to ET may decline in the future 
due to a lack of provision following the intervention. Future interventions for this 
patient group should be designed to optimise adherence and long-term participation 
in ET, giving consideration to the variety of exercise modalities available, the 
addition of lifestyle advice and education materials and the provision of similar ET 
programmes in the community supported by qualified exercise instructors.
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Chapter 6: Feasibility and power calculation for phase II efficacy trial.
For scientific rigour and ethical considerations, the sample size for a phase II 
efficacy or phase III trial needs to be carefully considered, striking a balance 
between both clinical and statistical factors. Phase II efficacy and III RCTs should be 
based on clinically important changes in key health outcomes, whilst being mindful 
of patient attrition data that has been observed in a previously executed phase II trial 
(Altman et al, 2001). Key prognostic outcomes for HF patients with low testosterone
status are exercise capacity as assessed by the ISWT and peak oxygen uptake ( v ° 2 ) 
(Malkin et al, 2006, Caminiti et al, 2009, Jankowska et al, 2009). Based on the
outcomes for ISWT and peak v ° 2  in this study, the following can be calculated:
From the 12 weeks intervention, the data distribution for changes in shuttle walk 
performance was skewed. As a result, natural logarithm transformation was 
performed. Following transformation, change ratios were obtained. The log 
transformed change ratio for each group was 0.152 for testosterone treated and 0.166 
for placebo corresponding to percentage increases of 16 and 18% from pre to post. 
The common log transformed SD for change was 0.197. Consequently, the required 
phase III RCT sample size is estimated at 1890 participants per group. Given a 30% 
dropout rate in the present study over the course of the intervention, this would 
therefore require a cohort of 4914 (2457 in each group) patients in order to detect 
significance at a level of 0.05 with 80% power.
The changes noted following the intervention in peak ^ 2  were 3.19 for treatment 
and 1.79 for placebo, a difference of 1.4. The common standard deviation for change
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was 3.45. Therefore, the required phase III RCT sample size is estimated at 97 
participants per group. Given a 30% dropout rate in the present study over the course 
of the intervention, this would therefore require a cohort of 252 (126 in each group) 
patients in order to detect significance at a level of 0.05 with 80% power.
These sample size calculations are based on clinically important changes in the key 
health outcomes (Malkin et al, 2006, Caminiti et al, 2009 and Jankowska et al, 2009) 
taken from data presented in the current study. Given that the primary outcome 
measure (ISWT) calculation suggests a sample of 4914, a multi-centre phase III trial 
approach is perhaps the best way to ensure adequate patient recruitment for such a 
trial. Given that recruitment is difficult to such a trial and also the requirement of a
large cohort it is advisable that any future trials should be powered to use peak v ° 2  
as a primary outcome measure in replacement of ISWT. It could also be argued that
utilising peak V (^ 2  as a primary outcome measure is potentially suitable for a single­
centre trial dependent upon the size of the individual heart failure service.
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Chapter 7: Summary and future research.
Study 2 was designed to build upon previous research that has demonstrated reduced 
exercise capacity and worse prognosis in HF with testosterone deficiency and also 
research suggesting the positive effects of ET (Jette et al, 1991, Coats et al, 1992, 
Smart et al, 2007) and testosterone supplemenation (Malkin et al, 2004 and 2006) in 
HF. The aim of the study was to assess the feasibility of a combined ET and 
testosterone therapy intervention for the first time in males with low testosterone and 
stable HF. In addition, the rationale for the study is further underpinned by study 1 
which details for the first time significant differences in exercise capacity and quality 
of life in males with HF and low versus normal testosterone values.
For feasibility research, the principle findings must relate to recruitment and study 
design as well as any observed changes in the outcome measures assessed. The 
major findings of the study indicated that recruitment to such trials is difficult. This 
is probably due to the nature of the population sampled rather than related to the 
intervention itself. Patients with HF often have numerous co-morbidities which may 
prevent them from exercising, together with the psychological notion that HF may 
not allow sufficient tolerance to exercise interventions. As testosterone levels decline 
with age, it follows that many of the eligible participants are elderly. As such, it also 
follows that an elderly population will have numerous co-morbidities that prevent 
them from exercising adequately. Committment to prolonged interventions is also an 
issue with older participants unwilling to travel to the research centre and younger 
participants unable to attend due to work commitments. Although recruitment was 
difficult, all patients who completed the intervention attended every ET session and
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there was 100% compliance to the IM testosterone injections. This demonstrates that 
a flexible approach to such an intervention by the investigators is key to ensuring 
that patients maintain compliance throughout such an intervention.
Testosterone therapy together with ET resulted in significant improvements in peak
v ° 2  and leg strength following the intervention when compared to baseline values. 
These changes were not observed in the EP group. In addition, testosterone treatment 
also resulted in improvements in many SF36 domains, reduced depression scores 
and reduced androgen deprivation scores which were not observed in the EP group. 
Both groups demonstrated similar improvements to peak power output during cycle 
ergometry, ISWT distance and reductions to BMI.
It can be concluded that ET and testosterone replacement therapy in HF patients is 
feasible and safe. The observed improvements in the treatment group not apparent in 
the EP group provide a solid foundation for future research. The planning of future 
trials should take into account the difficulties in recruitment, patient perception of 
this intervention and also the required power to obtain statistically meaningful 
results.
Further research should aim to clarify if ET and testosterone replacement therapy can 
provide significant benefits over placebo in the same population and this can be 
achieved from the foundation work of this feasibility trial. Furthermore, these studies 
should aim to address the physiological basis behind observed improvements in
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exercise capacity and muscular strength using more detailed physiological testing 
which demonstrates good reproducibility in this population. Longer duration studies 
using a variety of testosterone preparations should also be undertaken in order to 
fully comprehend the best mode of administration and to determine the safety of 
long-term physiological testosterone replacement.
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Chapter 8: Overall thesis summary and conclusions.
This chapter provides a summary and conclusions for the thesis as a whole and, for 
the purposes of clarity, is sub-divided into the following sections: overview of 
findings and contribution to knowledge; testosterone and HF / combined ET and 
testosterone therapy - take-home messages; and, implications for clinical practice.
8.1: Overview and contribution to knowledge.
Section 1 of this thesis was designed to ascertain for the first time if there are 
significant differences in exercise capacity, quality of life and detailed indices of 
cardiac structure and function in male HF patients with low and normal range 
testosterone. Previously, two small studies have used correlation and regression
models to identify relationships between peak right and left ventricular
function and total testosterone level (Bocchi et al, 2008 and Jankowska et al, 2009). 
This study aimed to build upon this initial research with a more robust study design 
and integration of more detailed aspects of quality of life and cardiac structure and 
function, together with a more accurate definition of hypogonadism using free and 
bio-available testosterone. The results of this study indicated that indeed there was 
significantly improved exercise capacity together with significantly improved 
physical and mental quality of life scores in males with HF and normal testosterone 
when compared to males with HF and low testosterone status. No change was noted 
in detailed echocardiographic assessment of cardiac function, which may be due to 
an under-powered design, but may also suggest that the mechanisms for improved 
exercise capacity in patients with normal testosterone concentration and HF may be
427
at the levels of the vasculature and / or skeletal muscle. Future research should build 
upon this notion and provide a more detailed insight into these mechanisms.
Section 2 of this thesis was designed to build upon the notions that testosterone 
deficiency is an important determinant of poorer outcome in HF and also the 
previous contradictory research investigating the effects of testosterone 
supplementation in males with testosterone deficiency and HF. The purpose of this 
study was to assess the feasibility of a combined exercise training and testosterone 
supplementation intervention on more detailed physiological and psychological 
outcomes than had previously been published in males with low testosterone and HF. 
This feasibility study was designed as a double-blind placebo controlled RCT with 
participants randomised to treatment or placebo. Importantly, high intensity interval 
ET and combined testosterone therapy was found to be safe in this patient group with 
no serious adverse events documented. Recruitment to the trial was challenging and 
together with a high attrition rate (although concordant to other research in a similar 
population) this must be considered when planning further research in this area. 
Testosterone therapy together with ET resulted in significant improvements in peak
v < ^ 2  and leg strength following the intervention when compared to baseline values. 
These changes were not observed in the placebo group but were not statistically 
significant between the groups. In addition, supplementation together with exercise 
also resulted in improvements in many SF36 domains, reduced depression scores 
and reduced androgen deprivation scores which were not observed in the placebo 
group. Both groups demonstrated similar improvements to peak power output during 
cycle ergometry, ISWT distance and reductions to BMI. The main outcome data was 
used in a power calculation to inform future phase II or III RCT’s and focus groups 
were performed in order to provide a detailed patient focussed insight into the future
design of such trials. As a result of this, any future trials should be ideally be multi- 
centre or have access to a large heart failure patient cohort and also bear in mind the 
difficulties experienced during recruitment.
8.2: Testosterone status and HF -  take home message.
Testosterone deficiency in HF appears to result in reduced exercise capacity as 
assessed by the 6 min walk test together with worse indices of quality of life both 
physical and mental as assessed by the SF36 Version 2 questionnaire. These 
reductions are independent of other important confounding variables such as age, 
NYHA score, NT-pro BNP, EF and BMI. Ultimately, as diminished exercise 
capacity and poor quality of life in HF are markers of poor prognosis, strategies to 
improve these should be investigated. The value of serelogical testosterone screening 
in HF needs to be established using economic evaluations and using data from large 
RCT’s of supplementation in HF in order to ascertain if testosterone screening and 
physiological replacement has a role in routine clinical care. This topic will become 
more pertinent with a continually ageing population, increased treatment costs and 
the scarcity of transplanted organs.
8.3: Combined ET and TS -  take home message.
Combined testosterone therapy and ET is safe and feasible in males with HF and low 
testosterone. However, recruitment to such trials is challenging due to co-morbidities 
associated with both HF and an ageing population. Testosterone treatment and 
exercise training result in improvements to important prognostic markers in HF
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which are not apparent in the ET and placebo group. In addition, high intensity 
interval training in HF can be deemed safe, resulting in a shift from traditional 
viewpoints. Qualitative focus group data suggests that patients benefit from such 
interventions and encourage their promotion in a clinical environment. However, 
power calculation and attrition data suggest that future phase III RCT’s must be 
multi-centre in order to achieve the required data in order to inform meaningful 
clinical decisions. Further trials are mandatory if testosterone sampling and 
physiological replacement are to become part of the clinical treatment regimen in 
eligible male HF patients.
8.4: Implications for clinical practise.
Clinicians must realise that testosterone deficiency, particularly in elderly HF male 
patients, but also in the younger population, can significantly augment the 
pathological processes of HF. This includes further reductions in exercise capacity 
and significantly attenuated general health related quality of life indices. As a result 
of this, there is an important clinical question to ask. Do clinicians need to routinely 
sample for testosterone deficiency in their HF patients? I believe that this question 
remains partly unanswered. Most evidence now points to worse outcome in 
testosterone deficient patients and of the small number of studies performed there is 
some observed benefits to physiological testosterone supplementation. However, 
with regard to screening cost and implications arising when testosterone deficiency 
is detected, it is prudent that much larger research trials assessing the effect of 
supplementation must be performed. Only when sufficiently powered and suitable 
length trials are performed can the safety, physiological and psychological benefits
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together with wise economic analysis of supplementation be sufficiently explored to 
inform future therapeutic treatment with testosterone. The research performed as part 
of this thesis reinforces the clinical concepts that exercise training is safe in HF and 
should be promoted as part of routine clinical care. I believe this information is now 
widely accepted in current clinical practise. However, traditionally exercise training 
has been performed at lower intensities in HF. It seems that higher intensity interval 
training can provide added physiological and psychological benefits and can be 
deemed safe in moderate to severe HF. As treatment costs rise in the NHS and the 
burden of HF and testosterone deficiency increases in line with with an ageing 
population, combined treatment strategies as promoted by this thesis should be 
investigated in order to provide augmentation to currently accepted treatment 
methods.
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Where the only involvement of the NHS organisation is as a Participant Identification Centre (PIC), 
management permission for research is not required but the R&D office should be notified of the 
study and agree to the organisation’s involvement. Guidance on procedures for PICs is available in 
IR A S .  Further advice should be sought from the R&D office where necessary.
Sponsors are not required to notify the Committee of approvals from host organisations.
Additional conditions
a. The following revisions are required to the Information Sheet:
i. Under the heading 'Visit (approximately 60 minutes duration)’, at points 3 & 4 reference 
has been made to 'your recovery', this should be replaced with 'whilst resting’ e.g. ‘This 
test will last no more than 15 minutes in total and you will be monitored whilst resting.*/ 
Point 4 should begin with 'Whilst resting you will be asked to complete....’ S
ii. Under the heading What are the possible results from measurements taken?’, at point 4, 
insert the word 'are’ between ‘inflammation’ and ‘caused’ so that it reads '...level of 
inflammation are caused by your heart failure.’ \ /
iii.
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Membership of the Committee
The members of the Ethics Committee present at the meeting are listed on the attached sheet. 
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees (July 2001} and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK.
After ethical review
Now that you have completed the application process please visit the National Research Ethics 
Service website > After Review
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views known 
please use the feedback form available on the website.
The attached document “After ethical review -  guidance for researchers” gives detailed guidance 
on reporting requirements for studies with a favourable opinion, including:
• Notifying substantial amendments
• Adding new sites and investigators
• Progress and safety reports
• Notifying the end of the study
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referenceQroup@nres.npsa.nhs.uk.
111/NW/0058 Please quote this number on all correspondence
With the Committee’s best wishes for the success of this project 
Yours sinc*sral'/
f c .9 ^
Mr Francis Chan
Chair
Email: elaine.hutchings@northwest.nhs.uk
Enclosures: List of names and professions of members present at the meeting. 
“After ethical review -  guidance for researchers"
Andrew Maines, R&D, University Hospital South Manchester.Copy to:
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N o rth  W e s t  8  R e s e a r c h  E th ic s  C o m m it te e  -  G r e a t e r  M a n c h e s te r  E a s t
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W y th e n s h a w e  H o sp ita l
S o u th m o o r  R o a d
M a n c h e s te r
M 23  9L T
D e a r  M r S to u t
F u ll  t i t le  o f  s t u d y :  T h e  E f fe c t  o f  T e s to s te r o n e  S t a tu s  o n  E x e r c is e  C a p a c ity ,
M u s c u la r  S t r e n g th  a n d  Q u a lity  o f  L ife  in  M a le s  w ith  
C h r o n ic  H e a r t  F a i lu re .
R E C  r e f e r e n c e  n u m b e r :  1 1 /N W /0058
T h a n k  y o u  fo r y o u r  le tte r  o f 10 M atch  2 0 1 1 .1 c a n  confirm  th e  R E C  h a s  re c e iv e d  th e  
d o c u m e n ts  lis te d  b e lo w  a s  e v id e n c e  o f c o m p lian c e  with th e  ap p ro v a l c o n d itio n s  d e ta i le d  in 
o u r  le t te r  d a te d  2 2  F e b ru a ry  2 0 1 1 . P le a s e  n o te  th e s e  d o c u m e n ts  a r e  fo r in fo rm ation  on ly  
a n d  h a v e  n o t b e e n  re v ie w e d  by th e  co m m itte e . ,
D o c u m e n t s  r e c e iv e d
T h e  d o c u m e n ts  re c e iv e d  w e re  a s  follow s:
Document Version Date
Covering Letter
Questionnaire: SF-36 v2
Participant Information Sheet 2 07 March 2011
Participant Consent Form 2 07 March 2011
Questionnaire: Beck Depression Inventory
Questionnaire; Minnesota Living with Heart Failure
Questionnaire: ADAM Questionnaire
Y o u  sh o u ld  e n s u r e  th a t  th e  s p o n s o r  h a s  a  c o p y  o f  th e  final d o c u m e n ta tio n  fo r th e  s tu d y . It 
is  th e  s p o n s o r 's  re sp o n sib ility  to  e n s u r e  th a t  th e  d o c u m e n ta t io n  is m a d e  av a ilab le  to  R&D 
o ff ic e s  a t  all p a r tic ip a tin g  s i te s .
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University Hospital of South Manchester Witt
NHS Foundation Trust
Research & Development Directorate 
Ground Floor. E&esttao & Research Cteao 
Td.0161 291 5768 Fw: 0161 2915771
J^rsfe.bo^g^Tnendbester.acuk
Wythenshcwe Hospital 
South moor Rood 
Wythcmhcwo 
Manchester 
M23 917
M -0161 998 7070
Mr Martin Stout
Advanced Specialist Cardiac Physiologist
Cardiology Department
Wythenshawe Hospital
Souihmoor Road
Manchester
M23 9LT
6* May 2011
Dear Mr Stout,
Study Title: The effect of testosterone status on exercise capacity, muscular 
strength and quality of life in males with chronic heart failure.
R&D Reft 2MICD00I
REC Ref: 11/NW/0Q58
Thank you for providing us with all of the documentation for the above mentioned 
research project
This research project has row been given R&D Management Approval.
1 have enclosed some labels for you to affix to any Trust hospital case notes used in 
your research proves.
This is a requirement o f the Trust Case Note Destruction Policy. These labels will 
ensure that case rotes used for research projects, which involve the treatment of 
patients, are kept for the required number of years. You will need to define the ‘do not 
destroy before' date, according to the minimum term defined in the ethical approval, 
please rote this will vary for different types of studies.
It is your responsibility to ensure that these labels arc affixed on the BACK INSIDE 
COVER of each case note. We will provide you with additional labels; please contact 
us when you require them.
You ore also required to document patient participation in a clinical trial on the alert 
page at the front of the patient case notes, and to place any supporting documentation 
behind this page.
Chairman - Fefidiy Good ay, CBS. 01 
Chief Emotive • Julian Mart ley. UK MBA Your Hospital
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Please note it is a requirement of the approval given by the Trust that the research 
project is being conducted in line with the guidance given within the Research 
Governance Framework as issued by the DH: (from the R&D website 
www.researchdirectorate.org.uk click on the link ‘Carrying out research’).
May I also draw to your attention the need to comply with the Health & Safety at 
Work Act, the Data Protection Act and the Human Tissue Act 2004.
I would also be grateful if you could supply us with copies of any substantial 
amendments submitted to the REC throughout the course of the study, along with a 
copy of the REC end of study report when it has been completed.
Thank you for your assistance. If you require any further information please do not 
hesitate to contact us on the above numbers.
Yours sincerely
Jennifer Boyle
Research Governance Co-ordinator
University Hospital of South Manchester NHS Foundation Trust
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Appendix 2. Patient Information leaflet for study 1.
University Hospital of South Manchester WJsM
NHS Foundation Trust
PARTICIPANT INFORMATION SHEET
Study name: The Effects of Testosterone Status on Exercise Capacity, 
Muscular Strength and Quality of Life in Male Patients with Chronic
Heart Failure.
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if you wish. Please 
ask us if there is anything that is not clear, or if you would like more information.
In Brief:
This study will build on work already completed as part of another project and will involve 
the collection of a blood sample to determine testosterone level. This study will collect data on 
male heart failure patients with normal and low testosterone and assess their walking ability, 
strength and quality of life. This data will then be compared to see if there are any significant 
differences between the two groups.
What is the purpose of the study?
The main purpose of this study is to see if males with heart failure and low testosterone level have 
lower levels of functional capacity, muscular strength and quality of life when compared to heart 
failure patients with normal testosterone.
Previous research work has already been completed which has suggested positive effects of 
testosterone replacement therapy in males with heart failure and low testosterone levels. This 
work has showed improved exercise performance, strength parameters, quality of life and in some 
cases, improved heart function. To date, there is no conclusive research that has shown that in 
male heart failure patients low testosterone level adversely effects these measurements.
Why have I  been chosen?
You have been chosen to take part in this research because you have been diagnosed with heart 
failure and are male.
Do I have to take part?
It is up to you to decide whether or not to take part, although the study is designed to cause 
minimal inconvenience to you. If you decide to take part, you are free to withdraw consent at any 
time without giving a reason. This would not affect the standard of care you receive. If you decide 
that you no longer wish to continue with the study, we would like to retain any data already 
obtained about you, unless you request otherwise.
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What will happen to me if I agree to take part?
In this study you will take part in one research visit whereby we will collect information about your 
physical fitness, strength, quality of life (using questionnaires) and level of inflammation within the 
body (using a blood sample).
Will my travel expenses be paid?
We will be unable to make payments regarding travel expenses as this study aims to complete 
data whilst you are here for your regular clinic appointment. However, if extra visits are required or 
contributions need to be made toward parking expenses in extended visits, extra expenses 
incurred will be made available.
Visit (approximately 60 minutes duration)
We will make an appointment for you at the Heart Failure Clinic.
If you are eligible and willing to participate in the study:
1. You will be assessed by your Consultant’s medical team as part of the normal work-up of 
your clinic appointment. During this assessment an additional tube of blood and a saliva 
sample will be collected and sent for analysis of testosterone level.
2. If you are asked to take part (based on your testosterone level) we will perform an 
ultrasound scan of your heart (an “echocardiogram” or “echo”). This is a safe and painless 
procedure that takes approximately 20-30 minutes. You will be asked to lie on a couch on 
your left side. A “probe” is placed on your chest and lubricating jelly is used to make good 
contact with the skin. Ultrasound waves then create images of your heart on the scanner 
monitor and we are able to look at the overall structure and function of your heart, including 
the valves.
3. Following this we will ask you to complete a shuttle walking test. As part of this test you will 
be asked to walk back and forth over a 10 m course for 6 mins, as fast as is physically 
possible. We will record your maximum walking distance together with your monitored 
heart rates and perceived effort. This test will last no more than 15 minutes in total and you 
will be monitored whilst resting following test completion.
4. Whilst resting you will be asked to complete some questionnaires that assess your quality 
of life and the effect of heart failure on your ability to complete daily activities. This should 
take approximately 10 minutes.
5. Finally, you will be asked to complete a short test of fore-arm strength by gripping a hand 
strength test machine tightly. You will be asked to do 3 tests on your left and right hands. 
This will last for about 5 minutes in total.
What are the possible results from measurements taken?
The results of this study will give us information regarding the following health parameters:
1. Details of how well your heart is pumping. We will use modern techniques to assess (in- 
depth) the function of your heart during the echocardiogram.
2. We will gain information as to your endurance capacity and an approximation of how strong 
you are. This information is important in heart failure as these levels are usually reduced 
and impact on quality of life.
3. The questionnaires will help us find out about your general health, how well you can cope 
with different activities in your daily life and if you have increased levels of depression.
4. Blood tests will help us determine if your testosterone level and level of inflammation are 
caused by your heart failure.
Are there any possible risks from taking part?
Possible risks include discomfort due to the blood and walking tests. Tiredness is also common 
after completing the walking test and you will be closely monitored during the clinic visit and also 
will be re-assessed before you are asked to leave the department. Ultrasound is painless and has 
been shown to be a safe procedure with no side effects known.
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What are the possible benefits?
The major benefit of this study is that your participation may help highlight that testosterone level is 
an important factor in male patients with heart failure. It is possible that lower levels of testosterone 
result in increased symptoms and therefore poorer quality of life. Research has already shown 
some positive effects of testosterone replacement therapy in male heart failure patients and this 
study will contribute to that data. Ultimately, this research may help initiate the use of testosterone 
supplementation as a therapeutic treatment in the male heart failure population.
What happens when the research study stops?
When this study is completed it will be written up and used as part of a PhD thesis. Additionally, it 
will be published in respected medical journals and presented at important meetings. It is hoped 
that this study will help raise awareness of the importance of testosterone status in heart failure.
Will my taking part in the study be kept confidential?
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. No personal data will be published at any time and your confidentiality is of the utmost 
importance to us. Data will be held in secure databases to which only authorised people will have 
access.
If the information in Part 1 has interested you and you are considering participation, please read 
the additional information in Part 2 before making any decision.
PART 2
What will happen if I don’t want to carry on with the study?
You are free to withdraw from the study at any time. If you wish, we can then just make use of the 
information we already have about you. Alternatively, we can ensure if your samples and 
information are used for future research it is entirely anonymously, or we can destroy any 
identifiable samples or information we hold about you.
What if something goes wrong or I have a complaint?
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions (contact Martin Stout on 0161 291 4632). If you 
wish to complain formally, you can do this through the NHS Complaints Procedure. In the event 
that something does go wrong and you are harmed during the research and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation against 
South Manchester Universities NHS Trust, but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to you (if appropriate). 
Compensation for any injury caused by taking part in this study will be in accordance with NHS 
indemnity.
What will happen to the data collected in this study?
If you take part in the study, this will be indicated on your medical records. Some parts of your 
medical records and the data collected from the study would be looked at by authorised persons to 
check that the study is being carried out correctly. They may also be looked at by authorised
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persons from the NHS Trust. All investigators have a duty of confidentiality to you as a research 
participant and nothing that could reveal your identity would be disclosed outside the research 
sites.
Participation in future research
If you consent to be approached for involvement in future research, we will store your contact 
details separately from research data you have provided. Both your details and data will carry the 
same ID which can “link up” your details to your data. In this way we can identify research relevant 
to your particular healthcare status, and approach you appropriately. You can withdraw your 
consent to be contacted in the future at any time.
What will happen to the results of the research study?
We anticipate that the results will be published in a scientific journal for the benefit of the wider 
medical community. However, individual patients will not be identified in any publication and your 
personal and clinical details will remain strictly confidential. Any scientific publications arising from 
the study will be available on request to all participants. You will have no legal right to a share of 
any profits that may arise from the research.
Who is organising and funding the research?
This study will be led by Martin Stout under the supervision of Professor John Saxton and 
Professor Kevin Channer who are the Chief Investigator’s supervisory team for his PhD research. 
Additionally, expert support will be received from Dr Simon Williams (Consultant Cardiologist), Dr 
Steve Shaw (Cardiology Registrar), Keith Pearce (Principal Cardiac Physiologist) and the Heart 
Failure Research Nurses that you visit during your clinic appointments.
Who has reviewed the study?
The study has been reviewed by North West 8 Research Ethics Committee - Greater Manchester 
East.
Where can I find independent information about taking part in research?
You can contact local branches of the NHS Patient Advisory Liaison Service (PALS). Here 
is their website: h ttp ://w w w .pa is .nhs .uk / Contact phone number is 0161 291 5600 or 
email: p ls@ uhsm .nhs.uk
Further information and contact details
Martin Stout.
Advanced Specialist Cardiac Physiologist.
Northwest Heart Centre.
Wythenshawe Hospital.
Southmoor Road.
Manchester.
M23 9LT.
Tel: 0161-2914632.
If you are concerned about any aspect of the study and feel the need for independent advice 
you are advised to approach your GP
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Appendix 3. Case report forms study 1.
University Hospital o f South Manchester IN!Pi
NHS Foundation Trust
The Effects of Testosterone Status on Exercise Capacity, Muscular Strength and 
Quality of Life in Males with Chronic Heart Failure.
Baseline Data Collection Sheet.
Participant number Date
Age Height Weight BMI NYHAScore Systolic BP Diastolic BP
HR
Current Medication and Dosage:
Serum Free Testosterone (mmol/l) Serum Total Testosterone (mmol/l)
Salivary Testosterone (mmol/l) NT Pro BNP (pg/di)
Completed by:   Date:
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University Hospital o f South Manchester hVwfci
NHS Foundation Trust
The Effects of Testosterone Status on Exercise Capacity, Muscular Strength 
and Quality of Life in Males with Chronic Heart Failure.
Primary Outcome Measure: 6 minute walk test.
Participant Number 
Resting HR
Date
Rest BP
ShuttleNumber ShuttleDistance(metres)
Max HR (bpm) Max RPE Recovery HR (bpm) 1 (3mins)
Recovery HR (bpm) 2 (6mins)
Recovery HR (bpm) 3 (9 mins)
Collected by: Date:
University Hospital o f South Manchester FJ/gfcj
NHS Foundation Trust
The Effects of Testosterone Status on Exercise Capacity, Muscular Strength 
and Quality of Life in Males with Chronic Heart Failure.
Secondary Outcome Measures:
Handgrip Strength (kg), Echocardiography and Quality of Life.
Participant Number Date
jectionraction%
TDIE/E’ TDI Peak S wave velocity (cm/s)
LVlength(cm)
LVdiameter(cm)
SphericityIndex TAPSE(mm) HandgripStrength
(kg).
SF 36 completed
BeckDepressionCompleted
MinesottaQuestionnComplet
Data collected by: Date:
Appendix 4. MLHFQ.
M INNESOTA LIVING WITH HEART FAILURE® QUESTIONNAIRE
T he following q u e s tio n s  a s k  how  m uch your h e a r t failure (h ea rt condition) a ffected  your 
life during th e  p a s t m onth  (4 w eek s). After e a c h  q u estion , circle th e  0 , 1 , 2 , 3 , 4  o r  5  to 
show  how  m uch  y our life w a s  a ffec ted . If a  q u estion  d o e s  no t ap p ly  to  you, circle th e  0 
a fte r th a t question .
Did your heart failure prevent
you from living as you wanted during Very Very
the past month (4 weeks) by -_____________No Little_____________ Much
8
9.
1. cau sin g  swelling in y o u r an k le s  o r  leg s?
2. m aking you sit o r lie dow n to  re s t  during 
th e  d ay ?
3. m aking your walking a b o u t o r  climbing 
sta irs  difficult?
4 . m aking your working a ro u n d  th e  h o u se  
o r yard difficult?
5. m aking your going p la c e s  aw ay  from  
hom e difficult?
6. m aking your s leep in g  well a t  night 
difficult?
7. m aking your relating to  o r  do ing  th ings 
with your friends o r fam ily difficult? 
m aking your working to  e a rn  a  living 
difficult?
m aking your recreational p a s tim e s , sp o rts  
o r hobb ies difficult?
10. m aking your sex u a l activities difficult?
11. m aking you e a t  le s s  o f th e  fo o d s you 
like?
12. m aking you sh o rt of b re a th ?  
m aking you tired , fa tigued , o r  low on 
energy?
m aking you s ta y  in a  h osp ita l?
15. costing you m o n ey  for m edical c a re ?
16. giving you sid e  e ffec ts  from  tre a tm e n ts?
17. m aking you feel you a re  a  bu rd en  to  your 
family o r friends?
18. m aking you feel a  lo ss  o f self-control 
in your life? 
m aking you worry?
m aking it difficult fo r you to  co n ce n tra te  
o r  rem em b er th in g s?  
m aking you feel d e p re s s e d ?
13
14
19.
20 .
21 .
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
2 3 4 5
©1986 Regents o f the University o f  Minnesota, All rights reserved. Do not copy or reproduce without permission. 
LIVING WITH HEART FAILURE® is a registered trademark o f the Regents o f the University o f Minnesota.
11/10/04
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Appendix 5. Example of informed consent form.
University Hospital of South Manchester fiV/HI
NHS Foundation Trust
The Effects of Testosterone Status on Exercise Capacity. Muscular Strength and Quality of
Life in Male Patients with Chronic Heart Failure.
Participant CONSENT FORM (To be completed at study visit)Patient Identification Number for this study:..................Name of Lead Researcher: Martin Stout.
Please initial all the relevant boxes
1. I confirm that I have read and understood the information sheet (version 
2) dated 07/03/2011 for the above study and have had the opportunity to 
ask questions.
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected.
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by relevant regulatory 
authorities including responsible members of UHSM Trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.
4. I agree to gift my blood and saliva samples for future research
5. I agree to take part in the above study.
6. I agree to being approached in future for possible participation in 
Ethics approved research relevant to me.
7. I understand that information held by the NHS and records maintained by 
The NHS Information Centre and the NHS Central Register may be used 
to help contact me and provide information about my health status.
Name of Patient Date Signature
Person Taking Consent Date Signature
(if different from Researcher)
Researcher Date Signature
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Appendix 6. SF 36 Version 2 Questionnaire.
SF-36 v2™ Health Survey
(SF-36 v2 Standard, US Verxion 2.0)
To be completed by the PATIENT
N am e ( la s t ,  hirst. M dch? loitiah
k ie n lif ir a x n  N um ber
Even!
Directions: Answer every question byfilling in the correct circle or writing in the information. If you need to change an answer, 
completely erase the incorrect mark andfill in the correct circle. If you are unsure about how to answer a question, please give the 
best answer you cm, Mark only one answer for each question unless instructed otherwise.
Today's Date (MM/DD/YY) 
/
Shade circles like this* •  Mark onI>’onc answcr for question.Not like this: ®  ^  Please do not mark outside the circles ormake stray marks on the questionnaire.
O Poor
01. Tn general, would you say your health is:
O Excellent O Very' Good O Good 0  Pair
02. Compared to one year ago, how would you rate your health in general now?
O Much tetter O Somewhat better O About the same O Somewhat worse O Much worse
The following questions are about activities you might do during a typical Yes,. limited 
a lot
Yes, 
limited 
a little
No, not 
limited 
at alldav. Does vour health now limit vou in these activities? If so. how much?
03. Vigorous activities, such as running, lifting heavy objects, participating in 
strenuous sports o o o
04. Moderate activities, such as moving a table, pushing a vacuum cleaner, o o obowling, or playing golf
05. Lifting or carrying groceries o o o
06. Climbing several flights of stairs o o o
07. Climbing one flight of stairs o o o
08. Bending, kneeling, or stooping o o o
09. Walking more than a mile o o o
10. Walking several hundred yards o o o
11. Walking one hundred yards o o o
12. Bathing or dressing yourself o o o
During the past 4 weeks, how much o f the time have you had any All Most Some A little None
of the following problems with your work or other regular daily of the of the of the of the of the
activities as a result of vour physical health? time time time time time
13. Cut down on the amount of time you spent on work o o o o oor other activities
14. Accomplished less than you would like o o o o o
15. Were limited in the kind of work or other activities o o o o o
16. Tlad difficulty performing the work or other activities o o o o o(for example, it took extra effort)
vlease continue on next page
C  1996,2000 by QualityMelric Inc. an<l 
Medical Outcomes Trust. All Rights Reserved.
SF-36® i* a registered trademark of Medical Outcomes Trust.
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Patient Last Name:
During the past 4 weeks, how much o f  the time have you had any of 
the following problems with your work or other regular daily 
activities as a result o f any emotional problems (such as feeling 
depressed or anxious)?
17. Cut down the amount of time you spent on work or 
other activities
18. Accomplished less than you would like
19. Did work or activities less carefully than usual
All Most Some A little None
of the of the of the of the of the
time time time time time
o o o o o
o o o o oo o o o o
20. During the nasi 4 weeks, to what extent has your physical health or emotional problems interfered with your normal 
social activities with family, friends, neighbors, or groups?
O Not at all O Slightly O Moderately O Quite a bit O Exlremely
21. How much bodily pain have you had during the past 4 weeks?
O N one OVeiymild O M ild  O Moderate O Severe O Very severe
22. During the past 4 weeks- how much did pain interfere with your normal work (including both work outside the home 
and housework)?
O Not at all O A little bit G Moderately O Quite a bit O Extremely
These questions are about how you feel and haw things have been 
with you during the vast 4 weeks. For each question, please give the 
one answer that comes closest to the way you have been feeling. How 
much of the time
23. Did you feel full of life?
24. Have you been vciy nervous?
25. Have you felt so down in the dumps that nothing 
could cheer you up?
26. Have you felt calm and peaceful?
27. Did you have a lot of energy?
28. Have you felt downhearted and depressed?
29. Did you feel worn out?
30. Have you been happy?
31. Did you feel tired?
32. During the past 4 weeks, how much of the time has your 
physical health or emotional problems interfered with your 
social activities (like visiting friends, relatives, etc.)?
All Most Some A little None
of the of the of the of the of the
time time time time timeo o o o oo o o o o
o o o o oo o o o oo o o o oo o o o oo o o o oo o o o oo o o o o
o o o o o
Haw TRUE or FALSE is each ofthe fallowing statementsfor you?
Definitely Mostly Don't Mostly Definitely
true true know false false
33. I seem to get sick a little easier than other people o o o o o
34. I am as healthy as anybody I know o o o o o
15. I expect my health to get worse o o o • o o
36. My health is excellent o o o o o
O  1996.2000 by QiulityMetric Inc. and 
Medical Outcomes Trust. All Rights Reserved.
SF-36**T* a registered trademark o f  Medical Outcomes Trust
14 -
-2 of 2-
5 2 8 5 2
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Appendix 7. BDI.
Beck Depression Inventory
Please circle the appropriate answer for each question. Please circle only 1 answer.
1.
0 1 do not feel sad.
1 1 feel sad
2 1 am sad all the time and I can't snap out of it.
3 I am so sad and unhappy that I can't stand it.
2.
0 1 am not particularly discouraged about the future.
1 1 feel discouraged about the future.
2 I feel I have nothing to look forward to.
3 I feel the future is hopeless and that things cannot improve.
3.
0 1 do not feel like a failure.
1 1 feel I have failed more than the average person.
2 As I look back on my life, all I can see is a lot of failures.
3 I feel I am a complete failure as a person.
4.
0 1 get as much satisfaction out of things as I used to.
1 I don't enjoy things the way I used to.
2 I don't get real satisfaction out of anything anymore.
3 I am dissatisfied or bored with everything.
5.
0 1 don't feel particularly guilty 
1 1 feel guilty a good part of the time.
2 1 feel quite guilty most of the time.
3 I feel guilty all of the time.
6.
0 1 don't feel I am being punished.
1 I feel I may be punished.
2 I expect to be punished.
3 I feel I am being punished.
7.
0 I don't feel disappointed in myself.
1 I am disappointed in myself.
2 1 am disgusted with myself.
3 I hate myself.
8.
0 1 don't feel I am any worse than anybody else.
1 I am critical of myself for my weaknesses or mistakes.
2 I blame myself all the time for my faults.
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3 I blame myself for everything bad that happens.
9.
0 1 don't have any thoughts of killing myself.
1 1 have thoughts of killing myself, but I would not carry them out.
2 1 would like to kill myself.
3 I would kill myself if I had the chance.
10.
0 1 don't cry any more than usual.
1 1 cry more now than I used to.
2 I cry all the time now.
3 I used to be able to cry, but now I can't cry even though I want to.
11.
0 1 am no more irritated by things than I ever was.
1 1 am slightly more irritated now than usual.
2 1 am quite annoyed or irritated a good deal of the time.
3 I feel irritated all the time.
12.
0 1 have not lost interest in other people.
1 1 am less interested in other people than I used to be.
2 1 have lost most of my interest in other people. 3 I have lost all of my interest in other 
people.
13.
0 1 make decisions about as well as I ever could.
I I put off making decisions more than I used to.
2 1 have greater difficulty in making decisions more than I used to.
3 I can't make decisions at all anymore.
14.
0 1 don't feel that I look any worse than I used to.
I I am worried that I am looking old or unattractive.
2 1 feel there are permanent changes in my appearance that make me look 
unattractive
3 I believe that I look ugly.
15.
0 I can work about as well as before.
1 It takes an extra effort to get started at doing something.
2 I have to push myself very hard to do anything.
3 I can't do any work at all.
16.
0 1 can sleep as well as usual.
1 I don't sleep as well as I used to.
2 I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.
3 I wake up several hours earlier than I used to and cannot get back to sleep.
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17.
0 1 don't get more tired than usual.
1 1 get tired more easily than I used to.
2 1 get tired from doing almost anything.
3 I am too tired to do anything.
18.
0 My appetite is no worse than usual.
1 My appetite is not as good as it used to be.
2 My appetite is much worse now.
3 I have no appetite at all anymore.
19.
0 1 haven't lost much weight, if any, lately.
1 1 have lost more than five pounds.
2 1 have lost more than ten pounds.
3 I have lost more than fifteen pounds.
20.
0 1 am no more worried about my health than usual.
1 1 am worried about physical problems like aches, pains, upset stomach, or 
constipation. 2 I am very worried about physical problems and it's hard to think of much 
else.
3 I am so worried about my physical problems that I cannot think of anything else.
21.
0 1 have not noticed any recent change in my interest in sex.
1 I am less interested in sex than I used to be.
2 1 have almost no interest in sex.
3 I have lost interest in sex completely.
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Appendix 8. ADAM Questionnaire.
ADAM questionnaire about symptoms of low testosterone - 
(Androgen Deficiency in the Aging Male).
This basic questionnaire can be very useful for men to describe the kind and 
severity of their low testosterone symptoms.
1. Do you have a decrease in libido (sex drive)?
Yes No
2. Do you have a lack of energy?
Yes No
3. Do you have a decrease in strength and/or endurance?
Yes No
4. Have you lost height?
Yes No
5. Have you noticed a decreased "enjoyment of life"
Yes No
6. Are you sad and/or grumpy?
Yes No
7. Are your erections less strong?
Yes No
8. Have you noticed a recent deterioration in your ability to 
play sports?
Yes No
9. Are you falling asleep after dinner?
Yes No
10. Has there been a recent deterioration in your work 
performance?
Yes No
If you answer Yes to number 1 or 7 or if you answer Yes to more than 3 
questions, you may have low Testosterone.
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Appendix 9. Ethics form for study 2.
NHS
North Sheffield Ethics Office
1st Floor Vickers Corridor
Direct Line: 0114271 4894 or 271 4011 
Fax: 0114 256 2489 
Email: sue.roseesth.nhs.ulc
Northern General Hospital
Henries Road 
Sheffield 
S5 7AU
02 June 2008
Professor Kevin S Channer 
Consultant Cardiologist 
Royal Hailamshire Hospital 
Glossop Road 
Sheffield 
S102JF
Dear Professor Channer
Full title of study: Testosterone therapy as an adjunct to exercise
rehabilitation: effects on exercise capacity, inflammatory
markers and quality of life in hypogonadal males with 
chronic heart failure.
REC reference number: 06/Q2308/73
Protocol number 4
EudraCT number 20064)01090-23
Thank you for your letter of 31 May 2006, responding to the Committee's request for further 
information on the above research land submitting revised documentation].
The further information has been considered on behalf of the Committee by the Chairman,
Confirmation of ethical opinion
On behalf of tee Committee, I am pleased to confirm a favourable ethical opinion for tee 
above research on the basis described in the application form, protocol and supporting 
documentation [as revised].
Ethical review of research sites
The favourable opinion applies to tee research sites listed on the attached form.
The Site Specific Assessment for tee HaJlam University Site will be assessed by a Sub­
committee of the Research Ethics Committee.
Conditions of approval
The favourable opinion is given provided teat you comply with tee conditions set out in tee 
attached document You are advised to study tee conditions carefully.
An advisory committee to South Yorkshire Strategic Health Authority
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i 30S/73 Page 2
Approved documents
The final fist of documents reviewed and approved by the Committee Is as follows:
Document , Version Date
Application 13ADriI200S
Investigator CV
Protocol 4 11 May 2006
Summary/Synopsis 1
Questionnaires (CHAMPS/Heafth and 
WeHbeing/Minesota living with Heart Failura/ADAM)
Letter of invitation to participant 3 11 Mav 2006
GP/Consultant Information Sheets 3 11 May 2008
Participant Information Sheet Main Study 4 31 Mav 2006
Participant Information Sheet Sub study 3 11 Mav 2006
Participant Consent Form: Main study 2 14 December2005
Participant Consent Form: MRI sub study 2 14 December 2005
Response to Request for Further Information 11 May 2006
Response to Request for Further Information 31 May 2006
Request for authorisation of CT1MP to the MHRA 04 April 2006
Research governance approval
The study should not commence at any NHS site until the local Principal Investigator has 
obtained final research governance approval from the R&D Department for the relevant NHS 
care organisation.
Statement of compliance
This Committee is recognised by the United Kingdom Ethics Committee Authority under the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and Is authorised to carry out the ethical review of clinical trials of investigational medicinal products.
The Committee is fully compliant with the Regulations as they relate to ethics committees 
and the conditions and principles of good clinical practice.
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Page 3
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and compiles fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK.
08/Q2308/73 ___________ Please quote this number on all correspondence
With the Committee's test wishes for the success of this project
Yours sincerely
Dr G P M Clark
CHAIRMAN - North Sheffield Research Ethics Committee
Email: aprii.dagnail@sth.nhs.uk
Enclosures: Standard approval conditions [SL-AC1 forCTIMPs, SL-AC2 for other
studies]
Site approval form
Copy to: Dr Brenda Zirtober, STH R & D Department
STH Research Office, 305 Western Bank,
Clinical Trials Unit, MHRA
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An advisory committee to south Yorkshire Strategic Health Authority
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Appendix 10. Case report forms for study 2
Sheffield  Teaching Hospitals flVgfrj
NHS Foundation Trust
Study Number STH
Patients Initials
Date
1 4 3 9 4
Patient ID No.
Visit No.
Primary Outcome Measure -  
a) Incremental Shuttle Walk Test.
Time (mins) Shuttle
Number
Max HR (bpm) Max RPE
b) Recovery measures
Recovery time 
(mins)
HR (bpm) BP (mmHg)
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Sheffield Teaching Hospitals I
NHS F o u n d a tio n  Trust
Secondary Outcome Measures -
a) Contractile Function and Isometric Strength
Contractile Function (Nm )
(highest peak torque)
1 .0  rad.s' rad.s' 5 .3  rad.s'
Isometric Strength (N)
(using a handgrip dynamometer) □ □
b) Peak Oxygen Uptake and Lower-Limb Skeletal 
Oxygenation
Workrate (W) Rest 25 50 75 100 125 150 175 200
Time (mins) 0 3 6 9 12 15 18 21
Heart Rate 
(beats.min'1)
Blood Pressure 
(mmHg)
RPE
(Borg 6-20)
V 02
(l.min*1)
vco2
(l.min'1)
RER
(VCO2/VO2)
VE
(l.min*1)
Vt (I)
Bf (br.min")
Deoxygenation 
HHb (NIRS)
Test duration = ____________________
Signature of person completing this form:
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Sheffield Teaching Hospitals UIbm
NHS Foundation Trust
Study Number STH 1 4 3 9 4
Patients Initials 
Date
Patient ID No.
Visit No.
Secondary Outcome Measures -  Recovery Following 
Exercise
Start Time
Stop Time
Time after
exercise
(mins)
0 5 10 15 20 25 30
Heart Rate 
(beats.min’1)
Blood
Pressure
(mmHg)
Deoxygenation 
HHb (NIRS)
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Centre for Sport and Exercise ScienceSTH 14394 ECHOCARDIOGRAPHY OUTCOME MEASURE
2D measurements:
LV wall thickness (cm)
LV dimension (cm)
IVS
LVPW
LVEDD
LVESD
Left atrial diameter (cm)
Aortic dimension (cm) Annulus
Right atrium (cm)
Right ventricle (cm)
LV systolic / diastolic function.
Left ventricular ejection fraction (%)
Left ventricular peak systolic excursion (TDI) 
Left ventricular diastology E/E"
Doppler.
Mitral valve
Aortic valve 
Pulmonary valve 
Tricuspid valve
E/A ratio
E velocity (cm/s)
A velocity (cm/s)
E decel time (cm/s)
Peak systolic velocity (cm/s) 
Peak systolic gradient (mmHg)
Peak systolic velocity (cm/s) 
Peak systolic gradient (mmHg)
Peak regurgitant velocity (cm/s) 
Peak RA pressure (mmHg) 
Peak PA pressure
Report / Comments.
Sonographer.
Date..
Reported by.
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Appendix 12. Patient information leaflet for study 2.
Sheffield Teaching Hospitals Sheffield Hallam University
NHS Foundation Trust
EXERCISE AND TESTOSTERONE REPLACEMENT THERAPY 
IN MEN WITH HEART FAILURE
Introduction
Testosterone deficiency is a common occurrence in men with chronic 
heart failure (CHF). Previous studies have shown that exercise 
rehabilitation can safely increase exercise capacity in stable patients 
with CHF. This is a pilot study, which will assess whether testosterone 
replacement therapy in addition to a 12-week programme of exercise 
rehabilitation, can improve the exercise capacity of men with CHF who 
also have low circulating testosterone levels. Patients will be randomly 
allocated into one of two groups. You will either receive testosterone or 
placebo therapy. Both groups will receive exercise rehabilitation, 
which will involve a combined programme of moderate intensity 
aerobic exercise and resistance training.
Exercise capacity will be assessed using an incremental shuttle walk  
test. W e  will also assess your cardiac and skeletal muscle function 
and take blood tests, and assess w hether there are changes in your 
quality of life as a result of undertaking this study. The data from this 
pilot study will provide the basis for a  further clinical trial, which will 
be aim ed at developing more effective strategies for the treatm ent of 
patients with C H F  by evaluating the long-term effects of physical 
training on functional status, morbidity and mortality in stable C H F  
patients.
Please find attached the patient information sheet for this study, which 
answers the most frequently asked questions. This is your copy to 
retain.
PATIENT INFORMATION SHEET
Q: What is the main purpose of this study?
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A: In men with chronic heart failure testosterone deficiency is a  
common occurrence. Replacing the level of testosterone  
improves symptoms and exercise capability, as does a 
program m e of exercise. T h e main purpose of this study is to 
investigate w hether testosterone therapy given during a  
program m e of exercises can provide additional benefit in 
comparison to exercise training alone.
Q: Why has my doctor asked me to take part in this study?
A: You have been selected as being a suitable patient from your
medical history.
Q: What will I have to do?
A: All patients entering the study will have a medical exam ination  
and will be randomly allocated to one of two groups. Before you 
can be given any testosterone replacem ent therapy it is essential 
to ensure that you do not have prostate cancer. There is no 
evidence that testosterone replacem ent will cause cancer, but it 
m ay m ake small pre-existing cancers grow m ore quickly. W e  will 
therefore need to check a  special blood test called prostate 
specific antigen and perform a prostate digital exam ination. This 
involves the doctor placing his gloved finger inside your rectum.
If the blood test or digital exam ination, are abnorm al this does  
not necessarily m ean that you have prostate cancer but w e will 
arrange for you to be seen by one of our Consultant Urologists 
who will do further tests to be sure and provide any treatm ent 
that m ay be necessary. If the prostate tests are abnorm al you will 
not be able to continue to take testosterone replacem ent 
therapy.
Both groups will undertake a  supervised 12-w eek exercise  
training program m e at the Centre for Sport and Exercise 
Science, Sheffield Hallam  University, Collegiate Crescent 
Cam pus (off Ecclesall Road). During the 12-w eek period one 
group will receive testosterone replacem ent, and the other will 
receive placebo or dum m y testosterone treatm ent. Both 
testosterone replacem ent and the placebo will be adm inistered  
via intramuscular injection. You will not know which group you 
were in until the end of the study. T h e  placebo group is required  
so that direct comparisons can be m ade to see whether 
testosterone therapy provides additional improvement, com pared  
to only exercise rehabilitation. Both groups are equally important 
for the success of this study.
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Q: What will the assessment visits entail?
A: Unless otherwise stated all assessm ents will be performed at 
the start and end of the study period. During the assessm ent 
visits we will:-
1. Assess the distance that you can walk, using an 
incremental shuttle-walk test. The test will involve walking  
back and forth along a horizontal 10 m course.
2. Assess your heart function using special scanning  
techniques. This m ay be by ultra-sound (an 
echocardiogram which you will have had before) or by 
magnetic resonance imaging which is a  painless technique  
which does not use radiation.
3. M easure skeletal muscle strength and endurance of your 
leg muscles. This procedure is safe and will take  
approximately 15 -20  minutes to complete.
4. M easure lower-limb arterial function using ultrasound. 
During this procedure, a cuff will be placed around your 
lower thigh and inflated to occlude the circulation for 5 
minutes. W e  will need to do this twice for each leg. You are  
likely to experience a degree of discomfort in the leg whilst 
the cuff is blown up. This will resolve when the cuff is let 
down.
5. M easure your oxygen consumption, blood pressure, heart 
rate and perceived exertion whilst you are undertaking 
cycle exercise. You will also have a  small piece of 
apparatus strapped to your calf, whilst w e perform this test. 
This technique is com pletely painless and harmless.
6. T ake  a blood sam ple from your arm every 4 w eeks during 
the study.
7. Ask you to complete four brief questionnaires at the start 
and end of the study. W e  will assess your physical activity 
status every 4 w eeks during the study.
Q: How long will the study last?
A: The programm e will last for a  total of 12 w eeks. W e  will monitor 
everyone's progress throughout, with assessm ents at the  
start and at the end of the program m e period using a standard  
walking test. W e  will also do som e blood tests looking at the  
effects of exercise and testosterone on m arkers of inflammation  
in the blood. W e  want to know what effects the two treatm ents  
have on heart function so w e will also do heart scans.
Q: How long will I have to exercise for?
A: The main component of the exercise training program m e is 
stationary cycling, which will be followed by som e m oderate
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weight lifting exercises. Each exercise session will last for 
approximately 4 5 -50  minutes in total and patients will be required 
to attend 2 sessions per w eek for all 12 weeks. All exercise will 
be carefully supervised and you will be shown how to use the 
equipment.
Q: Will my travel expenses be reimbursed?
A: Your travel expenses to the Centre for Sport and Exercise  
Science will be reimbursed at the end of the 12-w eek study 
period. A £5 reim bursem ent per visit will be m ade.
Q: What are the alternatives for diagnosis or treatment?
A: If you are diagnosed with testosterone deficiency, your doctor or 
Consultant might discuss testosterone replacem ent therapy with 
you. In stable C H F  patients your G P  might also encourage  
exercise rehabilitation.
Q: What are the possible benefits of taking part in this study?
A: W e  cannot promise that the study will help you, but the
information which we obtain might help improve the treatm ent of 
patients with heart failure.
Q: Are there side-effects of any treatment received when taking
part?
A: W e  expect that exercise will m ake you feel tired, but as you do it 
more regularly you will feel increasingly better. Testosterone will 
be administered via intramuscular injection. Possible side effects 
might include pain and redness around the injection site. 
Testosterone, should not be used in men who are trying to start a  
family, as it can temporarily reduce sperm counts. O ther rare 
side effects of testosterone include headaches, slight fluid 
retention causing swelling of the ankles, and a small increase in 
the number of red blood cells. Som e men notice an increased  
libido after testosterone treatm ent. There is no evidence that this 
replacem ent dose of testosterone will cause problems with the 
prostrate gland, but this will be monitored regularly throughout 
the study, using blood tests.
Q: What are the possible disadvantages and risks of taking 
part?
A: The potential for risks to occur will be minimised, since all 
patients prior to study acceptance will have a full clinical 
assessm ent performed by the Consultant Cardiologist or
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Research Registrar. Th e likelihood of anything untoward 
happening during the exercise will be minimal.
Q: What about the risks of intramuscular injections for patients 
on warfarin?
A: The risk of local bleeding complications could be increased when  
patients on warfarin are given intramuscular testosterone injections. 
However, the risks will be minimised by extra blood tests (known as 
INR tests), which will be undertaken before your first injection, within 
5-7  days after your first injection. Th ese extra blood tests will be 
taken to see if your warfarin dosage needs to be adjusted whilst you 
are participating in the study. In addition, pressure will be applied to 
the injection site for five minutes and you will be advised to keep a  
check on the injection site for up to two-hours to see if any serious 
bruising occurs. Any concerns you have about the injection site 
should be discussed with a clinical m em ber of the research  
team .
Q: If I decide to participate, will my GP be notified?
A: W ith your consent, w e will write and inform your G P about your 
decision to take part.
Q: What if I do not wish to take part?
A: This will in not affect your treatm ent at all.
Q: What if I change my mind during the study?
A: You are free to withdraw from the study at any time without 
affecting your treatment.
Q: What will happen to the information from the study?
A: T h e overall conclusions of the study will be available to you, 
however it will not be possible to produce an individualised  
report of your performance.
Q: Will my taking part in this study be kept confidential?
A: The confidentiality of our patients and the data, which this study  
will generate, is of utmost importance. All data from this study will 
be anonymised. In brief, you will be allocated a num ber during 
the study. W e  will need to obtain your permission to allow access  
for the research team  to your medical records, and to information 
collected during the study. This is one of the clauses, which you 
will sign in agreem ent on the official consent form. O ur 
procedures for handling, processing and storage of and  
destruction of data are compliant with the D ata Protection Act 
1998.
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Q: Who is organising and funding the research?
A: The research is funded by Heart Research UK. The study is 
organised and sponsored by the Sheffield Teaching Hospital.
Q: Who has reviewed this study?
A: The North Sheffield Research Ethics Committee has reviewed 
this study.
Q: What if I have further questions?
A: If you have any further questions with regards to this study you 
may phone:-
IF YOUR 
QUERY IS 
REGARDING ...
Participating in 
this study 
or 
the
arrangements 
for the training 
and 
assessment 
sessions at 
the:- 
CENTRE FOR 
SPORT & 
EXERCISE 
SCIENCE
CONTACT AT THE
Mr MARTIN 
STOUT
Or
Dr JOHN 
SAXTON
CENTRE FOR 
SPORT & 
EXERCISE 
SCIENCE
(SHEFFIELD
HALLAM
UNIVERSITY)
CARDIOLOGY 
DEPT, ROYAL 
HALLAMSHIR 
E HOSPITAL
TELEPH
ONE
NUMBER
0114 225 
5690 
(DIRECT 
LINE)
0114 225 
4414 
(DIRECT 
LINE)
Your health 
(i.e. medically 
related)
PROF KEVIN 
CHANNER 0114 271 3473
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Q: What if I wish to complain about the way this study has been 
conducted?
A: If you have any cause to complain about any aspect of the way 
in which you have been approached or treated during the 
course of this study, the normal National Health Service 
complaints mechanisms are available to you and are not 
compromised in any way because you have taken part in a 
research study. The normal hospital complaints procedure does 
apply, and you should contact the following person:
Name: Professor Chris Welch (Medical Director) Tel: 0114 271 
1900
You can also complain to any individual of the research team, 
contact details as above.
Q: What if I am Harmed?
A: In the event that something does go wrong and you are harmed 
during the research study, there are no special compensation 
arrangements. If you are harmed and this is due to someone's 
negligence then you may have grounds for legal action for 
compensation, but you may have to pay your legal costs.
Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been 
approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms will still 
be available to you.
Version 6 13th September 2007
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Appendix 13. Focus group transcript example -  unrelated discussion 
excluded.
How do you feel overall following the 12 week intervention period?
PI. Yes I felt a lot fitter -  definitely. But, I’ve been thinking about it recently, I 
could probably have been pushed a little harder and maybe got even more fit. I 
thought after perhaps 2-3 weeks I could have been definitely pushed harder.
P2.1 thought it was alright. But what you have to do when you finish is to keep 
the momentum going. Otherwise you start settling back into old ways. I mean I 
felt great straight after the exercise sessions but some mornings when I came in I 
felt a bit sore. Afterwards though, I felt great.
P3.1 felt as though it could be a little more intensive. For instance I would have 
liked to have done a warm up on the treadmill or perhaps the main training on a 
treadmill rather than a bike. That way, you can get your whole body working 
rather than just your legs.
P4. For me it’s been an excellent course and I ’m grateful to all the people here 
who have helped me. I have noticed it very much because I do a physical job and 
my breathing has improved very much recently.
P5.1 agree that the course too could have been a little more physical. O feel my 
fitness has improved but at the end there is nothing to take you any further at the 
end. For people like us in order to take the burden off the NHS you really need
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something in place at the end. Just fitness alone and the confidence definitely 
makes you improve.
P4. It definitely gives you confidence because the nurses tend to want to put you 
in bed, the confidence gives you value to go to the gymnasium.
P2. You just need to be careful that you know who is best suited to the exercise 
because you don’t want someone collapsing at the university.
P5. I agree too. That’s what puts you off going to a regular gym because the 
instructors there may not be qualified. As those here apparently are (laughter).
PI. Yeah that’s right. But I still would like to know exactly how far I can 
actually go.
P6. You just need someone to push you into it. You know, you’ve made an 
appointment and so you come -  don’t you? If you were left at home, I mean I’ve 
got a bit of a gym there but I don’t use it.
Is there anything that the researchers could have done to make you 
continue with exercise following the programme?
PI. I don’t think we could have done these exercises at home. It needs to be that 
we go somewhere with your mates so that you can push each other. If you are 
doing it at home then you just say “Oh, I don’t feel like doing it today”.
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P3.1 would have been happy coming for more than 12 weeks -  whether it be 14 
or 16 or more.
P2. Yes, I would have liked maybe more sessions in the week. I was motivated 
so could have come every day.
P5. Difficult if you’re working though.
PI. Twice was enough for me. It gives you time to do other things.
Is there anything that you particularly disliked about the exercise sessions? 
P2. No.
PI. Perhaps not being pushed and a bit more variety. Because if you want to 
carry on after you want to know how far you can push yourself.
P2. Sometimes you see other people exercising on other equipment and it makes 
you want to have a go on that too.
P4.1 thought the sessions were well structured although it got a bit monotonous 
towards the end doing the cycling all the time.
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What was it that made you want to keep on coming?
PI. The exercise. You’ve got someone else there doing it with you. It makes you 
want to do it and you have got good facilities.
P2. Yes. Having others here who are all in the same boat helped a lot. I’ve made 
some friends.
P4. The wife and kids encouraged me to go. It means I had a puropose and was 
getting motivated to get fit. They helped me a lot.
PI. Martin, I think you helped too. You and the other instructors were 
encouraging and made us feel safe and comfortable in what we were doing.
So, does there being a group of you make it easier to come?
P5.1 don’t know because I often came on my own. My motivation was that I 
wanted to get fitter and also find out if it was the exercise or testosterone or 
whatever made you feel better.
P2. It definitely does. Motivation like.
P3.1 always wanted to beat.... during the exercises. We pushed ourselves hard to 
win.
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PL You also can chat to each other -  it makes the session not feel so difficult 
even though you are working hard.
P3. Good for when you’ve got problems -  everyone has the same condition so 
you can ask questions and get re-assurance from each other about things.
P4. Like my gout!
What about family and friends -  do they give you support?
P3. Yes family have supported me. Doctors and nurses are interested in the 
course and also the outcome of it.
P2. Yes I had some support.
P3.1 would have come anyway I think.
What has been your doctors opinion?
P3. They have different opinions, some say don’t exercise. Thats rubbish 
because I know I can.
P4. Family are very protective. You sometimes have to hide it from them.
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PL Yes they are. It would help if you knew how far you can push yourself and 
what a safe limit is. You think wow I can do that and how far can I go.
P3. That’s up to yourself and you shouldn’t put so much pressure on those 
people here. You still have to be careful not to push too hard. The last thing they 
want to do here is call an ambulance.
How do you feel about coming to the University to exercise?
P5. There is no alternative. There’s no option to have one nearer to where I live. 
It was an incentive to get up and get going.
P2. It gets you up and out of bed.
P4. It’s okay but when you are working or busy you need alternatives like.
P6. Good point. Why isn’t there more stuff like this near to our homes? I mean, 
there is a gym around the comer from me but I wouldn’t want to go there with 
all the meat heads. We need something tailored to our condition and someone 
who knows what we can do safely.
P2. That’s why coming here was the best thing. And we are giving something 
back through research.
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If you had to design a programme such as this -  would you do anything 
different?
PI. Yeah. There would be more variety.
P5.1 would put the rowing machine in.
P2. Variety, definitely.
P2. The cross-walker too.
P6. Sometimes it was very rushed. I was often trying my best to get through 
things quickly.
P3. For me it has been a lesson. I can now go to the gym with my wife again 
with the confidence that I know what I am doing. I think I would be okay. 
Sometimes the traffic is bad and it takes time to get here but the gym is on my 
doorstep.
How would you feel if we opened up these sessions to family?
P3. That would be excellent and I think it would make more people want to 
come.
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P2.1 think it would be okay but then you have a work situation with people not 
being able to find the time to get here together.
P3. What we have got is a situation were we have had 30 patients and you get a 
picture of people who have been satisfied and benefited you should use them as 
an advert for others to attend.
P6. Excuse me. We have all come here because we have a problem, an illness. 
We’ve come here to go on a test to see if it benefits us. What you’re talking 
about is a free gym. You will have no problem getting people them. It should be 
strictly for those who are ill and can benefit from the programmes. It’s a medical 
situation -  not a free gym.
P2. Some people would not come regularly. I liked coming with your mates who 
are doing the same thing. Not your family.
PI. We have all got similar problems and it’s good to chat and compare with 
each other. You can’t do that with just your family.
What advice would you give to other heart patients?
PI. It has got to be encouraged.
P2. Definitely.
548
P6. People will be a lot more motivated when you get to know the results. The 
encouragement will come from the results.
P5. We should promote this because it clearly has worked. Some of us have lost 
weight and we all fit a lot more fit.
P2. We are examples that exercise does work and is safe.
P3. It’s not just us though. The doctors and nurses should know we can safely do 
this -  why aren’t they encouraging us more?
Do you think if this research is published in medical journals that will 
influence doctors?
PI. You have got to exercise otherwise you go backwards and they should know 
that.
P5. The GP’s should promote this and should know about it. They should use us 
as examples that it works.
PI. I never see the consultant anymore. I have been discharged and they don’t 
follow me up to check anything. They don’t force you to exercise.
P6. Did they not tell you to exercise?
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PL Yes they did but they don’t check you up.
P3. Sometimes you have to moan. Otherwise, you don’t get anything. Then it 
gets too late.
PI. National Health is not bothered unless you are ill. But some don’t even go 
then. There is no annual check up unless you go yourself. I think every year they 
should get in touch with you.
P6. Cost wise that is unrealistic. They cannot afford to do that.
PI. Other countries have annual physical check-ups.
P6. You will have to name those -  most countries you have got to pay for 
healthcare.
PI. If they spent more they may save money by sorting out problems in the 
earlier stages where it doesn’t cost as much.
PI and P4 we would pay for annual screening if it was on offer.
How did you benefit as a result of the intervention?
P5. Yes I could walk further and get up hills without getting as short of breath.
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P3. Most of us in here definitely get short of breath. It feels harder to get blood 
and oxygen to the muscles.
P2. Lost loads of weight and feel better gardening.
P4. It gives you more confidence.
P5. Them questionnaires we filled in must have proved that we are better than 
before. I was depressed and not doing very much. Now I know I can it changes a 
lot of my answers this last time.
P6. Even things like walking upstairs to the toilet. I’m not as short of breath 
when I get there now.
P3.1 have improved -  no doubt.
Any negative effects of the exercise?
PI. Tired at first but the more I did I felt better.
P3. Not many aches no.
P2. Sometimes sore in the morning but that soon wore off.
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PI. Injections made you bleed a bit.
P6. At first, I was aching all the time afterwards but after a couple of weeks I 
was okay. That’s what made me want to try and do some more to push myself 
harder.
P2. That seat on the bike. It hurt after about ten minutes. That’s why I started 
bringing my cushion!
Has what we have done here influenced how you exercise at the gym?
P5. Yes I do more cardio now.
P4. I’m joining up again I think.
P3. I’m going more with my wife now I know what I’m doing.
P2.1 can’t afford a gym -  but you can do most of the stuff at home; walking, 
jogging and some of the exercises too.
Any other comments.
P2. If you have any exercise kit at home you should try and use it. Put some 
music on and away you go.
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P6. Stop us putting weight on.
P2. Weight is a big issue and hinders you.
P4. It is difficult to lose weight and if you’re fat then you are at risk.
PI. Maybe dietary and educational advice should also be included because 
weight is a massive problem for lots of people.
P2. Just knowing what foods you can eat or should eat then that’s a good start.
P6.1 once joined weight watchers and that worked because I got into the habit of 
getting weighed. Here is the same, you come every week and it keeps working. 
You need to keep at it.
P5. Weight loss and exercise go hand in hand.
PI. We could all do with losing a little bit.
P2.1 hope I don’t settle back into my old ways because this has stopped. I’m 
going to look into some cardiac classes from the council or hospital.
P4. Let us know if you find any -  I’d be interested in that.
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P5. Can we not pay and keep attending here?
P2. You need to think of more research so we can keep coming doing exercises -  it’s 
popular there were lots of people with other illness attending at the same tiem as me. I 
was interested when talking to them abiout their problems too.
P6. My wife kept wanting to come in and exercise with me -  she watched a few 
sessions thoug. Something about insurance cover so she couldn;t use the equipment.
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